

FINAL PROGRAM




The Movement Disorder Society's
13th International Congress
OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS
JUNE 7-11, 2009

Paris, France

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders



Claiming CME Credit

To claim CME credit for your participation in the MDS 13th International Congress of Parkinson's Disease and Movement Disorders, International Congress participants must complete and submit an online CME Request Form. This Form will be available beginning June 10.

Instructions for claiming credit:

- After June 10, visit www.movementdisorders.org/congress/congress09/cme
- Log in following the instructions on the page. You will need your International Congress Reference Number, located on the upper right of the Confirmation Sheet found in your registration packet.
- Follow the on-screen instructions to claim CME Credit for the sessions you attended.
- You may print your certificate from your home or office, or save it as a PDF for your records.

Continuing Medical Education

The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Movement Disorder Society designates this educational activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Non-CME Certificates of Attendance were included with your on-site registration packet. If you did not receive one, please e-mail congress@movementdisorders.org to request one.

The Movement Disorder Society has sought accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA. www.ama-assn.org/ama/pub/category/1438.html.

TABLE OF CONTENTS

Welcome Letter	2
Acknowledgments	3
About MDS	4
Education Information	7
Membership Information	13
Map of Paris	16
International Congress Information	17
Speaker Ready Room Hours	17
Poster Sessions Hours	19
Social Events	20
Le Palais des Congrès Floor Plans	21
Awards Information	23
CME Information	28
Program-at-a-Glance	30
Session Definitions	31
Scientific Program	32
Faculty Listing	45
Corporate Therapeutic Symposia	48
Exhibitor Information	51
Exhibitor Directory	52
Exhibit Hall Floor Plan	59
Guided Poster Tours Information	62
Abstract Listing by Topic	68

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

WELCOME

Dear Colleagues and Friends,

Bonjour and welcome to Paris for the 13th International Congress of Parkinson's Disease and Movement Disorders!

Planning for this International Congress began more than a year ago. We would like to express our gratitude to the large number of our volunteer committees for designing this International Congress and we would especially like to thank the Congress Scientific Program Committee (CSPC) for their hard work and coordination of this superior Scientific Program. The 2009 Scientific Program will incorporate Therapeutic Plenary Sessions, Plenary and Parallel Sessions, Teaching Courses, Video Sessions, Skills Workshops, Posters sessions and Guided Poster Tours. This year's program features 59 sessions led by over 170 esteemed faculty from around the world. We are presenting a record number of 1,693 abstracts in poster sessions over the course of four days.

Although the city of Paris is one of the most popular tourist destinations in the world, we do hope that you will be able to allot time in your schedule to participate in our detailed program, visit the Exhibit Area and poster areas, and attend the social events in the evenings. We would also like to thank the members of the Congress Local Organizing Committee for their hard work in arranging the Congress social events that we are sure you will enjoy.

For the first year, the CSPC has selected a group of sessions on a specific theme allowing participants of the MDS International Congress to have an educational and comprehensive overview on a subject of broad interest to our community. For the 2009 meeting the selected topic is "Anatomy, physiology and pathology of the basal ganglia." At the end of the meeting the participants to these sessions should be able to have a more complete understanding of the basal ganglia function.


These sessions are designated with a .

Thank you for your support of The Movement Disorder Society and welcome to our 13th International Congress of Parkinson's Disease and Movement Disorders.

With kind regards,



Anthony E. Lang
President, The Movement
Disorder Society, 2007-2009




Serge Przedborski
Chair, Congress Scientific
Program Committee, 2008-2009



Etienne Hirsch
Co-Chair, Congress Scientific
Program Committee, 2009



Olivier Rascol
Co-Chair, Congress Scientific
Program Committee, 2009
Co-Chair, Congress Local
Organizing Committee, 2009



Marie Vidailhet
Co-Chair, Congress Local
Organizing Committee, 2009

ACKNOWLEDGMENTS

The International Congress Oversight Committee of the 13th International Congress of Parkinson's Disease and Movement Disorders wishes to acknowledge and thank the following companies for their support:

DOUBLE PLATINUM LEVEL



PLATINUM PLUS LEVEL



PLATINUM LEVEL



GOLD LEVEL



SILVER LEVEL



*These supporters are confirmed as of April 15, 2009

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

ABOUT MDS

The Movement Disorder Society (MDS) is an international, professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic Movement Disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to:

Ataxia
Blepharospasm
Dysphonia
Dystonic disorders
Gait disorders
Huntington's disease
Myoclonus
Parkinson's disease
Restless legs syndrome
Spasticity
Tardive dyskinesia
Tics and Tourette syndrome
Tremor

The Movement Disorder Society (MDS) was founded in 1985 on the initiative of Professors Stanley Fahn and C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. The organization merged in 1988 with the International Medical Society for Motor Disturbances.

Purpose, Mission and Goals

Purpose:

The object and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:

To disseminate knowledge about Movement Disorders by:

- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
- Sponsoring congresses and symposia on Movement Disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:

- Using the Society's influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

To formulate and promote public policy that will favorably affect the care of patients with Movement Disorders by:

- Working with regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- Informing the public (media) and patient support groups of new research and therapeutic advances
- Playing a proactive role in the development of policies that affect support of research and patient care
- Developing standards of training in the specialty

ABOUT MDS

MDS Officers



President

Anthony E. Lang,
Canada



President-Elect

Philip Thompson,
Australia



Secretary

Olivier Rascol,
France



Secretary-Elect

Matthew Stern,
USA



Treasurer

Yoshikuni
Mizuno,
Japan



Treasurer-Elect

Oscar Gershanik,
Argentina



Past-President

Andrew Lees,
United Kingdom

MDS International Executive Committee

Giovanni Abbruzzese, Italy
 Alim L. Benabid, France
 Shu-Leong Ho, Hong Kong
 Karl Kieburz, USA
 Irene Litvan, USA
 Demetrios Maraganore, USA
 Marcelo Merello, Argentina
 John Rothwell, United Kingdom
 Cristina Sampaio, Portugal
 Claudia Trenkwalder, Germany

International Congress Oversight Committee

Chair: C. Warren Olanow, USA
 Anthony E. Lang, Canada
 Andrew Lees, United Kingdom
 Yoshikuni Mizuno, Japan
 Werner Poewe, Austria
 Philip Thompson, Australia
 Ad-hoc: Serge Przedborski, USA
 Ad-hoc: Yves Agid, France
 Ad-hoc: Marie Vidailhet, France
 Ad-hoc: Olivier Rascol, France

Congress Scientific Program Committee

Chair: Serge Przedborski, USA
 Co-Chair 2009: Etienne Hirsch, France
 Co-Chair 2009: Olivier Rascol, France
 Cynthia Comella, USA
 Ted Dawson, USA
 Günther Deuschl, Germany
 Dennis Dickson, USA
 Thomas Gasser, Germany
 Oscar Gershanik, Argentina
 Christopher Goetz, USA
 Ryuji Kaji, Japan
 Christine Klein, Germany
 Thomas Klockgether, Germany
 Jeffrey Kordower, USA
 Paul Krack, France
 Joachim Krauss, Germany
 Anthony E. Lang, Canada
 Timothy Lynch, Ireland
 C. Warren Olanow, USA
 Henry Paulson, USA
 Ronald Pfeiffer, USA
 Werner Poewe, Austria
 Kapil Sethi, USA
 Clive Svendsen, USA
 Daniel Tarsy, USA
 Philip Thompson, Australia
 Marie Vidailhet, France

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABOUT MDS

Congress Local Organizing Committee

Honorary Chair: Yves Agid
Co-Chair: Marie Vidailhet
Co-Chair: Olivier Rascol
Jean Philippe Azulay
Alim-Louis Benabid
Hamid Bennazzouz
Erwan Bezard
Christine Brefel-Courbon
Alexis Brice
Emmanuel Broussolle
Pierre Burbaud
Pierre Cesaro
Philippe Damier
Alain Destée
Bruno Dubois
Franck Durif
Etienne Hirsch
Jean-Luc Houeto
Marie-Lou Kemel
Paul Krack
Stephane Lehericy
André Nieoullon
Pierre Pollak
Philippe Remy
Marc Savasta
François Tison
Jacques Touchon
Christine Tranchant
Marc Vérité

Past-Presidents


2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

International Medical Society for Motor Disturbances Past-Presidents

1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS International Secretariat

The Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: congress@movementdisorders.org
Web site: www.movementdisorders.org



EDUCATION INFORMATION

To better fulfill its global mission of advancing the neurological sciences as they relate to Movement Disorders, MDS is expanding its educational program. This growing program offers an increasing variety of high caliber Continuing Medical Education and continuing professional development opportunities in Movement Disorders.

Visiting Professor Program

This program is intended to provide an excellent educational opportunity in Movement Disorders to regions of the world not adequately served by resources within that region. Applications will be considered by the Education Committee of the appropriate MDS Regional Section. For more details, visit www.movementdisorders.org or call Linda Caples at +1-414-276-2145.

Ambassador Program

This program is intended to provide excellent regional faculty in the field of Movement Disorders to existing conferences around world. Applications will be considered by the MDS Education Committee. For more details, visit www.movementdisorders.org or call Linda Caples at +1-414-276-2145.

Slide Sets

This member only service enables learners to become familiar with the differential diagnosis and clinical features that define various common involuntary movements as well as the course of treatment and complications of Movement Disorders. Slide Sets are available at www.movementdisorders.org.

Current Slide Sets include:

- Ataxia (PPT) - *Jennifer G. Goldman, MD*
- Chorea (PPT) - *Kathleen M. Shannon, MD*
- The Diagnosis and Management of Dystonia (PPT) - *Steven J. Frucht, MD*
- Myoclonus: Diagnosis and Treatment (PPT) - *Steven J. Frucht, MD*
- Parkinsonism (PPT) - *Kathleen M. Shannon, MD*
- Restless Legs Syndrome (PPT)- *Charles H. Adler, MD, PhD*
- Tics and Tourette Syndrome (PPT) - *Jennifer G. Goldman, MD*

Video Library

This library consists of video supplements from the *Movement Disorders Journal* since 1986. You may search the Video Library by keyword, by author, by volume and issue, or a combination of these fields. The Video Library is a member benefit available at www.movementdisorders.org.

Case of the Month

Case of the Month (COM) is an interactive online feature that presents unique and challenging Movement Disorder cases. MDS members are invited to answer questions after analyzing video and case history, and are provided with the expert's analysis. Please visit the MDS Web site to watch this month's case.

MDS is currently accepting submissions for Case of the Month. Case of the Month provides an opportunity for members to share interesting cases for educational purposes, in a forum dedicated to Movement Disorder experts. For information about submission requirements, including video format and patient consent forms, please visit the MDS Web site at www.movementdisorders.org.

11th International Congress - Teaching Course Syllabi

Currently available syllabi include:

- Current treatment of Parkinson's disease: Motor symptoms
- Intersection of sleep and Movement Disorders:
- Evaluation and treatment
- Current management of Parkinson's disease: Non-motor symptoms
- Pediatric Movement Disorders in an office setting: Diagnosis and treatment

As a result of reviewing this material, you should be better able to:

- Describe the pathophysiology and neurobiology for Parkinson's disease and other Movement Disorders;
- Discuss the pharmacological and non-pharmacological treatment options available for Parkinson's disease and other Movement Disorders.



Medtronic

The Leader in Deep Brain Stimulation

Medtronic is proud to be a Gold Supporter of
The Movement Disorder Society's 13th International
Congress of Parkinson's disease and Movement Disorders.

Yesterday

For more than 20 years, Medtronic has collaborated with clinicians to respond to patient needs, resulting in more than 55,000 patients worldwide¹ with a Medtronic DBS system.

Today

Medtronic continues to innovate and respond to clinician and patient needs by introducing more choice with the most advanced programming features and the world's first rechargeable technology in its new DBS family, Activa® PC and Activa® RC.*

Tomorrow

Medtronic will continue to lead by investing in the future of DBS through new indications and best-in-class clinical research, procedure support, education, and technical innovation.

For the latest in clinical research at MDS, including DBS, stop by the Medtronic exhibit, #21, for a complimentary copy of *The Movement Disorder Society's 2009 Abstracts* on CD-ROM.

1. Medtronic, Inc. data on file.

* At the time of printing, Activa RC and Activa PC were not approved for use in the United States.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

Indications

Medtronic Activa Therapy is indicated for patients with disabling tremor or symptoms of Parkinson's disease. Studies have shown that deep brain stimulation with Activa system components is effective in controlling essential tremor and symptoms of Parkinson's disease that are not adequately controlled with medications. Additionally, deep brain stimulation is effective in controlling dyskinesias and fluctuations associated with medical therapy for Parkinson's disease.

Medtronic Activa Therapy is also indicated as an aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) for individuals 7 years of age and older.

Refer to the appropriate information for prescribers booklet for contraindications, warnings, precautions, adverse events summary, patient selection, and component disposal.

EDUCATION INFORMATION

12th International Congress - Teaching Course Webcasts

The Movement Disorder Society (MDS) is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians. MDS designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Currently available webcasts/podcasts include:

- Dysautonomia in Parkinson's disease: Spectrum, evaluation and treatment
- Neuropsychiatry in Parkinson's disease: Beyond dementia
- Tics and stereotypies
- Vascular and post-hypoxic movement disorders
- PSP and CBD
- Impulse control disorders

Online - Journal CME

Visit the MDS Web site's educational activities to view a list of available CME articles. The Movement Disorder Society (MDS) is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians. MDS designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The recent articles include:

- **September 2008:** "Nicotine and Parkinson's disease: implications for therapy"
Maryka Quik, PhD, et al.
- **August 2008:** "The current clinical management of Huntington's disease"
Wendy Phillips, MD, et al.
- **July 2008:** "The Hand That Has Forgotten Its Cunning—Lessons from Musicians' Hand Dystonia"
Anna M. Conti, MD, PhD, et al.
- **July 2008:** "The Relationship Between CAG Repeat Length and Clinical Progression in Huntington's Disease"
Bernard Ravina, MD, MSCE, et al.

Call for 2010 Supported Meeting Applications!

The Movement Disorder Society is now accepting applications from meeting organizers who wish to receive financial support for scientific meetings in the year 2010. MDS will be offering a total amount of \$70,000 USD to support scientific meetings in 2010, with an additional \$30,000 USD in funding available for request only by meeting organizers who belong to a group with MDS Affiliate Member status.

To apply, meeting organizers must submit a proposed program, including lecture topics, faculty, and a budget for the meeting along with the completed Supported Meetings application which is available on the MDS Web site: www.movementdisorders.org/announcements/supported_and_endorsed/

For further information or to request an application form, please contact:

The Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: pfirst@movementdisorders.org

EDUCATION INFORMATION

Available Online

In alignment with our educational mission, The Movement Disorder Society is pleased to provide a variety of online activities. These activities aid to expand the outreach of our educational offerings. The following online activities are now available:

Restless Leg Syndrome and Parkinson's Disease in the Office Setting: Case Studies

Available through October 1, 2009

At the conclusion of this activity, participants should be able to describe the clinical features and diagnostic criteria for RLS and periodic limb movements; differentiate between the clinical diagnosis of RLS and sleep phenomenons such as PLMS; describe the diagnostic workup for RLS; list the therapeutic approaches to RLS for mild to moderate or intermittent symptoms; list the therapeutic approaches to RLS for moderate to severe symptoms; discuss augmentation and rebound; identify the clinical features of PD; recognize features atypical for PD; discuss issues related to initiation of treatment in PD; discuss the management of motor complications; identify non-motor manifestations of PD.

Dopamine Transporter Imaging in Neurological Practice Webcast

At the conclusion of this activity, participants should be able to: describe how dopamine transporter imaging is performed and discuss the science underlying the procedure; discuss the interpretation of dopamine transporter images; list the diseases/symptoms for which dopamine transporter imaging may be an appropriate investigative tool; explain how patients suitable for this procedure would be identified; and discuss the current uses, potential future uses, and limitations of dopamine transporter imaging in neurological clinical practice and research applications. *Now also available on CD-ROM. For more information, please contact cbreckenridge@movementdisorders.org.*

Live Courses

Dopamine Transporter Imaging in Neurological Practice

Prague, Czech Republic • November 20, 2009

This workshop is intended to introduce participants to the potential of dopamine transporter single photon emission computed tomography (SPECT) imaging in neurological practice. The workshop will answer some common questions, such as when it is appropriate for dopamine transporter imaging to be ordered by general practitioners, neurologists or Movement Disorder specialists.

While some questions can be answered by a number of published dopamine transporter imaging studies of high scientific standard, answers to other questions are highly dependent upon expert opinion. The goal of the workshop will be to present a balanced view of the currently available information on dopamine transporter imaging studies. The scope of information to be presented and discussed has been chosen to not only identify the potential usefulness of dopamine transporter imaging in neurological practice, but also to guard against indiscriminate and injudicious use of dopamine transporter imaging, or erroneous interpretation of findings.

Register now at: www.movementdisorders.org/education/

Develop your own course

Do you have an idea for a course? MDS encourages you to visit our Web site at www.movementdisorders.org and submit a course abstract to be considered by MDS for implementation.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ASIAN AND OCEANIAN SECTION EDUCATION INFORMATION

The mission of the Asian and Oceanian Section (AOS) is to represent and promote The Movement Disorder Society in Asia and Oceania. In the past year, AOS educational programs have proven an important and effective tool in pursuing this mission. Through the AOS Educational Course Sponsorship Program and the MDS Visiting Professor Program, courses were hosted throughout the AOS region. Please see below for descriptions of the opportunities that were offered in 2008-2009.

Educational Course Sponsorship Program

The AOS Educational Course Sponsorship program was launched in January, 2008. The program was designed to address the needs of underserved regions in the AOS that do not have access to trained Movement Disorder specialists and are restricted by size and/or resources from establishing a training program. It is intended to support three course formats: a stand-alone course, courses conjoined with other local/regional meetings, and consecutive courses.

In 2008-2009 courses were held in the following locations: Varanasi, India; Nanchang, China; Bandung, Indonesia; Kuala Lumpur, Malaysia; and Ho Chi Minh City, Vietnam. Reports from past Course Directors may be accessed online at www.movementdisorders.org/regional_sections-aos/.

For information on how to apply for this program please visit our Web site at www.movementdisorders.org/regional_sections-aos/. For more information on past courses, please contact Catherine Breckenridge at cbreckenridge@movementdisorders.org.

AOS Online Calendar

To view information on upcoming Movement Disorder events in the AOS region or to advertise a meeting using the "Submit Event" feature, please visit the AOS online Calendar of Events at www.movementdisorders.org/regional_sections-aos/calendar.php.

Visiting Professor Programs

The AOS hosted three Visiting Professor Programs in March in Beijing, China; Shanghai, China; and Bangkok, Thailand.



VPP Beijing, March, 2009. Pictured above (left to right): Prof. Zhen-Xin Zhang, Course Director; Dr. Stanley Fahn, Visiting Professor; Dr. Louis Tan, Faculty, Co-Chair of AOS Education Committee

Upcoming VPP's in the AOS

Beijing, China – June 29-30, 2009

Course Director: Prof. Piu (Bill) Chan

Visiting Professors: Dr. Caroline Tanner & Dr. G. Webster Ross

For more information on the Visiting Professor Program please see the section of the Final Program regarding MDS Education on page 7.

AOS Educational Needs Assessment – Online Survey

The AOS continues to research the educational and regional needs of its members to provide you with the best possible educational opportunities. Please take the time to complete the online survey at www.movementdisorders.org/surveys-aos/.

For more information on any of the AOS programs please contact the Catherine Breckenridge at cbreckenridge@movementdisorders.org.

MEMBERSHIP INFORMATION

Membership Benefits

- A subscription to the print, DVD, and online journal, *Movement Disorders* including supplemental publications such as *Levodopa Treatment and Motor Complications in Parkinson's Disease: Scientific Basis and Therapeutic Approaches*.
- A unique selection of educational opportunities, including live and online CME/CPD activities and reference material on topics in Movement Disorders.
- A reduction in fees charged for participation in the Society's educational programs. Among these are the annual International Congress of Parkinson's Disease and Movement Disorders, and regional programs, courses and workshops held each year.
- A print and searchable online membership directory listing mailing addresses, telephone and fax numbers, and e-mail addresses for members.
- A Members Only Section of the MDS Web site at www.movementdisorders.org, including a searchable Video Library, Case of the Month, teaching slide sets, and one-time login access to full text articles in the *Movement Disorders* Journal.
- A quarterly newsletter entitled, *Moving Along*, highlighting current news and views in the field of Movement Disorders.
- Participation in the election of international and Regional Section leadership representatives.

Membership Categories

Regular Membership - \$300 (USD) Annually Clinicians, other healthcare professionals, researchers and policy makers in Movement Disorders.

Junior Membership - \$100 (USD) Annually Residents, fellows, and those training in healthcare or scientific research. Status must be certified in writing by employer and submitted with payment.

Waived Dues Membership - \$10 (USD) Annually MDS provides a reduced dues program specifically designed to enable those on a lower income to join the Society.

For more information on MDS membership or to apply online, please go to www.movementdisorders.org/membership/.

Non-Members Applying for Membership

Non-Members will have the opportunity to apply for MDS membership at the International Congress for no additional fee with limited benefits through 2009, and full membership status, receiving the print journal, in January 2010. Membership applications will be provided to all non-member attendees onsite in their registration packet and must be returned to the MDS booth prior to the conclusion of the International Congress. No applications will be accepted by the Secretariat after June 11, 2009. *Only those paying the Non-Member registration fee will be eligible to apply for membership at no additional cost. This option is not available to those registering as a Junior or Allied Health participant or anyone who registered as part of a group.

2009-2010 will be another exciting year for MDS and we look forward to bringing you news of these and other new initiatives through the *Movement Disorders* journal, *Moving Along* newsletter and the MDS Web site.

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

MEMBERSHIP INFORMATION

MDS Affiliate Member Societies

The Movement Disorder Society invites other neurological organizations and groups specializing in Movement Disorders to become Affiliate Members of MDS to encourage research and enhance the education of physicians and the public about Movement Disorders.

As an Affiliate Member of MDS, your organization is entitled to:

- Announce MDS Affiliated Member status on your organization's letterhead and Web site.
- Receive "fast track" consideration of applications for sponsorship, support or endorsement of your organization's scientific meetings; as well as the ability to apply for a portion of \$30,000 set aside annually to support scientific meetings of Affiliate Member Societies.
- Receive MDS mailings on future International Congresses and educational programs, as well as the official newsletter of the MDS, *Moving Along*.
- Request complimentary meeting space for your organization during the International Congress.

No application fee is required to file for Affiliate Membership status. To become an MDS Affiliate Member please submit a formal letter of application for Affiliate Member status, providing the following:

- Recent annual report of the activities of your organization
- An organizational mailing list, to include e-mail addresses if available (please note that 15% of your practicing clinical scientist members and all members of your executive committee must be members of MDS)
- A copy of your group's Constitution and Bylaws

The letter of application and supporting documentation should be sent to:

MDS International Secretariat
555 E. Wells Street, Suite 1100
Milwaukee, Wisconsin 53202-3823 USA
Fax: +1 414-276-3349
E-mail to pfierst@movementdisorders.org

Current Affiliate Members

All-Russian Society of Neurologists

Alla B. Guekht, Vice President
Movement Disorders Division of the All-Russian Society of Neurologists
Russian State Medical Center
Prospect Mira 118A, Apt. 46
Moscow, 129164
Russia

Argentine Neurological Society Movement Disorders Group

Tomoko Arakaki, Secretary
Olaya 1341, 5B
Buenos Aires 1414
Argentina
Web site: www.sna.org.ar/?page_id=219

Austrian Parkinson's Disease Society

Werner Poewe, President
University Hospital Innsbruck
Dept. of Neurology
Anichstrasse 35
Innsbruck 6020
Austria

Brazilian Movement Disorders Group

Brazilian Academy of Neurology
Academia Brasileira de Neurologia
DC Transtornos do Movimento
Rua Claudio Rossi, 394
Jardim da Gloria
Sao Paulo, SP, CEP 01547-000
Brazil
Web site: www.abneuro.org

British and Irish Neurologists' Movement Disorders Group (BRING MD)

Carl E Clarke, Chair, British and Irish Neurologists' Movement Disorders Group
City Hospital
Department of Neurology
Dudley Road
Birmingham B18 7QH
United Kingdom

MEMBERSHIP INFORMATION

Dutch Movement Disorders Study Group

Marina DeKoning-Tijssen
University of Amsterdam
Jan Trouwstaraat 3 abcoude, 1391 TT
The Netherlands

Ecuador Movement Disorders Group

Fernando Alarcon
Hospital Eugenio Espejo
Department of Neurology
P.O. Box 17-07-9515
Quito
Ecuador

Italian Association for the Study of Movement Disorders (DISMOV-SIN)

Mario Zappia, President
Azienda Ospedaliera Universitaria
Policlinico G. Rodolico
Via Santa Sofia, 78- ed 20
Catania, 95123
Italy

Web site: www.dismovsin.it

Moroccan Neurological Society Movement Disorders Group

Chafiq Hicham, AMA President
Aswak Essalam, Apt. 23
2e Etage
Marrakesh 40 000
Morocco

Movement Disorder Society of Australia

Rick Stell, President
Sir Charles Gairdner Hospital
Nedlands, Perth
Western Australia

Sociedad Latinoamericana de Movimientos Anormales (SOLAMA)

Elena Mary Dieguez, President
Instituto De Neurologia
Joanico 3311
Montevideo, 11600
Uruguay

Swedish Movement Disorder Society (SWEMODIS)

Per Odin, Chairman
Department of Clinical Neuroscience
University of Gothenburg
Sahlgren University Hospital
SE-41345 Göteborg
Sweden

Web site: www.swemodis.se/english/


The Danish Movement Disorder Society (DANMODIS)

Lene Werdelin, Chairman
Department of Neurology
Bispebjerg Hospital
Bispebjerg Bakke 23
DK-2400 Copenhagen NV
Denmark

Web site: www.danmodis.dk

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

MAP OF PARIS



SATELLITE SYMPOSIUM

International Pediatric DBS Interest Group

Meeting

Thursday, June 11

8:00 - 9:00

Room 304/305

This meeting is for clinicians and investigators actively involved in pediatric DBS. It is a forum to meet colleagues and lay the foundation for future collaborative efforts to understand and establish the role for DBS in pediatrics.



INTERNATIONAL CONGRESS INFORMATION

Dates

Sunday, June 7 through Thursday, June 11

Venue

Le Palais Des Congrès de Paris
2 Place de la Porte Maillot
75017 Paris
France

Badges

All International Congress attendees will receive a name badge with their registration materials. Badges should be worn at all times as they will be used to control access into all International Congress sessions and activities. Individuals will be identified as follows:

Blue = Delegate
Yellow = Exhibitor
Purple = Press
Black = Staff

Registration Desk

Location: Level 2

Name badges, session tickets, and International Congress registration bags can be collected at the International Congress Registration Desk. The Registration Desk hours are as follows:

Saturday, June 6	14:00 – 20:00
Sunday, June 7	8:00 – 18:30
Monday, June 8	8:00 – 18:30
Tuesday, June 9	8:00 – 18:30
Wednesday, June 10	8:00 – 18:30
Thursday, June 11	8:00 – 16:30

Speaker Ready Room

Location: Room 202/203, Level 2

All speakers must check in at the Speaker Ready Room with presentation materials on the day prior to their scheduled presentation. Equipment is available to allow faculty to review their presentations. Audio/Visual personnel will be available for assistance. The Speaker Ready Room hours are as follows:

Saturday, June 6	16:00 – 20:00
Sunday, June 7	8:00 - 18:30
Monday, June 8	8:00 - 18:30
Tuesday, June 9	8:00 - 18:30
Wednesday, June 10	8:00 - 18:30
Thursday, June 11	8:00 - 16:00

Internet Café

Location: Exhibit area, Level 2

Internet access is available to meeting attendees in the Exhibit Area. Please limit your Internet use to 15 minutes to allow other attendees use of this service. The Internet café will be open during the following hours:

Sunday, June 7	18:30 – 19:30 (during the Welcome Reception)
Monday, June 8	10:00 – 16:00
Tuesday, June 9	10:00 – 16:00
Wednesday, June 10	10:00 – 16:00
Thursday, June 11	10:00 – 15:00

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

INTERNATIONAL CONGRESS INFORMATION

MDS Exhibit and Information Booth

Location: Level 2 (near registration)

The Movement Disorder Society (MDS) is an international society of healthcare professionals committed to research and patient care in the fields of Parkinson's disease and other disorders of movement and motor control.

Created not only to further the goals and objectives of MDS International, The Movement Disorder Society's Regional Sections, the Asian and Oceanian Section and European Section strive to increase the interest, education and participation of neurologists, Movement Disorder specialists, non-Movement Disorder specialists, trainees, allied health professionals and scientists in the Asian, Oceanian and European regions.

MDS supports and promotes a wide range of educational programming and other initiatives to advance scientific understanding and standards of care as they pertain to Movement Disorders. For this, MDS provides forums such as a high-ranking journal, scientific symposia and International Congresses.

Attendees are invited to take advantage of MDS member benefits by applying to the Society. Learn more about MDS initiatives and speak with a representative at the MDS Exhibit and Information Booth during the following hours:

Saturday, June 6	14:00 – 20:00
Sunday, June 7	8:00 – 18:30
Monday, June 8	8:00 – 18:30
Tuesday, June 9	8:00 – 18:30
Wednesday, June 10	8:00 – 18:30
Thursday, June 11	8:00 – 16:30

No Cameras

Cameras are not permitted in any 13th International Congress educational sessions or in the poster areas.

Press Room

Location: Room 212/213 (through Exhibit Area), Level 2

Members of the working media receive waived registration fees for the 13th International Congress. Journalists and writers should report to the Registration Desk with their credentials to register for the International Congress and wear their name badge for admittance into MDS sessions. The Press Room will be open during the following hours:

Monday, June 8	10:00 – 16:00
Tuesday, June 9	10:00 – 16:00
Wednesday, June 10	10:00 – 16:00
Thursday, June 11	10:00 – 15:00

Abstract Volume

All abstracts accepted for poster presentation have been published in an abstract supplement to the MDS Journal, *Movement Disorders*. Each delegate should have received one copy with their registration materials. MDS members will receive an additional copy with an upcoming MDS Journal issue.

Abstracts-On-CD-ROM

All abstracts published in the supplement to the MDS Journal are available via Abstracts-On-CD-ROM sponsored by MDS and supported by an unrestricted educational grant from Medtronic. To obtain a copy, please visit the Medtronic Booth #21 and exchange the Medtronic Delegate bag insert.

Continuing Medical Education

Please refer to page 28 for Continuing Medical Education information.

Evaluations

Please take time to complete the evaluation forms provided for each session you attend. Your input and comments are essential in planning future educational programs for MDS.

When completed, evaluations may be returned to your meeting room attendants, the Speaker Ready Room (Room 202/203, Level 2), or to the MDS Registration Desk.

INTERNATIONAL CONGRESS INFORMATION

Scientific Sessions

The 2009 Scientific Program incorporates Therapeutic Plenary Sessions, Corporate Therapeutic Symposia, Plenary and Parallel Sessions, Teaching Courses, Video Sessions, Skills Workshops, Controversies, Poster Sessions and Guided Poster Tours.

Tickets are required for admission into all Parallel Sessions, Teaching Courses, Video Sessions and Skills Workshops. There is no additional fee for tickets to these sessions. Please check the Onsite Registration Desk for availability of these tickets.

Abstract Poster Sessions

Delegate feedback from past International Congresses has indicated great interest in Poster Sessions. Poster Sessions are featured each day based upon the following schedule:

Poster Session I

Abstracts: Mo-1 – Mo-431

Monday, June 8

Poster Viewing: 9:00 - 18:00

Authors Present: 12:30 - 14:30

Location: Level 2

Poster Session II

Abstracts: Tu-1 – Tu-426

Tuesday, June 9

Poster Viewing: 9:00 - 18:00

Authors Present: 12:30 - 14:30

Location: Level 2

Poster Session III

Abstracts: We-1 – We-418

Wednesday, June 10

Poster Viewing: 9:00 - 18:00

Authors Present: 12:30 - 14:30

Location: Level 2

Poster Session IV

Abstracts: Th-1 – Th-420

Thursday, June 11

Poster Viewing: 9:00 - 17:30

Authors Present: 12:30 - 14:30

Location: Level 2

Guided Poster Tours

Attendees may sign up for the Guided Poster Tours beginning on Monday, June 8 from 8:00 to 18:30 at the MDS Booth located near Registration on Level 2.

The Guided Poster Tours will be led by members of the MDS faculty and the authors will be present to discuss the abstracts. There will be 12 Guided Poster Tours and each tour will feature abstracts on a specific topic.

There will be four tours per day from Monday, June 8 through Wednesday, June 10 which will run simultaneously. Tours will meet each day at 12:45 at the MDS Booth on Level 2.

Monday, June 8

Guided Poster Tour I

13:00 – 14:30

Ataxia

Drug-Induced Movement Disorders
Huntington's Disease and Chorea, Non-Huntington's
Neuroimaging

For a complete listing of abstracts in each tour, please see pages 62-63.

Tuesday, June 9

Guided Poster Tour II

13:00 – 14:30

Dementia in Movement Disorders

Neuropharmacology

Non-Motor Manifestations of Parkinsonism

Parkinson's Disease: Clinical Trials

For a complete listing of abstracts in each tour, please see pages 63-65.

Wednesday, June 10

Guided Poster Tour III

13:00 – 14:30

Basic Science

Electrophysiology

Genetics and Epidemiology

Surgical Therapies

For a complete listing of abstracts in each tour, please see pages 65-67.

*For a listing of tour leaders, please see the "Late Breaking Abstracts and Guided Poster Tour" handout in your delegate bag.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

SOCIAL EVENTS

Opening Ceremony and Welcome Reception

SUNDAY, JUNE 7

Opening Ceremony:

18:00-18:30 in the Grand Amphitheatre, Level 2

Welcome Reception:

18:30-19:30 in the Exhibit Area, Level 2

All International Congress attendees are warmly invited to meet friends and colleagues during the traditional International Congress Opening Ceremony on Sunday evening, June 7, at Le Palais des Congrès de Paris. A Welcome Reception, held in the Exhibit Area, will directly follow the Opening Ceremony. These events are open to all registered delegates. Guests are welcome to purchase a Welcome Reception pass for \$40 USD that will allow them admission to the Opening Ceremony and Welcome Reception. Please check at the registration desk for availability.

Video Olympics

WEDNESDAY, JUNE 10

Reception with hors d'oeuvres and drinks:

19:30-20:00 in the Hall Maillot, Level 2

Video Olympics:

20:00-23:00 in the Grand Amphitheatre, Level 2

Please join Masters of Ceremony Anthony Lang and Kapil Sethi on Wednesday evening, June 10, as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world, and experts will consider each case and engage the audience in discussion. The final diagnosis will then be provided by the case presenter. The goal of this session is for attendees to learn from a series of unusual, very interesting patients and see how senior experts approach these types off challenging cases.

The experts are:

Kailash Bhatia, London, United Kingdom

Susan Bressman, New York, NY, United States

Oscar Gershanik, Buenos Aires, Argentina

Andrew Lees, London, United Kingdom

This event is open to all registered delegates.



www.movementdisorders.org

Connecting members with the latest research, education and developments in Movement Disorders globally

Special Features



Case of the Month –
Share your challenging cases with colleagues



Curbside Consult –
Join the discussion about unique cases in our forum or submit your own



Editor's Choice –
Read and listen to a podcast review of a featured Journal article



Education Portal –
Learn about CME and professional development opportunities in Movement Disorders

More Highlights

- Movement Disorders Journal access
- Video Library
- Moving Along newsletter
- EBM reviews and position papers
- Links to other resources (PubMed, funding agencies and organizations)
- Online and Mobile Membership Directories

How you can get involved

- E-mail your ideas, suggestions or comments to info@movementdisorders.org
- Bookmark the Web site and visit daily
- Tell colleagues about the Web site
- Submit feedback about the Web site from the home page
- Join The Movement Disorder Society group on Facebook®




PALAIS FLOOR PLAN



Le Palais des Congrès de Paris

NIVEAU 2 HALL MAILLOT LEVEL 2 HALL MAILLOT



Niveau
Level 2

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

PALAIS FLOOR PLAN




Le Palais des Congrès de Paris


NIVEAU 3 HALLS HAVANE & BORDEAUX

LEVEL 3 HALLS HAVANE & BORDEAUX

International
Congress Information



TERNES



Niveau
Level 3

ACCES / ACCESS	
	Ascenseur / Lift
	Monte-chARGE / Goods lift
	Toilettes / Restrooms
	Escaliers / Stairs
	Escalator

AWARDS INFORMATION

HONORARY MEMBERSHIP AWARDS

The Honorary Membership Awards recognize individuals who have made extraordinary contributions to the field of Movement Disorders or otherwise to The Movement Disorder Society.

The 2009 Recipients are:



Yoshikuni Mizuno, MD
Tokyo, Japan



Ira Shoulson, MD
Rochester, NY,
USA

Sunday, June 7 Opening Ceremony

17:45 to 18:30

Location: Grand Amphitheatre,
Level 2

PRESIDENT'S DISTINGUISHED SERVICE AWARD

The President's Distinguished Service Award is given in recognition of long and distinguished service to The Movement Disorder Society. The recipient may only receive this award once in their lifetime.

Sunday, June 7 Opening Ceremony

17:45 to 18:30

Location: Grand Amphitheatre, Level 2

STANLEY FAHN AWARD LECTURE

Tuesday, June 9 as part of the Presidential Lecture Plenary Session III

9:00 to 9:30

Location: Grand Amphitheatre, Level 2

The **Stanley Fahn Award Lecture** was created to recognize an outstanding scholar and role-model clinician in the field of Movement Disorders. The selected lecturer must show evidence of exceptional contributions which have resulted in better understanding of the cause, diagnosis, or treatment of Movement Disorders, and have translated into meaningful improvements in the standard of clinical practice. The selected lecturer must demonstrate evidence of consistent dedication to Movement Disorders education and research.

2009 Stanley Fahn Lecturer:

Christopher G. Goetz, MD

Jean-Martin Charcot Movement Disorders: Historical Legacies to the 21st Century



**Christopher G.
Goetz, MD**

Christopher G. Goetz, M.D. is Professor of the Department of Neurological Sciences and Pharmacology at Rush University

Medical Center in Chicago, IL and serves as Director of the Movement Disorders Program. The Movement Disorders Center is a Parkinson's Disease Foundation Center Research Center and a Huntington's Disease Society of America Center of Excellence. Dr. Goetz is a senior Fulbright Scholar and worked for two years at the *College de France* in Paris. During this period (1980-1982), he began his studies of Jean-Martin Charcot and the French Neurological School of the 19th century. As part of this effort, he has published several articles, two books on Charcot (1987, 1995), and has been the recipient of the McHenry Award of the American Academy of Neurology. He is the past History Section Editor of the *Archives of Neurology* journal and is an Advisory Editorial Board Member of the *Journal of the History of the Neurosciences*.

In addition to his historical research, Dr. Goetz's major interest is the pharmacology of movement disorders. He is particularly interested in non-motor aspects of movement disorders, including specifically, hallucinations, cognitive decline, and depression. Further research efforts have focused on scale development for evaluating movement disorders, and he has led The Movement Disorder Society Task Force to develop the MDS-UPDRS. He has also led pharmacologic and surgical efforts to treat movement disorders, including gene therapies.

Dr. Goetz has served on several national and international advisory boards, including the Tourette Syndrome Association Scientific Advisory Board and Dystonia Medical Research Foundation Advisory Board. He is a reviewer for several journals and is a member of The Movement Disorder Society, the American Neurological Association, the American Academy of Neurology, The American Otoler Society, and the French Neurological Society. Dr. Goetz has published over 350 peer-reviewed articles, and over 200 book chapters in the field. He has also

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

AWARDS INFORMATION

published and co-authored fourteen books and monographs. He is one of two co-Editors-in-Chief of the *Movement Disorders* journal, and former Editor-in-Chief of *Clinical Neuropharmacology*.

C. DAVID MARSDEN AWARD LECTURE

Tuesday, June 9 as part of the Presidential Lecture Plenary Session III

10:00 – 10:30

Location: Grand Amphitheatre, Level 2

The **C. David Marsden Lecture** was created to recognize an outstanding scholar and inspiring neuroscientist in the field of Movement Disorders. The selected lecturer must show evidence of exceptional contributions which have resulted in better understanding of the neurobiology of Movement Disorders, and have translated into tangible improvements in clinical therapy and/or providing insight into normal brain function in the control of movement. The selected lecturer must demonstrate evidence of consistent dedication to Movement Disorder education and research.

2009 C. David Marsden Lecturer:

Richard I. Morimoto, PhD

The Stress of Misfolded Proteins in Aging and Neurodegenerative Disease

Richard I. Morimoto is the Bill and Gayle Cook Professor of Biology, Professor of Biochemistry, Molecular Biology and Cell Biology, and Director of the Rice Institute for Biomedical Research at Northwestern University. He holds a B.S. from the University of Illinois at Chicago, received a Ph.D. in Molecular Biology from The University of Chicago, and was a postdoctoral fellow in the Department of Biochemistry and Molecular Biology at Harvard University in Cambridge, MA. Morimoto joined the faculty of the Department of Biochemistry, Molecular Biology, and Cell Biology at Northwestern University in Evanston, Ill. where he has served as Chair of the Department of Biochemistry, Molecular Biology, and Cell Biology and Dean of the Graduate School and Associate Provost of Graduate Education.

Morimoto is recognized for research on the regulation of the heat shock stress response and the function



**Richard I.
Morimoto, PhD**

of molecular chaperones. His work examines how the health of the proteome is maintained by protein quality control and the proteostasis network in the face of environmental and physiological stress, and ageing. The development of model systems using *C. elegans* and mammalian cell culture models for the regulated expression of disease-associated proteins that misfold led to the identification of a gene network that senses damaged proteins and prevents proteotoxicity. These studies have shown that the chronic expression of aggregation-prone proteins interferes with the folding and stability of other metastable proteins in the cell, which, over time, leads to a further amplification of proteotoxicity, disruption of diverse signaling pathways, cellular dysfunction, and organismal failure. These events can be reversed by enhancing cytoprotective stress responses and regulation of the insulin signaling pathway that controls lifespan. Heat shock factor, Hsf1, has emerged as the major stress sensor that responds to direct regulation by the NAD-dependent sirtuin, SIRT1, which itself is controlled by caloric restriction and ageing. In metazoans, the heat shock stress response is orchestrated by two thermosensory neurons that sense temperature and regulate the expression of heat shock genes in all other somatic tissues. This cell non-autonomous control of chaperone expression reveals the importance of a coordinated cellular stress response, and the molecular events that protect the proteome during metabolic flux to ensure healthspan of the cell and lifespan of the organism.

JUNIOR AWARDS

Two Junior Award recipients have been selected based on their significant contribution to clinical and basic science research in the field of Movement Disorders. One award will be presented for excellence in clinical research, and another for excellence in basic science research.

Tuesday, June 9 as part of the Presidential Lecture Plenary Session III

9:30 to 10:00

Location: Grand Amphitheatre, Level 2

Chairs: Anthony E. Lang, Andrew J. Lees,
Philip D. Thompson

AWARDS INFORMATION

Clinical Research

Helen Ling

London, United Kingdom

Diagnostic accuracy in 18 cases of pathologically confirmed corticobasal degeneration

H. Ling, S. O'Sullivan, D. Paviour, L. Massey, J. Holton, T. Revesz and A. Lees.

Objective: To assess the diagnostic accuracy of CBD in hospital practice.

Background: The pathological findings of corticobasal degeneration (CBD) may be associated with several distinct clinical syndromes and it is also acknowledged that 'look alikes' exist (corticobasal syndrome).

Methods: We reviewed cases in the Queen Square Brain Bank (QSB) between 1990 and 2008 with either a clinical or pathological diagnosis of CBD.

Results: Of 18 CBD cases, only 5 had been diagnosed correctly in life and 3 of these had received a different earlier diagnosis(sensitivity=27.8%). These cases had the classical clinical presentation: myoclonus(5), alien limb phenomena(2) and ideomotor apraxia(2). Moderate initial L-Dopa response was observed in 2 cases and transient L-Dopa-induced dyskinesias were noted in 1 case. The clinical diagnoses in the 13 false-negative cases included 9 progressive supranuclear palsy(PSP), 1 frontotemporal dementia(FTD), 1 progressive non-fluent aphasia(PNFA), 1 atypical Parkinson's disease(PD) and 1 undiagnosed. Common clinical features in the 9 cases diagnosed as PSP were falls in the first year(7), frontal lobe signs(4), pseudobulbar palsy(3) and apraxia of eyelid opening(3). Only 3 cases had slowing of vertical saccade or gaze palsy. One case had history of falls backwards. Symmetrical parkinsonism(5) was not uncommon in CBD cases diagnosed as PSP in life. Of 16 cases diagnosed with CBD in life, only 5 had CBD, with a positive predictive value(PPV) of 31.3%. Eleven false-positive cases had other pathological conditions(see table). Five out of 169 pathologically proven PSP cases had been diagnosed as CBD in life. In contrast to CBD, the sensitivities and PPV were 73.4%(124 out of 169) and 84.4%(124 out of 147) respectively for the 169 cases diagnosed as

PSP in the QSB. The PPV of a clinical diagnosis of multiple system atrophy(MSA) from a previous QSB study was 85.7%(30 out of 35).

Pathological Diagnoses of Cases Clinically Diagnosed as CBD

Pathological Diagnosis	Total Number of Cases
CBD	5
PSP	5
PD	3
Alzheimer's Disease	1
FTLD-TDP with MND	1
Dementia Lacking Distinct Histology	1

Conclusions: The diagnostic accuracy of CBD presenting to movement disorder specialists is much lower than for PSP and MSA. Errors of commission and omission occur in relation to the distinction between PSP and CBD. The scarcity of slowing of vertical saccade and gaze palsy in CBD even in terminal stages highlights that saccadic eye movements may prove to be particularly informative in the differential diagnosis between CBD and PSP.

Basic Science

Carlos Juri

Pamplona, Spain

Progression of MPTP induced Parkinsonism in monkeys. A multiligand PET study

Carlos Juri, MD, Javier Blesa, BSc, Elena Iglesias, BSc, MariCruz Rodriguez-Oroz, MD, PhD, Jose A. Obeso, MD, PhD, Maria Collantes, PhD, Elena Prieto, BEng and Ivan Penuelas, MD, PhD.

Objective: To describe changes in dopaminergic radioligand and 18F- Fluorodeoxyglucose (FDG) uptake by positron emission tomography (PET) in a progressive model of MPTP induced parkinsonism in monkeys.


Background: Parkinson's disease (PD) is characterised by dopaminergic depletion associated with metabolic and monoaminergic compensatory changes during disease evolution. There is a lack of in vivo information about such mechanisms in a progressive MPTP monkey model.

AWARDS INFORMATION

Methods: MPTP was chronically (every 2 weeks over 6 months) administered to 20 monkeys (*maccaca fascicularis*). PET studies using monoaminergic (6-fluoro-(18F)-L-3,4-dihydroxyphenylalanine (FDOPA) and (11C) Dihydrotetrabenazine (DTBZ)) and metabolic (FDG) radiotracers were conducted in different stages of evolution (basal, asymptomatic, recovered, mild and severe). The analysis based on Regions of interest was done over normalized parametric images in FDOPA and DTBZ PET and SPM2 analysis was also conducted for three radiotracers.

Results: The evolution of MPTP induced parkinsonism was associated with a progressive dopaminergic striatal depletion from 30% in the asymptomatic stage to 80%-90% depletion observed in the severe stage. DTBZ radiotracer was more sensitive to detect the degree of dopaminergic depletion as compared to FDOPA PET. The metabolic pattern in each state showed a progressive cortical hypo-metabolism in the different stages evaluated, more intense in the severely affected group. Contrary to PET findings in PD patients, no striatal hyper-metabolism was evident in any MPTP group.

Conclusions: MPTP induced progressive dopaminergic depletion when administered slowly and chronically. The dopaminergic and metabolic changes observed were distinctive for each motor stage. These findings validate the usefulness of *in vivo* PET imaging in MPTP induced parkinsonism for monitoring disease progression and putative neuroprotective therapies.



AWARDS INFORMATION

2009 Travel Grants

Annu Aggarwal
Adelaide, Australia
Roy Alcalay
New York, NY, USA
Phalguni Alladi
Bangalore, India
Erika Augustine
Rochester, NY, USA
Ruksana Azhu Valappil
Sunnyvale, CA, USA
Sheila Baez-Torres
Weson, FL, USA
Brandon Barton
Chicago, IL, USA
Cynthia Bedeschi Ferrari
São Paulo, Brazil
Magdalena Boczarska-Jedynak
Katowice, Poland
Marilyn Borromeo-Wesner
Kirkland, WA, USA
Tamine Capato
São Paulo, Brazil
Victoria Chang
Providence, RI, USA
Daniel Ciampi De Andrade
São Paulo, Brazil
Jacqueline Cristini
Edison, NJ, USA
Andres Deik
New York, NY, USA
Nancy Diaz
New York, NY, USA
Francisco J. Diaz-Corrales
Seville, Spain
Burcu Dursun
Istanbul, Turkey
Behzad Elahi
Toronto, ON, Canada
Michael Eller
Glenhuntley, Australia
Cordelia Erickson-Davis
New York, NY, USA
Mary Feldman
Cleveland, OH, USA
Andre Felicio
São Paulo, Brazil
Ondrej Fiala
Prague, Czech Republic

Thomas Foki
Vienna, Austria
Marie-Pierre Fournier-Gosselin
Toronto, ON, Canada
Brook Galna
Parkville, Australia
Hardeep Gambhir
New Delhi, India
Mohan Ganesan
Bangalore, India
Rose Celineau-Kattner
Houston, TX, USA
Brooke Gerton
Seattle, WA, USA
Sara Gombash
Cincinnati, OH, USA
Jifeng Guo
Changsha, China
Elizabeth Haberfeld
New York, NY, USA
Priya Jagota
Bangkok, Thailand
Sriranjini Jaideep
Bangalore, India
Samay Jain
Pittsburgh, PA, USA
Thomas Joseph
Thiruvananthapuram, India
Thomas Jubault
Montreal, QC, Canada
Michael Kalaitzakis
London, United Kingdom
Samantha Kerr
Johannesburg, South Africa
Norbert Kovacs
Pecs, Hungary
Ramon Kruschewsky
Salvador, Brazil
Stephen Ku
San Francisco, CA, USA
Hrishikesh Kumar
London, ON, Canada
Rima Kumari
New Delhi, India
Jee-Young Lee
Seoul, South Korea
Jongil Lim
Temple, TX, USA
Wey-Yil Lin
Taipei, Taiwan

Chin-Hsien Lin
Taipei, Taiwan
Katja Lohmann
Lübeck, Germany
Praween Lolekha
Bangkok, Thailand
Bram Meeus
Antwerp, Belgium
Prachi Mehta
Sydney, Australia
Marcello Moccia
Naples, Italy
Faruq Mohammed
New Delhi, India
Inder Singh Mudila
New Delhi, India
Martin Nevrly
Olomouc, Czech Republic
Khuen Yen Ng
Randwick, Australia
Gisele Oliveira
Fortaleza, Brazil
Jennifer O'Malley
Cincinnati, OH, USA
Fernando Padovan-Neto
São Paulo, Brazil
Toni Pearson
New York, NY, USA
Amie Peterson
Portland, OR, USA
Rizaldy Pinzon
Yogyakarta, Indonesia
Emily Plowman-Prine
Gainesville, FL, USA
Marios Politis
London, United Kingdom
Murtuza Hussain Qureshi
Hyderabad, India
Mayela Rodriguez
Mexico City, Mexico
Michael Rotstein
Tenafly, NJ, USA
Lindsay Rubenstein
Pittsford, NY, USA
Jason Rupp
Indianapolis, IN, USA
Mariano Saborido
Buenos Aires, Argentina
Taeko Sasai
Tokyo, Japan
Rodolfo Savica
Rochester, MN, USA

Katharina Schnopfhangen
Vienna, Austria

Cordelia Schwarz
New York, NY, USA

Katherine Schweitzer
Jacksonville, FL, USA

Marianna Selikhova
London, United Kingdom

Aasef Shaikh
Baltimore, MD, USA

Lu Shen
Changsha, China

Ludy Shih
Boston, MA, USA

Rita Simoes
Amadora, Portugal

Vladana Spica
Belgrade, Serbia

Anne Spieles-Engemann
Cincinnati, OH, USA

Mariana Spitz
Rio de Janeiro, Brazil

Vimal Stanislaus
Sydney, Australia

Diederick Stoffers
San Diego, CA, USA

Roy Stroud
Winston Salem, NC, USA

Brian Terpstra
Cincinnati, OH, USA

Emma Thornton
Adelaide, Australia

Michelle Troche
Gainesville, FL, USA

Giorgia Tropini
Vancouver, BC, Canada

Bayasgalan Tserensodnom
Ulaanbaatar, Mongolia

Travis Turner
Charleston, SC, USA

Simone Van de Loo
Frankfurt, Germany

Hana Vranova
Olomouc, Czech Republic

Rebecca Wolf-Gilbert
New York, NY, USA

Min Ney Wong
Brisbane, Australia

Toby Yaltho
Houston, TX, USA

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

CME INFORMATION

Purpose

The purpose of the MDS International Congress is to offer a forum for clinical and basic discussion on a variety of Movement Disorder topics, including presentations of current research and available treatments.

Learning Objectives

Through state-of-the-art lectures, hot topic reviews, controversy debates, Teaching Courses, Skills Workshops and Video Sessions, participants will be better able to:

- Describe the pathophysiology and neurobiology of Parkinson's disease and other Movement Disorders;
- Discuss the diagnostic approaches and tools available for Parkinson's disease and other Movement Disorders;
- Discuss the pharmacological and non-pharmacological treatment options available for Parkinson's disease and other Movement Disorders.

Continuing Medical Education

The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Movement Disorder Society designates this educational activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

The target audience of the 13th International Congress of Parkinson's Disease and Movement Disorders includes clinicians, researchers, post-doctoral fellows, medical residents, medical students and other healthcare professionals with an interest in the current research and approaches for the diagnosis and treatment of Movement Disorders.

Financial Disclosure

It is the policy of The Movement Disorder Society (MDS) to ensure balance, independence, objectivity, and scientific rigor in all MDS sponsored educational activities. All persons in control of content in any MDS sponsored activity are required to disclose to MDS and the activity audience all financial relationships with any commercial interest. Such persons include, but are not limited to: planning committee members, faculty, medical writers, joint sponsor staff (when applicable), co sponsor staff (when applicable) and MDS staff.

Relationships are defined as financial relationships in any amount occurring within the past 12 months from the signing date of the attestation. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the field of Movement Disorders. This disclosure will be provided to all participants prior to the beginning of the CME activity. Individuals must inform MDS of any changes in financial relationships that occur between the signing date of the attestation and the date of the activity. For an individual with no financial relationships to disclose, the learners must be informed that no financial relationships exist.

The intent of this policy is not to prevent a speaker with a conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified and resolved prior to the activity, so that there is no commercial bias present in the presentation. Failure by any faculty or planning committee member to disclose all such relationships will result in their inability to participate in the CME activity.

Faculty financial disclosure information will be provided to participants onsite in Paris.

CME INFORMATION

Claiming CME Credit

Physicians may claim their CME Certificates from their home or office upon the completion of the MDS 13th International Congress.


Visit www.movementdisorders.org/congress/congress09/cme after June 10 and use your Registration Confirmation Number (found in the upper right of your registration confirmation form) to log in and claim your credits. You will be able to print or save a PDF of your credit award from your own computer.

GO GLOBAL!

Join the MDS group on Facebook®

ON THE ROAD?

Connect with colleagues at movementdisorders.mobi



FP Pharmaceutical is pleased to be a supporter of the 13th International Congress of Parkinson's Disease and Movement Disorders
Paris, France
June 7-11, 2009

FP Pharmaceutical Corp.

1-3-40 Nishiotsuka, Matsubara, Osaka, Japan
URL:<http://www.fp-pharm.co.jp>

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

PROGRAM-AT-A-GLANCE

Time	June 7 (Sunday)	June 8 (Monday)	June 9 (Tuesday)	June 10 (Wednesday)	June 11 (Thursday)
8:00	Committee Meetings	Committee Meetings	Committee Meetings	Committee Meetings	MDS Annual Business Meeting - Open to all delegates
8:30					
9:00	Therapeutic Plenary Session I 9:00-10:30	Plenary Session V 9:00-10:30	Plenary Session VII 9:00-10:30	Plenary Session IX 9:00-10:30	Parallel Sessions 9:00-10:30
9:30					
10:00					
10:30	Break	Break	Break	Break	Break
11:00	Therapeutic Plenary Session II 11:00-12:30	Plenary Session VI 11:00-12:30	Plenary Session VIII 11:00-12:30	Plenary Session X 11:00-12:30	Video Sessions and Skills Workshops 11:00-12:30
11:30					
12:00					
12:30	Break	Break and Posters Guided Poster Tours	AOS General Assembly Meeting 12:30-13:30	Break and Posters Guided Poster Tours	Break and Posters Guided Poster Tours
13:00					
13:30					
14:00	Therapeutic Plenary Session III 14:00-15:30	Corporate Therapeutic Symposia 14:30-15:30	Corporate Therapeutic Symposia 14:30-15:30	Corporate Therapeutic Symposia 14:30-15:30	Corporate Therapeutic Symposium 14:15-15:45
14:30					
15:00					
15:30	Break	Break	Break	Break	Break
16:00	Therapeutic Plenary Session IV 16:00-17:30	Parallel Sessions 16:00-17:30	Parallel Sessions 16:00-17:30	Parallel Sessions 16:00-17:30	Plenary XI (Controversies) 16:00-18:00
16:30					
17:00					
17:30		Break	Break	Break	
18:00	Opening Ceremony and Welcome Reception 18:00-19:30	Video Sessions and Skills Workshops 18:00-19:30	Video Sessions and Skills Workshops 18:00-19:30	Video Sessions and Skills Workshops 18:00-19:30	END
18:30					
19:00					
19:30				Video Olympics 19:30-23:00	
20:00					
20:30					
21:00					
21:30					

Daily Schedule

MDS 13TH INTERNATIONAL CONGRESS SESSION DEFINITIONS

Controversies:

This Plenary Session is designed to involve all International Congress attendees. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected "hot" topics will be open for debate among the panelists.

Corporate Therapeutic Symposia:

These company-based informational sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

Please see pages 48-49 for more information.

Guided Poster Tours:

Guided Poster Tours will give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories.

Please see page 19 for more information.

Parallel Sessions:

These concurrent sessions provide an in-depth report of the latest research findings, state-of-the-art treatment options, as well as a discussion of future strategies. Parallel sessions will have evidence-based components and incorporate the "hot" issues in Parkinson's disease and other Movement Disorders.

Plenary Sessions:

These sessions provide a broad overview of the latest clinical and basic science research findings and state-of-the-art information.

Poster Sessions:

Poster sessions give each delegate an opportunity to view their colleagues' posters on the most current research in the field of Movement Disorders. Authors will be present for two hours each day to explain their work and answer questions.

Skills Workshops:

These clinic-based training sessions provide an educational illustration of clinical techniques and treatment procedures through demonstrations utilizing patient videotapes and proper equipment to further develop practitioners' skills and knowledge within the field of treatment of Movement Disorders.

Teaching Courses:

These educational programs provide up-to-date information focused on a single topic. The sessions highlight both clinical and basic sciences of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides. In addition, these programs provide ample time for questions and a discussion period at the conclusion of the presentations.

Therapeutic Plenary Sessions:

These sessions provide the latest information regarding the scientific and clinical evidence supporting treatment options for Parkinson's disease and other Movement Disorders. Therapeutic Plenary Sessions are planned by the Congress Scientific Program Committee and offer Continuing Medical Education credits.

Video Sessions:

Designed to provide a broad overview of related Movement Disorders, the video sessions will focus on the phenomenology covering the many different kinds of Movement Disorders affecting the population today.



= Ticket required for entry. Please check the Registration Desk for ticket availability.

There is no extra charge for session tickets.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

SCIENTIFIC PROGRAM

SUNDAY, JUNE 07

1101 Therapeutic Plenary I:

Early management of Parkinson's disease

9:00 – 11:00

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Anthony E. Lang
Toronto, ON, Canada

Yves Agid
Paris, France

9:00 When?
Regina Katzenschlager
Vienna, Austria

9:30 How?
Stanley Fahn
New York, NY, USA

Panel: Yves Agid
Paris, France
Stanley Fahn
New York, NY, USA
Regina Katzenschlager
Vienna, Austria

Anthony E. Lang
Toronto, ON, Canada
C. Warren Olanow
New York, NY, USA
Cristina Sampaio
Lisboa, Portugal

1102 Therapeutic Plenary II:

Management of motor complications: Medical and surgical

11:00 – 12:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Andres M. Lozano
Toronto, ON, Canada
Pierre Pollak
Grenoble, France

11:00 Pharmacological
Heinz Reichmann
Dresden, Germany

11:30 Surgical
Patricia Limousin-Dowsey
London, United Kingdom

Panel: Angelo Antonini
Monza, Italy
Alim Benabid
Meylan, France
Erwan Bezard
Bordeaux, France
Patricia Limousin-Dowsey
London, United Kingdom

1102 Therapeutic Plenary II, continued

Andres M. Lozano
Toronto, ON, Canada

Pierre Pollak
Grenoble, France
Heinz Reichmann
Dresden, Germany

1103 Therapeutic Plenary III:

Management of neuropsychiatric non-motor aspects

14:00 – 15:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Paolo Barone
Napoli, Italy
Marcelo Merello
Buenos Aires, Argentina

14:00 Disease-related psychiatric and behavioral abnormalities

Anette Schrag
London, United Kingdom

14:30 Cognitive
David John Burn
Newcastle Upon Tyne, United Kingdom

Panel: Yves Agid
Paris, France
Paolo Barone
Napoli, Italy

David John Burn
Newcastle Upon Tyne, United Kingdom
Jaime Kulisevsky
Barcelona, Spain
Marcelo Merello

Buenos Aires, Argentina
Anette Schrag
London, United Kingdom

1104 Therapeutic Plenary IV:

Hyperkinetic disorders

16:00 – 17:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Alfredo Berardelli
Roma, Italy
Niall P. Quinn
London, United Kingdom

16:00 Dystonia
Marie Vidailhet
Paris, France

16:30 Tremor
Rodger J. Elble
Springfield, IL, USA

SCIENTIFIC PROGRAM

1104 Therapeutic Plenary IV, continued

Panel: Alfredo Berardelli
Roma, Italy
 Rodger J. Elble
Springfield, IL, USA
 Murat Emre
Istanbul, Turkey
 Niall P. Quinn
London, United Kingdom
 Louis CS Tan
Singapore
 Marie Vidailhet
Paris, France

Opening Ceremony

18:00 – 18:30

Grand Amphitheatre—Please use entrances on Level 2

Welcome Reception

18:30 – 19:30

Exhibit Area, Level 2

MONDAY, JUNE 08

2101 Plenary Session I:



The secrets of the basal ganglia

9:00 – 10:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Wolfgang H. Oertel
Marburg, Germany
 John C. Rothwell
London, United Kingdom

9:00 **Linking anatomy and physiology: Historical contributions of neurosurgery**

Andres M. Lozano
Toronto, ON, Canada

9:30 **Functional neuroanatomy of the basal ganglia: Current view**

J. Paul Bolam
Oxford, United Kingdom

10:00 **Lessons from cellular electrophysiology on the functional anatomy of the basal ganglia**

Paolo Calabresi
Perugia, Italy

2102 Plenary Session II:

What's new in Parkinson's disease therapeutics

11:00 – 12:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Stanley Fahn
New York, NY, USA
 Olivier Rascol
Toulouse, France

11:00 **The major clinical trials of the past year**

C. Warren Olanow
New York, NY, USA

11:45 **Promising new therapies in development**

Werner Poewe
Innsbruck, Austria

Poster Presentations

Poster Session 1

Abstracts: Mo-1 – Mo-431

Monday, June 8

Poster Viewing: 9:00 - 18:00

Authors Present: 12:30 - 14:30

Location: Level 2



Guided Poster Tours

Guided Poster Tour I

13:00 – 14:30

Location: All Guided Poster Tours will meet at the MDS Booth, Level 2 near Registration.

Tickets may be reserved at the MDS Booth beginning Monday, June 8 at 9:00. A ticket is required for participation in each tour.

Ataxia

Drug-Induced Movement Disorders
 Huntington's Disease and Chorea,
 Non-Huntington's
 Neuroimaging

For a complete listing of abstracts in each tour, please see pages 62-63.

Corporate Therapeutic Symposia

14:30 – 15:30

Please see page 48-49 for more information.



= Ticket required for entry. Please check the Registration Desk for ticket availability.

There is no extra charge for session tickets.

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

SCIENTIFIC PROGRAM

2201	Parallel Session:		2203	Parallel Session:	
	Gait and balance impairment in movement disorders: From laboratory to clinic			From bench to bedside: What's new in hyperkinetic disorders	
	16:00 – 17:30			16:00 – 17:30	
Chairs:	Location: Bleu Amphitheatre, Level 2 Nir Giladi <i>Tel Aviv, Israel</i>		Chairs:	Location: Room Maillot, Level 2 Massimo Pandolfo <i>Brussels, Belgium</i>	
	Evzen Ruzicka <i>Prague, Czech Republic</i>			Eduardo Tolosa <i>Barcelona, Spain</i>	
16:00	Gait and balance impairment are cognitive, not motor disorders Bastiaan R. Bloem <i>Nijmegen, Netherlands</i>		16:00	Neurocanthocytosis Adrian Danek <i>Munich, Germany</i>	
16:30	New pathophysiological insights from unexpected techniques Fay B. Horak <i>Portland, OR, USA</i>		16:30	Ataxias Massimo Pandolfo <i>Brussels, Belgium</i>	
17:00	Man on the moon: Current and future management of gait and balance impairment Nir Giladi <i>Tel Aviv, Israel</i>		17:00	Paroxysmal dyskinesias Holger Lerche <i>Ulm, Germany</i>	
2202	Parallel Session:		2205	Parallel Session:	
	Basal ganglia oscillations as a window on the pathophysiology of movement disorders			Cognitive impairment in Parkinson's disease	
	16:00 – 17:30			16:00 – 17:30	
Chairs:	Location: Bordeaux Amphitheatre, Level 3 Peter Brown <i>London, United Kingdom</i>		Chairs:	Location: Grand Amphitheatre, Level 2 Bruno Dubois <i>Paris, France</i>	
	Alberto Priori <i>Milano, Italy</i>			Murat Emre <i>Istanbul, Turkey</i>	
16:00	Basal ganglia oscillations: What do they mean? Andrea A. Kuehn <i>Berlin, Germany</i>		16:00	Clinical spectrum of cognitive impairment in Parkinson's disease Jaime Kulisevsky <i>Barcelona, Spain</i>	
16:30	Controversy: The bad boy of Parkinson's disease: Low frequencies or beta rhythm? Alberto Priori <i>Milano, Italy</i>		16:30	Anatomical and molecular pathology underlying the cognitive impairment in Parkinson's disease Glenda M. Halliday <i>Randwick, Australia</i>	
17:00	Oscillations, dyskinesias and behavior Maria C. Rodriguez-Oroz <i>Pamplona, Spain</i>		17:00	Imaging in cognitive impairment: Lessons from other forms of dementia Nick C. Fox <i>London, United Kingdom</i>	



= Ticket required for entry. Please check the Registration Desk for ticket availability.
There is no extra charge for session tickets.

SCIENTIFIC PROGRAM

2306 Teaching Course:



The genetics of movement disorders

16:00 – 17:30

Location: Room 242AB, Level 2

Chairs: Christine Klein

Lübeck, Germany

Andrew B. Singleton

Bethesda, MD, USA

16:00 Basic concepts of genetics in movement disorders

Christine Klein

Lübeck, Germany

16:30 Tools and techniques

Henry L. Paulson

Ann Arbor, MI, USA

17:00 Neurogenetics in clinical practice

Oksana Suchowersky

Calgary, AB, Canada

2307 Teaching Course:



Movement disorders emergencies

16:00 – 17:30

Location: Room 252AB, Level 2

Chairs: Alain Destee

Lille, France

Steven Frucht

New York, NY, USA

16:00 Neuroleptic associated emergencies, serotonin syndrome and malignant catatonia

Timothy Lynch

Dublin, Ireland

16:30 Acute hyperkinetic movement disorders

Steven Frucht

New York, NY, USA

17:00 Post-operative emergencies in Movement Disorders

Michael S. Okun

Gainesville, FL, USA

2401 Skills Workshop:



How to prepare a video of a movement disorder patient and how to train patients to take videos that are useful

18:00 – 19:30

Location: Room 342AB, Level 3

Janis M. Miyasaki

Toronto, ON, Canada

Carol Brown Moskowitz

New York, NY, USA

2402 Skills Workshop:



Practical management of DBS side effects

18:00 – 19:30

Location: Room 252AB, Level 2

Boulos-Paul W. Bejjani

Byblos, Lebanon

Joachim K. Krauss

Hannover, Germany

Elena Moro

Toronto, ON, Canada

2503 Video Session:



Psychogenic movement disorders

18:00 – 19:30

Location: Bleu Amphitheatre, Level 2

Victor Fung

Westmead, Australia

David E. Riley

Cleveland Heights, OH, USA

2504 Video Session:



Primary and secondary dystonias

18:00 – 19:30

Location: Bordeaux Amphitheatre, Level 3

Kailash P. Bhatia

London, United Kingdom

Mohit H. Bhatt

Mumbai, India

2505 Video Session:



Unusual hyperkinetic movement disorders

18:00 – 19:30

Location: Grand Amphitheatre, Level 2

Niall P. Quinn

London, United Kingdom

Kathleen M. Shannon

Chicago, IL, USA

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

SCIENTIFIC PROGRAM

TUESDAY, JUNE 09

3101 Plenary Session III:

Presidential Lectures

9:00 – 10:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Anthony E. Lang, MDS President
Toronto, ON, Canada

Andrew J. Lees, MDS Past-President
London, United Kingdom

Philip D. Thompson, MDS President-Elect
Adelaide, Australia

9:00 **Stanley Fahn Lecture:**
Jean-Martin Charcot and Movement Disorders: Historical Legacies to the 21st Century.
Christopher G. Goetz
Chicago, IL, USA



Christopher G.
Goetz, MD

9:30 **Junior Award Lecture: Clinical Science**
Helen Ling
London, United Kingdom

9:45 **Junior Award Lecture: Basic Science**
Carlos Juri
Pamplona, Spain

10:00 **C. David Marsden Lecture: The Stress of Misfolded Proteins in Aging and Neurodegenerative Disease**
Richard I. Morimoto
Chicago, IL, USA



Richard I.
Morimoto

For more information on the Award Lectures, and the abstracts for the Junior Awards, please see pages 25-27.

3102 Plenary Session IV:



Basal ganglia beyond motor control: Behavioral considerations

11:00 – 12:30

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Philippe Damier
Nantes, France

Kathleen M. Shannon
Chicago, IL, USA

11:00 **Cognitive circuits and the basal ganglia in normal function and disease**
Richard Levy
Paris, France

11:45 **Reinforcement methods in the basal ganglia**
Peter Redgrave
Sheffield, United Kingdom

AOS General Assembly Meeting

12:30-13:30

Location: Room 252AB, Level 2

All delegates from Asia and Oceania are encouraged to attend.

Poster Presentations

Poster Session II

Abstracts: Tu-1 – Tu-426

Tuesday, June 9

Poster Viewing: 9:00 - 18:00

Authors Present: 12:30 - 14:30

Location: Level 2



Guided Poster Tours

Guided Poster Tour II

13:00 – 14:30

Location: All Guided Poster Tours will meet at the MDS Booth, Level 2 near Registration.

Tickets may be reserved at the MDS Booth beginning Monday, June 8 at 9:00. A ticket is required for participation in each tour.

Dementia in Movement Disorders
Neuropharmacology
Non-Motor Manifestations of Parkinsonism
Parkinson's Disease: Clinical Trials

For a complete listing of abstracts in each tour, please see pages 63-65.

Corporate Therapeutic Symposia

14:30 – 15:30

Please see page 48-49 for more information.



3201 Parallel Session:

New horizons in Parkinson's disease genetics

16:00 – 17:30

Location: Bleu Amphitheatre, Level 2

Chairs: Henry L. Paulson
Ann Arbor, MI, USA
Eng-King Tan
Singapore

16:00 **Update on the Mendelian genetics of Parkinson's disease**
Zbigniew K. Wszolek
Jacksonville, FL, USA

16:30 **The rare variants: The glucocerebrosidase story**
Ellen Sidransky
Bethesda, MD, USA

17:00 **The common variants: The genome wide studies**
Andrew B. Singleton
Bethesda, MD, USA

SCIENTIFIC PROGRAM

3202 Parallel Session: 

Progress in basal ganglia surgery

16:00 – 17:30

Location: Bordeaux Amphitheatre, Level 3

Chairs: Alim Benabid

Meylan, France

Joachim K. Krauss

Hannover, Germany

16:00 Ongoing clinical trials in DBS

Matthew B. Stern

Philadelphia, PA, USA

16:30 Update on neurotransplantation for movement disorders

Anders Björklund

Lund, Sweden

17:00 DBS: New sites, indications and hardware

Tipu Aziz

Oxford, United Kingdom

3203 Parallel Session: 

Hot topics in sleep and Movement Disorders

16:00 – 17:30

Location: Grand Amphitheatre, Level 2

Chairs: Valerie Cochen De Cock

Toulouse, France

Alejandro Iranzo

Barcelona, Spain

16:00 REM behavior disorder

Ron B. Postuma

Toronto, ON, Canada

16:30 Restless legs syndrome

Juliane Winkelmann

Munich, Germany

17:00 Parasomnias

Alejandro Iranzo

Barcelona, Spain

3204 Parallel Session: 

Nurses and movement disorders:

Expanding the quality of care

16:00 – 17:30

Location: Room 242AB, Level 2

Chairs: Robert Iansek

Elsternwick, Australia

Carol Brown Moskowitz

New York, NY, USA

16:00 Nurses addressing primary motor concerns in medical and surgical care

Anna Lena Tornqvist

Lund, Sweden

16:30 Nurses prioritizing non-motor concerns in movement disorder patients

Orna Moore

Tel Aviv, Israel

17:00 Nurses in education, research and patient advocacy programs

To be announced

3205 Parallel Session: 

Botulinum toxin: Special issues

16:00 – 17:30

Location: Room 342AB, Level 3

Chairs: Ryuji Kaji

Tokushima City, Japan

Ib R. Odderson

Seattle, WA, USA

16:00 New applications

Ib R. Odderson

Seattle, WA, USA

16:30 Spasticity

Alberto Albanese

Milano, Italy

17:00 Challenges and controversies

Cynthia L. Comella

Chicago, IL, USA

3206 Parallel Session: 

Ethical issues in Movement Disorders

16:00 – 17:30

Location: Room 251, Level 2

Chairs: Hubert Henry Fernandez

Gainesville, FL, USA

Henrik Walter

Bonn, Germany

16:00 Principles of ethics in medicine

Henrik Walter

Bonn, Germany

16:20 Ethics of interventional therapies for movement disorders

Hubert Henry Fernandez

Gainesville, FL, USA

16:40 Ethics of genetic research and testing

To be announced

3307 Teaching Course: 

Differential diagnosis of parkinsonism

16:00 – 17:30

Location: Room 252AB, Level 2

Chairs: Andrew J. Lees

London, United Kingdom

Stephen G. Reich

Baltimore, MD, USA

16:00 Diagnosis of Parkinson's disease: Clinical features, Motor and non-motor

Stephen G. Reich

Baltimore, MD, USA

16:30 Atypical parkinsonism: Differential diagnosis and work-up

François Tison

Pessac, France

17:00 Rare causes of parkinsonism

Vladimir Kostic

Belgrade, Serbia

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

SCIENTIFIC PROGRAM

<p>3308 Teaching Course: </p> <p>Neuroimaging in movement disorders 16:00 – 17:30 Location: Room Maillot, Level 2 Chairs: Joel S. Perlmutter <i>St. Louis, MO, USA</i> Philippe Remy <i>Creteil, France</i></p> <p>16:00 MR methods including diffusion tensor imaging with a focus on clinical and diagnostic applications to parkinsonism: What do we really know? Klaus Seppi <i>Innsbruck, Austria</i></p> <p>16:45 PET, SPECT techniques with a focus on clinical and diagnostic applications to parkinsonism: What do we really know? Joel S. Perlmutter <i>St. Louis, MO, USA</i></p> <p><i>This Teaching Course is supported by an unrestricted educational grant from Boehringer Ingelheim GmbH.</i></p> <p>3401 Skills Workshop: </p> <p>Eye movements and ophthalmologic exams 18:00 – 19:30 Location: Bleu Amphitheatre, Level 2 R. John Leigh <i>Cleveland, OH, USA</i> David Zee <i>Ellicott City, MD, USA</i></p> <p>3402 Skills Workshop: </p> <p>Distinguishing normal and abnormal movements in children 18:00 – 19:30 Location: Room Maillot, Level 2 Donald L. Gilbert <i>Cincinnati, OH, USA</i> Roser Pons <i>Athens, Greece</i></p> <p>3503 Video Session: </p> <p>Metabolic movement disorders 18:00 – 19:30 Location: Bordeaux Amphitheatre, Level 3 Emilio Fernandez-Alvarez <i>Barcelona, Spain</i> Hyder A. Jinnah <i>Atlanta, GA, USA</i></p>	<p>3504 Video Session: </p> <p>Task-specific dystonia 18:00 – 19:30 Location: Room 252AB, Level 2 Charles H. Adler <i>Scottsdale, AZ, USA</i> Eckart Altenmueller <i>Hannover, Germany</i></p> <p>3505 Video Session: </p> <p>Atypical parkinsonism 18:00 – 19:30 Location: Grand Amphitheatre, Level 2 Irene Litvan <i>Louisville, KY, USA</i> Eduardo Tolosa <i>Barcelona, Spain</i></p> <p>WEDNESDAY, JUNE 10</p> <p>4101 Plenary Session V: </p> <p>Lessons on the basal ganglia from neighboring disciplines 9:00 – 10:30 Location: Grand Amphitheatre—Please use entrances on Level 2 Chairs: Etienne C. Hirsch <i>Paris, France</i> Joseph Jankovic <i>Houston, TX, USA</i></p> <p>9:00 Autism James Bodfish <i>Chapel Hill, NC, USA</i></p> <p>9:45 Schizophrenia Ariel Y. Deutch <i>Nashville, TN, USA</i></p> <p>4102 Plenary Session VI:</p> <p>Complexity of genetics in hyperkinesias 11:00 – 12:30 Location: Grand Amphitheatre—Please use entrances on Level 2 Chairs: Timothy Lynch <i>Dublin, Ireland</i> Yoshikuni Mizuno <i>Tokyo, Japan</i></p> <p>11:00 Rett syndrome in stereotypies Paolo M. Moretti <i>Houston, TX, USA</i></p> <p>11:45 Fragile X and Fragile X-associated Tremor/Ataxia Syndrome Elizabeth Berry-Kravis <i>Chicago, IL, USA</i></p>
---	---

SCIENTIFIC PROGRAM

Poster Presentations

Poster Session 3

Abstracts: We-1 – We-418
 Wednesday, June 10
 Poster Viewing: 9:00 - 18:00
 Authors Present: 12:30 - 14:30
 Location: Level 2

Guided Poster Tours



Guided Poster Tour III

13:00 – 14:30

Location: All Guided Poster Tours will meet at the MDS Booth, Level 2 near Registration.
Tickets may be reserved at the MDS Booth beginning Monday, June 8 at 9:00. A ticket is required for participation in each tour.

Basic Science
Electrophysiology
Genetics and Epidemiology
Surgical Therapies

For a complete listing of abstracts in each tour, please see pages 65-67.

4601 Special Session:

The challenge of Parkinson's disease management in Africa

13:00 – 14:30

Location: Bordeaux Amphitheatre, Level 3
 Chairs: Daniel Tarsy
Boston, MA, USA
 Richard W. Walker
North Shields, United Kingdom
 13:00 **How to identify cases in an area where there is limited awareness among the public and health professionals**
 Richard W. Walker
North Shields, United Kingdom
 13:30 **How to enable access to, and monitoring of, sustainable drug treatment**
 Njideka U. Okubadejo
Lagos, Nigeria
 14:00 **Provision of education to health professionals and the future - Is there a role for professional organizations (WFN, MDS, etc.)?**
 James H. Bower
Rochester, MN, USA

Corporate Therapeutic Symposia

14:30 – 15:30

Please see page 48-49 for more information.

4201 Parallel Session:



Gilles de la Tourette syndrome

16:00 – 17:30

Location: Room 252AB, Level 2
 Chairs: Donald L. Gilbert
Cincinnati, OH, USA
 Irene Litvan
Louisville, KY, USA
 16:00 **Clinical spectrum and pathophysiology**
 Jonathan W. Mink
Rochester, NY, USA
 16:30 **Co-morbidities**
 Jorge Luis Juncos
Atlanta, GA, USA
 17:00 **Management: Pharmacological and surgical**
 Paul Krack
Grenoble, France

4202 Parallel Session:



Assessment of neural circuitry in movement disorders: Imaging advances

16:00 – 17:30

Location: Bleu Amphitheatre, Level 2
 Chairs: Emmanuel Broussolle
Lyon, France
 David Eidelberg
Manhasset, NY, USA
 16:00 **Using imaging and TMS to map abnormal neural circuitry in movement disorders**
 Antonio P. Strafella
Toronto, ON, Canada
 16:30 **Mapping latent circuit abnormalities in movement disorders: The study of clinically non-manifesting mutation carriers**
 Hartwig R. Siebner
Hvidovre, Denmark
 17:00 **Can functional imaging predict the cognitive effects of dopaminergic therapy for Parkinson's disease?**
 David Eidelberg
Manhasset, NY, USA



= Ticket required for entry. Please check the Registration Desk for ticket availability.

There is no extra charge for session tickets.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

SCIENTIFIC PROGRAM

4203 Parallel Session:



Are the pieces of Parkinson's disease pathogenic puzzle starting to fall into place?

16:00 – 17:30

Location: Bordeaux Amphitheatre, Level 3
Chairs: Mark R. Cookson
Bethesda, MD, USA
Shu-Leong Ho
Hong Kong

16:00 What do we know about LRRK2 neurobiology?

William T. Dauer
New York, NY, USA

16:30 PINK1 involvement in mitochondrial and extramitochondrial cellular processes

Mark R. Cookson
Bethesda, MD, USA

17:00 Neuroinflammatory processes in Parkinson's disease

Etienne C. Hirsch
Paris, France

4204 Parallel Session:



What's new in multiple system atrophy?

16:00 – 17:30

Location: Grand Amphitheatre, Level 2
Chairs: François Tison
Pessac, France
Gregor K. Wenning
Innsbruck, Austria

16:00 Clinical diagnosis of MSA: New criteria, work-up and diagnosis

Carlo Colosimo
Rome, Italy

16:30 Natural history and disease progression

Sid Gilman
Ann Arbor, MI, USA

17:00 Advances in the etiopathogenesis of MSA: Oligodendrocytes, genes and environment

Gregor K. Wenning
Innsbruck, Austria

4207 Parallel Session:



Cell and gene therapies for movement disorders

16:00 – 17:30

Location: Room 242AB, Level 3
Chairs: Jeffrey H. Kordower
Chicago, IL, USA

Stephane Palfi
Creteil, France

16:00 Pre-clinical gene therapy

Deniz Kirik
Lund, Sweden

4207 Parallel Session, continued

16:30 Progress and Prospects: Gene therapy clinical trials for Movement Disorders

Stephane Palfi
Creteil, France

17:00 Induced pluri-potent stem cells: Relevance for Movement Disorders

Ron McKay
Bethesda, MD, USA

4305 Teaching Course:



Drug-induced movement disorders

16:00 – 17:30

Location: Room Maillot, Level 2
Chairs: Stewart A. Factor
Atlanta, GA, USA

Kapil D. Sethi
Augusta, GA, USA

16:00 Movement disorders caused by dopamine receptor antagonists

Oscar S. Gershanik
Buenos Aires, Argentina

16:30 Movement disorders related to use of psychiatric drugs other than neuroleptics

Joseph Jankovic
Houston, TX, USA

17:00 Movement disorders related to non-neurologic drugs (cyclosporine, etc.)

Stewart A. Factor
Atlanta, GA, USA

4306 Teaching Course:



Ocular abnormalities in Movement Disorders

16:00 – 17:30

Location: Room 342AB, Level 3
Chairs: R. John Leigh
Cleveland, OH, USA

David Zee
Ellicott City, MD, USA

16:00 Anatomy and physiology of normal eye movement

Charles Pierrot-Deseilligny
Paris, France

16:30 Eye movement abnormalities in neurodegenerative diseases

Tim J. Anderson
Christchurch, New Zealand

17:00 Eye movement abnormalities associated with hereditary ataxias, other rare movement disorders

R. John Leigh
Cleveland, OH, USA
David Zee
Ellicott City, MD, USA

SCIENTIFIC PROGRAM

4401 Skills Workshop:



Electrophysiological evaluation of patients with movement disorders

18:00 – 19:30

Location: Room Maillot, Level 2

Peter Brown

London, United Kingdom

Robert Chen

Toronto, ON, Canada

4402 Skills Workshop:



How to examine mental function in patients with movement disorders

18:00 – 19:30

Location: Bordeaux Amphitheatre, Level 3

Bruno Dubois

Paris, France

Evzen Ruzicka

Prague, Czech Republic

4503 Video Session:



Toxic, immune-mediated, infectious movement disorders

18:00 – 19:30

Location: Room 252AB, Level 2

Francisco E. Cardoso

Belo Horizonte, Brazil

Regina Katzenschlager

Vienna, Austria

4504 Video Session:



Gait disorders

18:00 – 19:30

Location: Bleu Amphitheatre, Level 2

Rodger J. Elble

Springfield, IL, USA

Fay B. Horak

Portland, OR, USA

4505 Video Session:



Pediatric movement disorders

18:00 – 19:30

Location: Room 342AB, Level 3

Jonathan W. Mink

Rochester, NY, USA

Teresa Temudo

Porto, Portugal

Video Olympics Reception with hors d'oeuvres and drinks

19:30-20:00

Location: Hall Maillot, Level 2

Video Olympics

20:00 – 23:00

Grand Amphitheatre—Please use entrances on Level 2

Masters of Ceremony:

Anthony E. Lang

Kapil Sethi

Panel of Experts:

Kailash Bhatia

Susan Bressman

Oscar Gershanik

Andrew Lees

THURSDAY, JUNE 11

MDS Business Meeting

8:00 – 9:00

Location: Bordeaux Amphitheatre, Level 3

Open to all delegates.

5201 Parallel Session:



Dyskinesias in Parkinson's disease: New insights

9:00 – 10:30

Location: Grand Amphitheatre, Level 2

Chairs:

Susan H. Fox

Toronto, ON, Canada

Oscar Gershanik

Buenos Aires, Argentina

9:00

Neurophysiological mechanisms underlying levodopa-induced dyskinesia

Stella M. Papa

Atlanta, GA, USA

9:30

Molecular mechanisms involved in levodopa- and graft-induced dyskinesia

Jose A. Obeso

Pamplona, Spain

10:00

Therapeutic approaches in the management of levodopa- and graft-induced dyskinesia: Pre-clinical and clinical data

Susan H. Fox

Toronto, ON, Canada

5202 Parallel Session:



Dystonia - An update

9:00 – 10:30

Location: Bleu Amphitheatre, Level 2

Chairs:

Kailash P. Bhatia

London, United Kingdom

Susan B. Bressman

New York, NY, USA

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

SCIENTIFIC PROGRAM

5202 Parallel Session, continued

- 9:00 **Update on genetics and neurobiology of dystonia**
Laurie J. Ozelius
New York, NY, USA
- 9:30 **Dopa-responsive dystonias: An update**
Ryuji Kaji
Tokushima City, Japan
- 10:00 **Is dystonia the result of abnormal brain plasticity?**
John C. Rothwell
London, United Kingdom

5203 Parallel Session:

Exercise and brain training

9:00 – 10:30

- Location: Room 342AB, Level 3
Chairs: Bastiaan R. Bloem
Nijmegen, Netherlands
Carl W. Cotman
Irvine, CA, USA

9:00 **Exercise builds brain health**

- Carl W. Cotman
Irvine, CA, USA

9:30 **Neuroprotective effects of exercise in experimental models of Parkinson's disease**
Giselle Petzinger
Los Angeles, CA, USA

10:00 **Translation into clinical practice**

- Marten Munneke
Nijmegen, Netherlands

5204 Parallel Session:

Restless legs syndrome: Daytime and nighttime symptoms, pathophysiology and treatment update

9:00 – 10:30

- Location: Room 242AB, Level 2
Chairs: Cynthia L. Comella
Chicago, IL, USA
Claudia M. Trenkwalder
Kassel, Germany

9:00 **Daytime and nighttime symptoms**

- Birgit Högl
Innsbruck, Austria

9:30 **Pathophysiology**

- William Ondo
Houston, TX, USA

10:00 **Treatment**

- Claudia M. Trenkwalder
Kassel, Germany

5305 Teaching Course:



Neuropharmacology of Parkinson's disease

9:00 – 10:30

- Location: Room 252AB, Level 2
Chairs: Karl D. Kieburtz
Rochester, NY, USA
John G. Nutt
Portland, OR, USA

9:00 **Mechanisms of action of dopaminergic drugs in the normal and diseased state**

- John G. Nutt
Portland, OR, USA

9:30 **Non-dopaminergic neurotransmission in Parkinson's disease: Pre-clinical evidence for newer therapeutic targets**

- Erwan Bezard
Bordeaux, France

10:00 **Novel dopaminergic and non-dopaminergic medications for Parkinson's disease: What is the clinical evidence?**

- Olivier Rascol
Toulouse, France

5306 Teaching Course:



Myoclonus: Pathophysiology, diagnosis, clinical syndromes and treatment

9:00 – 10:30

- Location: Room Maillot, Level 2
Chairs: Daniel D. Truong
Fountain Valley, CA, USA
Marie Vidailhet
Paris, France

9:00 **The pathophysiology of cortical, subcortical and spinal myoclonus**

- Hiroshi Shibasaki
Kyoto, Japan

9:30 **Clinical features of myoclonus subtypes**

- Philip D. Thompson
Adelaide, Australia

10:00 **Treatment of myoclonus depending on etiology and clinical features**

- Marina AJ De Koning-Tijssen
Amsterdam, Netherlands

5401 Skills Workshop:



Evaluation of the ataxic patient

11:00 – 12:30

- Location: Bordeaux Amphitheatre, Level 3
Sid Gilman
Ann Arbor, MI, USA
Tanja Schmitz-Hubsch
Bonn, Germany

SCIENTIFIC PROGRAM

5402 Skills Workshop:



Evaluation of a dysautonomic patient

11:00 – 12:30

Location: Room 342AB, Level 3
 Christopher Mathias
London, United Kingdom
 Anne Pavly-Le Traon
Brest, France

5403 Skills Workshop:



The MDS-UPDRS: How to apply the new UPDRS in practice and research settings

11:00 – 12:30

Location: Bleu Amphitheatre, Level 2
 Christopher G. Goetz
Chicago, IL, USA
 Glenn T. Stebbins
Chicago, IL, USA

5504 Video Session:



Metals and movement disorders

11:00 – 12:30

Location: Room 252AB, Level 2
 Neeraj Kumar
Rochester, MN, USA
 Kapil D. Sethi
Augusta, GA, USA

5505 Video Session:



Unusual features of parkinsonian disorders

11:00 – 12:30

Location: Room Maillot, Level 2
 Alberto J. Espay
Cincinnati, OH, USA
 Leo Verhagen
Chicago, IL, USA

Poster Presentations

Poster Session IV

Abstracts: Th-1 – Th-420

Thursday, June 11

Poster Viewing: 9:00 - 17:30

Authors Present: 12:30 - 14:30

Location: Level 2



= Ticket required for entry. Please check the Registration Desk for ticket availability.

There is no extra charge for session tickets.

Corporate Therapeutic Symposia

12:30 – 14:00

14:15 – 15:45

Please see page 48-49 for more information.

5101 Controversies in Movement Disorders

16:00 – 18:00

Location: Grand Amphitheatre—Please use entrances on Level 2

Chairs: Giovanni Abbruzzese
Genova, Italy
 Vladimir Kostic
Belgrade, Serbia

The PPN is a promising target for treatment-resistant gait disorders in Parkinson's disease

16:00

Yes
 Paolo Mazzone
Roma, Italy

16:15

No
 Pierre Pollak
Grenoble, France

Do cholinesterase inhibitors make a meaningful difference in treating PDD?

16:30

Yes
 David John Burn
Newcastle Upon Tyne, United Kingdom

16:45

No
 William J. Weiner
Baltimore, MD, USA

Lewy bodies in grafted dopaminergic cells: Do they tell us anything about the pathogenesis of and the promise of cell replacement therapies in Parkinson's disease?

17:00

Yes
 Jeffrey H. Kordower
Chicago, IL, USA

17:15

No
 Ole Isacson
Belmont, MA, USA

Transcranial sonography: A useful diagnostic tool for movement disorders?

17:30

Yes
 Daniela Berg
Tübingen, Germany

17:45

No
 Johann M. Hagenah
Lübeck, Germany

The Controversies Session is supported by an unrestricted educational grant from Boehringer Ingelheim GmbH.



EFNS EUROPEAN FEDERATION OF
NEUROLOGICAL SOCIETIES

EFNS GENEVA 2010

14TH CONGRESS OF THE EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES GENEVA, SWITZERLAND, SEPTEMBER 25 – 28, 2010



Don't miss the opportunity
to meet more than 5,000
neurologists and join us at
the EFNS Congress in 2010.

The Preliminary Congress
Programme is online now.

For details please visit www.efns.org/efns2010

HOST



Organised in co-operation with
the Swiss Neurological Society

CO-SPONSORSHIP



Co-sponsored by the European
Section of the Movement Disorder
Society (MDS-ES)



Co-sponsored by the
World Federation of Neurology
(WFN)

CONGRESS
ORGANISERS



EFNS EUROPEAN FEDERATION OF
NEUROLOGICAL SOCIETIES

FACULTY LISTING

Giovanni Abbruzzese

Genova, Italy
5101

Charles H. Adler

Scottsdale, AZ, USA
3504

Alberto Albanese

Milano, Italy
3205

Eckart Altenmueller

Hannover, Germany
3504

Tim J. Anderson

Christchurch, New Zealand
4306

Angelo Antonini

Monza, Italy
1102

Tipu Aziz

Oxford, United Kingdom
3202

Paolo Barone

Napoli, Italy
1103

Boulos-Paul W. Bejjani

Byblos, Lebanon
2402

Alim Benabid

Meylan, France
1102, 3203

Alfredo Berardelli

Roma, Italy
1104

Daniela Berg

Tübingen, Germany
5101

Elizabeth Berry-Kravis

Chicago, IL, USA
4102

Erwan Bezard

Bordeaux, France
1102, 5305

Kailash P. Bhatia

London, United Kingdom
2504, 5202

Mohit H. Bhatt

Mumbai, India
2504

Anders Björklund

Lund, Sweden
3202

Bastiaan R. Bloem

Nijmegen, Netherlands
2201, 5203

James Bodfish

Chapel Hill, NC, USA
4101

J. Paul Bolam

Oxford, United Kingdom
2101

James H. Bower

Rochester, MN, USA
4601

Susan B. Bressman

New York, NY, USA
5202

Emmanuel Broussolle

Lyon, France
4202

Peter Brown

London, United Kingdom
2202, 4401

David John Burn

*Newcastle Upon Tyne,
United Kingdom*
1103, 5101

Paolo Calabresi

Perugia, Italy
2101

Francisco E. Cardoso

Belo Horizonte, Brazil
4503

Robert Chen

Toronto, ON, Canada
4401

Valerie Cochen De

*Cock
Toulouse, France*
3203

Carlo Colosimo

Rome, Italy
4204

Cynthia L. Comella

Chicago, IL, USA
3205, 5204

Mark R. Cookson

Bethesda, MD, USA
4203

Carl W. Cotman

Irvine, CA, USA
5203

Philippe Damier

Nantes, France
3102

Adrian Danek

Munich, Germany
2203

William T. Dauer

New York, NY, USA
4203

Marina AJ De Koning-Tijssen

*Amsterdam,
The Netherlands*
5306

Alain Destee

Lille, France
2307

Ariel Y. Deutch

Nashville, TN, USA
4101

Bruno Dubois

Paris, France
2205, 4402

David Eidelberg

Manhasset, NY, USA
4202

Roger J. Elble

Springfield, IL, USA
1104, 4504

Murat Emre

Istanbul, Turkey
1104, 2205

Alberto J. Espay

Cincinnati, OH, USA
5505

Stewart A. Factor

Atlanta, GA, USA
4305

Stanley Fahn

New York, NY, USA
1101, 2102

Hubert Henry Fernandez

Gainesville, FL, USA
3206

Emilio Fernandez-Alvarez

Barcelona, Spain
3503

Nick C. Fox

London, United Kingdom
2205

Susan H. Fox

Toronto, ON, Canada
5201

Steven Frucht

New York, NY, USA
2307

Victor Fung

Westmead, Australia
2503

Oscar Gershnik

Buenos Aires, Argentina
4305, 5201

Nir Giladi

Tel Aviv, Israel
2201

Donald L. Gilbert

Cincinnati, OH, USA
3402, 4201

Sid Gilman

Ann Arbor, MI, USA
4204, 5401

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

FACULTY LISTING

Christopher G. Goetz

Chicago, IL, USA
3101, 5403

Johann M. Hagenah

Lübeck, Germany
5101

Glenda M. Halliday

Randwick, Australia
2205

Etienne C. Hirsch

Paris, France
4101, 4203

Shu-Leong Ho

Hong Kong
4203

Birgit Högl

Innsbruck, Austria
5204

Fay B. Horak

Portland, OR, USA
2201, 4504

Robert Iansek

Elsternwick, Australia
3204

Alejandro Iranzo

Barcelona, Spain
3203

Ole Isacson

Belmont, MA, USA
5101

Joseph Jankovic

Houston, TX, USA
4101, 4305

Hyder A. Jinnah

Atlanta, GA, USA
3503

Jorge Luis Juncos

Atlanta, GA, USA
4201

Ryuji Kaji

Tokushima City, Japan
3205, 5202

Regina Katzenschlager

Vienna, Austria
1101, 4503

Karl D. Kieburtz

Rochester, NY, USA
5305

Deniz Kirik

Lund, Sweden
4207

Christine Klein

Lübeck, Germany
2306

Jeffrey H. Kordower

Chicago, IL, USA
4207, 5101

Vladimir Kostic

Belgrade, Serbia
3307, 5101

Paul Krack

Grenoble, France
4201

Joachim K. Krauss

Hannover, Germany
2402, 3202

Andrea A. Kuehn

Berlin, Germany
2202

Jaime Kulisevsky

Barcelona, Spain
1103, 2205

Neeraj Kumar

Rochester, MN, USA
5504

Anthony E. Lang

Toronto, ON, Canada
1101, 3101

Andrew J. Lees

London, United Kingdom
3101, 3307

R. John Leigh

Cleveland, OH, USA
3401, 4306

Holger Lerche

Ulm, Germany
2203

Richard Levy

Paris, France
3102

Patricia Limousin-

Dowsey
London, United Kingdom
1102

Irene Litvan

Louisville, KY, USA
3505, 4201

Andres M. Lozano

Toronto, ON, Canada
1102, 2101

Timothy Lynch

Dublin, Ireland
2307, 4102

Christopher Mathias

London, United Kingdom
5402

Paolo Mazzone

Roma, Italy
5101

Ron McKay

Bethesda, MD, USA
4207

Marcelo Merello

Buenos Aires, Argentina
1103

Jonathan W. Mink

Rochester, NY, USA
4201, 4505

Janis M. Miyasaki

Toronto, ON, Canada
2401

Yoshikuni Mizuno

Tokyo, Japan
4102

Orna Moore

Tel Aviv, Israel
3204

Paolo M. Moretti

Houston, TX, USA
4102

Richard Morimoto

Chicago IL, USA
3101

Elena Moro

Toronto, ON, Canada
2402

Carol Brown Moskowitz

New York, NY, USA
2401, 3204

Marten Munneke

Nijmegen, Netherlands
5203

John G. Nutt

Portland, OR, USA
5305

Jose A. Obeso

Pamplona, Spain
5201

Ib R. Odderson

Seattle, WA, USA
3205

Wolfgang H. Oertel

Marburg, Germany
2101

Njideka U. Okubadejo

Lagos, Nigeria
4601

Michael S. Okun

Gainesville, FL, USA
2307

C. Warren Olanow

New York, NY, USA
1101, 2102

William Ondo

Houston, TX, USA
5204

Laurie J. Ozelius

New York, NY, USA
5202

Stephane Palfi

Creteil, France
4207

Massimo Pandolfo

Brussels, Belgium
2203

FACULTY LISTING

Stella M. Papa <i>Atlanta, GA, USA</i> 5201	Stephen G. Reich <i>Baltimore, MD, USA</i> 3307	Ellen Sidransky <i>Bethesda, MD, USA</i> 3201	Claudia M. Trenkwalder <i>Kassel, Germany</i> 5204
Henry L. Paulson <i>Ann Arbor, MI, USA</i> 2306, 3201	Heinz Reichmann <i>Dresden, Germany</i> 1102	Hartwig R. Siebner <i>Hvidovre, Denmark</i> 4202	Daniel D. Truong <i>Fountain Valley, CA, USA</i> 5306
Anne Pavly-Le Traon <i>Brest, France</i> 5402	Philippe Remy <i>Creteil, France</i> 3308	Andrew B. Singleton <i>Bethesda, MD, USA</i> 2306, 3201	Leo Verhagen <i>Chicago, IL, USA</i> 5505
Joel S. Perlmutter <i>St. Louis, MO, USA</i> 3308	David E. Riley <i>Cleveland Heights, OH, USA</i> 2503	Glenn T. Stebbins <i>Chicago, IL, USA</i> 5403	Marie Vidailhet <i>Paris, France</i> 1104, 5306
Giselle Petzinger <i>Los Angeles, CA, USA</i> 5203	Maria C. Rodriguez-Oroz <i>Pamplona, Spain</i> 2202	Matthew B. Stern <i>Philadelphia, PA, USA</i> 3202	Richard W. Walker <i>North Shields, United Kingdom</i> 4601
Charles Pierrot-Deseilligny <i>Paris, France</i> 4306	John C. Rothwell <i>London, United Kingdom</i> 2101, 5202	Antonio P. Strafella <i>Toronto, ON, Canada</i> 4202	Henrik Walter <i>Bonn, Germany</i> 3206
Werner Poewe <i>Innsbruck, Austria</i> 2102	Evzen Ruzicka <i>Prague, Czech Republic</i> 2201, 4402	Oksana Suchowersky <i>Calgary, AB, Canada</i> 2306	William J. Weiner <i>Baltimore, MD, USA</i> 5101
Pierre Pollak <i>Grenoble, France</i> 1102, 5101	Cristina Sampaio <i>Lisboa, Portugal</i> 1101	Eng-King Tan <i>Singapore</i> 3201	Gregor K. Wenning <i>Innsbruck, Austria</i> 4204
Roser Pons <i>Athens, Greece</i> 3402	Tanja Schmitz-Hubsch <i>Bonn, Germany</i> 5401	Louis CS Tan <i>Singapore</i> 1104	Juliane Winkelmann <i>Munich, Germany</i> 3203
Ron B. Postuma <i>Toronto, ON, Canada</i> 3203	Anette Schrag <i>London, United Kingdom</i> 1103	Daniel Tarsy <i>Boston, MA, USA</i> 4601	Zbigniew K. Wszolek <i>Jacksonville, FL, USA</i> 2102, 3201
Alberto Priori <i>Milano, Italy</i> 2202	Klaus Seppi <i>Innsbruck, Austria</i> 3308	Teresa Temudo <i>Porto, Portugal</i> 4505	David Zee <i>Ellicott City, MD, USA</i> 3401, 4306
Niall P. Quinn <i>London, United Kingdom</i> 1104, 2505	Kapil D. Sethi <i>Augusta, GA, USA</i> 4305, 5504	Philip D. Thompson <i>Adelaide, Australia</i> 3101, 5306	
Olivier Rascol <i>Toulouse, France</i> 2102, 5305	Kathleen M. Shannon <i>Chicago, IL, USA</i> 2505, 3102	François Tison <i>Pessac, France</i> 3307, 4204	
Peter Redgrave <i>Sheffield, United Kingdom</i> 3102	Hiroshi Shibasaki <i>Kyoto, Japan</i> 5306	Eduardo Tolosa <i>Barcelona, Spain</i> 2203, 3505	
		Anna Lena Tornqvist <i>Lund, Sweden</i> 3204	

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

CORPORATE THERAPEUTIC SYMPOSIA

Novartis Pharma AG and Orion Pharma

Monday, June 8

14:30 – 15:30

Location: Bleu Amphitheatre, Level 2

Levodopa: Recent developments and future directions

Chair : C. Warren Olanow
New York, NY, USA

STRIDE - PD: the rationale

Fabrizio Stocchi
Roma, Italy

STRIDE – PD study outcomes

Karl Kieburtz
Rochester, NY, USA

Panel discussion – evidence-based clinical recommendations

Chair: C. Warren Olanow
New York, NY, USA

Karl Kieburtz
Rochester, NY, USA

Olivier Rascol

Toulouse, France

Fabrizio Stocchi
Roma, Italy

Closing remarks

C. Warren Olanow
New York, NY, USA

Merck Serono

Monday, June 8

14:30 – 15:30

Location: Grand Amphitheatre, Level 2

Enlightening the dark side of Parkinson's disease

Chairs: Anthony Schapira
London, United Kingdom

Paolo Barone

Napoli, Italy

Welcome and Introduction

Anthony Schapira
London, United Kingdom

Optimizing treatments for Parkinson's disease

Robert Hauser

Tampa, FL, USA

Need for comprehensive approach to the management of motor and non-motor symptoms of Parkinson's disease

Werner Poewe
Innsbruck, Austria

Merck Serono, continued

Is neuroprotection a possible target for new drugs in Parkinson's disease?

Cristina Sampaio
Lisboa, Portugal

Closing remarks

Paolo Barone
Napoli, Italy

Glaxo SmithKline

Tuesday, June 9

14:30 – 15:30

Location: Bleu Amphitheatre, Level 2

Day and night treatment of Parkinson's disease

Chair: Fabrizio Stocchi
Roma, Italy

The challenge of managing Parkinson's disease during the day and night

Fabrizio Stocchi
Roma, Italy

Practical tools for assessing non-motor symptoms in Parkinson's disease

Ray Chaudhuri
London, United Kingdom

Ropinirole prolonged release: an approach to managing day and night symptoms

Evzen Ruzicka
Prague, Czech Republic

Ipsen

Tuesday, June 9

14:30 – 15:30

Location: Grand Amphitheatre, Level 2

State of the art: Botulinum toxin A in cervical dystonia and spasticity

Chair: Marie Vidailhet
Paris, France

Current data on products in use

Andrew Pickett
Wrexham, United Kingdom

Cervical Dystonia

Matthew Brodsky
Portland, OR, USA

Spasticity

Austen Peter Moore
Liverpool, United Kingdom

Summary and conclusion

Marie Vidailhet
Paris, France

CORPORATE THERAPEUTIC SYMPOSIA

Solvay Pharmaceuticals GMBH

Wednesday, June 10

14:30 – 15:30

Location: Bleu Amphitheatre, Level 2

Continuous dopaminergic stimulation in Parkinson's disease – beyond motor benefits

Chair: Phillippe Damier
Nantes, France

The increasing evidence base for continuous dopaminergic stimulation in Parkinson's disease

Maral Mouradian
Piscataway, NJ, USA

Can continuous dopaminergic stimulation improve the treatment of non-motor symptoms of Parkinson's disease?

Angelo Antonini
Monza, Italy

Continuous dopaminergic stimulation in French patients with advancing Parkinson's disease

Luc Defebvre
Lille, France

Boehringer Ingelheim GMBH

Thursday, June 11

12:30 – 14:00

Location: Grand Amphitheatre, Level 2

Depression and Pain in Parkinson's disease—Impact and Management

Chairs: Eduardo Tolosa
Barcelona, Spain
Werner Poewe
Innsbruck, Austria

Parkinson's Disease—A Multisystem, Neuropsychiatric Disease

Yves Agid
Paris, France

Depressive Symptoms and Pain in Parkinson's Disease—Impact on Quality of Life

Anette Schrag

London, United Kingdom

Treatment of Depressive Symptoms in PD

Paolo Barone
Naples, Italy

Pharmacologic Advances in Dopaminergic Treatment

Heinz Reichmann
Dresden, Germany

Discussion

UCB Pharma SA

Wednesday, June 10

14:30 – 15:30

Location: Grand Amphitheatre, Level 2

Parkinson's disease treatment - where do we go from here?

Chair: Anthony Schapira
London, United Kingdom

Introduction

Anthony Schapira
London, United Kingdom

Second generation dopamine agonists: fulfilling expectations?

Eduardo Tolosa
Barcelona, Spain

Continuous delivery: optimized patient outcomes and beyond

Heinz Reichmann
Dresden, Germany

Discussion

Teva Pharmaceutical Industries Ltd., Teva Neuroscience Inc. and H. Lundbeck

Thursday, June 11

14:15-15:45

Location: Bleu Amphitheatre, Level 2

Azilect in early Parkinson's disease: Evidence and reflections

Chairs: Olivier Rascol
Toulouse, France
C. Warren Olanow
New York, NY, USA

Treating early in Parkinson's disease: how will this make a difference for patients?

Jose Obeso
Pamplona, Spain

The benefits of Azilect in early Parkinson's disease:

- **Symptomatic and long-term effects**

Robert Hauser
Tampa, FL, USA

- **Outcomes from the ADAGIO study**

Olivier Rascol
Toulouse, France

Reflections on emerging concepts in the treatment of Parkinson's disease

C. Warren Olanow
New York, NY, USA

Panel discussion



XVIII WFN World Congress on *Parkinson's Disease and Related Disorders*

Improving long-term outcome



Miami Beach, Fl, USA, December 13-16, 2009

Join over 3,000 international clinicians, researchers and allied healthcare professionals at this biennial congress, which this year celebrates half a century as a leading international summit on scientific progress in discovering real solutions for Parkinson's patients.

Congress Highlights:

- Multi-disciplinary scientific programme
- Latest information on the etiology, pathophysiology & treatment
- Lectures by international experts
- New reports from clinical researchers & basic research laboratories

**For more information about CMEs, CEUs and to Register
visit: www.kenes.com/parkinson**

Congress Secretariat

KENES International
CARES FOR YOUR ORGANIZATION

1-3, Rue de Chantepoulet, P.O. Box 1726 CH-1211 Geneva 1 Switzerland
Tel: +41 22 908 0488, Fax: +41 22 906 9140, E-mail: parkinson@kenes.com
© Kenes International 2009. All rights reserved.

Jointly Sponsored by USF Health and the
World Federation of Neurology (WFN)
Research Group on Parkinsonism and
Related Disorders



EXHIBITOR INFORMATION

General Information and Exhibit Hours

Please allow adequate time in your daily schedule to visit the Exhibit Area, located in the Hall Maillot which is on Level 2 of Le Palais des Congrès de Paris. The exhibition is an integral component of your International Congress experience, offering you the opportunity to speak with representatives of companies providing services or marketing products directly related to Movement Disorders. Delegates may visit the Exhibit Area during the following hours:

Sunday, June 7	18:30 – 19:30 (during the Welcome Reception)
Monday, June 8	10:00 – 16:00
Tuesday, June 9	10:00 – 16:00
Wednesday, June 10	10:00 – 16:00
Thursday, June 11	10:00 – 15:00

Exhibitor Registration

Location: Level 2

Exhibitors must register at the Exhibitor Registration Desk (located next to the Attendee Registration Desk) during the following hours:

Saturday, June 6	14:00 – 20:00
Sunday, June 7	8:00 – 18:30
Monday, June 8	8:00 – 18:30
Tuesday, June 9	8:00 – 18:30
Wednesday, June 10	8:00 – 18:30
Thursday, June 11	8:00 – 16:30

Exhibitor Badge Policy

Admission to the Exhibit Area will be by name badge only. Security guards will monitor the Exhibit Area entrances for proper identification. Exhibit stand personnel must show an official MDS exhibitor name badge in order to gain access to the Exhibit Area during installation, show, or dismantlement hours.

Exhibitor Badge (Yellow): Allows admittance to the Exhibit Area only.

Endorsement Disclaimer

Products and services displayed in the Exhibit Area or advertised in the program occur by contractual business arrangements between MDS and participating companies and organizations. These arrangements do not constitute nor imply an endorsement by MDS of these products and services.



The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

EXHIBITOR DIRECTORY

ALLERGAN LTD

Marlow International, Parkway
Marlow, Buckinghamshire SL7 1YI
United Kingdom
Telephone: +44 1628 494444
Fax: +44 1628 494449
Web site: www.allergan.com

Booth #: 08

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices. Allergan is proud to exhibit at the 13th International Congress of Parkinson's Disease and Movement Disorders.

BENIGN ESSENTIAL BLEPHAROSPASM RESEARCH FOUNDATION

P.O. Box 12468
Beaumont, TX 77726-2468
United States
Telephone: +1 409 832 0788
Fax: +1 409 832 0890
Web site: www.blepharospasm.org

Table #: G

The Benign Essential Blepharospasm Research Foundation, founded in 1981, is the only organization dedicated solely to finding the cause and cure for Blepharospasm, Meige and related disorders. BEBRF, a volunteer directed, nonprofit organization, has support groups nationwide, promotes awareness and research, distributes educational material to patients and physicians and serves as a referral clearing house.

BRITANNIA PHARMACEUTICALS LIMITED

41-51 Brighton Road
Redhill, Surrey RH1 6YS
United Kingdom
Telephone: +44 1737 773741
Web site: www.britannia-pharm.com

Booth #: 15

Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specializing in innovative products for niche medical conditions. We have a particular focus on treatment of patients with complex Parkinson's disease.

BOEHRINGER INGELHEIM GMBH

Binger Strasse 173
Ingelheim am Rhein 55216
Germany
Telephone: +49 6132 770
Fax: +49 6132 720
Web site: www.boehringer-ingelheim.com

Booth #: 22

Mirapexin® (Sifrol®/Mirapex®) is approved for the symptomatic treatment of all stages of idiopathic Parkinson's disease and moderate to severe idiopathic Restless Legs Syndrome (RLS). The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries. Since it was founded in 1885, the family-owned company has been committed to researching, developing and marketing novel products of high therapeutic value.

CAMBRIDGE LABORATORIES (IRELAND) LTD

Alexandra House, The Sweepstakes
Ballsbridge, Dublin 4
Ireland
Telephone: +353 1 668 7895
Fax: +353 1 631 9452
Web site: www.camb-labs.com

Booth #: 09

Cambridge Laboratories is a fast growing, dynamic and entrepreneurial pharmaceutical company with extensive product development and commercialization expertise focused on innovative products in diseases of the central nervous system. Cambridge has an exciting portfolio of products, both on the market and in development, derived from its proprietary discovery efforts and a carefully constructed network of international partnerships for research, development, sourcing and global commercialization. Utilizing this unusual business model, Cambridge is dedicated to delivering significant value to patients, physicians and partners around the world.

EXHIBITOR DIRECTORY

EISAI EUROPE LTD

Titan Court, 3 Bishop Square
Hatfield, Herts AL10 9NE
United Kingdom
Telephone: +44 845 676 5209
Web site: www.eisai.co.uk

Booth #: 17

Eisai is one of the world's leading research-driven biopharmaceutical companies. Our Corporate mission is to be a 'human health care' (*hhc*) company, which means that we regard patients and their families as the most important stakeholders in the health care process. Our goal is clear: we seek to produce innovative solutions, that satisfy the unmet medical needs of patients, and contribute to the health and welfare of the world's population.

EUROPEAN DYSTONIA FEDERATION

69 East King Street
Helensburgh G84 7RE
United Kingdom
Telephone: +44 1436 678799
Fax: +44 1436 678799
Web site: www.dystonia-europe.org

Table #: F

European Dystonia Federation is a union of national patient groups in Europe, supporting all forms of dystonia.

Working at the European level, we promote the interests of dystonia patients within the structures and institutions of the EU, while acting in partnership with the medical profession and others to improve the profile of the condition in research and treatment. Our successful 2008 medical congress on dystonia in Hamburg was awarded the maximum possible 14 CME points!

EUROPEAN PARKINSON'S DISEASE ASSOCIATION

4 Golding Road
Sevenoaks, Kent TN13 3NJ
United Kingdom
Telephone: +44 1732 457683
Fax: +44 1732 457683
Web site: www.epda.eu.com

Table #: C

'To develop a dialogue between science and society.' Formed in 1992 with 9 PD organizations, it now has a membership of 41 European Organizations and 7 Associate members. It is non-political, non-religious and non-profit making, concerned with the health and welfare of people with PD and their families. Collaboration with European patient and neurological organizations, European Commission, World Health Organization, World Federation of Neurology, and pharmaceutical industry have resulted in the development of QoL research projects, education materials and multidisciplinary conferences.

FHC, Inc.

1201 Main Street
Bowdoin, ME 04287
USA
Telephone: +1 207-666-8191
Fax: +1 207-666-8292
Web site: www.fh-co.com

Booth #: 18

FHC's microTargeting™ products include:

- Patient-customized "frame-free" Platform with STarFix™ guidance which transforms functional neurosurgery from a marathon surgical event to an efficient out-patient scanning visit followed by a shorter surgery;
- Standard and custom microelectrodes including the new D.ZAP electrodes with exceptional recording properties;
- Manual and motor controlled positioning devices; and
- Guideline 4000 microrecording system which can be configured for up to 10 channel MER and LFP recording, micro-/macro-stimulation. "Innovation through collaboration."

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

EXHIBITOR DIRECTORY

GE HEALTHCARE

Pollards Wood, Nightingales Lane
Chalfont St. Giles
Buckinghamshire HP8 4SP
United Kingdom
Telephone: +44 1494 544000
Fax: +44 1494 498234
Web site: www.gehealthcare.com

Booth #: 06

GE Healthcare is dedicated to helping you transform healthcare delivery by driving critical breakthroughs in biology and technology. Our expertise in medical imaging is enabling healthcare professionals around the world discover new ways to predict, diagnose and treat disease earlier. We call this model of care "Early Health." Our goal is to help clinicians detect disease earlier, access more information and intervene earlier with more targeted treatments, so they can help their patients live their lives to the fullest. While at ICPD/MDS, please visit our stand to learn more about our offerings in the field of neurology.

GLAXOSMITHKLINE

980 Great West Road
Brentford TW8 9GS
United Kingdom
Telephone: +44 20 8047 6174
Web site: www.gsk.com

Booth #: 05

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GSK makes medicines, vaccines and consumer healthcare products. Its business accounts for 5.3% of the world's pharmaceutical market. Every hour GSK spends more than £300,000 (US\$562,000) to find new medicines.

GSK provides money, medicines, time and equipment to non-profit organizations to help improve health and education in under-served communities. It focuses on programs that are innovative, sustainable, and bring real benefits to those most in need.

IPSEN

65 Quai Georges Gorse
Boulogne Billancourt 92650
France
Telephone: +33 1 53 88 50 00
Fax: +33 1 53 88 50 01
Web site: www.ipsen.com

Booth #: 16

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neurology), and primary care products which contribute significantly to its research financing. For more information on Ipsen, visit our Web site at www.ipsen.com.

MEDTRONIC, INC.

710 Medtronic Parkway
Minneapolis, MN 55432
USA
Telephone: +1 800-328-2518
Web site: www.medtronic.com

Booth #: 21

Medtronic is the world leader in medical technology providing lifelong solutions for people with chronic disease. Each year, six million patients benefit from our technology. Medtronic DBS Therapy has been used in more than 55,000 patients for the treatment of Parkinson's disease, essential tremor and dystonia.

EXHIBITOR DIRECTORY

MERCK SERONO

9, Chemin des Mines
Geneva 1202
Switzerland
Telephone: +41 22 414 3000
Fax: +41 22 414 2179
Web site: www.merckserono.net

Booth #: 03

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Merck Serono has a long-term commitment to the development of innovative treatments to help manage neurological disorders such as Multiple Sclerosis (MS) and Parkinson's disease (PD).

Merck Serono is committed to growing its business in specialists-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

MERZ PHARMACEUTICALS GMBH

Eckenheimer Landstrasse 100
Frankfurt 60318
Germany
Telephone: +49 69 15030
Fax: +49 69 1503 722
Web site: www.merz.com

Booth #: 04

Merz Pharmaceuticals is a research based pharmaceutical company, headquartered in Frankfurt, Germany, focused on unmet needs in neurology and related diseases. It has developed memantine for moderate to severe Alzheimer's disease. Recently, it launched Xeomin®, a botulinum toxin free from complexing proteins. Currently, Merz is conducting a phase III development program of neramexane, a dual NMDA and alpha9/10 nicotinic receptor antagonist, for the treatment of Tinnitus.

NATIONAL SPASMODIC TORTICOLLIS ASSOCIATION

9920 Talbert Avenue
Fountain Valley, CA 92708
USA
Telephone: +1 714-378-9837
Web site: www.torticollis.org

Table #: A

The National Spasmodic Torticollis Association (NSTA) is a non-profit organization formed to provide information and support to people with spasmodic torticollis (ST), also known as cervical dystonia. The NSTA offers an outreach program designed to increase awareness of the disorder. Chapters, Support Groups and Contact people are available throughout the United States.

NOVARTIS PHARMA AG

Forum 1, Novartis Campus
Basel 4056
Switzerland
Telephone: +41 61 324 1111
Fax: +41 61 324 8001
Web site: www.novartis.com

Booth #: 10

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 96,700 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

EXHIBITOR DIRECTORY

ORION CORPORATION ORION PHARMA

Orionintie 1
Espoo 02101
Finland
Telephone: +358 10 4261
Web site: www.orion.fi

Booth #: 10

Orion Corporation is a Finnish listed company which is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. Orion is the originator of Stalevo® (levodopa, carbidopa, entacapone) for Parkinson's disease.

Oxford University Press

Great Clarendon Street
Oxford OX2 6DP
United Kingdom
Telephone: 44 1865 556 767
Web site: www.oup.co.uk

Table: H

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. We publish both high quality neurology books and journals. Visit the Wisepress stand to browse our range of titles, including Brain's Diseases of the Nervous System, 12th edition. <http://www.oup.co.uk/academic/medicine/> <http://www.oxfordjournals.org/subject/medicine/>

SOLVAY PHARMACEUTICALS GMBH

Hegenheimattweg 127
Allschwil 4123
Switzerland
Telephone: +41 61 48702 00
Fax: +41 61 48702 99
Web site: www.solvaypharmaceuticals.com

Booth #: 07

Solvay Pharmaceuticals is a global player in selected disease target areas. A strong focus concentrates research and development efforts into clinical indications where doctors and patients want new and better therapies to choose from. The same focus in sales and marketing teams gives us a strong presence in segments such as neurology. Solvay Pharmaceuticals is spreading quickly from Europe, USA and Canada into other countries, including Brazil, Australia, China and Mexico today.

ST. JUDE MEDICAL

The corporate Village
Av Da Vinci Laan, Box F1
Zaventem 1935
Belgium
Telephone: +32 2 774 6844
Fax: +32 2 774 6843
Web site: www.sjm.com

Booth #: 02

St. Jude Medical develops medical technology designed to put more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful patient outcomes. Learn more at www.sjm.com.

EXHIBITOR DIRECTORY

TEVA PHARMACEUTICAL INDUSTRIES LTD. TREMOR ACTION NETWORK

P.O. Box 3190
Petah-Tiqva 49131
Israel
Telephone: +972 3 926 7152
Fax: +972 3 926 7852
Web site: www.tevapharm.com

Booth #: 01

Azilect – a new treatment for Parkinson's disease both as monotherapy in early disease and as adjunctive therapy in more advanced disease. Several large clinical trials demonstrated Azilect's dual benefit of high symptomatic efficacy and disease modification by slowing clinical progression of PD. Azilect has a good safety profile and high tolerability among elderly patients and convenient dosing – once daily, no titration.

H. LUNDBECK A/S

Ottiliavej 9
Valby DK-2500
Denmark
Telephone: +45 36 43 2930
Fax: +45 36 43 8900
Web site: www.lundbeck.com

Booth #: 01

TEVA NEUROSCIENCE

901 E. 104th Street, Suite 900
Kansas City, MO 64131
USA
Telephone: +1 816-508-5000
Fax: +1 816-508-5010
Web site: www.tevaneuroscience.com

Booth #: 01

PO Box 5013
Pleasanton, CA 94566-0513
USA
Telephone: +1 925-462-0111
Fax: +1 925-369-0485
Web site: www.tremoraction.org

Table #: B

TremorAction.org connects the bench to Tremor patients through awareness, advocacy and research. Stop by our booth to discuss services we provide. TAN DVD, Spikes & Spasms newsletter and other resources are available.

UCB PHARMA SA

Allée de la Recherche 60
1070 Brussels
Belgium
Telephone: +32 2 559 9999
Fax: +32 2 559 9900
Web site: www.ucb-group.com

Booth #: 19, 20

UCB, Brussels, Belgium is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10,000 people in over 40 countries, UCB expects to achieve revenue of at least 3.3 billion Euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

EXHIBITOR DIRECTORY

WILEY-BLACKWELL

111 River Street
Hoboken, NJ 07030-5774
USA
Telephone: +1 201-748-6000
Web site: www.wiley.com

Table #: E

Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business of John Wiley & Sons, publishes on behalf of more societies and membership associations than anybody else and offers libraries and individuals 1,250 online journals, thousands of books in print and online reviews, reference works, databases, and many other innovative resources for teaching and learning, including across the social sciences and humanities.

Wiley-Blackwell is proud to publish Movement Disorders on behalf of The Movement Disorder Society.

Wisepress Online Bookshop

The Old Lamp Works
25 High Path
London SW19 2JL
United Kingdom
Telephone: 44 20 8715 1812
Fax: 44 20 8715 1722
Web site: www.wisepress.com

Booth #: 13

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you. Wisepress has a comprehensive medical and scientific bookshop online with great offers.

WORLD PARKINSON CONGRESS

1359 Broadway, Suite 1509
New York, NY 10018
USA
Telephone: +1 212-923-4700
Fax: +1 212-923-4778
Web site: www.worldpdcongress.org

Table #: D

The second World Parkinson Congress will take place from September 28 - October 1, 2010 in Glasgow, Scotland. The WPC 2010 is planned and hosted by the World Parkinson Congress Inc., a nonprofit organization dedicated to providing an international forum for the latest scientific discoveries, medical practices and care initiatives related to Parkinson's disease (PD). By bringing physicians, scientists, allied health professionals, caregivers and people with PD together, the WPC aims to create a worldwide dialogue to help expedite the discovery of a cure and best treatment practices for this devastating disease.

XVIII WFN WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS

1-3 Rue de Chantepoulet
Geneva CH-1200
Switzerland
Telephone: +41 22 908 0488
Fax: +41 22 906 9140
Web site: www.kenes.com/parkinson


Booth #: 14

This congress, under the direction of the 'Research Group on Parkinsonism and Related Disorders' of the World Federation of Neurology, is a key meeting for acquiring the most recent and authoritative information on the etiology, pathophysiology and treatment of Parkinson's disease and related disorders. By bringing together clinical neurologists, neuroscientists, and allied health care professionals, the Congress promotes exchange of basic/clinical science ideas in an effort to improve outcomes for patients.

For further information: www.kenes.com/Parkinson

June 7-11, 2009 Paris, France

EXHIBITOR AREA FLOOR PLAN





Committed to Innovation in the Neurosciences

Schering-Plough is an innovation-driven, science-centered global health care company. Through our own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. In addition to being a core part of our global heritage, the Neurosciences are now a large and growing component of our extensive global Research and Development organization. Schering-Plough is committed to better understanding the basis of CNS disorders and to creating innovative solutions for the needs of patients.

 **Schering-Plough**

www.schering-plough.com

Copyright © 2009, Schering Corporation, Kenilworth NJ 07033

0910010



The *Movement* Disorder Society

14TH International Congress of Parkinson's Disease AND Movement Disorders

Save the Date



Buenos Aires
ARGENTINA June 13-17
2010



The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

GUIDED POSTER TOURS

GUIDED POSTER TOUR I

Hall Bordeaux, Level 3

13:00 - 14:30

Monday, June 8

Ataxia

- Mo-3** Presymptomatic markers of neurodegeneration in SCA17. A multimodal imaging approach by transcranial sonography, MRI and PET
K. Brockmann, M. Reimold, C. Globas, T.K. Hauser, J.H. Machulla, U. Walter, A. Rolfs, L. Schoels (Tuebingen, Germany)
- Mo-9** The cerebellar phenotype of adult-onset Sandhoff disease: Three new cases
C.C.S. Delnooz, D.J. Lefeber, S. Hoffjan, J. Schelhaas, B.P.C. van de Warrenburg (Nijmegen, Netherlands)
- Tu-3** A new phenotype (SAP) for the spinocerebellar ataxias resulting from senataxin, aprataxin, and protein kinase C gamma gene mutations
M. Feldman, J.J. Esper, A. Ahmed (Cleveland, Ohio)
- Tu-8** Restless Legs syndrome and sleep disturbance in Friedreich ataxia
B. Högl, S. Hering, B. Frauscher, V. Gschliesser, W. Poewe, S.M. Boesch (Innsbruck, Austria)
- Tu-11** Spinocerebellar ataxia 14: Study of a Norwegian family with a novel mutation in exon 5 in the PRKCC gene
J. Koht, G. Stevanin, E. Mundwiller, A. Durr, A. Brice, C.M.E. Tallaksen (Paris, France)
- We-9** Genetic heterogeneity of SCA linked to chromosome 15?
I.N. Petrovic, A. Weissbach, A. Djarmati, K. Lohmann, N. Dragasevic, C. Zuhlke, M. Svetel, C. Klein, V.S. Kostic (Belgrade, Serbia)
- We-12** Ataxia with ophthalmoplegia and/or sensory neuropathy is frequently caused by POLG mutations
C. Schulte, M. Synofzik, T. Gasser, L. Schöls (Tübingen, Germany)
- Th-2** Movement disorders in ataxia-telangiectasia
A.G. Shaikh, T.O. Crawford, D.S. Zee, H.A. Jinnah (Baltimore, Maryland)
- Th-4** Genotype-Phenotype (G2P) correlations in SCA12
A.K. Srivastava, F. Mohammed, I. Singh, M.V. Padma, M. Mukerji, M. Behari (New Delhi, Delhi, India)
- Th-10** Spinocerebellar ataxia type 2: clinical, molecular, neurochemical and electrophysiological study of the mutation in 106 Cuban families
L. Velazquez-Perez, G. Sanchez-Cruz, L. Galicia-Polo, G. Auburger, J. Garcia-Rodriguez, R. Rodriguez-Laborda, L. Almaguer-Mederos, D. Coello-Almarales, J. Laffita-Mesa, R. Aguilera-Rodriguez, C. Gonzalez, N. Canales-Ochoa (Holguin, Cuba)

Drug-induced Movement Disorders

- Mo-40** Tardive chorea secondary to low dose quetiapine
F. Amjad, S.E. Lo (Washington, District of Columbia)
- Mo-41** Could tardive dystonia be cured with botulinum toxin treatment?
M. Anca-Herschkovitsch (Holon, Israel)
- Tu-42** Manganese-induced extrapyramidal symptoms: Methcathinone encephalopathy
D. Ince Gunal, K. Agan, H. Horozoglu, P. Kahraman Koytak (Istanbul, Turkey)
- Tu-43** Levosulpiride-induced hemichorea
S.Y. Kang, H.-I. Ma, Y.J. Kim, S. Jung, S.-B. Kwon, S.H. Hwang (Seoul, Republic of Korea)
- Tu-44** Clinical course of ephedrone encephalopathy
M. Kapianidze, I. Khatiashvili, M. Megrelishvili, N. Kvirkvelia (Tbilisi, Georgia)
- Tu-45** Ephedrone encephalopathy: Treatment approaches
I. Khatiashvili, M. Kapianidze, M. Megrelishvili, K. Akhvlediani (Tbilisi, Georgia)
- Tu-46** Akathisia and second-generation antipsychotic drugs
R. Kumar, P. Sachdev (Woden, ACT, Australia)
- We-43** Effects of risperidone at "protective" doses on balance control in healthy individuals
E. Pourcher, H. Cohen, P. Corbeil, M. Simoneau, J.-F. Rodrigue (Quebec, Quebec, Canada)
- We-44** Acute onset tremor associated with combination of chipmax and fluoxetine
A.Q. Rana (Toronto, ON, Canada)
- Th-41** Two year follow up in ephedrone induced parkinsonism with dystonia
Y. Sanotsky, M. Selikhova, L. Fedoryshyn, Y. Matvienko, I. Komnatska, M. Kyrylchuk, A. Friedman, A.J. Lees (London, United Kingdom)
- Huntington's disease and Chorea, Non-Huntington's**
- Mo-111** Dopamine D2 receptors vulnerability in Huntington's disease: A role of the Rho/ROCK signaling pathway
S. Betuing, C. Deyts, E. Martin, N. Bouveyron, B. Galan-Rodriguez, D. Charvin, E. Roze, J. Caboche (Paris, France)
- Mo-112** A phase 2 trial of minocycline in Huntington's disease
M.E. Cudkowicz, M. McDermott, R. Doolan, F. Marshall, K. Kieburtz, HSG (Charlestown, Massachusetts)
- Tu-107** Acoustic analysis of voice in Huntington's disease patients
M.J. Velasco, I. Cobeta, G. Martín, H. Alonso-Navarro, F.J. Jiménez-Jiménez (Madrid, Spain)
- Tu-108** Neuroprotective effects of kynurenic acid analog in a transgenic mouse model of Huntington's disease
P. Klivenyi, D. Zadori, F. Fulop, J. Toldi, L. Vecsei (Szeged, Hungary)

Please see page 19 for information on how to participate in a Guided Poster Tour

GUIDED POSTER TOURS

Tu-110 An ADORA2A polymorphism modifies age at onset in Huntington's disease
 S. Burnouf, C.-M. Dhaenens, C. Simonin, E. Vanbrussel, A. Duhamel, L. Defebvre, C. Duru, I. Vuillaume, C. Cazeneuve, P. Charles, P. Maison, S. Debruxelles, C. Verny, H. Gervais, J.-P. Azulay, C. Tranchant, A.-C. Bachoud-Levi, A. Dürr, L. Buée, B. Sablonnière, D. Blum, P. Krystkowiak, Huntington French Speaking Network (Amiens, France)

We-31 Movement disorders associated with diabetes mellitus: A prospective case series
 M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Arrambide-García, T. Corona (Mexico City, Mexico)

We-109 Social intelligence in Huntington's disease
 S.L. Mason, M. Armstrong, A.A.O. Goodman, R.A. Barker (Cambridge, Cambridgeshire, United Kingdom)

We-111 Dysfunctional error monitoring in the anterior cingulate cortex in prediagnostic and manifest HD during an anti-saccade task
 J.D. Rupp, T. Blekher, M. Dzemidzic, V. Bragulat, J.D. West, J. Wojcieszek, A.J. Saykin, D.A. Kareken, T. Foroud (Indianapolis, Indiana)

We-114 DNA instability in replicating Huntington's disease lymphoblasts
 M. Cannella, V. Maglione, T. Martino, G. Ragona, L. Frati, G.-M. Li, F. Squitieri (Pozzilli, IS, Italy)

Th-116 The degree of atrophy of striatum and pallidum in preclinical Huntington's disease strongly predicts estimated years to clinical onset
 D. Stoffers, J. Kuperman, S. Sheldon, D.J. Hagler, J. Goldstein, A.M. Dale, J. Corey-Bloom, A.R. Aron (San Diego, California)

Neuroimaging

Mo-148 FMRI correlates of ideomotor apraxia in Parkinson's disease
 T. Foki, N. Klinger, A. Geissler, J. Rath, T. Steinkellner, I. Hoellinger, S. Gruber, D. Haubenberger, J. Lehrner, G. Pusswald, G. Grabner, S. Trattnig, W. Pirker, E. Auff, R. Beisteiner (Vienna, Austria)

Tu-133 Cortico-striatal activation during implicit sequence learning in Parkinson's disease with deep brain stimulation of the subthalamic nucleus
 M. Jahanshahi, L. Wilkinson, G. Hotton, Y. Tai, N. Pavese, D.J. Brooks (London, United Kingdom)

Tu-146 A systematic, comprehensive, blinded radiological study of MR findings in pathologically confirmed PSP, MSA and PD
 L. Massey, D. Paviour, S. O'Sullivan, D. Burn, J. Holton, T. Revesz, A. Lees, R. Jager, C. Micallef (London, United Kingdom)

We-124 Usefulness of cardiac ^{123}I -MIBG scintigraphy in the differential diagnosis of parkinsonism
 R. Miyamoto, H. Shibayama, F. Katada, S. Sato, T. Fukutake (Kamogawa City, Chiba, Japan)

We-129 Diffusion weighted imaging of the olfactory tract and its association with hyposmia in PD
 M. Nocker, K. Seppi, M. Schocke, R. Esterhammer, I. Virgolini, S. Boesch, W. Poewe, C. Scherfler (Innsbruck, Austria)

We-146 Metabolic-morphometric correlates of preclinical compensation in asymptomatic heterozygous PINK1 mutation carriers
 K. Reetz, C. Eggers, J. Hagenah, C. Gaser, H.R. Siebner, Y. von Cramon, G.R. Fink, C. Klein, R. Hilker, F. Binkofski (Lubeck, Germany)

Th-134 Changes in brain metabolism and dysphagia in Parkinson's disease
 A. Kikuchi, A. Takeda, T. Baba, N. Sugeno, M. Kobayashi, T. Hasegawa, E. Mori, Y. Itoyama (Sendai, Japan)

Th-141 Equally normalized motor activation in medicated Parkin-associated and sporadic PD
 T. van Eimeren, C. Buhmann, J. Hagenah, P.P. Pramstaller, H.R. Siebner, C. Klein (Toronto, Canada)

Th-140 Tonic stimulation of the orbitofrontal cortex by dopamine agonists in PD wipes out reward processing and increases risk taking behaviour: Are they at risk of gambling?
 T. van Eimeren, B. Ballanger, G. Pellecchia, J. Miyasaki, R. Chuang, T. Steeves, A.E. Lang, A.P. Strafella (Toronto, Canada)

Th-142 Genotype-related changes in brain activity are influenced by the speed of task performance in non-manifesting carriers of a single mutant Parkin or PINK1 allele
 B.F.L. van Nuenen, B.R. Bloem, J.P.M. van der Vegt, M.M. Weiss, F. Binkofski, C. Klein, H.R. Siebner (Nijmegen, Netherlands)

GUIDED POSTER TOUR II

Hall Bordeaux, Level 3

13:00 - 14:30

Tuesday, June 9

Dementia in Movement Disorders

Mo-118 Mesencephalic ^{123}I -FP-CIT uptake differentiates Lewy body dementia from other parkinsonisms
 F. Roselli, N.M. Pisciotta, L. Catalano, D. Martino, P. Livrea, G. Rubini, G. Defazio (Bari, Italy)

Please see page 19 for information on how to participate in a Guided Poster Tour

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

GUIDED POSTER TOURS

Mo-117 Association of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A ¹²³I-FP-CIT SPECT study

F. Roselli, N.M. Pisciotta, M. Pennelli, M.S. Aniello, M.F. De Caro, E. Ferrannini, D. Liuzzi, B. Tartaglione, G. Defazio, G. Rubini, P. Livrea (Bari, Italy)

Mo-119 Prevalence of parkinsonism and other movement disorders in outpatients with Alzheimer's disease using cholinesterase inhibitors and/or memantine

G. Fabiani, H. Teive, R.P. Munhoz, N. Becker (Curitiba, Parana, Brazil)

Tu-113 Rapidly progressive diffuse Lewy body disease

C. Gaig, F. Valldeoriola, S. Llufrí, M.J. Rey, E. Tolosa (Barcelona, Spain)

Tu-115 Computerized tracing in Huntington patients: A standard measure for hyperkinetic activity

S. Thanendarajan, A. Hoffmann, B. Landwehrmeyer, J. Andrich, P.H. Kraus (Bochum, Germany)

We-115 Quantitative map of hypoperfusion in 62 stereotactic cerebral cortical segments by IMP-SPECT reveals a specific pattern of Lewy body dementia

K. Ohta, M. Seki, Y. Shinohara (Tachikawa, Tokyo, Japan)

We-116 Whole brain diffusion tensor imaging in Parkinson's disease, Parkinson's disease with dementia and dementia with Lewy bodies

B. Park, J.-H. Seo, H.-J. Park, S.K. Song, Y.H. Sohn, P.H. Lee (Seoul, Korea)

We-117 The CERAD-(plus) neuropsychological battery does not clearly differentiate Parkinson's disease dementia from Alzheimer's disease and mixed dementia

G. Ransmayr, G. Baumgartner, A. Fuchs, V. Bayr, M. Stefflbauer, H. Traegner, C. Dorninger (Linz, Austria)

We-118 Olfactory dysfunction in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)

P. Robowski, J. Slawek, E. Narozanska, M. Schinwelski, E.J. Sitek, W. Kucharska, B. Brockhuis, P. Lass, D. Wieczorek, M. Dubaniewicz, B. Jasinska-Myga, M.C. Baker, R. Rademakers, Z.K. Wszolek (Gdansk, Pomorskie, Poland)

Th-117 Visual hallucinations are related to gray matter volume in the dorsal visual pathway in Dementia with Lewy bodies and in the orbitofrontal cortex in Parkinson's disease with dementia

C. Sanchez-Castaneda, B. Ramirez-Ruiz, R. Rene, J. Campdelacreu, J. Gascon, C. Falcon, M. Calopa, S. Jauma, M. Juncadella, C. Junque (Barcelona, Spain)

Neuropharmacology

Mo-151 A pharmacoeconomic evaluation of botulinum toxin A therapy in the Philippines

J.T. Colacion, L.G. Fugoso, Jr., R.D.G. Jamora (Manila, Philippines)

Mo-153 "Espresso coffee" for the treatment of excessive daytime sleepiness in Parkinson's disease: Results of four pilot n-of-one clinical trials

J.J. Ferreira, L. Correia-Guedes, R.A. Freire, M. Coelho, M.M. Rosa, O. Rascol, C. Sampaio (Lisbon, Portugal)

Mo-154 A systematic review of the incidence of fatigue as an adverse event in placebo-controlled trials for Parkinson's disease

J.J. Ferreira, T. Teodoro, D. Pires, T. Mestre, M. Coelho, M.M. Rosa, C. Sampaio (Lisbon, Portugal)

Tu-152 Valvular heart regurgitation and pergolide in Parkinson's disease: Follow-up of an observational study

C. Jean-Christophe, B. Anne-Marie, L. Lucette, I. Richard (Paris, France)

Tu-154 Pore-forming iron-induced alpha-synuclein oligomers – A target for developing compounds against pathological protein aggregation

J. Levin, K. Boetzel, T. Hoegen, M. Kostka, H. Kretzschmar, A. Giese (Munich, Germany)

We-153 Overexpression of cannabinoid CB2 receptors results in decreased behavioral and neurochemical vulnerability to intracaudate administration of 6-hydroxydopamine

A. Ternianov, M.S. Garcia-Gutierrez, M.J. Cano, F. Navarrete, J.M. Perez-Ortiz, C. de Cabo, C. Leiva, M.F. Galindo, J. Manzanares (Alicante, Spain)

We-155 An environmental xenobiotic compound realise an neuroprotective effect against neurodegeneration of dopaminergic neurons from striatum nigra

A.G. Mitiitelu (London, United Kingdom)

We-156 A metanalysis of neutralizing antibody conversion following a specific formulation of botulinum toxin type A (BoNTA, Allergan, Inc): An analysis of large clinical trials across five indications

M. Naumann, S. Abu-Shakra, T. Boodhoo, M.A. Miller-Messana, G. Demos, M.F. Brin (Augsburg, Germany)

Th-153 The use of dopamine agonists (DAGs) in "de novo" Parkinson's disease patients (PDpts) first diagnosed after 70years old

J.M. Rabey, E. Dubronevsky, A. Miniovich, T. Prokhovic (Beer Yakov, Israel)

Th-156 Botulinum toxin type A injection as a novel treatment for kinetic tremors associated with FXTAS

L. Zhang, L.L. Lua, P. Adams, R.J. Hagerman (Sacramento, California)

Non-Motor Manifestations of Parkinsonism

Mo-156 Sexual Health in Parkinson's disease

J. Azevedo, A. Palha, M.J. Rosas, M. Esteves, M.A. Vieira-Coelho, C. Sousa, R. Fonseca, P. Linhares, C. Garrett, R. Vaz (Porto, Portugal)

Please see page 19 for information on how to participate in a Guided Poster Tour

GUIDED POSTER TOURS

- Mo-158 Effects of continuos application of L-dopa/carbidopa gel on psychiatric symptoms in advanced Parkinson's disease (PD)**
K. Fox, T. Fox, K. Dietrich, A. Gies, H. Honig, R. Chaudhuri, A. Antonini, P. Martinez-Martin, A. Rüssmann, P. Odin (Bremerhaven, Bremen, Germany)
- Tu-157 Regulation of movement energetic costs is impaired in pre-symptomatic Huntington's disease (pHD) and in the early stages Parkinson's disease (PD)**
D. Crupi, C. Moisello, A. Di Rocco, B. Perfetti, A. Feigin, D. Eidelberg, M.F. Ghilardi (New York, New York)
- Tu-158 Progressive supranuclear palsy impairs emotion recognition**
B.C.P. Ghosh, A.J. Calder, P. Peers, A.D. Lawrence, J. Hodges, J.M. Rowe (Cambridge, United Kingdom)
- We-158 Limitations of traditional screening tools to detect depression in Parkinson's disease**
J.E. Howard, S. Varanese, D. Penesetti, C. Morrison, S. Hirsch, R. Brown, A. DiRocco (New York, New York)
- We-159 Cognitive impairment in essential tremor without dementia**
J.-S. Kim, I.-U. Song, Y.-S. Shim, K.-S. Lee, Y.-D. Kim, H.-T. Kim (Seoul, Korea)
- Th-158 Prevalence of pseudobulbar affect in movement disorders and its relationship with mood symptoms**
R.E. Strohd, M.S. Cartwright, M.S. Okun, M.S. Siddiqui (Winston-Salem, North Carolina)
- Th-159 Mood differences between women diagnosed with psychogenic movement disorders and psychogenic seizures**
A.M. Strutt, J. Ferrera, S. Hill, M.K. York, L. Uber-Zak, T. Fogel, J. Jankovic (Houston, Texas)
- Th-160 Hemichorea-hemiballism caused by hyperglycemia associated with hypomania in acute stage: A brief report**
C.-S. Su, J.-S. Liu, M.-Y. Lan, Y.-Y. Chang (Kaohsiung, Taiwan)
- We-157 Autonomic and sensory symptoms are frequent and of mild severity in patients with incident, untreated PD**
B. Muller, K. Haugarvoll, G.O. Skeie, J.P. Larsen, O.-B. Tysnes (Bergen, Norway)

Parkinson's disease: Clinical Trials

- Mo-177 Observer bias in biological/surgical trials of novel Parkinson's disease therapies**
R.L. Alterman, M. Tagliati, W. Olanow (New York, New York)
- Mo-193 Cholinergic augmentation in frequently falling subjects with Parkinson's disease**
K.A. Chung, B.M. Lobb, J.G. Nutt, F. Horak (Portland, Oregon)

- Tu-185 Efficacy of preladenant, a novel A_{2A} antagonist, as an adjunct to levodopa for the treatment of Parkinson's disease**
R.A. Hauser, E. Pourcher, F. Micheli, V. Mok, M. Onofrj, S.B. Huyck, K. Wolski, M. Cantillon (Tampa, Florida)
- Tu-202 Evaluation of a computerized telephone system to monitor falls**
M.A. van der Marck, M.Ph.C. Klok, S. Overeem, B.R. Bloem, M. Munneke (Nijmegen, Netherlands)
- We-182 Amantadine given as adjuvant to levodopa in the treatment of levodopa induced dyskinesias and motor fluctuations in Parkinson's disease**
N. Oztekin, F. Oztekin, H. Okkan, S. Bilen, F. Ak (Ankara, Turkey)
- We-184 Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson's disease: Assessment with the revised MDS-UPDRS**
W. Poewe, R. Hauser, A.E. Lang, ADAGIO Investigators (Innsbruck, Austria)
- We-192 A longitudinal program for biomarker development in Parkinson's disease**
B. Ravina, C. Tanner, D. DiEuliis, E. Flagg, I. Shoulson, Parkinson Study Group, LABS-PD Investigators (Rochester, New York)
- We-199 Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease**
A. Schapira, P. Barone, R.A. Hauser, Y. Mizuno, W. Poewe, O. Rascol, M. Busse, N. Juvel, Pramipexole ER Studies Group (London, United Kingdom)
- Th-182 Ropinirole prolonged release is effective in reducing "off" time in patients with advanced Parkinson's disease even at low doses**
F. Stocchi, L. Giorgi, N. Earl, R. Pahwa (Rome, Italy)
- Th-192 Motivations and concerns of Parkinson's disease patients to participate in clinical trials**
A. Valadas, M. Coelho, M. Finisterra, A. Noronha, M. Rosa, C. Sampaio, J. Ferreira (Lisbon, Portugal)

GUIDED POSTER TOUR III

Hall Bordeaux, Level 3

13:00 - 14:30

Wednesday, June 10

Basic Science

- Mo-15 The role of muscarinic transmission in the substantia nigra reticulata of normal and 6-OHDA hemilesioned rats**
D.R. Andersson, E. Björnsson, F. Bergquist, H. Nissbrandt (Goteborg, Sweden)

Please see page 19 for information on how to participate in a Guided Poster Tour

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

GUIDED POSTER TOURS

- Mo-17 Identification and functional characterization of a novel mutation in the mortalin/GRP75 gene in German Parkinson's disease patients**
L.F. Burbulla, C. Schelling, B. Maurer, L. Schöls, O. Riess, R. Krüger (Tubingen, Germany)
- Mo-20 Aging and Parkinson's disease: A stochastic acceleration hypothesis**
T.J. Collier, N.M. Kanaan, J.H. Kordower (Cincinnati, Ohio)
- Mo-30 Comparative analyses of Purkinje cell gene expression profiles reveal common molecular abnormalities in different polyglutamine diseases**
B. Friedrich, P. Euler, R. Ziegler, A. Kuhn, B. Landwehrmeyer, C. Weiller, B. Zucker (Freiburg, Baden-Wuerttemberg, Germany)
- Tu-16 SNARE protein accumulation in a model of early Parkinson's disease**
P. Garcia Reitbock, O. Anitchtchik, G.K. Tofaris, M. Goedert, M.G. Spillantini (Cambridge, United Kingdom)
- Tu-30 Modulation of mitochondrial morphology and function by interaction of Omi/HtrA2 with the fusion protein OPA1 – Implications for neurodegeneration**
N. Kieper, K. Holmström, D. Ciceri, L.M. Martins, P.J. Kahle, R. Krüger (Tuebingen, Germany)
- Tu-32 Mitochondrial dysfunction and impaired lysosomal degradation due to loss of Parkinson's disease associated protein DJ-1**
G. Krebiehl, S. Ruckerbauer, J. Waak, H. Wolburg, Z. Gizatullina, F.N. Gellerich, O. Riess, P.J. Kahle, T. Proikas-Cezanne, R. Krüger (Tubingen, Germany)
- We-13 Proteomic analysis of the substantia nigra in patients with Parkinson's disease**
V. Licker, L. Dayon, N. Turck, M. Côte, N. Rodrigo, D.F. Hochstrasser, J.-C. Sanchez, P.R. Burkhard (Geneva, Switzerland)
- We-17 Detection of elevated levels of alpha-synuclein oligomers in cerebrospinal fluid from patients with Parkinson's disease and dementia with Lewy bodies**
W. Maetzler, M.M. Qureshi, D. Berg, M. Synofzik, T. Gasser, O.M.A. El-Agnaf (Tuebingen, Germany)
- Th-27 Isolation and characterization of genetically modified neural stem cells by fluorescence-activated cell sorting (FACS) analysis**
M. Tani, T. Nihira, H. Hayakawa, N. Hattori, Y. Mizuno, H. Mochizuki (Tokyo, Japan)
- Electrophysiology**
- Mo-38 Integrative function of single neurons in the human subthalamic nucleus during checking behavior**
P. Burbaud, M.-L. Welter, M. Goillandeau, A.-L. Clair, P. Sauleau, M. Simonetta-Moreau, S. Chabardes, S. Besnard, H. Magnie-Mauro, J. Coste, L. Mallet (Bordeaux, Paris, France)
- Tu-37 Increased excitability induced by tDCS can unmask mirror movements**
J.E. Dundas, G.W. Thickbroom, A. Fox, F.L. Mastaglia (Perth, Western Australia, Australia)
- Th-35 Real-time analysis of EEG in the elucidation of volition**
L. Schneider, E. Houdayer, O. Bai, A. Ellenstein, M. Hallett (Bethesda, Maryland)
- Th-36 Neuronal mechanisms of motor signals transmission in nonspecific (CM-Pf) and motor (Voi) human brain thalamic nuclei in spastic torticollis patients**
A.S. Sedov, S.N. Raeava (Moscow, Russian Federation)
- Mo-234 Pedunculopontine and subthalamic deep brain stimulation affects motor cortex network function**
B.R. Aravamuthan, C.E. Hatch, R.A. French, N.I. Novikov, D.A. Bergstrom, J.R. Walters (Bethesda, Maryland)
- Mo-235 Lack of efficiency of levodopa treatment on motor cortex excitability in dyskinetic patients with Parkinson's disease**
L. Barbin, C. Leux, C. Meyniel, P. Sauleau, J.M. N'Guyen, Y. Pereon, P. Damier (Nantes, France)
- Mo-241 Cortical plasticity in Parkinson's disease (PD) with levodopa-on**
W.-L. Chuang, R.-S. Chen, Y.-Z. Huang, S.-C. Lai, C.-S. Lu (Taoyuan, Taiwan)
- Mo-243 Modulation of sensorimotor integration by intermittent theta-burst stimulation in Parkinson's disease**
A. Degardin, F. Cassim, D. Devos, L. Defebvre, P. Derambure, H. Devanne (Lille, France)
- Tu-236 Resonance in subthalamo-cortical circuits in Parkinson's disease**
A. Eusebio, A. Pogosyan, S. Wang, B. Averbeck, L. Doyle Gaynor, S. Cantiniaux, T. Witjas, P. Limousin, J.-P. Azulay, P. Brown (London, United Kingdom)
- Tu-245 Lack of plasticity in the motor cortex (M1) is a primary marker of Parkinson's disease (PD) and is L-dopa sensitive only when motor dysfunction sets in: A TMS study**
T. Joseph, S. Meunier, A. Kishore (Thiruvananthapuram, Kerala, India)
- Genetics and Epidemiology**
- Mo-78 Prevalence and incidence study of Parkinson's disease in the metropolitan city of Kolkata, India – A community based study**
S.K. Das, A. Hazra, B.K. Ray, A. Misra, M. Ghosal, T.K. Banerjee, T. Roy, D.K. Raut, A. Chaudhuri (Kolkata, West-Bengal, India)
- Tu-75 Study of the prevalence of Parkinson's disease using dopamine transporter imaging**
J.S. Kim, J.M. Kim, K.W. Kim, Y.K. Kim, S.E. Kim, B.S. Jeon (Seong nam-si, Kyeong ki -do, Korea)

Please see page 19 for information on how to participate in a Guided Poster Tour

GUIDED POSTER TOURS

- Tu-79 NSAID use and the risk of Parkinson's disease: The influence of comorbidity**
J.A. Driver, G. Logroscino, J.M. Gaziano, T. Kurth (Paris, France)
- Tu-80 Co-occurrence of substantia nigra hyperechogenicity and putative premotor signs as well as risk factors of PD in a large cohort older than 50 years**
I. Liepelt, S. Behnke, K.J. Schweitzer, B. Wolf, U. Dillmann, A. Gaenslen, A. Di Santo, J. Godau, D. Berg (Tuebingen, Germany)
- Th-81 A 15-year population-based longitudinal study of incidence of Parkinson's disease (PD) and parkinsonian syndromes (PS) in an elderly French population (PAQUID)**
F. Perez, C. Helmer, S. Auriacombe, J.-F. Dartigues, F. Tison (Pessac, France)
- Mo-91 CTCF depletion in the FXN gene constitutes an epigenetic switch in Friedreich ataxia**
S.I. Bidichandani, Y. Chutake, I. De Biase (Oklahoma City, Oklahoma)
- Tu-89 The phenotype of the 202A deletion in the Parkin gene in two large Muslim Israeli-Arab kindreds**
S. Hassin-Baer, N. Hattori, C. Cohen, M. Massarwa, S.D. Israeli-Korn, R. Inzelberg (Tel Hashomer, Israel)
- Tu-98 Comprehensive molecular genetic analysis of the LRRK2 gene in a UK familial Parkinson's disease cohort**
A.J. Lewthwaite, T.D. Lambert, F.E. Marely, N.W. Wood, D.J. Nicholl, K.E. Morrison (Birmingham, West Midlands, United Kingdom)
- We-99 Parkinsonism and early cortical involvement in a Swedish family with alpha-synuclein Ala53Thr mutation**
A.J. Puschmann, O.A. Ross, C. Vilarino-Guell, S.J. Lincoln, Z.K. Wszolek, M.J. Farrer, H. Widner, C. Nilsson (Lund, Sweden)
- Th-99 Genome-wide association study for sporadic Parkinson's disease**
T. Toda, W. Satake, Y. Nakabayashi, I. Mizuta, T. Yoshikawa, M. Yamamoto, N. Hattori, M. Murata, Y. Nakamura, Japan PD Gene Consortium (Suita, Osaka, Japan)
- Mo-328 Motor and cognitive effects of subthalamic nucleotomy in one hundred patients with Parkinson's disease**
L. Alvarez, R. Macias, N. Pavon, M.C.O. Rodriguez, J.A. Obeso (Havana City, Cuba)
- Mo-339 Localization and anatomo-clinical correlation of DBS electrodes contacts in the MLR in Parkinson's disease**
S. Chabardès, L. Goetz, N. Torres, M. Ferraye, E. Seigneuret, B. Debu, B. Piallat, V. Fraix, C. Mainieri, E. Bardinet, J. Yelnik, J.F. Lebas, P. Pollak, A.L. Benabid (Grenoble, France)
- Mo-341 Subthalamic nucleus-deep brain stimulation modulates thermal sensation and pain thresholds in Parkinson's disease**
D. Ciampi de Andrade, Y. Beaugendre, J.-M. Gurruchaga, D. Boërio, C. Goujon, H. Lepetit, S. Palfi, J.-P. Lefaucheur (Creteil, France)
- Tu-330 Effects of PPN area stimulation on gait disorders in PD**
M.U. Ferraye, B. Debû, V. Fraix, L. Goetz, S. Chabardès, E. Lhommée, C. Ardouin, C. Lagrange, P. Krack, E. Seigneuret, A.L. Benabid, P. Pollak (Grenoble, France)
- Tu-331 Effects of unilateral pedunculopontine nucleus deep brain stimulation (PPN-DBS) in parkinsonian patients with prominent freezing of gait (FOG)**
N.B. Galifianakis, P.A. Starr, P.S. Larson, G.A. Glass, M.M. Volz, S.L. Heath, J.L. Ostrem (San Francisco, California)
- We-324 Pallidotomy abolishes STN lesion induced dyskinésias in Parkinson's disease without further deterioration**
R. Macias, N. Pavon, G. Lopez, M.C.R. Oroz, J.A. Obeso (Havana City, Cuba)
- We-328 Brain tissue changes following deep brain stimulation**
K. Nolte, M. Kronenbuerger, J. Burgunder, V. Coenen, J. Weis, J. Krauss (Aachen, Germany)
- Th-340 Gamma knife subthalamotomy in Parkinson's disease: Long-term follow-up**
T. Witjas, J.P. Azulay, A. Eusebio, J.C. Peragut, J. Régis (Marseille, France)

Surgical Therapies

- Mo-348 Combined neurostimulation therapy (DBS and SCS) for orthostatic tremor: A case report**
S. Biguzzi, M. Haefele, C. Lettieri, C. Mantovan, G. Devigili, C. Conti, M. Brollo, G. Trincia, E. Cagliari, M. Bevilacqua, M. Barca, P. Fontana, G. Pinato, R. Eleopra (Mestre-Venice, Italy)
- Tu-352 Long-term follow-up of pallidal deep brain stimulation for secondary dystonias**
I.U. Isaias, J. Volkmann, R.L. Alterman, M.H. Mehdorn, M. Pinsker, R. Reese, G. Deuschl, M. Tagliati (Monza, Italy)

Please see page 19 for information on how to participate in a Guided Poster Tour

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

Ataxia	
Mo-1	Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France M. Anheim, M. Fleury, B. Monga, V. Laugel, D. Chaigne, G. Rodier, E. Ginglinger, C. Boulay, S. Courtois, N. Drouot, J.-P. Delaunoy, M. Fritsch, D. Stoppa-Lyonnet, C. Tranchant, M. Koenig (Strasbourg, France)
Mo-2	Comparative study of prevalence of depression between autosomal dominant ataxia and sequel of cerebrovascular accident – Organic component (cerebellar) of depression N.F. Bernardo, R.A. Krushevsky, I.B.M. Barreto, C. Reis, R.A.R.C. Adry, A.S. Andrade-Filho (Salvador, Bahia, Brazil)
Mo-3	Presymptomatic markers of neurodegeneration in SCA17. A multimodal imaging approach by transcranial sonography, MRI and PET K. Brockmann, M. Reimold, C. Globas, T.K. Hauser, J.H. Machulla, U. Walter, A. Rolfs, L. Schoels (Tuebingen, Germany)
Mo-4	Autosomal dominant cerebellar ataxia- frequency analysis and clinical characterization of 45 families from Portugal P. Bugalho, J. Vale, I. Silveira, J. Sequeiros, J. Guimarães, P. Coutinho (Lisboa, Portugal)
Mo-5	The pattern of instability and its dependence on posture in spino-cerebellar ataxia type 6 (SCA6) L.M. Bunn, J.F. Marsden, P. Giunti, B.L. Day (London, United Kingdom)
Mo-6	Vestibular processing for balance control in spino-cerebellar ataxia type 6 (SCA6) L.M. Bunn, P. Giunti, J.F. Marsden, B.L. Day (London, United Kingdom)
Mo-7	Phenotype-genotype correlation in autosomal dominant cerebellar ataxias (SCA): MRI findings distinguish between forms with point mutations and polyglutamine expansions P. Charles, A. Tourbah, A. Brice, D. Alexandra (Paris, France)
Mo-8	Abetalipoproteinemia – Long term observation M. Dec, M. Rudzinska, M. Krawczyk, M. Wojcik, T. Tomaszewski, A. Szczudlik (Cracow, Poland)
Mo-9	The cerebellar phenotype of adult-onset Sandhoff disease: Three new cases C.C.S. Delnooz, D.J. Lefeber, S. Hoffjan, J. Schelhaas, B.P.C. van de Warrenburg (Nijmegen, Netherlands)
Mo-391	Idiopathic ataxia responsive to a gluten-free diet N.F. Bernardo, R.A. Krushevsky, I.B.M. Barreto, M.N.C. Pereira, A.S. Andrade-Filho (Salvador, Bahia, Brazil)
Mo-392	Frontal ataxia as a late sequel of severe traumatic brain injury N.F. Bernardo, R.A. Krushevsky, I.B.M. Barreto, M.N.C. Pereira, A.S. Andrade-Filho (Salvador, Bahia, Brazil)
Tu-1	Gait and limb ataxia in posterior circulation stroke: Clinical-MRI correlations C. Deluca, S. Mazzucco, A. Di Matteo, A.M. Basile, C. Baracchini, G. Meneghetti, D. Bonifati, M. Ottina, T. Mesiano, M. Bonometti, A. De Boni, D. Idone, E. Turinese, C. Palestini, A. Tonon, L. Piron, P. Lochner, F. Pizzini, G.P. Tomelleri, P. Bovi, B. Bonetti, G. Moretto, A. Fiaschi, M. Tinazzi (Verona, Italy)
Tu-2	Ataxia with oculomotor apraxia type 2: Two Spanish families and three novel mutations in the senataxin gene I.J. Posada, J. Gazulla, C. Domínguez-González, M. Hernández-Hernández, J. Esteban, J. Díaz-Guzmán, M. Koenig, A. García-Redondo (Madrid, Spain)
Tu-3	A new phenotype (SAP) for the spinocerebellar ataxias resulting from senataxin, aprataxin, and protein kinase C gamma gene mutations M. Feldman, J.J. Esper, A. Ahmed (Cleveland, Ohio)
Tu-4	Spinocerebellar ataxia type 7 in four Venezuelan families: Clinical characterization and genetic features M. Gallardo, A. Soto (Caracas, Venezuela)
Tu-5	Clinical characterization of a Venezuelan family with spinocerebellar ataxia type 10 M. Gallardo, A. Soto (Caracas, Venezuela)
Tu-6	A clinico-pathological report of SCA17 associated with a heterozygote small trinucleotide expansion G. Garraux, G. Moonen, D. Manuel (Liege, Belgium)
Tu-7	Inter-disciplinary therapy assessment and intervention in ataxia: Current clinical model and case study P. Giunti, M.J. Loucas, J.L. Hurford, C.A. Peplow, B. Taylor, H. Wilkinson (London, United Kingdom)
Tu-8	Restless Legs syndrome and sleep disturbance in Friedreich ataxia B. Högl, S. Hering, B. Frauscher, V. Gschliesser, W. Poewe, S.M. Boesch (Innsbruck, Austria)
Tu-9	Transcranial sonography in Friedreich's ataxia reveals hypoechoogenicity of the substantia nigra S. Hering, H. Stockner, M. Sojer, C. Schmidauer, W. Poewe, S. Boesch (Innsbruck, Austria)
Tu-10	The wide clinical spectrum and nigrostriatal dopaminergic damage in spinocerebellar ataxia type 6 J.-M. Kim, J.-Y. Lee, H.J. Kim, J.S. Kim, Y.K. Kim, S.S. Park, S.E. Kim, B.S. Jeon (Seongnam, Korea)
Tu-11	Spinocerebellar ataxia 14: Study of a Norwegian family with a novel mutation in exon 5 in the PRKCG gene J. Koht, G. Stevanin, E. Mundwiller, A. Durr, A. Brice, C.M.E. Tallaksen (Paris, France)
Tu-12	The Cuban pathological CAG mutation causing SCA2 was introduced by Hispanics and probably originated between 1408CE and 1733CE in the Cuban population J.M. Laffita-Mesa, L. Velázquez-Perez, G. Auburger, S. Gispert, L. Pena-Serrano (Holguín, Cuba)
Tu-13	Loss of CAA interruption in large normal alleles ATX2 is a risk factor to SCA2 gene instability: A haplotype and sequence based study in large Cuban kindreds J.M. Laffita-Mesa, L. Velázquez-Perez, G. Auburger, S. Gispert, G. Sanchez, J. Santiago, R. Rodriguez (Holguín, Cuba)
Tu-392	Fahr's syndrome as a late manifestation of hypoparathyroidism secondary to subtotal thyroidectomy N.F. Bernardo, R.A. Krushevsky, M.N.C. Pereira, I.B.M. Barreto, A.S. Andrade-Filho (Salvador, Bahia, Brazil)
Tu-393	Cerebrovascular accident in parietal lobe leading to voluntary movement disorders – Parietal ataxia N.F. Bernardo, R.A. Krushevsky, M.N.C. Pereira, I.B.M. Barreto (Salvador, Bahia, Brazil)
We-1	Spinocerebellar variant of adrenoleukodystrophy with a novel ABCD1 gene mutation J.-Y. Li, C.-C. Hsu, C.-R. Tsai (Kaohsiung, Taiwan)

ABSTRACT LISTING BY TOPIC

We-2	Safety and tolerability study of lithium carbonate in spinocerebellar ataxia type 1 (SCA1) patients G.J. Lopez, E. Considine, B. McElroy, D. Haubenberger, A. Razzook, H. Zoghbi, M. Hallett (Bethesda, Maryland)	Th-2	Movement disorders in ataxia-telangiectasia A.G. Shaikh, T.O. Crawford, D.S. Zee, H.A. Jinnah (Baltimore, Maryland)
We-3	Sleep pathology characterization in presymptomatic relatives of the SCA2 V.-P. Luis, R.-L. Roberto, C.-O. Nalia, G. Sanchez-Cruz, G.-P. Lourdes, G.-Z. Yanetza, H.-V. Reyes, A.-R. Raul, T.-P. Cira (Holguin, Cuba)	Th-3	SUMO-1 modification modulates transrepression activity but not ubiquitination or subcellular localization of ataxin-3 L. Shen, Y.-F. Zhou, S.-S. Liao, J. Du, J.-G. Tang, B.-S. Tang (Changsha, Hunan, China)
We-4	A need for global networking to clarify phenotypic dilemma in hereditary ataxias: An overview from clinicogenetic analysis of SCA families of Indian origin F. Mohammed, V. Scaria, I. Singh, B. Natt, A. Srivastava, M. Mukerji (New Delhi, India)	Th-4	Genotype-Phenotype (G2P) correlations in SCA12 A.K. Srivastava, F. Mohammed, I. Singh, M.V. Padma, M. Mukerji, M. Behari (New Delhi, Delhi, India)
We-5	Molecular analysis of Friedreich's ataxia (FRDA) mutation in Indian families: Evidence for common founder I.S. Mudila, F. Mohammed, A.K. Srivastava, M. Mukerji, M.V. Padma, S. Jain, M. Bihari (New Delhi, Delhi, India)	Th-5	Degeneration of synapses in spinocerebellar ataxia 6 may depend on disease duration: Neuropathological study of two autopsy cases from a family X.-J. Wang, H. Wang, Y.-J. Xia, B.-S. Tang (Changsha, Hunan, China)
We-6	Dysarthria in Friedreich's ataxia J.E. Folker, B.E. Murdoch, L.M. Cahill, A.P. Vogel, M.B. Delatycki, L.A. Corben (Brisbane, QLD, Australia)	Th-6	Spinocerebellar ataxia types 3 and 10. Progression rate of gait ataxia in a group of 40 patients H.A.G. Teive, R.P. Munhoz, A.C. Dariva, L.C. Werneck, T. Ashizawa (Curitiba, Parana, Brazil)
We-7	Articulatory disturbance in Friedreich's ataxia: An electropalatographic study J.E. Folker, B.E. Murdoch, L.M. Cahill, M.B. Delatycki, L.A. Corben, A.P. Vogel (Brisbane, QLD, Australia)	Th-7	Postural cerebellar axial tremor after Malaria J.T. Teo, O. Swayne, E. Silber (London, United Kingdom)
We-8	Autosomal dominant ophthalmoplegia and ataxia in an Austrian family carrying the SCA28 mutation W. Nachbauer, S. Hering, D. Di Bella, F. Taroni, M. Schocke, W. Poewe, S. Boesch (Innsbruck, Tirol, Austria)	Th-8	A novel mitochondrial ATPase mutation in adult-onset Leigh syndrome presenting with ataxia D. Thyagarajan, M. Krupa, J. Temlett, T. Chataway, P. Blumbergs (Adelaide, South Australia, Australia)
We-9	Genetic heterogeneity of SCA linked to chromosome 15? I.N. Petrovic, A. Weissbach, A. Djarmati, K. Lohmann, N. Dragasevic, C. Zuhlike, M. Svetel, C. Klein, V.S. Kostic (Belgrade, Serbia)	Th-9	Novel compound heterozygous mutations in a family with Sacsin-related ataxia (ARSACS) J. Tsugawa, Y. Tsuboi, Y. Naitoh, H. Inoue, S. Ohma, H. Shimazaki, Y. Takiyama, T. Yamada (Fukuoka, Japan)
We-10	Using a simplified trail making test B to assess visuo-spatial and sequencing abilities in hereditary spinocerebellar ataxias (SCA) E. Pretegiani, G. Veneri, P. Federighi, N.R. Polizzotto, G. Cevenini, F. Rosini, M.T. Dotti, A. Federico, A. Rufa (Siena, SI, Italy)	Th-10	Spinocerebellar ataxia type 2: A clinical, molecular, neurochemical and electrophysiological study of the mutation in 106 Cuban families L. Velazquez-Perez, G. Sanchez-Cruz, L. Galicia-Polo, G. Auburger, J. Garcia-Rodriguez, R. Rodriguez-Laborda, L. Almaguer-Mederos, D. Coello-Almarales, J. Laffita-Mesa, R. Aguilera-Rodriguez, C. Gonzalez, N. Canales-Ochoa (Holguin, Cuba)
We-11	Saccadic movements in SCA2. From disorders to electrophysiological biomarkers for genetic and clinical researchs R.-L. Roberto, V.-P. Luis, C.-O. Nalia, S. Carola, A. Georg, M.-M. Jacqueline, T.-P. Cira, G.-Z. Yanetza (Holguin, Cuba)	Th-393	Detection of cerebellar dysfunction clinically masked by severe sensory ataxia in a patient with Paraneoplastic syndrome T. Shimizu, M. Hamada, Y. Terao, R. Hanajima, M. Tanaka, R. Tsutsumi, H. Kowa, S. Tsuji, Y. Ugawa (Tokyo, Japan)
We-12	Ataxia with ophthalmoplegia and/or sensory neuropathy is frequently caused by POLG mutations C. Schulte, M. Synofzik, T. Gasser, L. Schöls (Tubingen, Germany)		Basic Science
We-387	SCA-2 and periodic limbs movements during sleep with anticipation phenomenon H. Orrego-Castellanos, M. Rodriguez, V. Alastrite, M. Merlos (Mexico City, Mexico)	Mo-10	Expression of GDNF receptors of nigral dopaminergic neurons is preserved during normal aging in humans P.A. Alladi, A. Mahadevan, T.R. Raju, S.K. Shankar, U.B. Muthane (Bangalore, Karnataka, India)
We-388	Objectification of spinocerebellar syndrome in hereditary ataxias by combined dynamic and kinematics motion analysis J. Schwabova, F. Zahalka, Z. Musova, M. Kopeckova, A. Zumrova (Prague, Czech Republic)	Mo-11	Extracellular proteases in experimental parkinsonism: mRNA expression and protein synthesis of MMP-9, plasminogen and tissue-type activator V. Annese, C. Barcia, F. Ros Bernal, A. Gomez, P. Paggi, M.T. Herrero, M.E. De Stefano (Rome, Italy)
Th-1	Postural sways in ataxia-telangiectasia A.G. Shaikh, T.O. Crawford, D.S. Zee, D. Solomon (Baltimore, Maryland)	Mo-12	Increased expression of a T-helper-cell transcriptional factor t-bet in Parkinson's disease Y. Baba, M.-A. Higuchi, Y. Uehara, A. Kuroiwa, T. Yamada (Fukuoka, Japan)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Mo-13** Release your horses: Deep brain stimulation of the subthalamic nucleus improves motor functions at the expense of response inhibition. A H₂¹⁵O PET study
B. Ballanger, T. van Eimeren, E. Moro, A.M. Lozano, C. Hamani, P. Boulinguez, G. Pellecchia, S. Houle, Y.Y. Poon, A.E. Lang, A.P. Strafella (Toronto, Canada)
- Mo-14** Increase of glial IFN- γ and TNF- α in the substantia nigra pars compacta of parkinsonian macaques years after MPTP intoxication
C. Barcia, C.M. Ros, E. Fernandez-Villalba, A. Gomez, V. de Pablos, J. Martin, M.-T. Herrero (Murcia, Spain)
- Mo-15** The role of muscarinic transmission in the substantia nigra reticulata of normal and 6-OHDA hemisioned rats
D.R. Andersson, E. Björnsson, F. Bergquist, H. Nissbrandt (Goteborg, Sweden)
- Mo-16** Chronic L-dopa treatment modifies serotonin function in depression-related structures of the hemiparkinsonian rat brain
C.R. Bishop, K.B. Dupre, C.J. Barnum, T. Button, K.L. Jaunarajs (Binghamton, New York)
- Mo-17** Identification and functional characterization of a novel mutation in the mortalin/GRP75 gene in German Parkinson's disease patients
L.F. Burbulla, C. Schelling, B. Maurer, L. Schöls, O. Riess, R. Krüger (Tubingen, Germany)
- Mo-18** MPP+ impairs autophagic clearance of α -synuclein by interfering the activity of dynein
Z.-L. Cai, J.-J. Shi, Y.-P. Yang, F. Wang, C.-F. Liu (Suzhou, Jiangsu, China)
- Mo-19** Analysis of aggregates dynamics and mitochondrial function in synphilin-1 overexpressing cells
D. Ciceri, G. Krebiehl, N. Kieper, C. Ferrarese, R. Krueger (Monza, Italy)
- Mo-20** Aging and Parkinson's disease: A stochastic acceleration hypothesis
T.J. Collier, N.M. Kanaan, J.H. Kordower (Cincinnati, Ohio)
- Mo-21** Impact of substantia nigra pars compacta lesion on the spontaneous discharge and the electrophysiological properties of identified pyramidal neurons in the rat motor cortex: An *in vivo* study
B. Degos, M. Chavez, J.-M. Deniau, N. Maurice (Paris, France)
- Mo-22** Dopamine turnover decrease accompanies 7-nitroindazole reduction of L-dopa induced dyskinesia
E.A. Del Bel, R.S. Szawka, F.E. Padovan-Neto, C.A. da Silva, J.A. Anselmo-Franci (Ribeirao Preto, Sao Paulo, Brazil)
- Mo-23** Proteasome inhibition induces protein aggregation at the centrosome and disrupts golgi apparatus transport; relevance in the pathogenesis of Parkinson's disease
F.J. Diaz-Corrales, R.M. Rios-Sanchez (Seville, Spain)
- Mo-24** Identification of kinases and phosphatases involved in α -synuclein phosphorylation
S. Gore, A. Siegel, R.L. Robeson, D. Azorsa, S. Mousses, T. Dunckley (Phoenix, Arizona)
- Mo-25** An improved sham stimulation protocol for transcranial direct current stimulation (tDCS)
J.E. Dundas, G.W. Thickbroom, F.L. Mastaglia (Perth, Western Australia, Australia)
- Mo-26** Anodal tDCS over left M1 produces simultaneous bidirectional effects on bilateral M1 excitability
J.E. Dundas, G.W. Thickbroom, F.L. Mastaglia (Perth, Western Australia, Australia)
- Mo-27** Parkin dysfunction results in defective depolarization-induced exocytosis of large dense core vesicles
H. Eguchi, M. Ohara-Imaiizumi, Y. Chikaoka, S. Sato, T. Hatano, S.-I. Kubo, Y. Mizuno, S. Nagamatsu, N. Hattori (Bunkyo, Tokyo, Japan)
- Mo-28** Regulatory role of short interval intracortical inhibition during paired associative stimulation
B. Elahi, R. Chen (Toronto, Ontario, Canada)
- Mo-29** Metabolic activity of the subthalamic nucleus in a primate model of L-dopa unresponsive parkinsonism
P.O. Fernagut, Q. Barraud, E. Bezard, I. Ghorayeb, F. Tison (Bordeaux, France)
- Mo-30** Comparative analyses of Purkinje cell gene expression profiles reveal common molecular abnormalities in different polyglutamine diseases
B. Friedrich, P. Euler, R. Ziegler, A. Kuhn, B. Landwehrmeyer, C. Weiller, B. Zucker (Freiburg, Baden-Wuerttemberg, Germany)
- Mo-31** Only the labile iron pool is increased in parkinsonian substantia nigra
J.J. Galazka-Friedman, A. Wypijewska, A. Jaklewicz, E.R. Bauminger, Z.K. Wszolek, A. Friedman (Warsaw, Poland)
- Mo-393** The study on safety of quantum materials for the diagnosis and treatment of Parkinson's disease
U. Lee, Y.-M. Yoo, Y.-J. Kim, H.-T. Yoo (Incheon, Republic of Korea)
- Tu-14** Effect of Parkinson's disease on medio-lateral motion of the centre of mass when walking over a ground-based obstacle
B. Galna, A.T. Murphy, M.E. Morris (Melbourne, Victoria, Australia)
- Tu-15** PINK1 associated Parkinson's disease is caused by neuronal vulnerability to calcium induced cell death
S. Gandhi, A. Wood-Kaczmar, N.W. Wood, M.R. Duchen, A.Y. Abramov (London, United Kingdom)
- Tu-16** SNARE protein accumulation in a model of early Parkinson's disease
P. Garcia Reitbock, O. Anitchchik, G.K. Tofaris, M. Goedert, M.G. Spillantini (Cambridge, United Kingdom)
- Tu-17** Pole test and dopaminergic cell loss correspondence in two different MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models
T. Gioltzoglou, A. Lourbopoulos, E. Nousiopoulou, O. Touloumi, I. Milonas, N. Taskos, N. Grigoriadis (Thessaloniki, Greece)
- Tu-18** Increased cytosolic calcium levels and oxidative stress promote alpha-synuclein aggregation *in vivo*
J.J. Goodwin, D.L. Pountney (Gold Coast, Queensland, Australia)
- Tu-19** Motor dysfunction is more severe in predominantly right-than left-hemispheric Parkinson's disease
C.A. Haaxma, R.C.G. Helmich, G.F. Borm, A.C. Kappelle, M.W.I.M. Horstink, B.R. Bloem (Nijmegen, Netherlands)

ABSTRACT LISTING BY TOPIC

- Tu-20** Rotigotine protects dopaminergic neurons against glutamate excitotoxicity via dopamine receptor activation and PI3-Akt signalling
S. Harder, D. Scheller, H. Reichmann, G. Gille (Dresden, Germany)
- Tu-21** The role of α -synuclein in neural stem cells *in vivo*
H. Hayakawa, M. Tani, T. Nihira, N. Hattori, Y. Mizuno, H. Mochizuki (Tokyo, Japan)
- Tu-22** Kinetics of microglial activation and degeneration of dopamine-containing neurons induced by 6-OHDA in a rat model of Parkinson's disease
V. Henry, V. Paille, F. Lelan, P. Brachet, P. Damier (Nantes, France)
- Tu-23** Characterization and regulation of the promoter region of human neuronal uncoupling protein-4 (UCP4) and its neuroprotective role in Parkinson's disease
J.W.-M. Ho, P.W.-L. Ho, K.H.-H. Kwok, H.-F. Liu, X. Ge, M.H.-W. Kung, D.B. Ramsden, S.-L. Ho (Hong Kong, Hong Kong)
- Tu-24** Synergistic role of neuronal uncoupling protein homologues, UCP2, 4 and 5, in neuroprotection against mitochondrial dysfunction in Parkinson's disease
P.W.-L. Ho, J.W.-M. Ho, K.H.-H. Kwok, H.-F. Liu, X. Ge, M.H.-W. Kung, D.B. Ramsden, S.-L. Ho (Hong Kong, Hong Kong)
- Tu-25** Rotenone reduces magnesium-dependent block of NMDA currents in substantia nigra dopamine neurons
S.W. Johnson, Y.-N. Wu (Portland, Oregon)
- Tu-26** Progression of MPTP induced parkinsonism in monkeys. A multiligand PET study
C. Juri, J. Blesa, E. Iglesias, M.C. Rodriguez-Oroz, J.A. Obeso, M. Collantes, E. Prieto, I. Penuelas (Pamplona, Navarra, Spain)
- Tu-27** Effect of minocycline on dopamine neurons and microglia in the nigra of zitter mutant rats
T. Kadokawa, A. Nakamura, K. Hashimoto, K. Nakadate, S. Komatumoto, K. Hirata, S. Ueda (Ashikaga, Tochigi, Japan)
- Tu-28** Simple magnetic swallowing detection system
A. Kandori, Y. Sano, T. Miyashita, M. Onuma, T. Yamamoto, M. Murata, M. Yokoe, S. Sakoda (Tokyo, Japan)
- Tu-29** Animal model of endotoxin induced neurodegeneration in Parkinson's disease
M. Schiess, M. Schurdell, M. Gordon, G. Kidder, B. Poindexter, R. Bick (Houston, Texas)
- Tu-30** Modulation of mitochondrial morphology and function by interaction of Omi/HtrA2 with the fusion protein OPA1 – Implications for neurodegeneration
N. Kieper, K. Holmström, D. Ciceri, L.M. Martins, P.J. Kahle, R. Krüger (Tuebingen, Germany)
- Tu-31** Motor behavioral and oxidative stress alterations in nigrostriatal system of mice treated with mitochondrial inhibitor rotenone
K.S. Kietzer, J.J.S. Freitas, E.S. Yamada (Belem, Para, Brazil)
- Tu-32** Mitochondrial dysfunction and impaired lysosomal degradation due to loss of Parkinson's disease associated protein DJ-1
G. Krebiehl, S. Ruckerbauer, J. Waak, H. Wolburg, Z. Gizzatullina, F.N. Gellerich, O. Riess, P.J. Kahle, T. Proikas-Cezanne, R. Krüger (Tuebingen, Germany)
- Tu-33** Early diagnosis of Parkinson's disease from plasma fluid by Fourier-Transform infrared spectroscopy (FTIR)
S. Kumar, F.S.S.J. Sheikh Ahmed, H.T.T. Christlet (Kattankulathur, Tamilnadu, India)
- Tu-34** Hepatic de novo lipogenesis in the different types of Wilson's disease
D. Labunskiy, T. Fedotova, A. Dyachenko, V. Poleshchuk (Santa Rosa, California)
- Tu-394** Neurotropic autoantibodies in the blood serum of children first 2 years old with perinatal CNS pathology different severity
T.G. Mardovina (Minsk, Belarus)
- We-13** Proteomic analysis of the substantia nigra in patients with Parkinson's disease
V. Licker, L. Dayon, N. Turck, M. Côte, N. Rodrigo, D.F. Hochstrasser, J.-C. Sanchez, P.R. Burkhard (Geneva, Switzerland)
- We-14** The crosstalk between autophagy or proteasome degradation pathways and apoptosis in PC12 with overexpression of human α -synuclein
F. Yang, Y.-P. Yang, C.-J. Mao, B.-Y. Cao, Z.-L. Cai, J.-J. Shi, C.-F. Liu (Suzhou, Jiangsu, China)
- We-15** Rab11a and HSP90 regulate recycling of extracellular α -synuclein
J. Liu, S. Chen, J. Zhang (Shanghai, China)
- We-16** Bilateral stereotactic lesions of the rat entopeduncular nucleus prevent apomorphine-induced deficient sensorimotor gating and motor activity
G. Luetjens, J.K. Krauss, K. Schwabe (Hannover, Germany)
- We-17** Detection of elevated levels of alpha-synuclein oligomers in cerebrospinal fluid from patients with Parkinson's disease and dementia with Lewy bodies
W. Maetzler, M.M. Qureshi, D. Berg, M. Synofzik, T. Gasser, O.M.A. El-Agnaf (Tuebingen, Germany)
- We-18** Quantification of alpha-synuclein in venous blood from a newly established, longitudinal case-control study
B. Mollenhauer, J. Ng, N. Maher, C. Sunny, B. Hart, J.J. Locascio, O.M. El-Agnaf, M.H. Schwarzschild, N.R. McFarland, S.U. Sohur, U. Vivec, B.T. Hyman, A. Ivinston, A. Hung, J.H. Growdon, L.R. Sudarsky, C.R. Scherzer, M.G. Schlossmacher, Biomarker Discovery Study (Boston, Massachusetts)
- We-19** Rescue of DJ-1 null mice from hypersensitivity to MPTP by ASK1 deletion
M.M. Mouradian, K.W. Lee, X. Zhao, P.K. Sonsalla, D.C. German, I. Khobahy, E. Andres-Mateos, V.L. Dawson, T.M. Dawson, H. Ichijo, E. Junn (Piscataway, New Jersey)
- We-20** Deregulation of immune system pathways in peripheral blood cells of parkinsonian patients
E. Mutez, C.C. Vanbesien-Mailliot, A. Kreisler, A. Duflot, A. Destee, M.-C. Chartier-Harlin (Lille, France)
- We-21** Different effects of sensory afferent stimulation on subgroups of interneurons in human primary motor cortex
Z. Ni, S. Charab, C. Gunraj, R. Chen (Toronto, Ontario, Canada)
- We-22** Factors influencing dopamine terminal replacement in Parkinson's disease: Perspective gained through grafting in the parkinsonian rat
J.A. O'Malley, K.E. Soderstrom, C.E. Sortwell, T.J. Collier, K. Steele-Collier (Cincinnati, Ohio)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- We-23 Proapoptotic protein Bax expression and increased oxidative stress in fibroblasts from parkin mutation carriers
S. Orolicki, A. Grunewald, A. Rakovic, P. Seibler, K. Lohmann, N. Kock, C. Klein (Luebeck, Germany)
- We-24 Aging effect on dopamine release in parkin knockout mice
G. Oyama, K. Yoshimi, S. Natori, Y. Chikaoka, Y.-R. Ren, Y. Shimo, R. Takahashi, T. Nakazato, S. Kitazawa, N. Hattori (Tokyo, Japan)
- We-25 Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice
F.J. Pan-Montojo, O. Anichtchik, Y.F. Dening, S. Pursche, G. Gille, M.G. Spillantini, H. Reichmann, R.H.W. Funk (Dresden, Germany)
- We-26 Neural correlates of corticobulbar and corticospinal dysfunction in Parkinson's disease
E.K. Plowman-Prine, N.J. Thomas, S.C. Fowler, C.M. Sapienza, J.A. Kleim (Gainesville, Florida)
- We-27 Continuous delivery as a new strategy to test neuroprotection in a rotenone rat model of Parkinson's disease
B.O. Popescu, R. Stoica, M. Tuineag, D.F. Muresanu, L.M. Popescu (Bucharest, Romania)
- We-28 Interhemispheric conflicts and diagonalistic apraxia after corpus callosum infarct: An oculomotor study
P. Pouget, P. Pradat-Diehl, S. Rivaud-Péchoux, N. Wattiez, B. Gaymard (Paris, France)
- We-29 REM sleep primary deregulation following MPTP in the monkey model of Parkinsons disease
B. Quentin, L. Virgine, F. Claude, S. Mc Guire, H. Michael, B. Bernard, B. Emmanuel, B. Erwan, T. François, G. Imad (Bordeaux, France)
- We-389 Serum proteomic biomarkers correlate with disease status and severity in Parkinson's disease
K. Markopoulou, J. Bryson, B.A. Chase, S. Quintero, E. Dardiots, P. Kountra, S. Ralli, A. Papadimitriou, G. Hatzigeorgiou, V. Tsimourtou, C. Vogiatzi, I. Patramani, E. Sheta (Larissa, Greece)
- We-390 Self-teaching and self-evaluation on movement disorders
M. Machkour, S. Bojraf, M.F. Belahsen, S. Chaouki, M.E. Chaoui, A. Lakhdar, O. Messouak (Fez, Morocco)
- Th-11 Pharmacologic effects of repeated administration of botulinum toxin type B on rat salivary glands
S. Reinhard, W. Birmingham (Malvern, Pennsylvania)
- Th-12 Protein synthesis inhibition effects on dyskinesia induction
M.D. Saborido, C. Laramendy, I.R.E. Taravini, M.G. Murer, O.S. Gershman (Ciudad Autonoma de Buenos Aires, Argentina)
- Th-13 Effects of G-CSF in the MPTP mouse model of PD
J. Sanchez-Ramos, T. Mori, V. Sava, S. Song (Tampa, Florida)
- Th-14 Acoustic metrics of dysarthric vowel articulation: Comparison with vowel space area in Parkinson's disease and healthy aging
S. Sapir, L.O. Ramig, J.L. Spielman, C. Fox (Haifa, Israel)
- Th-15 Effect of deep brain stimulation of the pedunculopontine tegmental nucleus on c-fos expression in the rat 6-hydroxydopamine Parkinson model
A. Saryeva, K. Schwabe, M. Nakamura, J.K. Krauss (Hannover, Germany)
- Th-16 CSF from Parkinson's disease patients affects a-synuclein density and cell growth in microglia and astrocytes
M. Schiess, J. Barnes, M. Gordon, B. Poindexter, R. Bick (Houston, Texas)
- Th-17 Are oxidative stress markers useful to predict clinical progression in Parkinson's disease? A case-control study
R.C.S. Seet, J.C.Y. Lee, E.C.H. Lim, J.J.H. Tan, A.M.L. Quek, W.-L. Chong, W.-F. Looi, H. Huang, S.-H. Huang, B. Halliwell (Singapore, Singapore)
- Th-18 Co-transplantation with olfactory ensheathing cells activate phosphatidylinositol 3-kinase/Akt signaling and protects neural progenitor cells in 6-OHDA lesioned rat model of Parkinson's disease
K. Seth, A. Shukla, R.W. Ansari, A.K. Agrawal (Lucknow, U.P., India)
- Th-19 Neuroprotective effects of deep brain stimulation of the rat STN: Advantages and limitations of the intrastriatal 6-OHDA model
A.L. Spieles-Engemann, M.M. Behbehani, T.J. Collier, S.L. Wohlgenant, G.T. Mandybur, J.W. Lipton, B.T. Terpstra, C.E. Sortwell (Cincinnati, Ohio)
- Th-20 Deep brain stimulation of the subthalamic nucleus in a rodent model: Effects on trophic factors
A.L. Spieles-Engemann, M.M. Behbehani, T.J. Collier, K. Steece-Collier, S.L. Wohlgenant, V.B. Thompson, J.W. Lipton, C.E. Sortwell (Cincinnati, Ohio)
- Th-21 Effects of oligodendroglial a-synucleinopathy on striatal grafts in a transgenic mouse model of MSA
N. Stefanova, M. Hainzer, S. Stemberger, S. Couillard-Despres, L. Aigner, W. Poewe, G.K. Wenning (Innsbruck, Austria)
- Th-22 Blood brain barrier integrity in a mouse model of MSA: towards mesenchymal stem cell therapy
S. Stemberger, N. Stefanova, L. Aigner, G.K. Wenning (Innsbruck, Austria)
- Th-23 Cytoprotective effects of extracellular dopamine under the dopamine overproduction
N. Sugeno, M. Kobayashi, T. Hasegawa, A. Takeda, A. Kikuchi, T. Baba, Y. Itoyama (Sendai, Japan)
- Th-24 The effects of chronic administration of ephedrone (methcathinone) and manganese in mice
A. Asser, S. Köks, M. Haaparanta-Solin, T. Grönroos, A. Pakkanen, J. Nairismägi, M. Plaas, U. Soomets, M. Sauk, P. Piip, M. Eltermaa, H. Lindmäe, P. Taba (Tartu, Estonia)
- Th-25 The research of the interaction between parkin and OGCP
C.-Y. Wang, J.-F. Guo, L. Cao, D. He, B.-S. Tang (Changsha, Hunan, China)
- Th-26 Piclozotan (SUN N4057), a 5-HT1A receptor agonist, improves motor complications induced by repeated administration of levodopa without reducing levodopa efficacy in parkinsonian rats
Y. Tani, A. Ogata, M. Koyama, T. Inoue (Mishima-gun, Osaka, Japan)
- Th-27 Isolation and characterization of genetically modified neural stem cells by fluorescence-activated cell sorting (FACS) analysis
M. Tani, T. Nihira, H. Hayakawa, N. Hattori, Y. Mizuno, H. Mochizuki (Tokyo, Japan)

ABSTRACT LISTING BY TOPIC

- | | | | |
|--------|--|--------|---|
| Th-28 | Allantoin, not uric acid, is the active neuroprotective metabolite of inosine in a rodent model of Parkinson's disease
B.T. Terpstra, J.W. Lipton, T.J. Collier, K.L. Paumier, N.D. Levine, S.L. Wohlgemant, C.E. Sortwell (Cincinnati, Ohio) | Tu-36 | Ischemic stroke and movement disorder
N. Chtaou, M. Messouak, M. Alaoui Ismaili, A. El Machkour, S. Boujraf, I. Kamaoui, M.F. Belahsen, S. Tizniti, O. Messouak (Fez, Morocco) |
| Th-29 | Substance P plays a deleterious role in early experimental Parkinson's disease
E. Thornton, R. Vink (Adelaide, Australia) | Tu-395 | Peak-dose chorea secondary to "brivudine" treatment in patients with Parkinson's disease
J. Lopez del Val, L. Martinez Martinez, E. Lopez Garcia, S. Santos Lasaosa, T. Corbalan Sevilla, L. Garcia Fernandez (Zaragoza, Old Aragon Kingdom, Spain) |
| Th-30 | LRRK2 processing revealed by new monoclonal antibody
I. Toyoshima, H. Ichinose, Y. Imai, K. Hasegawa (Akita, Japan) | Tu-396 | A case of amyotrophic lateral sclerosis with chorea
T. Yamamoto, N. Sumita, M. Fukui, K. Sayaka, T. Abe, T. Mizoi, T. Komori, N. Tamura, N. Araki (Iruma-gun, Saitama, Japan) |
| Th-31 | Nonhomologous end joining: A novel deleterious pathogenic mechanism for parkinsonism?
C.C. Vanbesien-Mailliot, E. Mutez, A. Kreisler, V. Mouroux, A. Destée, M.-C. Chartier-Harlin (Lille, France) | We-30 | Chorea in iatrogenic hypocalcemia due to parathyroid gland removal during total thyroidectomy
A.Q. Rana (Toronto, Ontario, Canada) |
| Th-32 | Mitochondrial dysfunction in genetic parkinsonism: What muscles can tell us about the brain
C. Verstappen, M. Te Riele, B. Bloem, J. Smeitink, B. van de Warrenburg (Nijmegen, Netherlands) | We-31 | Movement disorders associated with diabetes mellitus: A prospective case series
M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Arrambide-García, T. Corona (Mexico City, Mexico) |
| Th-33 | Effects of optic flow speed, gait asymmetry and egocentric reference point on navigation
R.C. Wagenaar, Y.E. Daniel, C.-C. Lin, Y.-H. Chou, A. Cronin-Golomb (Boston, Massachusetts) | We-32 | Choreatic movement disorder with non-ketotic hyperglycemia – A case report
S. Schmidegg, M. Guger, W. Struhal, S. Hoedl, H. Huber, G. Ransmayr (Linz, Oberoesterreich, Austria) |
| Th-34 | Behavioural disorders produced by electrical stimulation of the anterior striatum in monkeys
Y. Worbe, J. Epinat, J. Feger, T. Leon (Paris, France) | We-33 | Acute hemichorea-hemiballism ipsilateral to ischemic stroke involving middle cerebral artery territory
S. Tamburini, M.L. Praitalo, C. Foscato, A. Fiaschi, G. Zanette (Peschiera del Garda, VR, Italy) |
| Th-394 | Involvement of human motor cortex in the recognition of hand-written or block letters – A TMS study
M. Nakatsuka, T. Mima, H. Fukuyama (Kyoto, Japan) | We-391 | Neuroacanthocytosis – McLeod syndrome
I. Ybot Gorrín, F. Vivancos Matellano, F.J. Arpa Gutiérrez, E. Díez Tejedor (Madrid, Madrid, Spain) |
| Th-395 | Relation between post-movement-beta-synchronisation and corticomuscular coherence
J. Raethjen, M. Muthuraman, G. Tamas, H. Hellriegel, G. Deuschl (Kiel, Germany) | Th-396 | Contrastive findings on PET images in two cases of hemichorea with hyperglycemia
Y.H. Yun, J.H. Park, S.A. Park, T.K. Lee, K.B. Sung (Bucheon, Gyeonggi, Korea) |

Choreas (Non-Huntington's disease)

- | | |
|--------|---|
| Mo-32 | Paroxysmal choreathetosis in GLUT 1 deficiency syndrome – case report
I.C. Carrilho, M.A. Santos, F.M. Pichel, M. Magalhaes (Porto, Portugal) |
| Mo-33 | Painless legs, moving toes and fingers: Symptom variability related to hormonal state
N.L. Diaz, P. Mazzoni (New York, New York) |
| Mo-34 | Neuroacanthocytosis in Japan: Review of epidemiological and neuropathological studies
G. Hirose, C. Ishida (Kanazawa, Ishikawa Prefecture, Japan) |
| Mo-394 | Hemic chorea revealing Moya-Moya syndrome in neurofibromatosis 1
R.N. Gospodaru, E. Schmitt, L. Maillard, P. Beauchesne, C. Hubsch, A. Auhire, H. Vespiagnani (Nancy, France) |
| Mo-395 | Chorea presented in the syndrome of acute bilateral basal ganglia lesion in diabetic uremic patients
J.-J. Lin, K.-C. Yueh (Chushang Jenn, Nantou County, Taiwan) |
| Tu-35 | Phenotypic variation in an Irish kindred with chorea-acanthocytosis
A. Merwick, T.H. Mok, B. McNamara, B. Bader, A. Danek, B.J. Sweeney, A.M. Ryan (Cork, Ireland) |

Clinical Electrophysiology

- | | |
|--------|---|
| Mo-35 | Facial reflex hyperexcitability in geniospasm suggests a brainstem origin
A. Aggarwal, J.E. Warren, J.D. Warren, P.D. Thompson (Adelaide, Australia) |
| Mo-36 | Cognitive activity promotes oscillatory changes in the subthalamic nucleus. Intracerebral recording study
M. Balaz, P. Jurak, M. Bockova, I. Rektor (Brno, Czech Republic) |
| Mo-37 | Executive functions processed in the subthalamic nucleus. An intracerebral recording study
M. Bockova, J. Chladek, P. Jurak, J. Halamek, M. Balaz, I. Rektor (Brno, Czech Republic) |
| Mo-38 | Integrative function of single neurons in the human subthalamic nucleus during checking behavior
P. Burbaud, M.-L. Welter, M. Goillandeau, A.-L. Clair, P. Sauleau, M. Simonetta-Moreau, S. Chabardes, S. Besnard, H. Magnie-Mauro, J. Coste, L. Mallet (Bordeaux, Paris, France) |
| Mo-396 | Homeostatic metaplasticity of the trigeminal blink reflex in healthy humans
M. Bologna, R. Agostino, B. Gregori, D. Belvisi, L. Marsili, F. Di Stasio, A. Berardelli (Rome, Italy) |

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Mo-397 Cutaneous and mixed nerve silent periods in paroxysmal dystonia**
J. Cogez, O. Etard, N. Derache, G. Defer (Caen, France)
- Tu-37 Increased excitability induced by tDCS can unmask mirror movements**
J.E. Dundas, G.W. Thickbroom, A. Fox, F.L. Mastaglia (Perth, Western Australia, Australia)
- Tu-38 EEG biofeedback training for Parkinson's disease with levodopa-induced dyskinesia**
C. Erickson-Davis, J. Anderson, S. Richter, C. Wielinski, S. Parashos (Golden Valley, Minnesota)
- Tu-39 Idiopathic spinal myoclonus: A clinical and neurophysiological assessment of a movement disorder of uncertain origin**
M. Esposito, M.J. Edwards, K.P. Bhatia, N.J. Toms, P.J. Allen, P. Brown, C. Cordivari (London, United Kingdom)
- Tu-40 Comparison of extensor-digitorum-brevis (EDB) test vs mouse diaphragm assay (MDA) as indirect test methods for detection of botulinumtoxin A (BTXA) antibodies in clinical practice**
A.M. Garcia, T. Trottenberg, E. Lobsien, K. Andreas (Berlin, Germany)
- Tu-397 Effects of continuous magnetic theta-burst stimulation on early motor learning and retention of simple fast finger movements**
E. Iezzi, R. Agostino, A. Suppa, A. Conte, L. Dinapoli, A. Nardella, L. Rocchi, F. Di Stasio, A. Berardelli (Rome, Italy)
- We-34 Modulation of premotor cortex activity normalises measures of spinal and cortical inhibition without affecting MEPs in dystonia**
Y.-Z. Huang, J.C. Rothwell, C.-S. Lu, J.J. Wang, Y.-H. Weng, S.-C. Lai, W.-L. Chuang, J. Hung, R.-S. Chen (Taipei, Taiwan)
- We-35 Electrophysiological evaluation of tremors secondary to space occupying lesions and trauma: Correlation with nature and sites of lesions**
P.Kr. Pal, M. Netravathi, S. Ravishankar, B.I. Devi (Bangalore, Karnataka, India)
- We-36 Human subthalamic nucleus neuronal activity participates in visuomotor learning**
C.L. Ojakangas, R. Penn (Chicago, Illinois)
- We-37 The oscillatory activities in the human putamen**
I. Rektor, R. Kuba, M. Brazdil, J. Halamek, P. Jurak (Brno, Czech Republic)
- We-392 Magnetic brainstem stimulation study and multimodal evoked potentials in patients with Adrenoleukodystrophy**
H. Matsumoto, R. Hanajima, Y. Terao, M. Hamada, A. Yugeta, Y. Shirota, K. Yuasa, F. Sato, T. Matsukawa, Y. Takahashi, J. Goto, S. Tsuji, Y. Ugawa (Tokyo, Japan)
- Th-35 Real-time analysis of EEG in the elucidation of volition**
L. Schneider, E. Houdayer, O. Bai, A. Ellenstein, M. Hallett (Bethesda, Maryland)
- Th-36 Neuronal mechanisms of motor signals transmission in nonspecific (CM-Pf) and motor (Voi) human brain thalamic nuclei in spasmodic torticollis patients**
A.S. Sedov, S.N. Raeva (Moscow, Russian Federation)
- Th-37 Synaptic plasticity at brainstem and cortical level in Tourette syndrome**
A. Suppa, M. Bologna, D. Belvisi, L. Marsili, I. Berardelli, G. Moretti, G. Fabbrini, A. Berardelli (Rome, Italy)
- Th-38 Post-movement beta synchronization in Wilson's disease**
G. Tamas, A. Folhoffer, M. Muthuraman, J. Raethjen, F. Szalay, A. Takats, I. Szirmai, A. Kamondi (Budapest, Hungary)
- Th-39 Subthalamic neuronal activity in patients with obsessive-compulsive disorders or Parkinson's disease**
M.-L. Welter, P. Burbaud, A.-H. Clair, A. Bastian, E. Bardinet, S. Fernandez-Vidal, P. Sauleau, M. Simonetta-Moreau, S. Besnard, B. Pidoux, J. Coste, J. Yelnik, L. Mallet, STOC Study Group (Paris, France)
- Th-397 High frequency oscillation in adrenoleukodystrophy**
N. Tanaka, M. Hamada, R. Hanajima, Y. Terao, S. Okabe, S. Tsuji, Y. Ugawa (Bunkyo-ku, Tokyo, Japan)

Drug-induced Movement Disorders

- Mo-39 Reversible hyperkinetic movement disorder related to quetiapine withdrawal**
M.T. Ahmad, K.M. Prakash, C.W. Yip (Singapore, Singapore)
- Mo-40 Tardive chorea secondary to low dose quetiapine**
F. Amjad, S.E. Lo (Washington, District of Columbia)
- Mo-41 Could tardive dystonia be cured with botulinum toxin treatment?**
M. Anca-Herschkovitsch (Holon, Israel)
- Mo-42 New treatment (BN82451) and assessment for L-dopa-induced dyskinesias in parkinsonian macaques**
R. Aron Badin, E. Brouillet, B. Spinnewyn, M. Auguet, P.E. Chabrier, P. Hantraye (Fontenay-aux-Roses, France)
- Mo-43 Long-term outcomes after pallidal deep brain stimulation for tardive dystonia/dyskinesia**
E.F. Chang, L. Schrock, P.A. Starr, J.L. Ostrem (San Francisco, California)
- Mo-44 Towards optimization of the rat model of L-dopa induced dyskinesia**
M.C.J. van der Elst, A. Dekundy, D. Schaefer, W. Danysz (Frankfurt am Main, Germany)
- Mo-398 Copulatory dyskinesia with an outstanding response to tetrabenazine**
A. Alentorn, A. Palasi, J. Campdelacreu, M. Calopa, J. Bruna, F. Rubio (Barcelona, Spain)
- Tu-41 Drug-induced parkinsonism in hospitalized patients**
M. Ponte, P.F. Garcia Merletti, A. Wachs, A. Noel (Buenos Aires, C.A.B.A., Argentina)
- Tu-42 Manganese-induced extrapyramidal symptoms: Methcathinone encephalopathy**
D. Ince Gunal, K. Agan, H. Horozoglu, P. Kahraman Koytak (Istanbul, Turkey)
- Tu-43 Levosulpiride-induced hemichorea**
S.Y. Kang, H.-I. Ma, Y.J. Kim, S. Jung, S.-B. Kwon, S.H. Hwang (Seoul, Republic of Korea)
- Tu-44 Clinical course of ephedrone encephalopathy**
M. Kapianidze, I. Khatiashvili, M. Megrelishvili, N. Kvirkvelia (Tbilisi, Georgia)
- Tu-45 Ephedrone encephalopathy: Treatment approaches**
I. Khatiashvili, M. Kapianidze, M. Megrelishvili, K. Akhvlediani (Tbilisi, Georgia)
- Tu-46 Akathisia and second-generation antipsychotic drugs**
R. Kumar, P. Sachdev (Woden, ACT, Australia)

ABSTRACT LISTING BY TOPIC

- Tu-398** **Parkinsonism due to chronic artemisinin use**
L.B. Bahroo, R.P. Gandhi, F.L. Pagan (Washington, District of Columbia)
- We-38** **Ephedrone and motor neuron damage – Can there be a relationship?**
N. Lobjanidze, I. Khatiashvili, M. Okujava, K. Akhvlediani, N. Kvirkvelia (Tbilisi, Georgia)
- We-39** **A patient-centric disease framework for Parkinson's disease levodopa induced dyskinesia**
A.L. Shields, U.G. Mallya, R.M. Lane, S.K. Thomas (East Hanover, New Jersey)
- We-40** **Neuroleptic malignant syndrome complicating alcohol withdrawal**
C. Mihailescu, G. Mihailescu (Bucharest, Romania)
- We-41** **Class specific manifestation in drug induced parkinsonism**
R.P. Munhoz, H.A. Teive, L.C. Werneck (Curitiba, PR, Brazil)
- We-42** **Catamenial and oral contraceptive-induced exacerbation of chorea in chorea-acanthocytosis: Case report**
R.P. Munhoz, P.A. Kowacs, M.G. Soria, S. Raskin, H.A. Teive, R.D. Ducci (Curitiba, PR, Brazil)
- We-43** **Effects of risperidone at “protective” doses on balance control in healthy individuals**
E. Pourcher, H. Cohen, P. Corbeil, M. Simoneau, J.-F. Rodrigue (Quebec, Quebec, Canada)
- We-44** **Acute onset tremor associated with combination of chipmax and fluoxetine**
A.Q. Rana (Toronto, Canada)
- We-393** **Tricyclic antidepressant-induced myoclonus: Case report and literature review**
Y.-D. Kim, K.S. Yum (Daejeon, Korea)
- Th-40** **Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs**
S.A. Schneider, V. Udani, C. Sawant, K.P. Bhatia (Luebeck, Germany)
- Th-41** **Two year follow up in ephedrone induced parkinsonism with dystonia**
Y. Sanotsky, M. Selikhova, L. Fedoryshyn, Y. Matvienko, I. Komnatska, M. Kyrylchuk, A. Friedman, A.J. Lees (London, United Kingdom)
- Th-42** **Tardive tongue dyskinesia and burning mouth syndrome: Successful concurrent treatment with botulinum toxin A**
M.-W. Seo, M.-H. Lim (Jeonju, Jeonbuk, Republic of Korea)
- Th-43** **New treatment (BN82451) and assessment for L-dopa-induced dyskinésias in hemiparkinsonian rats**
B. Spinnewijn, M.N. Rocher, M. Idrissi, P. Plas, F. Schmidlin, E. Ferrandis, M. Auguet, P.E. Chabrier (Les Ulis, France)
- Th-398** **Anticholinergics use in elderly with Parkinson's disease may lead to the development of chorea**
A.Q. Rana (Toronto, Canada)
- Th-399** **Involuntary movements and electroencephalogram (EEG) features in cefepime induced encephalopathy with renal insufficiency**
Y. Shirota, R. Hanajima, Y. Terao, M. Hamada, R. Ohtomo, A. Yugeta, H. Matsumoto, Y. Ugawa, S. Tsuji (Tokyo, Japan)

Dystonia

- Mo-45** **To report a patient with familial bilateral striopallidodentate calcinosis**
P. Agarwal, A. Griffith, M. Borromeo-Wesner (Kirkland, Washington)
- Mo-46** **Retrospective evaluation of 29 oromandibular dystonic cases who underwent botulinum toxin treatment**
O. Burclukose, F. Selcuk, A.Y. Akin, C.M. Akbostanci (Ankara, Turkey)
- Mo-47** **Oromandibular dystonia due to cerebellar infarct: A case report**
F. Selcuk, C.M. Akbostanci (Ankara, Turkey)
- Mo-48** **Hallervorden-Spatz syndrome: A clinical and genetic study of 10 patients**
S. Assami, S. Mahoui, E. Mundwiller, S. Belarbi, A. Brice, G. Stevanin, M. Tazir (Alger, Algeria)
- Mo-49** **Anticipation in DYT1 dystonia**
E.U. Augustine, J.W. Mink (Rochester, New York)
- Mo-50** **Deficient consolidation of new motor memories in dystonic patients**
M. Balas, D. Grabli, C. Bonnet, E. Bertasi, M. Pelegreni-Issac, H. Benali, M. Vidailhet, S. Lehericy (Paris, France)
- Mo-51** **Increased inhibition from the left dorso-lateral premotor cortex in focal hand dystonia**
S. Beck, E. Houdayer, S. Pirio Richardson, M. Hallett (Bethesda, Maryland)
- Mo-52** **Cervical dystonia: Clinical and therapeutic features in 85 patients**
C.H.F. Camargo, N. Becker, H.A.G. Teive, M.H.H. Baran, R.H. Scola, L.C. Werneck (Curitiba, Parana, Brazil)
- Mo-53** **Psychiatric disorders in patients with primary focal dystonia**
I. Berardelli, M. Bloise, G. Moretti, M. Pasquini, G. Fabbrini, C. Colosimo, A. Berardelli (Rome, Italy)
- Mo-54** **Chylomicron retention disease: Dystonia as a new clinical feature**
G. Bernard, M. Panisset, A. Sadikot, S. Chouinard (Montreal, Quebec, Canada)
- Mo-55** **Neurostimulation therapy for primary and secondary dystonia: The Venetian experience**
S. Biguzzi, M. Haefele, C. Lettieri, D. Volpe, E. Cagliari, C. Conti, G. Rizzo, G. Trincia, R. Eleopra (Mestre-Venice, Italy)
- Mo-56** **Autosomal dominant mirror movement in a French family**
S. Billot, C. Depienne, S. Meunier, A. Brice, M. Vidailhet, E. Roze (Paris, France)
- Mo-57** **Long-term (7-year) cervical dystonia safety study with Myobloc®**
W. Birmingham, E. Salazar-Grueso (Malvern, Pennsylvania)
- Mo-58** **A family with a hereditary form of torsion dystonia from Northern Sweden treated with bilateral pallidal deep brain stimulation (DBS)**
P. Blomstedt, T.A. Bergenheim, S. Tisch, M.I. Hariz, L. Forsgren (Umea, Sweden)
- Mo-59** **Further evidence for pallidal output abnormalities in cervical dystonia**
A.J. Blood, J. Kuster, T.J. Multhaup-Buell, N. Makris, M.L. Makhlouf, L.R. Sudarsky, N. Sharma (Charlestown, Massachusetts)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Mo-60 Profound generalized dystonia and psychomotor delay without hyperphenylalaninemia – A novel phenotype of GTP cyclohydrolase 1 deficiency associated with a GCH1 promoter mutation**
M. Bodzioch, K. Lapicka-Bodzioch, M. Rudzinska, B. Zapala, A. Dembinska-Kiec, A. Szczudlik (Krakow, Poland)
- Mo-61 Temporal discrimination thresholds in familial AOPTD Pedigrees – Use of a new endophenotype**
D. Bradley, R. Whelan, R. Walsh, R. Reilly, S. Hutchinson, F. Molloy, M. Hutchinson (Dublin, Ireland)
- Mo-62 Genotypic changes in cerebello-thalamo-cortical connectivity in primary dystonia**
M. Carbon, M. Argyelan, M. Niethammer, S.B. Bressman, D. Eidelberg (Manhasset, New York)
- Mo-63 Imagination of writing reveals a primary deficit of basal ganglia-premotor activation in patients with idiopathic focal hand dystonia**
F. Castrop, C. Dresel, A. Hennenlotter, C. Zimmer, B. Haslinger (Muenchen, Germany)
- Mo-64 Sonography during writer's cramp treatment with botulotoxin injections**
T. Charnukha, S. Likhachev, N. Charnenka (Minsk, Belarus)
- Mo-65 Internal globus pallidus deep brain stimulation in status dystonicus: A study of eleven cases**
L. Cif, V. Gonzalez, H. Elferit, E. Andre, C. Geniez, P. Coubes (Montpellier, France)
- Mo-66 Factors predicting improvement in primary dystonia treated by pallidal deep brain stimulation**
L. Cif, X. Vasques, V. Gonzalez, P. Coubes (Montpellier, France)
- Mo-67 Cerebellar vermis hypoplasia in a case of Joubert syndrome associated with cervical dystonia**
S.M. Cinar, S. Bilge, E.D. Polat, O. Akdemir, A. Yildirim (Istanbul, Beyoglu, Turkey)
- Mo-68 Deep brain stimulation for dystonia: Follow up at Sheba Medical Center**
O.S. Cohen, H. Strauss, Z. Nitsan, R. Spiegelmann, S. Hassin-Baer (Ramat-Gan, Israel)
- Mo-69 Effects of muscle contraction on the efficacy of botulinum toxin treatment in patients with blepharospasm**
A. Conte, D. Belvisi, L. Marsili, L. Rocchi, F. Di Stasio, G. Fabbrini, A. Berardelli (Rome, Italy)
- Mo-70 Botulinum toxin type B (BoNT-B) effects on pain associated with cervical dystonia: Results of placebo- and comparator-controlled studies**
M. Corliss, Y. Zhang, M. Lew (Malvern, Pennsylvania)
- Mo-71 Clinical and epidemiologic profile of dystonia in El Salvador: 8 months of pursuit**
E.A. Cornejo-Valse, E.P. Siliézar-Pineda, H. Orrego-Castellanos, M. Rubio (Delegacion Tlalpan, Ciudad de Mex, Mexico)
- Mo-72 Decreased functional interactions in the motor network of patients with focal hand dystonia using fMRI**
D. Coynel, M. Vidailhet, C. Delmaire, G. Marrelec, V. Perlberg, A. Krainik, J. Doyon, S. Lehéricy, H. Benali (Paris, France)
- Mo-73 Secondary dopamine and serotonin deficiencies in children with movement disorders**
E. De Grandis, B. Pérez-Dueñas, M. Serrano, A. Ormazábal, R. Montero, E. Veneselli, R. Artuch, A. García-Cazorla (Esplugues, Barcelona, Spain)
- Mo-399 To report two patients with Parkinson's disease and severe lateral trunk flexion with varying response to treatment**
P. Agarwal, A.F. Griffith, M. Borromeo-Wesner (Kirkland, Washington)
- Mo-400 Paroxysmal nonkinesigenic dyskinesia: A case report**
M.H. Sorgun, S. Erdogan, C. Yucesan, N. Mutluer, C.M. Akbostancı (Ankara, Turkey)
- Mo-401 Dystonic features in adult sporadic tremor dominant Parkinson's disease: A case series**
N.N.P.S. Bajaj, V.K. Gontu, J. Birchall, D.G. Grosset, A.J. Lees (Nottingham, United Kingdom)
- Mo-402 Can handwriting distinguish dystonic pseudoparkinsonism from Parkinson's disease?**
N.P.S. Bajaj, V.K. Gontu, J. Birchall, J. Patterson, D.G. Grosset, A.J. Lees (Nottingham, United Kingdom)
- Mo-403 Overall clinical efficacy and overall tolerability of NT 201; botulinum neurotoxin free from complexing proteins**
R. Benecke, S. Grafe, I. Sassin, G. Comes (Rostock, Germany)
- Mo-404 The thalamus revisited – A suitable target for deep brain stimulation in myoclonus dystonia**
H.-H. Capelle, C. Blahak, C. Schrader, T. Kinfe, H. Baezner, J.K. Krauss (Hannover, Germany)
- Mo-405 SPECT with dopamine transporter-specific radiotracer 123I-FP-CIT in benign essential blepharospasm**
F. Roselli, N.M. Pisciotta, D. Liuzzi, D. Martino, P. Livrea, G. Rubini, A. Berardelli, G. Defazio (Bari, Italy)
- Mo-406 Occupational focal dystonia and thalamic injury**
M.J.M.J. Gallardo, S.S. Carrasco, R.R. Ibáñez, J.J. Vaamonde (Ciudad Real, Spain)
- Tu-47 Postural stability in cervical dystonia and the effect of botulinum toxin**
M. Demirkiran, T. Demir, S. Bicakci, H. Bozdemir (Adana, Turkey)
- Tu-48 Mapping muscle contraction patterns in rotatory cervical dystonia by multiple simultaneous paired intramuscular EMG**
R.N. Dille, D.D. Duane (Scottsdale, Arizona)
- Tu-49 Impaired somatosensory activation during tactile stimulation in orofacial dystonia**
C. Dresel, F. Bayer, F. Castrop, C. Rimpau, C. Zimmer, B. Haslinger (Muenchen, Germany)
- Tu-50 Assessment of outcome following surgical treatment of paediatric dystonia with deep brain stimulation**
P. Epaliyanage, J. Lin, R. Selway (London, United Kingdom)
- Tu-51 Speech disturbance in neurometabolic hyperkinetic disorder**
C. Flamand Rouvière, E. Guettard, N. Bahi-Buisson, L. Maintigneux, D. Grablé, J. Motte, V. Valayannopoulos, A. Roubertie, D. Adams, M. Vidailhet, E. Roze (Le Kremlin Bicetre, France)
- Tu-52 Lower limb occupational dystonia in a flamenco dancer**
P.J. Garcia Ruiz, V. Sanchez (Madrid, Spain)

ABSTRACT LISTING BY TOPIC

Tu-53	Objective analysis of the voice in primary focal and segmentaries cranial dystonias (no larynges) N.S. Garreto, T. Arakaki, M.M. Miranda, C.G. Guallart, N. Molina, H.N. Berdeja, M.I. Rosa (Buenos Aires, Argentina)	Tu-68	Repeated sessions of repetitive transcranial magnetic stimulation (rTMS) given during an 'active motor state' in focal hand dystonia (FHD) T.J. Kimberley, M.R. Borich, H.R. Siebner (Minneapolis, Minnesota)
Tu-54	Optimising outcomes following paediatric deep brain stimulation (DBS) H. Gimeno, K. Tustin, R. Mahoney, S. Jupp, M. Kaminska, R. Selway, J.P. Lin (London, United Kingdom)	Tu-69	The syndrome of deafness-dystonia – A case series of 11 patients M. Kojovic, M.J. Edwards, S. Schneider, M. Bitner, E.M. Valente, K.P. Bhatia (London, United Kingdom)
Tu-55	Clinical assessment of patients with acquired hemidystonia: Selecting patients for deep brain stimulation treatment V. Gonzalez, L. Cif, E. Le Bars, H. El Fertit, N. Menjot, M. Zanca, P. Coubes (Montpellier, France)	Tu-70	Blepharospasm and the modulation of cortical excitability in primary and secondary motor areas G. Kranz, S.A. Ejaz, L. Peter, G.S. Kranz, B. Voller, M. Hallett (Vienna, Austria)
Tu-56	Effect of delayed use of reconstituted refrigerated botulinum toxin (BoNT) in hemifacial spasm (HFS) and blepharospasm (BS) V. Goyal, G. Shukla, S. Singh, M. Behari (New Delhi, India)	Tu-71	Mutation analysis of the GTP cyclohydrolase I (GCH1) and Parkin genes in 76 cervical dystonia patients in Taiwan S.-C. Lai, H.-C. Chang, Y.-H. Wu Chou, Y.-Z. Huang, R.-S. Chen, C.-S. Lu (Taoyuan, Taiwan)
Tu-57	Assessment of the alterations in early & late components of contingent negative variation (CNV) in simple writer's cramp (WC) C. Goyal, G. Shukla, A. Srivastava, K.K. Deepak, V. Goyal, M. Behari (New Delhi, India)	Tu-399	Cognitive assessments in children with severe movement disorders who undergo deep brain stimulation (DBS) require multidisciplinary (MDT) involvement H. Gimeno, R. Mahoney, K. Tustin, S. Jupp, M. Kaminska, R. Selway, J.-P. Lin (London, United Kingdom)
Tu-58	Frequency-specific effects of deep brain stimulation on hand motor function in patients with cervical dystonia J. Hübl, A. Kupsch, A.A. Kühn (Berlin, Germany)	Tu-400	Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients S. Grafe, C. Comella, J. Jankovic, D. Truong, A. Hanschmann (Frankfurt/Main, Germany)
Tu-59	A qualitative approach to perceived changes in everyday life in patients with dystonia treated with deep brain stimulation (DBS) G.-M. Hariz, S. Tisch, P. Limousin, A. Fjellman-Wiklund (Umea, Sweden)	Tu-401	Efficacy and safety of NT 201; botulinum neurotoxin type A free from complexing proteins) in treatment-naïve cervical dystonia patients S. Grafe, C. Comella, J. Jankovic, D. Truong, A. Hanschmann (Frankfurt, Germany)
Tu-60	Musicians with embouchure dystonia show primary sensorimotor overactivity B. Haslinger, E. Altenmueller, F. Castrop, C. Zimmer, C. Dresel (Muenchen, Germany)	Tu-402	A case of Ear Moving syndrome: Treatment with botulinium toxin injection K. Hatice, C. Betul, S. Hatice, K. Semiha, I. Mumcuoglu (Tokat, Turkey)
Tu-63	In vivo metabolomics of M1 hand area in patients with focal hand dystonia: A 3T MR spectroscopy study P. Herath, S. Horvitz, J.W. Van der Veen, R. Moore, M. Hallett (Bethesda, Maryland)	Tu-403	Treatment of heterogeneous subtypes of cervical dystonia with botulinum toxin A (500 Units Dysport®)– First aspects of a multicentre open study H. Heftner, R. Benecke, F. Erbguth, W. Jost, G. Reichel (Duesseldorf, Germany)
Tu-64	Patients with adult-onset cervical dystonia and marked improvement to a sensory trick perform better in multimodal temporal discrimination G. Kägi, P. Katschnig, M. Fiorio, M. Tinazzi, J. Rothwell, K. Bhatia (London, United Kingdom)	Tu-404	Pallidal deep brain stimulation in dystonia restores physiological feeding, toileting, ambulation & allows reduced rate of intrathecal baclofen infusion in severe childhood primary dystonia M. Kaminska, L. Baker, S. Jupp, R. Mahoney, H. Gimeno, K. Tustin, D.E. Lumsden, R. Selway, J.-P. Lin (London, United Kingdom)
Tu-65	Complications of deep brain simulation for primary and secondary dystonias in children M. Kaminska, S. Jupp, H. Gimeno, R. Mahoney, L. Baker, D.E. Lumsden, R. Selway, K. Tustin, J.-P. Lin (London, United Kingdom)	Tu-405	Decline in Soletra® neurostimulator battery voltage associated with decline in response to pallidal deep brain stimulation before complete battery failure has occurred M. Kaminska, S. Jupp, H. Gimeno, K. Tustin, R. Mahoney, D.E. Lumsden, R. Selway, J.-P. Lin (London, United Kingdom)
Tu-66	Effects of long-term potentiation (LTP)-like and long-term depression (LTD)-like plasticity on subsequent motor learning in healthy subjects and writer's cramp (WC) patients J.-S. Kang, J. Roggendorf, C. Seifried, H. Steinmetz, R. Hilker, U. Ziemann (Frankfurt/Main, Germany)	Tu-406	Electroacupuncture in movement disorders after peripheral trauma. A Soleus h-reflex study J.H.T.M. Koelman, R.E. Wong-Chung, B.W. Ongerboer de Visser, L.J. Bour, M.W.I.M. Horstink (Amsterdam, Netherlands)
Tu-67	Is "target panic" phenomenon a form of task-specific dystonia in archers? W. Kielis, A. Bogucki, L. Szafraniec (Lodz, Poland)	We-45	Disruption of sensorimotor integration in writer's cramp N. Langbour, V. Michel, B. Dilharreguy, D. Guehl, J.-Y. Rotge, M. Allard, P. Burbaud (Bordeaux, France)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- We-46 Dystonia secondary to tetrahydrobiopterin deficiency(BH4); recognition and therapy of the disorder
B.L. Lavenstein, C. Tift, U. Lichter (Washington, District of Columbia)
- We-47 Table tennis dystonia
A.A. Le Floch, J.-M.J.M. Mayer, C.C. Flamand-Rouviere, D.D. Grabi, M.M. Gonc, E.E. Broussolle, M.M. Vidailhet, E.E. Roze (Nimes, France, Metropolitan)
- We-48 Mechanisms of non-compliance in spasmody torticollis patients undergoing botulinum toxin treatment
B. Leplow, R. Schoenfeld (Halle(Saale), Germany)
- We-49 Serotonin responsive sleep disturbances in a patient with sepiapterin reductase deficiency
S. Leu, I. Arnulf, C. Decaux, F. Moussa, F. Clot, C. Boniot, Y. Touitou, R. Levy, M. Vidailhet, E. Roze (Paris, France)
- We-50 Characterization of cerebral cortex-specific and Purkinje cell-specific Sgce conditional knockout mice
Y. Li, F. Yokoi, M.T. Dang (Birmingham, Alabama)
- We-51 Bilateral pallidal deep brain stimulation (DBS) for primary and secondary paediatric dystonia improves quality of life (QOL) measured by the caregiver priorities and child health index of life with disabilities (CPCHILD)
D.E. Lumsden, S. Jupp, H. Gimeno, K. Tustin, R. Mahoney, M. Kaminska, R. Selway, J.-P. Lin (London, United Kingdom)
- We-52 Paediatric quality of life (QOL) using the caregiver priorities and child health index of life with disabilities (CPCHILD) correlates with changes in the Burke, Fahn, Marsden dystonia rating scale (BFMDRS) following bilateral DBS
D.E. Lumsden, H. Gimeno, S. Jupp, K. Tustin, R. Mahoney, M. Kaminska, R. Selway, J.-P. Lin (London, United Kingdom)
- We-53 Pallidal deep brain stimulation improves dystonic symptoms in patients with pre-existing intrathecal baclofen pumps
D.E. Lumsden, S. Jupp, H. Gimeno, K. Tustin, R. Mahoney, M. Kaminska, R. Selway, J.-P. Lin (London, United Kingdom)
- We-54 Cognitive functioning in children with pantothenate kinase-associated neurodegeneration (PKAN) undergoing deep brain stimulation (DBS)
R. Mahoney, H. Gimeno, K. Tustin, S. Jupp, M. Kaminska, D. Lumsden, R. Selway, J.-P. Lin (London, United Kingdom)
- We-55 Cervical dystonia reduces working capacity
K.K. Martikainen, T.H. Luukkaala, R.J. Marttila (Turku, Finland)
- We-57 Frequency and clinical features of lower limb dystonia in a large Italian series of primary late-onset dystonia
D. Martino, G. Abbruzzese, A.R. Bentivoglio, A. Berardelli, P. Girlanda, R. Liguori, A. Macerollo, L. Santoro, G. Defazio (Bari, Italy)
- We-58 Brain-derived neurotrophic factor and risk for primary adult-onset cranial-cervical dystonia
D. Martino, M. Muglia, G. Abbruzzese, A. Berardelli, P. Girlanda, A. Macerollo, A. Quattrone, F. Roselli, T. Sprovieri, E.M. Valente, G. Defazio (Bari, Italy)
- We-59 Central motor conduction time in children with severe dystonia aids assessment for deep brain stimulation (DBS)
V.M. McClelland, K.R. Mills, R. Selway, J.-P. Lin (London, United Kingdom)
- We-60 Shot put like paroxysmal arm dystonia
A. Cammarota, G. Raggio, D. Cerquetti, S. Perez-Iloret, M. Merello (Buenos Aires, Argentina)
- We-61 Neurophysiological and kinematic factors associated to spreading of symptoms in primary late-onset focal dystonia
F. Morgante, C. Terranova, A. Naro, V. Rizzo, C. Sorbera, M. Bove, P. Girlanda, H.R. Siebner, A. Quartarone (Messina, Italy)
- We-62 Psychogenic movement disorders – A Brazilian series of 72 cases
R.P. Munhoz, N. Becker, J.A. Zavala, H.A.G. Teive (Curitiba, Parana, Brazil)
- We-63 Additional deep brain stimulation of subthalamic fiber tracts is effective for mobile segmental dystonia
N. Murase, S. Goto, H. Shimadu, K. Matsuzaki, S. Nagahiro, R. Kaji (Tokushima City, Japan)
- We-64 Long-term effect of repetitive transcranial magnetic stimulation over the premotor cortex for writer's cramp
N. Murase, R. Urushihara, H. Hosono, H. Shimadu, K. Asanuma, R. Kaji (Tokushima City, Japan)
- We-65 Anti-NMDA receptor (NMDAR) encephalitis presenting with psychiatric and extrapyramidal symptoms in a patient without tumor
T. Nissen, H. Honig, A. Gies, J. Dalmau, P. Odin, F. Wodarg, R. Stingele, J. Volkmann (Bremerhaven, Bremen, Germany)
- We-66 New and recurrent mutations in the ATP1A3 gene in patients with rapid-onset dystonia parkinsonism (RDP)
A. Clark, D. Raymond, V. Kostic, R. Barbano, M.A. Tijssen, J.T. Penniston, S.B. Bressman, A. Brashears, K.J. Swedner, L.J. Ozelius (New York, New York)
- We-67 Familial primary blepharospasm
M.F. Oztekin, N. Oztekin (Ankara, Turkey)
- We-68 Impairment of health related quality of life in cervical dystonia: Gender differences
M.T. Pérez-Saldaña, M. Boscá, I. Martínez, J.A. Burguera (Castellon, Spain)
- We-69 Functional imaging of the brain in dystonia
A. Paschali, Z. Kefalopoulou, C. Constantoyannis, P. Vassilakos (Patras, Greece)
- We-70 Health-related quality of life in patients with focal dystonia
T. Pekmezovic, M. Svetel, N. Ivanovic, I. Petrovic, D. Kisic Tepavcevic, V.S. Kostic (Belgrade, Serbia)
- We-71 Characteristics and concordance of mirror dystonia in patients with writer's cramp
M.H. Qureshi, R.M. Kandadai, S.A. Jabeen, M.A. Kanikannan, R. Borgohain (Hyderabad, AP, India)
- We-394 Tetany as a differential diagnosis of musician's cramps
K. Kollewe, C. Schrader, R. Dengler, E. Altenmueller, D. Dressler (Hannover, Germany)
- We-395 Acute blepharospasm and torticollis associated with an ependymoma of the lateral ventricle
V. Lambrecq, I. Sibon, H. Loiseau, S. Jeannin, J.-Y. Rotge, D. Guehl, P. Burbaud (Bordeaux, France)
- We-396 A patient with a novel mutation of e-sarcoglycan gene responded to anticholinergic treatment and improved spontaneously
J.H. Lee, C.H. Lyoo, M.S. Lee (YangSan, Korea)
- We-397 Paroxysmal kinesigenic dyskinesia (PKD) and focal epilepsy: Association or coincidence
P. Lolekha (Pathumtani, Thailand)

ABSTRACT LISTING BY TOPIC

We-398	Use of botulinum toxin type B (neurobloc) for segmental dystonia in a regional neurology centre S.-J. Martin, E.J. Newman, K.A. Grosset, D.G. Grosset (Glasgow, United Kingdom)	Th-57	Effects of botulinum toxin on the oscillatory head movements in cervical dystonia A.G. Shaikh, D.S. Zee, H.A. Jinnah (Baltimore, Maryland)
We-399	The phenomenology of the geste antagoniste in blepharospasm and cervical dystonia D. Martino, M.S. Aniello, D. Liuzzi, A. Macerollo, G. Defazio (Bari, Italy)	Th-58	Oscillatory head movements in cervical dystonia: Essential tremor, dystonic tremor, or head nystagmus? A.G. Shaikh, D.S. Zee, H.A. Jinnah (Baltimore, Maryland)
We-400	A novel, easier and safer botulinum toxin injection technique for the treatment of epiphora M.T. Pérez-Saldaña, I. Barroeta, J. Pagonabarraga (Castellon, Spain)	Th-59	Sinusoidal head oscillations in idiopathic cervical dystonia A.G. Shaikh, H.A. Jinnah, L.M. Optican, D.S. Zee (Baltimore, Maryland)
We-401	Pseudoathetotic movements due to cervical stenosis mimicking a thalamic hand syndrome J. Pagonabarraga, B. Vives, I. Aviles-Olmos, A. Vidal, J. Kulisevsky (Barcelona, Spain)	Th-60	Novel GCH1 mutation and clinical study Chinese patients with dopa-responsive dystonia S. Zhang, X. Liu, X. Hu, H.F. Shang (Chengdu, China)
Th-45	Impaired lateral inhibition in focal dystonia V. Rizzo, G. Liotta, L. Ricciardi, R. Allegra, F. Morgante, P. Girlanda, C. Messina, A. Quartarone (Messina, Italy)	Th-61	Writer's cramp rehabilitation approaches O.A. Shavlovskaya, O.R. Orlova (Moscow, Russian Federation)
Th-46	Painful legs moving toes treated with botulinum toxin as a dystonic syndrome R.L. Rodriguez, M.S. Okun, J. Romrell, H.H. Fernandez (Gainesville, Florida)	Th-62	Striatal dopaminergic function in spastic dysphonia K. Simonyan, P. Herscovitch (Bethesda, Maryland)
Th-47	Clinical spectrum of dopa-responsive dystonia in the Polish families M. Rudzinska, A. Potolska-Chromik, M. Bodzioch, K. Lapicka-Bodzioch, B. Zapala, P. Janik, A. Kostera-Pruszczyk, D. Hoffman-Zachara, A. Dembinska-Kiec, A. Szczudlik (Krakow, Poland)	Th-63	The phenomenology of cervical dystonia. Proposed new treatment strategy with botulinum toxin G. Reichel, A. Stenner, A. Jahn (Zwickau, Germany)
Th-48	Longitudinal effects of deep brain stimulation in the globus pallidus on intracortical GABAergic inhibition and LTP-like plasticity in dystonia D. Ruge, S. Tisch, P. Limousin, M.I. Hariz, K.P. Bhatia, N. Quinn, L. Zrinzo, M. Jahanshahi, J.C. Rothwell (London, United Kingdom)	Th-64	Novel compound heterozygous mutations in the PANK2 gene in a Korea patient with atypical pantothenate kinase associated neurodegeneration Y.H. Sung, S.H. Kim, G. Kim (Incheon, Republic of Korea)
Th-49	Clinical and genetic description of a family with paroxysmal exercise-induced dystonia M. Rutishauser, M.W.M. Schüpbach, A. Kaelin-Lang, U. Wirthmüller, J.-M. Burgunder (Bern, Switzerland)	Th-65	Rapid onset Dystonia-parkinsonism: Symptoms in a mouse deficient in Na,K-ATPase a3 A. Sacino, T.G. Hampton, J.B. Lingrel, A. Brashear, K.J. Sweadner (Boston, Massachusetts)
Th-52	Target point optimization in pallidal deep brain stimulation in cervical dystonia T. Schönecker, A. Kivi, G.-H. Schneider, K.-T. Hoffmann, A. Kupsch (Berlin, Germany)	Th-66	Botulinum toxin treatment for oromandibular dystonia (OMD): Clinical features and treatment response of series of 20 patients R. Taipa, M. Magalhaes (Porto, Portugal)
Th-53	GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskineticas S.A. Schneider, C. Paisan-Ruiz, I. Garcia-Gorostiaga, N.P. Quinn, Y. Weber, H. Lerche, J. Hardy, K.P. Bhatia (London, United Kingdom)	Th-67	Quality of life in patients with various forms of dystonia S. Telarovic, M. Relja (Zagreb, Croatia)
Th-54	Long-term follow-up of DYT-1 dystonia C.S. Schwarz, D. Raymond, N. Lubarr, M. Tagliati, R. Saunders-Pullman, S. Bressman (New York, New York)	Th-68	Movement related potentials recorded from the human internal globus pallidus during voluntary movements E. Tsang, C. Hamani, E. Moro, F. Mazzella, U. Saha, A. Lozano, M. Hodaie, R. Chen (Toronto, Ontario, Canada)
Th-55	Gait analysis in a dystonic patient pre and post pallidal deep brain stimulation M. Sensi, M. Manca, M. Mancini, L. Rocchi, L. Chiari, R. Quatrali, M.A. Cavallo, M.R. Tola (Ferrara, Emilia Romagna, Italy)	Th-69	Differential diagnostics of facial dyskinesia using the 'gesture antagonistic' E. Veevnik, S. Likhachev, L. Vasilevskaya (Minsk, Belarus)
Th-56	Feedback influences the function of head neural integrator A.G. Shaikh, H.A. Jinnah, D.S. Zee (Baltimore, Maryland)	Th-70	Temporal discrimination thresholds in AOPTD – Voxel based morphometry in unaffected relatives validates a new endophenotype R. Whelan, D. Bradley, R. Walsh, R. Reilly, S. Hutchinson, F. Molloy, M. Hutchinson (Dublin, Ireland)
		Th-71	Mutations in ATP7B explain Wilson's disease but not the whispering dysphonia and dystonia in the original DYT4 family S. Winkler, K. Lohmann, C. Klein, R.A. Wilcox (Luebeck, Schleswig-Holstein, Germany)
		Th-72	A 10 year retrospective audit of epileptic seizures post deep brain stimulation for dystonia K. Wu, S. Nightingale, M.J. Devine, T. Saifee, M. Johnson, T.Z. Aziz, P.G. Bain (London, United Kingdom)
		Th-73	Comparison of dystonia between Parkinson's disease and atypical parkinsonism W.T. Yoon, W.Y. Lee, S.H. Jeon, J. Ahn, J. Cho (Seoul, Republic of Korea)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-74** Task-specific versus non-task-specific retraining after immobilization – A one year follow-up in writer's cramp patients
K.E. Zeuner, M. Peller, A. Knutzen, G. Deuschl, H.R. Siebner (Kiel, Germany)
- Th-400** A primary torsion dystonia phenotype with substantia nigra hyperechogenicity: A case report
G. Pavlic, I. Moldovanu, S. Odobescu, L. Rotaru, G. Corcea (Chisinau, Republic of Moldova)
- Th-401** The X-ray symptoms of spasmotic torticollis
Y. Rushkevich, S. Likhachev, T. Charnukha, A. Avlasevich (Minsk, Belarus)
- Th-402** Quantitative EEG analysis in assessment of blepharospasm treatment efficiency by botulotoxin type A
V. Rybakova, S. Likhachev, E. Veevnik (Minsk, Belarus)
- Th-403** Improvement of primary blepharospasm after needle orbicularis oculi muscle puncture: Report of one case
F. Alarcon, R. Salinas (Quito, Ecuador)
- Th-404** Visual evoke potentials in pallidal surgery
M.S. Sankhe (Mumbai, Maharashtra, India)
- Th-405** The observation of patients with dystonia at the clinical diagnostic center
L.P. Shperling, V.V. Vardosanidze (Novosibirsk, Russian Federation)
- Th-406** Zerviton: A new tool to measure head position in patients with cervical dystonia: Preliminary results
S. Sommer, R. Viga, H. Petersen, E. Koletzki, W. Jost (Wiesbaden, Germany)
- Th-407** Displacement of deep brain stimulation electrode causing epileptic seizures in a dystonic patient
K. Wu, D. Nandi, T. Aziz, P. Bain (London, United Kingdom)
- Th-408** Late onset dystonia secondary to static encephalopathy in the newborns: Physiopathological mechanisms and surgical treatment
F. Vivancos Matellano, I. Ybot Gorrín, E. Díez Tejedor (Madrid, Madrid, Spain)

Education in Movement Disorders

- Mo-74** Botulinum toxin type B may alleviate pain and movements in Painful Legs Moving Toes
M.V. Alvarez, V.G. Evidente (Lackland AFB, Texas)
- Mo-75** Parkinson's disease on the internet: An evaluation of the readability, quality, and content of patient-accessible information
B.R. Barton (Chicago, Illinois)
- Mo-407** Ancient walking to primal rhythms: therapeutic "continuum of movement" rituals employed to alleviate symptoms of movement disorder
R. Eady (Boca Raton, Florida)
- Tu-72** Unified Wilson's disease rating scale (UWDRS) training and evaluation DVD – A new training tool for evaluation of neurological symptoms of patients with Wilson's disease
A. Czlonkowska, C. Möller, G. Chabik, M. Lesniak, T. Litwin, B. Tarnacka, J.-M. Trocello (Warsaw, Poland)
- We-73** Final results from a Canada-wide survey to assess regional differences in the diagnosis and management of movement disorders responsive to botulinum toxin type-A (Botox®)
M. Jog, Canadian Movement Disorder Survey Group, S. Simonyi (London, Ontario, Canada)

- We-74** Recommendations for optimal organization of care in Parkinson's disease
S.H.J. Keus, T. van Laar, J.A. Vriezen, S. Flikweert †, M. Hulscher, M. Munneke, B.R. Bloem (Leiden, Netherlands)
- Th-75** Use of Parkinson's disease research as a model for teaching aspiring young scientists
R.B. Rosenbaum, J.T. Rosenbaum, K.H. Farris, T. Martin, E.A. Neuweit (Portland, Oregon)

Epidemiology

- Mo-76** Parkinson's disease registry in Thailand launched: The first pilot project
R. Bhidayasiri, N. Wannachai, S. Limpabandhu, T. Asawawichienchinda, T. Poolpolamnuay, L. Kaewwilai, R. Devahastin, K. Phanthumchinda (Bangkok, Thailand)
- Mo-77** An observatory study of primary and secondary hemifacial spasm
Y.P. Chang, P.Y. Shih (Kaohsiung, Taiwan)
- Mo-78** Prevalence and incidence study of Parkinson's disease in the metropolitan city of Kolkata, India – A community based study
S.K. Das, A. Hazra, B.K. Ray, A. Misra, M. Ghosal, T.K. Banerjee, T. Roy, D.K. Raut, A. Chaudhuri (Kolkata, West-Bengal, India)
- Mo-79** Long-term mortality of Parkinson's disease and other types of parkinsonism. Data from a populational study
E. de Pablo, I.J. Posada, J. Benito, F. Bermejo, R. Trincado, C. Rodríguez, M.J. Medrano (Madrid, Spain)
- Mo-80** Patients' perception of premotor symptoms before motor manifestation of Parkinson's disease – Occurrence according to Braaks' staging
A. Gaenslen, I. Swid, J. Godau, M. Fruhmann-Berger, I. Liepelt, D. Berg (Tuebingen, Germany)
- Mo-81** Alternative therapies and Parkinson's disease in Portugal
L.O. Gouveia, A. Noronha, M. Finisterra, M. Coelho, M.M. Rosa, C. Sampaio, J.J. Ferreira (Lisbon, Portugal)
- Mo-82** Mild parkinsonian signs are associated with cognitive impairment without dementia in a door-to-door study of an elderly Arab population
S.D. Israeli-Korn, M. Masarwa, E. Schechtman, A. Abuful, R. Strugatsky, S. Avni, L.A. Farrer, R.P. Friedland, R. Inzelberg (Tel Hashomer, Israel)
- Mo-83** Asymmetry of symptoms and signs in multiple system atrophy
A. Iwata, Y. Momose, S. Tsuji (Tokyo, Japan)
- Mo-84** Urate and the risk of Parkinson's disease in a community-based population in the United States (Cardiovascular Health study)
S. Jain, T.G. Ton, R.M. Bourdreau, E.L. Thacker, S.A. Studenski, S.L. Rhodes, W.T. Longstreth, E.S. Strotmeyer, A.B. Newman (Pittsburgh, Pennsylvania)
- Mo-408** Pharmacogenetic determinants for discontinuation of non-ergoline dopamine agonists in Parkinson's disease
M.E.L. Arbouw, K.L.L. Movig, T.C.G. Egberts, P.J.E. Poels, J.P.P. van Vugt, J.A.M. Wessels, T. van der Straaten, C. Neef, H.-J. Guchelaar (Enschede, Netherlands)
- Tu-73** Drug interaction with genes in early Parkinson's disease
C. Jean-Christophe, E. Alexis, B. Cecilia, B. Anne-Marie, B. Alexis, V. Marie (Paris, France)

ABSTRACT LISTING BY TOPIC

Tu-74	Movement disorders post stroke M. Kapianidze, M. Janelidze, M. Beridze, N. Lobjanidze, N. Kvirkvelia, I. Khatiashvili (Tbilisi, Georgia)	We-80	Anti-Parkinson drugs consumption. A pharmacoepidemiological study M. Ponte, P.F. Garcia Merletti, E. Jurisic (Buenos Aires, Argentina)
Tu-75	Study of the prevalence of Parkinson's disease using dopamine transporter imaging J.S. Kim, J.M. Kim, K.W. Kim, Y.K. Kim, S.E. Kim, B.S. Jeon (Seong nam-si, Kyeong ki -do, Korea)	We-81	Statin use and the risk of developing Parkinson's disease in Denmark B. Ritz, A.D. Wahner, L. Qian, E. Schernhammer, J. Olsen, S. Friis (Los Angeles, California)
Tu-76	Cholesterol and apolipoproteins in patients with Parkinson's disease: A case-control study M.-J. Kim, S.R. Kim, S.H. Lee, J.M. Koh, H.K. Kim, M.C. Lee, S.J. Chung (Seoul, Korea)	We-82	L-Type calcium channel blockers and the risk of developing Parkinson's disease in Denmark B. Ritz, L. Qian, E. Schernhammer, J. Olsen, S. Friis (Los Angeles, California)
Tu-77	Non-uniformity of movement disorders care across the world – More is needed H. Kumar, M.S. Jog (London, Ontario, Canada)	We-83	Occurrence and treatment of depression and anxiety prior to Parkinson's disease E. Jacob, N. Gatto, A. Thompson, Y. Bordelon, B. Ritz (Los Angeles, California)
Tu-78	Trends in mortality from Parkinson's disease in Chile C. Juri, V. Diaz, C. Kunstmann, P. Chana (Santiago, Chile)	We-84	Psychogenic movement disorders in children and adolescents M. Rotstein, T. Pearson, D.T. Williams, S. Frucht (New York, New York)
Tu-79	NSAID use and the risk of Parkinson's disease: The influence of comorbidity J.A. Driver, G. Logroscino, J.M. Gaziano, T. Kurth (Paris, France)	Th-76	Risk for Parkinson's disease after hospitalisation for a head injury: A population-based case-control study K. Rugbjerg, B. Ritz, L. Korbo, N. Martinussen, J.H. Olsen (Copenhagen, Denmark)
Tu-80	Co-occurrence of substantia nigra hyperechogenicity and putative premotor signs as well as risk factors of PD in a large cohort older than 50 years I. Liepelt, S. Behnke, K.J. Schweitzer, B. Wolf, U. Dillmann, A. Gaenslen, A. Di Santo, J. Godau, D. Berg (Tuebingen, Germany)	Th-77	Cross-sectional analysis of parkinsonian features in the Einstein aging study M. San Luciano, A. Sanders, K. Mindy, R. Saunders-Pullman (New York, New York)
Tu-81	Movement disorder among the new Parkinson diseases patients in China Y. Luo, X. Tan, P. Wang, B. Chen, Z. Lv, H. Lei, L. Wang (Xiangfan, Hubei, China)	Th-78	Environmental risk factors in a population based incidence study of Parkinson's disease. Differential effect of alcohol and smoking on akinetic rigid and tremor dominant Parkinson's disease G.O. Skeie, B. Muller, K. Haugarvoll, J.P. Larsen, O.-B. Tysnes (Bergen, Norway)
Tu-82	Prevalence of gait disorders in elderly men and women aged 58-97 years (Bruneck study cohort): A population-based study P. Mahlknecht, V. Rastner, A. Hotter, M. Nocker, H. Stockner, K.J. Mair, A. Gasperi, G. Rungger, C. Scherfler, K. Seppi, W. Poewe (Innsbruck, Austria)	Th-79	Microelement change of the Parkinson diseases movement disorder patients in China X. Tan, Y. Luo, P. Wang, W. Chen, Z. Lv, H. Lei, L. Wang (Wuhan, China)
Tu-407	Influence of vascular risk factors on the prevalence and progression of sporadic amyotrophic lateral sclerosis: An 85-case study A.C. Wiart, C. Moreau, J. Salleron, V. Brunaud Danel, A. Destee, L. Defebvre, D. Devos (Lille, France)	Th-80	Parkinson's disease and nutritional survey X. Tan, Y. Luo, J. Pan, P.-Q. Wang, B. Cheng, Z. Lv (Wuhan, China)
We-75	Evaluation of types and distribution of movement disorders in adults with cerebral palsy M.A. Mezaal, A.S. Nadeem, K.A. Noori, K. Al Safar, M. Al Ani (Dubai, United Arab Emirates)	Th-81	A 15-year population-based longitudinal study of incidence of Parkinson's disease (PD) and parkinsonian syndromes (PS) in an elderly French population (PAQUID) F. Perez, C. Helmer, S. Auriacombe, J.-F. Dartigues, F. Tison (Pessac, France)
We-76	Prevalence of Parkinson's disease in five French districts and its relation with type of farming F. Moisan, J.L. Dupupet, J. Houssinot, Y. Hammon, J.L. Mazurie, J. Spinosi, M. Goldberg, E. Imbernon, C. Tzourio, A. Elbaz (Paris, France, Metropolitan)	Th-82	Long-term outcome of patients with Wilson's disease in Serbia A. Tomic, M. Svetel, T. Pekmezovic, N. Kresojevic, I. Petrovic, V. Spica, M. Jecmenica Lukic, T. Stojkovic, E. Stefanova, V.S. Kostic (Belgrade, Serbia)
We-77	Risk factors for psychosis in patients with Parkinson's disease: Regional perfusion change on SPECT study in pre-psychotic state T. Oeda, K. Yamamoto, H. Sawada (Kyoto, Japan)	Th-83	Survey of presentation and natural history of Wilson's disease (WD) in childhood M. Ullah, M. Samuel, R. Taylor, A. Dhawan, T. Hedderly (London, United Kingdom)
We-78	Atypical parkinsonisms in a rural Japan Y. Osaki, Y. Morita, I. Miyano, T. Kuwahara, Y. Doi (Nankoku, Kochi, Japan)	Th-84	Distinct motor features of young onset Parkinson's disease – A community based case control study M.M. Wickremaratchi, Y. Ben-Shlomo, M. Moran, E. Morgan, D. Davies, A. Jones, D. Sastry, R. Weiser, C. Butler, H.R. Morris (Cardiff, United Kingdom)
We-79	Parkinson's disease in a rural Japan Y. Osaki, Y. Morita, I. Miyano, T. Kuwahara, Y. Doi (Nankoku, Kochi, Japan)		

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-85** Interaction of pesticide exposure and glutathione transferase polymorphism with the risk of the development of Parkinson's disease
R.-M. Wu, C.-W. Cheng, C.-S. Fong (Taipei, Taiwan)
- Th-86** Risk factors for psychosis in Parkinson's disease: Cohort study using Cox proportional hazards models
K. Yamamoto, T. Oeda, H. Sawada (Kyoto, Japan)
- Genetics**
- Mo-85** Clinical findings and molecular characterization of perlecan gene in 4 Jordanian children with Schwartz Jampel syndrome
S.K. Aburahma, S.A. Jaradat (Irbid, Jordan)
- Mo-86** Motor phenotype of LRRK2 G2019S carriers in early onset PD
R. Alcalay, L. Clark, H. Mejia-Santana, M. Tang, L. Rosado, E. Louis, C. Comella, A. Colcher, D. Jennings, M. Nance, S. Bressman, W. Scott, C. Tanner, S. Mickel, H. Andrews, C. Waters, S. Fahn, B. Ross, L. Cote, S. Frucht, M. Rezak, B. Ford, K. Novak, J. Friedman, R. Pfeiffer, L. Marsh, E. Caccappolo, B. Hiner, A. Siderowf, R. Ottman, K. Marder (New York, New York)
- Mo-87** GBA gene variants are associated with PD in France
M. Anheim, C. Condroyer, S. Lesage, A. Troiano, A. Durr, A. Brice (Paris, France)
- Mo-88** Ataxia with oculomotor apraxia type 2 (AOA2): Clinical and molecular delineation, genotype to phenotype correlations and strategy for diagnosis
M. Anheim, M. Fleury, P. Charles, C. Barbot, M. Salih, J.-P. Delaunoy, L. Arning, L. Schols, J. Sequeiros, C. Goizet, C. Marelli, I. Le Ber, J. Koht, J. Gazulla, N. Drouot, L. Ali-Pacha, M. Chbicheb, B. Chabrol, A. MZahem, P. Calvas, R. Murphy, M. Watanabe, P. Coutinho, M. Tazir, B. Monga, A. Durr, A. Brice, C. Tranchant, M. Koenig (Strasbourg, France)
- Mo-89** Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (*Danio rerio*)
L. Flinn, H. Mortiboys, K. Volkmann, R.W. Koester, P.W. Ingham, O. Bandmann (Sheffield, United Kingdom)
- Mo-90** a-synuclein gene dosage study in individuals with parkinsonian syndromes and other neurodegenerative disorders
S. Bech, A. Norremolle, K. Svenstrup, K. Winge, J.E. Nielsen, L.E. Hjermind (Copenhagen, Denmark)
- Mo-91** CTCF depletion in the FXN gene constitutes an epigenetic switch in Friedreich ataxia
S.I. Bidichandani, Y. Chutake, I. De Biase (Oklahoma City, Oklahoma)
- Mo-92** Two types of neurological manifestation in Woodhouse-Sakati syndrome
S.A. Bohlega, A.A. Al-Semari, A.M. Alazami, A. Al-Saif, B. Meyer, F.S. Alkuraya (Riyadh, Saudi Arabia)
- Mo-93** Decreased expression of alpha-synuclein isoforms in peripheral blood cells of sporadic parkinsonian patients
E. Mutez, L. Larvor, C.C. Vanbesien-Mailliot, V. Mouroux, A. Destee, M.-C. Chartier-Harlin (Lille, France)
- Mo-94** Analysis of lysosomal storage disorder genes in Lewy body disorders
L.N. Clark, B. Dorado, M. Wei, B. Ross, M. Verbitsky, J.-P. Vonsattel, K. Marder, J. Lee, L.S. Honig (New York, New York)
- Mo-95** Twenty novel mutations in SPG11/spatacsin identified using both direct sequencing and MLPA
C. Depienne, E. Denis, E. Fedirko, E. Mundwiller, S. Forlani, C. Cazeneuve, E. Leguern, A. Durr, A. Brice, G. Stevanin (Paris, France)
- Mo-96** Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation
D. Devos, P. Jissendi Tchofo, I. Vuillaume, C. Moreau, L. Defebvre, A. Destée, S. Batey, J. Burn, P. Chinnery (Lille, France)
- Mo-97** Autosomal-recessive gene mutation frequencies in Turkish patients with Parkinson's disease
B. Dursun, E. Lohmann, S. Lesage, H. Hanagasi, O. Aydin, G. Babaca, H. Gurvit, J. Yazici, N. Erginel-Unaltuna, M. Emre, A. Brice (Istanbul, Turkey)
- Mo-98** Phenotypic and genotypic characteristics of patients with early-onset Parkinson's disease: A pilot study in the Czech Republic
O. Fiala, J. Prochazkova, L. Pospisilova, M. Matejkova, P. Martasek, E. Ruzicka (Prague, Czech Republic)
- Mo-99** Complete screening for glucocerebrosidase mutations in Parkinson's disease patients from Greece
K. Kalinderi, S. Bostantjopoulou, C. Paisan-Ruiz, Z. Katsarou, J. Hardy, L. Fidani (Thessaloniki, Greece)
- Mo-100** The interaction between GSK3b and MAPT genes modify the risk of Parkinson's disease
I. Garcia-Gorostiaga, C. Sanchez-Quintana, P. Sanchez-Juan, S. Curiel del Olmo, E. Rodriguez-Rodriguez, I. Mateo, J. Berciano, O. Combarros, J. Infante (Santander, Cantabria, Spain)
- Mo-101** De novo interstitial duplication 4q associated with sporadic young-onset dopa-responsive parkinsonism
G. Garraux, V. Jean-François, J. Mauricette, B. Vincent, M. Gustave, D. Dominique (Liege, Belgium)
- Mo-102** Novel mutations in the PANK2 gene in an Argentinean patient with pantothenate kinase-associated neurodegeneration
J.L. Etcheverry, D.P. Converso, A.L. Rosa, C. Bidinost, E.M. Gatto (Buenos Aires, Argentina)
- Mo-103** Search for pre-motor signs and symptoms of Parkinson's disease in first degree relatives of PD patients who are LRRK2 G2019S mutation carriers. A pilot study
N. Giladi, A. Mirelman, N. Synhaeve, M. Arends, S. Levy, A. Thaler, O. Moore, E. Ash, A. Bar-Shira, A. Orr-Urtreger, T. Gurevich (Tel Aviv, Israel)
- Mo-104** Anticipation of disease onset in Brazilian patients with early-onset Parkinson's disease, PINK1 polymorphisms and exposure to environmental risk factors
C. Godeiro-Junior, P.M. Carvalho-Aguiar, A.C. Felicio, O.G.P. Barsottini, S.M.A. Silva, V. Borges, L.A.F. Andrade, H.B. Ferraz (Sao Paulo, Brazil)
- Mo-409** A novel mutation of e-Sarcoglycan in a Taiwanese family of myoclonus-dystonia
C.-L. Huang, S.-C. Lai, Y.-H. Wu-Chou, C.-Y. Hsu, C.-S. Lu (Taoyuan, Taiwan)
- Tu-83** PINK 1 mutations in a Brazilian cohort of early-onset Parkinson's disease patients
C. Godeiro-Junior, P.M. Carvalho-Aguiar, A.C. Felicio, O.G.P. Barsottini, S.M.A. Silva, V. Borges, L.A.F. Andrade, H.B. Ferraz (Sao Paulo, SP, Brazil)

ABSTRACT LISTING BY TOPIC

Tu-84	Neurocognitive and psychiatric profile of patients with type 1 Gaucher disease presenting with a movement disorder O. Goker-Alpan, G. Lopez, E. Wiggs, J. Davis, E. Sidransky (Bethesda, Maryland)	Tu-98	Comprehensive molecular genetic analysis of the LRRK2 gene in a UK familial Parkinson's disease cohort A.J. Lewthwaite, T.D. Lambert, F.E. Marely, N.W. Wood, D.J. Nicholl, K.E. Morrison (Birmingham, West Midlands, United Kingdom)
Tu-86	Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with early-onset parkinsonism J.-F. Guo, X.-W. Zhang, L.-L. Nie, H.-N. Zhang, B. Liao, J. Li, L. Wang, X.-X. Yan, B.-S. Tang (Changsha, Hunan, China)	Tu-99	Recurrent expansion of a 700kb deletion on chromosome 14 in a family with dopa-responsive dystonia K. Lohmann, R. Saunders-Pullman, A. Rakovic, I. Martin-Subero, H. Tonnes, K. Wiegers, F. Hinrichs, Y. Hellenbroich, D. Raymond, L.J. Ozelius, E. Schwinger, R. Siebert, S.B. Bressman, C. Klein (Luebeck, Germany)
Tu-87	Mutations in the LRRK2 (G2019S) and the glucocerebrosidase genes can influence the clinical course and pre-morbid behavior of patients with Parkinson's disease T. Gurevich, A. Mirelman, I. Alroey, S. Levy, T. Zilberman, E. Ash, A. Orr-Urtreger, N. Giladi (Tel Aviv, Israel)	Tu-408	Polymorphism of CYP2D6 alleles in Parkinson's disease M. Lisak, M. Stefanovic, M. Roje Bedekovic, Z. Trkanjec, V. Demarin (Zagreb, Croatia)
Tu-88	LRRK2 Exon 41 mutations are not common in Turkey H.A. Hanagasi, E. Lohmann, B. Dursun, A. Honoré, S. Lesage, O. Aydin, G. Babacan, H. Gurvit, J. Yazici, N. Erginel-Unaltuna, A. Brice, M. Emre (Istanbul, Turkey)	Tu-409	The Jackson Laboratory mouse repository: A genetic resource available to the scientific community for Friedreich's ataxia and other movement related disorders C.M. Lutz, M. Sasner, S.F. Rockwood, R.J. Bartek (Bar Harbor, Maine)
Tu-89	The phenotype of the 202A deletion in the Parkin gene in two large Muslim Israeli-Arab kindreds S. Hassin-Baer, N. Hattori, C. Cohen, M. Massarwa, S.D. Israeli-Korn, R. Inzelberg (Tel Hashomer, Israel)	We-86	Variation in the 3' region of the alpha-synuclein gene modifies risk for Parkinson's disease I. Mata, A. Samii, S. Factor, D. Higgins, A. Griffith, J. Roberts, H. Kim, P. Agarwal, D. Yearout, C. Hutter, J. Wan, K. Edwards, D. Kay, H. Payami, C. Zabetian (Seattle, Washington)
Tu-90	Analysis of the GRN 3'UTR+78 C>T polymorphism as a risk factor for Parkinson's disease B. Jasinska-Myga, C. Wider, G. Opala, A. Krygowska-Wajs, M. Barcikowska, K. Czyszewski, M. Baker, R. Rademakers, R.J. Uitti, M.J. Farrer, O.A. Ross, Z.K. Wszolek (Jacksonville, Florida)	We-87	DLB locus on chromosome 2q35-q36 represents a separate genetic entity B. Meeus, K. Nuytemans, D. Crosiers, S. Engelborghs, B. Pickut, K. Peeters, M. Mattheijssens, E. Corsmit, P.P. De Deyn, C. Van Broeckhoven, J. Theuns (Antwerpen, Belgium)
Tu-91	Tetracycline-regulated stable expression of wild type and mutant parkin proteins in HeLa cells M. Kasap, A. Sazci, H.A. Idrisoglu (Kocaeli, Turkey)	We-88	The role of ALA746THR variant in the ATP13A2 gene among Hong Kong Chinese Parkinson's disease patients A. Chan, F. He, C. Lau, V. Mok, N. Tang (Hong Kong, China)
Tu-92	DNA methylation pattern in the human IGF-2 imprinted region of Parkinson's disease patients is not altered by the dosage of L-dopa treatment comparing high versus low L-dopa administration O. Kaut, H. Pieper, S. Paus, I. Schmitt, A. Wahla, U. Wüllner (Bonn, Germany)	We-89	Prevalence of LRRK2, synuclein and parkin mutations in Parkinson's disease patients from Extremadure (southern Spain) J.M. Moran, M.A. Ortiz-Ortiz, I. Casado, F. Castellanos, C. Duran, R.A. Gonzalez-Polo, M. Niso-Santano, J.M. Bravosanpedro, A.D. Moreno, J.M. Fuentes (Caceres, Spain)
Tu-93	Molecular analysis PARK2 mutations in the group of Polish patients with early onset Parkinson's disease D. Koziorowski, D. Hoffman-Zacharska, M. Nawara, J. Slawek, J. Bal, A. Friedman (Warsaw, Poland)	We-90	Genetic and familial study of young onset Parkinson's disease in Wales H.R. Morris, E. Majounie, V. Newsday, D.W. Perera, Y. Ben-Shlomo, M.M. Wickremaratchi, N.M. Williams (Cardiff, United Kingdom)
Tu-94	Transcription factor PITX3 in Parkinson's disease W. Le, D. Nguyen, W. Lin, P. Rawal, Y. Ding, W. Xie, H. Deng, J. Jankovic (Houston, Texas)	We-91	Influence of apolipoprotein E alleles on cognitive status and motor complications in Parkinson's disease J.J. Martin, R. Carles, F. Canizares, O. Morsi, M.T. Herrero, I. Villegas, A.F. Barreiro (Murcia, Spain)
Tu-95	SCA17 mutation for ataxia and chorea in Korea W.-W. Lee, J.-Y. Kim, S.S. Park, B.S. Jeon (Seoul, Republic of Korea)	We-92	Assessment of frequencies of simple mutations and copy number variations in five PD genes in Belgian Parkinson's disease patients K. Nuytemans, B. Meeus, D. Crosiers, N. Brouwers, P. Pals, S. Engelborghs, B. Pickut, V. Bogaerts, E. Corsmit, M. Van Den Broeck, P. Cras, P.-P. De Deyn, C. Van Broeckhoven, J. Theuns (Antwerpen, Belgium)
Tu-96	Different origins and demographic histories of the LRRK2 G2019S mutation in Parkinson's disease S. Lesage, E. Patin, C. Condroyer, A.-L. Leutenegger, E. Lohmann, P. Pollak, A.-M. Ouvrard-Hernandez, S. Bardien-Kruger, H. Tomiyama, N. Basak, A. Durr, N. Hattori, A. Orr-Urtreger, M. Tazir, L. Quintana-Murci, A. Brice (Paris, France)	We-93	Differential expression of mitochondrial and proteasomal genes in Parkinson's disease patients with severe GBA mutations Z. Gan-Or, N. Giladi, M. Kedmi, T. Gurevich, A. Bar-Shira, A. Orr-Urtreger (Tel-Aviv, Israel)
Tu-97	A novel GTP cyclohydrolase 1 mutation identified in a British kindred with variable phenotypes ranging from Parkinson's disease to dopa-responsive dystonia A.J. Lewthwaite, T.D. Lambert, V. Bonifati, E.J. Simons, K.E. Morrison, D.J. Nicholl (Birmingham, West Midlands, United Kingdom)		

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

We-94	A comprehensive genome-wide genomic and transcriptomic analysis of Parkinson's disease in Ashkenazim A. Orr-Urtreger, A. Bar-Shira, E. Kenny, I. Pe'er, N. Giladi, M. Kedmi (Tel Aviv, Israel)	Th-89	Glucocerebrosidase (GBA) mutations and familial Parkinson's disease in Japan T. Sekine, L. Li, Y. Li, Y. Imamichi, H. Yoshino, M. Funayama, H. Tomiyama, S. Kubo, N. Hattori (Tokyo, Japan)
We-95	Molecular study and response to levodopa therapy in eight children with tyrosine hydroxylase deficiency B. Pérez-Dueñas, M. Serrano, Á. García-Cazorla, A. Ormazábal, R. Montero, E. De Grandis, M. Pineda, E. Fernández-Alvarez, R. Pons, R. Artuch (Esplugues, Barcelona, Spain)	Th-90	Evaluation of the genetic contribution of Omi/HtrA2 to Parkinson's disease in an international collaborative study R. Kruger, M. Sharma, O. Riess, C. vanBroeckhoven, D.M. Maraganore, J. Aasly, G. Annesi, A.R. Bentivoglio, A. Brice, A. Elbaz, M. Farrer, C. Ferrarese, A. Ferraris, G. Hadjigeorgiou, N. Hattori, C. Klein, J.J. Lin, G.D. Mellick, G. Opala, A. Prigione, E.K. Tan, T. Toda, E.M. Valente, K. Wirdefeldt, Z. Wszolek, T. Gasser, GEOPD Consortium (Tuebingen, Germany)
We-96	Tremor in Parkinson's disease – Endophenotype defined by the DRD3 Ser9Gly polymorphism? S. Paus, F. Gadow, O. Kaut, M. Knapp, C. Klein, T. Klockgether, U. Wuellner (Bonn, Germany)	Th-91	Familial congenital mirror movements: Report of a large 4-generation family M. Srour, M. Philbert, M.-H. Dion, A. Duquette, F. Richer, G. Rouleau, S. Chouinard (Montreal, QC, Canada)
We-97	Mutation screening of ATP13A2 in patients with early-onset Parkinson's disease and familial Parkinson's disease from mainland China X.Y. Mao, R. Peng, Z.J. Zhang (Chengdu, Sichuan, China)	Th-92	Glucocerebrosidase gene mutations and Parkinson's disease in Chinese population Q.-Y. Sun, J.-F. Guo, L.-Y. Yao, L. Wang, X. Zuo (Changsha, Hunan, China)
We-98	Genetic analysis of GIGYF2 in Parkinson's disease K.M. Prakash, H.Q. Lim, R. Lee, R. Pavanni, L. Tan, E.-K. Tan (Singapore, Singapore)	Th-93	Domain location of heterozygous PINK1 mutations associated with differential stress induced cellular response E.K. Tan, F. Saffrah, M. Siddique (Singapore, Singapore)
We-99	Parkinsonism and early cortical involvement in a Swedish family with alpha-synuclein Ala53Thr mutation A.J. Puschmann, O.A. Ross, C. Vilarino-Guell, S.J. Lincoln, Z.K. Wszolek, M.J. Farrer, H. Widner, C. Nilsson (Lund, Sweden)	Th-94	Analysis of the UCHL1 genetic variant in Parkinson's disease among Chinese E.K. Tan, C.S. Lu, R. Peng, Y.Y. Teo, Y.H. Wu-Chou, R. Chen, Y.H. Weng, C.M. Chen, H.C. Fung, L.C. Tan, Z.J. Chang, X.K. An, J.G. Lee-Chen, M.C. Lee, S. Fook-Chong, J.M. Burgunder, R.M. Wu, Y.R. Wu (Singapore, Singapore)
We-100	Gene-gene interaction of iron-related genes variants on Parkinson's disease in the PEG study S.L. Rhodes, J.M. Bronstein, K.D. Taylor, B. Ritz (Los Angeles, California)	Th-95	PLA2G6 mutations and Parkinson's disease E.K. Tan, P. Ho, L. Tan, K.M. Prakash, Y. Zhao (Singapore, Singapore)
We-101	Cumulative effect of multiple risk and protective iron-related genes variants on Parkinson's disease in the PEG study S.L. Rhodes, C. Bandong, J.M. Bronstein, J.S. Sinsheimer, J.I. Rotter, K.K. Taylor, B. Ritz (Los Angeles, California)	Th-96	Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China genetic, clinical, and PET findings J.-L. Wang, B. Xiao, X.-X. Cui, J.-F. Guo, L.-F. Lei, X.-W. Song, L. Shen, H. Jiang, X.-X. Yan, Q. Pan, Z.-G. Long, K. Xia, B.-S. Tang (Changsha, China)
We-102	Adult onset Alexander's disease with cognitive impairment and autosomal dominant transmission associated with a novel mutation in the GFAP gene J.P. Rodrigues, R. Gooding, P. Lamont, R. Stell, F.L. Mastaglia, M. Davis (Perth, Western Australia, Australia)	Th-97	GABA(A) receptor as susceptibility genes in essential tremor S. Thier, S. Klebe, D. Lorenz, K. Christensen, G. Kuhlenbaumer, A. Nebel, S. Schreiber, G. Deuschl (Kiel, Germany)
We-103	Mutation screening of GIGYF2 gene in familial and sporadic Parkinson's disease L. Samaranch, E. Lorenzo, M. Riverol, R. Luquin, M.C. Rodriguez-Oroz, J.A. Obeso, P. Pastor (Pamplona, Navarra, Spain)	Th-98	Predictive testing in Huntington's disease: The experience of a neurology clinic A.R. Timoteo, I.M. Gaspar, C.M. Costa (Amadora, Portugal)
We-402	ALS phenotypes with mutations in SPG11 A. Orlacchio, C. Babalini, C. Patrono, P. Montieri, M.L. Varlese, A. Borreca, V. Moschella, N.B. Mercuri, G. Bernardi, T. Kawarai (Rome, Italy)	Th-99	Genome-wide association study for sporadic Parkinson's disease T. Toda, W. Satake, Y. Nakabayashi, I. Mizuta, T. Yoshikawa, M. Yamamoto, N. Hattori, M. Murata, Y. Nakamura, Japan PD Gene Consortium (Suita, Osaka, Japan)
We-403	Familial cases of paroxysmal kinesogenic dyskinesia A.Q. Rana (Toronto, Canada)	Th-100	LRRK2 P755L variant in Parkinson's disease H. Tomiyama, I. Mizuta, Y. Li, M. Funayama, H. Yoshino, L. Li, M. Murata, M. Yamamoto, S.-I. Kubo, Y. Mizuno, T. Toda, N. Hattori (Tokyo, Japan)
Th-87	Development of the Parkinson's disease mouse model resource M. Sasner, S.F. Rockwood, C.M. Lutz (Bar Harbor, Maine)	Th-101	French experience for liver transplantation in Wilson's disease with severe neurological impairment J.-M. Trocello, R. Sobesky, W. Meissner, C. Vanlemmehens, E. Medeiros de Bustos, V. de Ledinghen, J.-C. Duclos Vallee, F. Woimant (Paris, France, Metropolitan)
Th-88	Association mapping of the chromosome 5 Parkinson's disease linkage region W.K. Scott, A. Burt, K. Yu, L. Wang, E.R. Martin, J.M. Vance (Miami, Florida)		

ABSTRACT LISTING BY TOPIC

- Th-102** The MAPT gene haplotype H1 and susceptibility to Parkinson's disease: The Norwegian ParkWest study
H. Vefring, K. Haugarvoll, K. Bronnick, O.-B. Tysnes, D. Aarsland, J.-P. Larsen, M. Kurz (Stavanger, Norway)
- Th-103** Failure to find mutations in GIGYF2 gene in Chinese patients with Parkinson's disease
L. Wang, F.J. Guo, W.W. Zhang, Q. Xu, X. Zuo, L. Shen, H. Jiang, Q. Pan, X.Xin Yan, K. Xia, S.B. Tang (Changsha, Hunan, China)
- Th-104** Expanding the clinical phenotype of Perry disease
C. Wider, F. Chapon, B. Lechevalier, M.J. Farrer, Z.K. Wszolek, C. Schupp, G. Defer (Jacksonville, Florida)
- Th-105** Clinical and genetic study of an autosomal dominant PD family from eastern Switzerland
C. Wider, B. Jasinska-Myga, M.J. Farrer, F. Vingerhoets, F.G. Otto, Z.K. Wszolek (Jacksonville, Florida)
- Th-106** Molecular-genetic research of Torsion dystonia, Huntington's disease and Parkinson's disease in Belarus
O. Yacuts, K. Mosse, I. Pleshko, S. Lichachev (Minsk, Belarus)
- Th-409** Effect of Val158Met COMT polymorphism in age of onset of Parkinson's disease
A.F.S. Schuh, C.R.M. Rieder, T.L. Monte, C. Francisconi, M.H. Hutz (Porto Alegre, RS, Brazil)

Gene Therapies and Cell-based Therapies

- Mo-105** Transplantation of stem cells for Parkinson's disease: Repair, replace, or regenerate?
R.A.E. Bakay, L.P. Kelly, A.P. Smith, M.B. Newman (Chicago, Illinois)
- Mo-106** Imaging of AAV2-hAAADC infusion in a phase I study of AAV2-hAAADC gene therapy for Parkinson's disease
K.S. Bankiewicz, F. Valles, P.A. Starr, P. Larson, C.W. Christine, M.S. Fiandaca, W.J. Jagust, R.A. Hawkins, J. Forsayeth, M.J. Aminoff, J.L. Eberling (San Francisco, California)
- Tu-100** Lentivirally-mediated overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease
M.R. Ahmed, A. Berthet, G. Porras, E. Bychkov, Q. Li, B.H. Bioulac, B. Bloch, S. Koos, I. Aubert, S. Dovero, E. Doudnikoff, V.V. Gurevich, E.V. Gurevich, E. Bezard (Bordeaux, France)
- Tu-101** Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys
J.L. Eberling, A. Kells, P. Pivitrotto, J. Beyer, H.J. Federoff, J. Forsayeth, K.S. Bankiewicz (Berkeley, California)
- Tu-102** Refining pleiotrophin gene transfer for Parkinson's disease: Quantification of developmental striatal levels
S.E. Gombash, A. Cole-Strauss, J.W. Lipton, T.J. Collier, K. Steele-Collier, B.T. Terpstra, A.L. Spieles-Engemann, B.F. Daley, S.L. Wohlgemant, V.B. Thompson, R.J. Mandel, F.P. Manfredsson, C.E. Sortwell (Cincinnati, Ohio)
- We-104** Effects of allogeneic bone marrow stromal cells and reduced glutathione in the unilateral 6-OHDA rat model of Parkinson's disease
W.-F. Luo, L. Wang, S.-Y. Bao, C.-F. Liu, Z.-L. Zhang, B.-Y. Li, H.-M. Huo, W. Han, G.-H. Wu (Suzhou, Jiangsu, China)
- We-105** The primate study of parkin gene therapy
H. Mochizuki, T. Yasuda, T. Nihira, N. Hattori, T. Shimada, M. Takada, Y. Mizuno (Tokyo, Japan)

- Th-107** Expression of MHC class I antigens on the TH cells, which were derived from mouse ES cells, transplanted into syngeneic or allogeneic mouse PD models without immunosuppressive agents
A. Kumazawa, T. Yawata, M. Tamura, K. Shimizu (Nankoku, Kochi, Japan)
- Th-108** Human bone marrow-derived mesenchymal stem cells protect monoaminergic neurones in vitro from oxidative stress via the secretion of glial cell line derived neurotrophic factor (GDNF)
A.L. Whone, K. Kemp, N.J. Scolding, A. Wilkins (Bristol, United Kingdom)
- Th-109** Activation of glial cell line-derived neurotrophic factor by an engineered ZFP transcription factor provides functional neuroprotection in a rat model of Parkinson's disease
H.S. Zhang, J. Laganiere, A.P. Kells, Q. Yu, J. Lai, P.D. Gregory, J. Forsayeth, K.S. Bankiewicz (Richmond, California)

History

- Mo-107** Parkinson's disease was known much before James Parkinson – A review of history of Parkinson's disease
A.Q. Rana (Toronto, Canada)
- Mo-410** Case of progressive supranuclear palsy with unusual clinical course
N. Lobjanidze, I. Khatiashvili, M. Janelidze, M. Beridze, M. Shalikashvili (Tbilisi, Georgia)
- Tu-104** Who introduced surgery for movement disorders?
A.Q. Rana (Toronto, Canada)
- Tu-105** Dystonia-psychogenic or organic, historical review
A.Q. Rana (Toronto, Canada)
- Tu-410** History of levodopa use in Parkinson's disease
A.Q. Rana (Toronto, Canada)
- We-106** Contribution of James Parkinson to movement disorders
A.Q. Rana (Toronto, Canada)
- We-107** What ancient practitioners said about tremor?
A.Q. Rana (Toronto, Canada)
- We-108** When, where and who described different movement disorders?
A.Q. Rana (Toronto, Canada)
- We-404** Charcot's contribution to the study of Tourette's syndrome
H.A.G. Teive, C.H. Fein, R.P. Munhoz, E.R. Barbosa (Curitiba, Parana, Brazil)
- Th-110** Belladonna plant and Parkinson's – A review of history of non-dopaminergic treatments of Parkinson's disease
A.Q. Rana (Toronto, Canada)
- Th-111** A film of patients with movement disorders made in Queen Square in the mid-1920's by Samuel Alexander Kinnear Wilson
E.H. Reynolds, A.J. Lees, D. Healy (London, United Kingdom)

Huntington's disease

- Mo-109** Predictors of functional capacity, quality of life and caregivers' burden in Huntington's disease
K. Banaszkiewicz, M. Rudzinska, A. Szczudlik (Cracow, Poland)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Mo-110 Longitudinal study of cognitive and affective functioning in Huntington's disease**
B.A. Bernard, G.T. Stebbins, K.M. Shannon (Chicago, Illinois)
- Mo-111 Dopamine D2 receptors vulnerability in Huntington's disease: A role of the Rho/ROCK signaling pathway**
S. Betuing, C. Deyts, E. Martin, N. Bouveyron, B. Galan-Rodriguez, D. Charvin, E. Roze, J. Caboche (Paris, France)
- Mo-112 A phase 2 trial of minocycline in Huntington's disease**
M.E. Cudkowicz, M. McDermott, R. Doolan, F. Marshall, K. Kieburtz, HSG (Charlestown, Massachusetts)
- Mo-113 Extrastriatal dopamine D2 receptor distribution in Huntington's disease using PET**
M. Esmaeilzadeh, P. Karlsson, C. Halldin, L. Farde, J. Tedroff (Stockholm, Sweden)
- Mo-114 Huntington's disease and age at onset in a cohort from Argentina**
E.M. Gatto, V. Parisi, G. Persi, J. Etcheverry, F. Leiguarda, D. Converso, V. Varela (Buenos Aires, Argentina)
- Mo-115 Effect of rTMS on motor functions in Huntington's disease**
S.J. Groiss, J. Netz, H.W. Lange, C.M. Bueteifisch (Duesseldorf, Germany)
- Mo-411 Treatment of chorea in Huntington's disease with ropinirole and pramipexole**
S.A. Gunzler, M. Buczek (Cleveland, Ohio)
- Tu-107 Acoustic analysis of voice in Huntington's disease patients**
M.J. Velasco, I. Cobeta, G. Martín, H. Alonso-Navarro, F.J. Jiménez-Jiménez (Madrid, Spain)
- Tu-108 Neuroprotective effects of kynurenic acid analog in a transgenic mouse model of Huntington's disease**
P. Klivenyi, D. Zadori, F. Fulop, J. Toldi, L. Vecsei (Szeged, Hungary)
- Tu-109 Olanzapine in different phenotypes of Huntington's disease: First experience in Russia**
S.A. Klyushnikov, S.N. Illarioshkin, I.A. Ivanova-Smolenskaya (Moscow, Russian Federation)
- Tu-110 An ADORA2A polymorphism modifies age at onset in Huntington's disease**
S. Burnouf, C.-M. Dhaenens, C. Simonin, E. Vanbrussel, A. Duhamel, L. Defebvre, C. Duru, I. Vuillaume, C. Cazeneuve, P. Charles, P. Maison, S. Debruxelles, C. Verny, H. Gervais, J.-P. Azulay, C. Tranchant, A.-C. Bachoud-Levi, A. Dürr, L. Buée, B. Sablonnière, D. Blum, P. Krystkowiak, Huntington French Speaking Network (Amiens, France)
- Tu-111 Effect of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain**
A. Kumar, P. Kumar (Chandigarh, India)
- Tu-112 Restoration of mitogen and stress-activated kinase: A new therapeutic approach in HD?**
E. Martin, S. Béting, E. Roze, N. Déglon, J. Caboche (Paris, France, Metropolitan)
- Tu-411 Multidisciplinary approach to Huntington's disease in north Staffordshire**
A. Valanciute, G. El-Nimr (Stoke on Trent, Staffordshire, United Kingdom)
- We-109 Social intelligence in Huntington's disease**
S.L. Mason, M. Armstrong, A.A.O. Goodman, R.A. Barker (Cambridge, Cambridgeshire, United Kingdom)
- We-110 Exploratory 7T MRS in Huntington's disease**
S.J.A. van den Bogaard, E.M. Dumas, W. Teeuwisse, M.A. van Buchem, J. van der Grond, R.A.C. Roos (Leiden, ZH, Netherlands)
- We-111 Dysfunctional error monitoring in the anterior cingulate cortex in prediagnostic and manifest HD during an anti-saccade task**
J.D. Rupp, T. Blekher, M. Dzemidzic, V. Bragulat, J.D. West, J. Wojcieszek, A.J. Saykin, D.A. Karenk, T. Foroud (Indianapolis, Indiana)
- We-112 Neuroendocrine disturbances in Huntington's disease**
N. Saleh, S. Moutereau, A. Durr, P. Krystkowiak, J.-P. Azulay, C. Tranchant, E. Broussolle, F. Morin, A.-C. Bachoud-Lévi, P. Maison (Creteil, France)
- We-113 Abnormal explicit but intact implicit sequence learning in pre-symptomatic and early Huntington's disease**
S.A. Schneider, L. Wilkinson, K.P. Bhatia, S. Henley, J. Rothwell, S.J. Tabrizi, M. Jahanshahi (London, United Kingdom)
- We-114 DNA instability in replicating Huntington's disease lymphoblasts**
M. Cannella, V. Maglione, T. Martino, G. Ragona, L. Frati, G.-M. Li, F. Squitieri (Pozzilli, IS, Italy)
- Th-112 Riluzole protects Huntington's disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins**
F. Squitieri, S. Orobello, T. Martino, M. Cannella, A. Ciarmiello (Pozzilli, Italy)
- Th-113 Cerebral spinal fluid (CSF) is the main marker of Huntington's disease progression severity and age at onset prediction**
F. Squitieri, M. Cannella, M. Simonelli, T. Martino, C. Colonnese, A. Ciarmiello (Pozzilli, IS, Italy)
- Th-114 Early defect of transforming growth factor b-1 formation in Huntington's disease**
F. Squitieri, M. Cannella, E. Aronica, S. Sipione, V. Bruno, A. Ciammola, S. Orobello, F. Nicoletti, G. Battaglia (Pozzilli, Italy)
- Th-115 Patients with clinical features suggestive of Huntington's disease carrying CAG repeats of intermediate length below the pathological range of 36, in the HTT gene**
F. Squitieri, Y. Pollack, I. Shelef, B. Marom, T. Martino, M. Cannella, Y.O. Herishanu (Pozzilli, IS, Italy)
- Th-116 The degree of atrophy of striatum and pallidum in preclinical Huntington's disease strongly predicts estimated years to clinical onset**
D. Stoffers, J. Kuperman, S. Sheldon, D.J. Hagler, J. Goldstein, A.M. Dale, J. Corey-Bloom, A.R. Aron (San Diego, California)

Lewy Body Dementia and other dementias in Movement Disorders

- Mo-116 Screening for REM sleep behavior disorder in patients with cognitive impairment and/or parkinsonism: Updated validation data on the Mayo Sleep Questionnaire**
B.F. Boeve, J.R. Molano, T.J. Ferman, G.E. Smith, S.-C. Lin, K. Bieniek, W. Haidar, M. Tippmann-Peikert, D.S. Knopman, N.R. Graff-Radford, V.S. Pankratz, Y.E. Geda, R.C. Petersen, M.H. Silber (Rochester, Minnesota)

ABSTRACT LISTING BY TOPIC

- Mo-117** Association of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I-FP-CIT SPECT study
F. Roselli, N.M. Pisciotta, M. Pennelli, M.S. Aniello, M.F. De Caro, E. Ferrannini, D. Liuzzi, B. Tartaglione, G. Defazio, G. Rubini, P. Livrea (Bari, Italy)
- Mo-118** Mesencephalic 123I-FP-CIT uptake differentiates Lewy body dementia from other parkinsonisms
F. Roselli, N.M. Pisciotta, L. Catalano, D. Martino, P. Livrea, G. Rubini, G. Defazio (Bari, Italy)
- Mo-119** Prevalence of parkinsonism and other movement disorders in outpatients with Alzheimer's disease using cholinesterase inhibitors and/or memantine
G. Fabiani, H. Teive, R.P. Munhoz, N. Becker (Curitiba, Parana, Brazil)
- Tu-113** Rapidly progressive diffuse Lewy body disease
C. Gaig, F. Valdeoriola, S. Llufrui, M.J. Rey, E. Tolosa (Barcelona, Spain)
- Tu-114** Creutzfeldt-Jakob disease presenting as acute corticobasal degeneration syndrome: A videoclinical and neuropathological study
D. Gayraud, A. Maues de paula, E. Guedj, L. Renie, B. Bernadette, V. Francois (Aix en Provence, France)
- Tu-115** Computerized tracing in Huntington patients: A standard measure for hyperkinetic activity
S. Thanendarajan, A. Hoffmann, B. Landwehrmeyer, J. Andrich, P.H. Kraus (Bochum, Germany)
- Tu-116** Intrahippocampal NAC61-95 injections in the rat: Attenuation of behavioural effects following vitamin-E treatment
E. O'Hare, J.J. Elliot, E.-M. Kim (Belfast, United Kingdom)
- We-115** Quantitative map of hypoperfusion in 62 stereotactic cerebral cortical segments by IMP-SPECT reveals a specific pattern of Lewy body dementia
K. Ohta, M. Seki, Y. Shinohara (Tachikawa, Tokyo, Japan)
- We-116** Whole brain diffusion tensor imaging in Parkinson's disease, Parkinson's disease with dementia and dementia with Lewy bodies
B. Park, J.-H. Seo, H.-J. Park, S.K. Song, Y.H. Sohn, P.H. Lee (Seoul, Korea)
- We-117** The CERAD-(plus) neuropsychological battery does not clearly differentiate Parkinson's disease dementia from Alzheimer's disease and mixed dementia
G. Ransmayr, G. Baumgartner, A. Fuchs, V. Bayr, M. Steffelbauer, H. Traegner, C. Dorninger (Linz, Austria)
- We-118** Olfactory dysfunction in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
P. Robowski, J. Slawek, E. Narozanska, M. Schinwelski, E.J. Sitek, W. Kucharska, B. Brockhuis, P. Lass, D. Wieczorek, M. Dubaniewicz, B. Jasinska-Myga, M.C. Baker, R. Rademakers, Z.K. Wszolek (Gdansk, Pomorskie, Poland)
- Th-117** Visual hallucinations are related to gray matter volume in the dorsal visual pathway in Dementia with Lewy bodies and in the orbitofrontal cortex in Parkinson's disease with dementia
C. Sanchez-Castaneda, B. Ramirez-Ruiz, R. Rene, J. Campdelacreu, J. Gascon, C. Falcon, M. Calopa, S. Jauma, M. Juncadella, C. Junque (Barcelona, Spain)
- Th-118** Effects of daytime or nocturnal hypoxemia on cognitive impairment in patients with multiple system atrophy
T. Shimohata, K. Kawamura, Y. Takado, H. Nakayama, T. Ozawa, M. Nishizawa (Niigata, Japan)
- Th-119** Interhemispheric inhibition in Alzheimer's disease
R. Tsutsumi, R. Hanajima, M. Hamada, H. Kowa, A. Iwata, Y. Terao, H. Matsumoto, A. Yugeta, S. Tsuji, Y. Ugawa (Tokyo, Japan)
- Th-120** Autopsy proven diffuse Lewy body disease (DLBD) and Alzheimer's disease (AD) presenting as progressive aphasia and levodopa-responsive parkinsonism
S.E. Zuber, E.J. Cochran (Chicago, Illinois)

Myoclonus

- Mo-120** Intractable hiccup (IH): Underlying causes and management
C. Ha (Inchon, Korea)
- Mo-412** Myoclonic hypoxic encephalopathy: Presentation of 2 cases and review of the literature
R. Zaidan, A.A. Al Zeer (Riyadh, Saudi Arabia)
- Tu-117** Altered motor cortical plasticity induction by quadripulse stimulation in benign adult familial myoclonic epilepsy
M. Hamada, Y. Terao, R. Hanajima, S. Okabe, H. Matsumoto, Y. Shirota, S. Ominami, T. Shimizu, N. Tanaka, R. Tsutsumi, S. Tsuji, Y. Ugawa (Tokyo, Japan)
- Tu-118** Paroxysmal unilateral cortical arm myoclonus induced by holding a weight
P. Katschnig, P. Schwingenschuh, M.J. Edwards, M. Walker, K.P. Bhatia (London, United Kingdom)
- Tu-119** Multifocal cortical myoclonus in a patient with middle pharyngeal cancer
Y. Motoi, N. Izawa, K. Chijiwa, K. Sakai, A. Hayashi, Y. Okuma, M. Nagaoka, H. Miwa, Y. Mizuno, N. Hattori (Tokyo, Japan)
- Tu-412** Hemifacial spasm resulting from a herpes zoster ophthalmicus infection: A new causative etiology with review of the English literature
M. Feldman, I. Itin (Cleveland, Ohio)
- We-119** Anti-Glutamic acid decarboxylase antibodies: A Brazilian neurological series
H.A. Teive, R.P. Munhoz, W.O. Arruda, L.C. Werneck (Curitiba, PR, Brazil)
- We-120** Neurologic outcome in adult onset idiopathic Opsoclonus-Myoclonus syndrome
E.P. Pharr, S.R. Haines, K.H. Nawaz, M.S. Siddiqui (Winston Salem, North Carolina)
- We-121** Movement disorder turned out to be Epilepsy-Unverricht-Lundborg disease presenting to movement disorders clinic – A dilemma of epilepsy versus movement disorder
A.Q. Rana (Toronto, Ontario, Canada)
- Th-122** TENS for the treatment of propriospinal myoclonus
P. Verdure, L. Verdure, E. Roze, M. Vidailhet, E. Apartis, D. Maltete (Rouen, France)
- Th-123** Psychogenic "propriospinal myoclonus" and transcutaneous electrical nerve stimulation
L. Wojtecki, P. Albrecht, S. Groiss, D. Scherfeld, A. Schnitzler (Duesseldorf, Germany)

Poster presentation information can be found on page 19.

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

Neuroimaging

- Mo-121 Arterial spin labeling (ASL) perfusion with statistical parametric mapping in Parkinson's disease**
T.R. Melzer, R. Watts, M.R. MacAskill, R. Keenan, A. Shankaranarayanan, D.C. Alsop, C. Graham, L. Livingston, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, Canterbury, New Zealand)
- Mo-122 Voxel-based morphometry and voxel-based relaxometry in the parkinsonian variant of multiple system atrophy**
L.C. Tzorouchi, L.G. Astrakas, S.T. Konitsiotis, S. Tsouli, P.N. Margariti, A.K. Zikou, M.I. Argyropoulou (Ioannina, Greece)
- Mo-123 Changes in brain metabolism and hyposmia in Parkinson's disease**
T. Baba, A. Takeda, A. Kikuchi, N. Sugeno, M. Kobayashi, T. Hasegawa, K. Hirayama, E. Mori, Y. Itoyama (Sendai, Japan)
- Mo-124 Dopamine transporter SPECT and motor cortex excitability in de novo Parkinson's disease**
L. Barbin, P. Sauleau, C. Leux, C. Meyniel, J.M. N'Guyen, Y. Pereon, P. Damier (Nantes, France)
- Mo-125 Unilateral decrease of T1 in brainstem and midbrain in early Parkinson's disease (PD) revealed by quantitative MRI**
S. Baudrexel, L. Nürnberg, J.C. Klein, U. Rüb, H. Steinmetz, R. Deichmann, R. Hilker (Frankfurt am Main, Germany)
- Mo-126 Substantia nigra hyperechogenicity in healthy controls: Correlation with neuropsychological deficits**
S. Behnke, F.A. Wollenweber, M. Probst, T. Hiry, V. Schneider, U. Dillmann, F. Klaus (Homburg Saar, Germany)
- Mo-127 Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease patients**
V. Berti, C. Polito, S. Ramat, E. Vanzi, P. Marini, S. Sorbi, A. Pupi (Florence, FL, Italy)
- Mo-128 Gray matter volume increase in Friedreich ataxia after treatment with erythropoietin**
S. Boesch, K. Egger, W. Santer, S. Hering, B. Sturm, B. Scheiber-Mojdehdar, R. Schneider, W. Poewe, M. Schocke (Innsbruck, Austria)
- Mo-129 Imaging characteristics in Parkinson's disease and atypical parkinsonian syndromes using 3T MR siderotractography**
R. Borgohain, V. Rammohan, R.M. Kandadai, S.A. Jabeen, M.A. Kanikannan (Hyderabad, India)
- Mo-130 Life-long increase of substantia nigra hyperechogenicity in healthy children and adults**
N. Brüggemann, I. König, J. Sperner, L. Wessel, L. Wünsch, G. Seidel, K. Condefer, R. Saunders-Pulman, C. Klein, J. Hagenah (Lubeck, Germany)
- Mo-131 Basal ganglia volume and psychometric intelligence**
M.L. Bringas, G.A. Hernandez, Y. Lorenzo, A. Lage, P. Valdes, M. Sanchez (Havana, Cuba)
- Mo-132 Aging and striatum**
M.L. Bringas, G.A. Hernandez, Y. Lorenzo, M. Sanchez-Bornot, P.A. Valdes-Sosa, A. Lage (Havana, Havana City, Cuba)
- Mo-133 MR volumetric study of posterior fossa in hemifacial spasm**
L.L. Chan, K. Ng, E.K. Tan (Singapore, Singapore)
- Mo-134 Case control MRI study of leukoaraiosis in vascular parkinsonism**
L.L. Chan, K. Ng, E.K. Tan (Singapore, Singapore)
- Mo-135 Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy**
M.-H. Chang (Taichung, Taiwan)
- Mo-136 Midbrain atrophy in vascular parkinsonism**
S.M. Choi, B.C. Kim, T.S. Nam, J.T. Kim, S.H. Lee, M. Park, M.K. Kim, K.H. Cho, M.K. Song (Gwangju, Korea)
- Mo-137 Test-retest reliability of 18F-AV-133 PET imaging to assess striatal dopaminergic neuron integrity**
C.M. Clark, M.J. Pontecorvo, K. Saha, D. Jennings, L. Adler, R.M. Zweig, A. Joshi, M. Lowery, D. Skovronsky (Philadelphia, Pennsylvania)
- Mo-138 Ventricular enlargement and mild cognitive impairment in incident Parkinson's disease. A case-control study**
T.O. Dalaker, R. Zivadinov, D.P. Ramasamy, M.K. Beyer, G. Alves, K.S. Bronnick, O.-B. Tysnes, D. Aarsland, J.P. Larsen (Stavanger, Norway)
- Mo-139 Hippocampal volume in patients with Parkinson's disease (PD)**
K. Dashtipour, M. Zarifi, A. Hakimi, N.V. Demattos, N. Sadiqua, A. Obenaus (Loma Linda, California)
- Mo-140 Basal ganglia volume decrease in writer's cramp**
C. Delmaire, A. Elbaz, C. Nombela Otero, J.P. Bleton, S. Sangla, E. Roze, D. Grablé, F. Bourdain, M. Vidailhet, S. Lehericy (Lille, France)
- Mo-141 Evidence for increased upper brain stem activity following STN-DBS in Parkinson's disease: An 18FDG-PET study**
A.A. Desoulieres, B.B. Kaschten, J.J. Cremers, E.E. Salmon, G.G. Garraux (Liege, Belgium)
- Mo-142 Striatal dopaminergic dysfunction in autosomal recessive familial parkinsonism associated with PINK1 mutations**
C. Eggers, J. Hagenah, J. Klein, A. Schmidt, N. Brüggemann, V. Tadic, L. Kertelje, J. van der Vegt, K. Lohmann, F. Binkofski, Y. von Cramon, H. Siebner, G. Fink, C. Klein, R. Hilker (Cologne, Germany)
- Mo-143 A systems perspective on the effective connectivity of overt speech production**
S.B. Eickhoff, S. Heim, K. Zilles, K. Amunts (Aachen, Germany)
- Mo-144 Dopamine transporter imaging in Parkinson's disease patients with and without depression**
A.C. Felicio, T.S. Moriyama, C. Godeiro-Junior, M.C. Shih, M.Q. Hoexter, V. Borges, S.M.A. Silva, R.A. Bressan, H.B. Ferraz (Sao Paulo, Brazil)
- Mo-145 Striatal dopamine transporter SPECT study in patients with tremor-dominant, akinetic-rigid, and mixed type Parkinson's disease**
A.C. Felicio, C. Godeiro-Junior, M.C. Shih, M.Q. Hoexter, V. Borges, S.M.A. Silva, R.A. Bressan, H.B. Ferraz (Sao Paulo, Brazil)
- Mo-146 Parkinsonism-myotonia complex: A TRODAT-1 SPECT study**
A.C. Felicio, E.P.V. Felix, C. Godeiro-Junior, M.C. Shih, M.Q. Hoexter, W.A.C. Santos, R.A. Bressan, H.B. Ferraz (Sao Paulo, Brazil)
- Mo-147 fMRI correlates of limb-kinetic apraxia in Parkinson's disease**
T. Foki, N. Klinger, A. Geissler, J. Rath, T. Steinkellner, I. Hoellinger, S. Gruber, D. Haubenberger, J. Lehrner, G. Pusswald, G. Grabner, S. Trattnig, W. Pirker, E. Auff, R. Beisteiner (Vienna, Austria)

ABSTRACT LISTING BY TOPIC

- | | |
|--|---|
| <p>Mo-148 FMRI correlates of ideomotor apraxia in Parkinson's disease
T. Foki, N. Klinger, A. Geissler, J. Rath, T. Steinkellner, I. Hoellinger, S. Gruber, D. Haubenberger, J. Lehrner, G. Pusswald, G. Grabner, S. Trattnig, W. Pirker, E. Auff, R. Beisteiner (Vienna, Austria)</p> <p>Mo-149 Parkinson's disease and pathological gambling: Preliminary results from an fMRI study investigating cue induced brain activity
D. Frosini, I. Pesaresi, G. Belmonte, C. Rossi, U. Bonuccelli, R. Ceravolo, M. Cosottini (Pisa, Italy)</p> <p>Mo-150 Functional imaging of presynaptic part of nigrostriatal system with ¹²³I ioflupane (DaTSCAN) in differential diagnosis of parkinsonian syndromes
A. Gajos, M. Gorska-Chrzastek, M. Bienkiewicz, W. Soltan, J. Slawek, J. Kusmirek, A. Bogucki (Lodz, Poland)</p> <p>Mo-413 Cerebellar pathology and the triangle of Mollaret in cerebrotendinous xanthomatosis assessed by modern neuroimaging
S. Seidel, G. Kasprian, D. Prayer, M. Krssák, T. Sycha, E. Auff (Vienna, Austria)</p> <p>Tu-120 Differential effect of motor coordination and visual constraints on basal ganglia connectivity
C.M. Gallea, M. Hallett (Bethesda, Maryland)</p> <p>Tu-121 Dopaminergic imaging (DaTSCAN) in a French general hospital: A four years prospective study
D. Gayraud, P. Desvignes, S. Siles, B. Bonnefoi, L. Renie, F. Viallet (Aix en Provence, France)</p> <p>Tu-122 Significant improvement in magnetic resonance imaging brain of a Wilson's disease patient with psychiatric onset after beginning chelating therapy
M. Gennuso, M. Crispino (Crema, Cremona, Italy)</p> <p>Tu-123 Training induced motor network plasticity in Parkinson's disease
J. Godau, J. Bühlmeier, A. Gaenslen, U. Klose, W. Alt, D. Berg (Tubingen, Germany)</p> <p>Tu-124 Mismatch between FP-CIT results and the clinical scenario: A retrospective clinical audit
V.K. Gontu, J. Birchall, N.P.S. Bajaj (Derby, United Kingdom)</p> <p>Tu-125 Increased striatal metabolism on PET imaging in antiphospholipid antibody – Associated chorea
R.N. Gospodaru, M. Sauvee, D. Wahl, L. Maillard, M. Muresan, A. Darlix, B. Meneroux (Nancy, France)</p> <p>Tu-126 Quantitative ¹H magnetic resonance spectroscopic imaging of normal basal ganglia and thalamus
A. Groeger, A. Wolpert, D. Berg, U. Klose (Tuebingen, Germany)</p> <p>Tu-127 Brain dopaminergic modulation associated to executive function in Parkinson's disease
K. Farid, I. Sibon, D. Guehl, E. Cuny, P. Burbaud, M. Allard (Bordeaux, France)</p> <p>Tu-128 Clinical features and [¹¹C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early-onset parkinsonism
J.-F. Guo, L. Wang, D. He, Q.-H. Ou Yang, Z.-X. Duan, X.-W. Zhang, L.-L. Nie, X.-X. Yan, B.-S. Tang (Changsha, Hunan, China)</p> <p>Tu-129 Mechanisms underlying motor and cognitive slowing in Parkinson's disease
T. Hanakawa, M. Hallett (Kodaira, Tokyo, Japan)</p> | <p>Tu-130 A novel MRI sequence, the fast gray matter acquisition T1 inversion recovery (FGATIR), is superior to fluid attenuated inversion recovery (FLAIR) for the resolution of white matter lesions (WMLs)
I.U. Haq, A. Sudhyadhom, F.J. Bova, K.D. Foote, T. Morishita, M. Okun (Gainesville, Florida)</p> <p>Tu-131 Longitudinal MRI changes in Parkinson's disease patients with visual hallucinations
N. Ibarretxe-Bilbao, C. Junque, B. Ramirez-Ruiz, M.J. Martí, F. Valldeoriola, N. Bargallo, E. Tolosa (Barcelona, Spain)</p> <p>Tu-132 ¹H-MRS finding of substantia nigra in patients with Parkinson's disease
K. Isonishi, F. Moriwaka, S. Kaneko, T. Kashiwaba (Sapporo, Hokkaido, Japan)</p> <p>Tu-133 Cortico-striatal activation during implicit sequence learning in Parkinson's disease with deep brain stimulation of the subthalamic nucleus
M. Jahanshahi, L. Wilkinson, G. Hotton, Y. Tai, N. Pavese, D.J. Brooks (London, United Kingdom)</p> <p>Tu-134 Selective brain atrophy in Parkinson's disease treated with STN DBS
R. Jech, F. Ruzicka, D. Urhošík, J. Vymazal, E. Ruzicka (Prague, Czech Republic)</p> <p>Tu-135 Scans without evidence of dopaminergic deficit. Long-term follow-up in a clinical cohort
H.-V. Jorge, L.-B. Carles, C.-B. Gemma, C.-C. Joan, A.-B. Miquel (Terrassa, Spain)</p> <p>Tu-136 Reduction of the motor cortex thickness in Parkinson's disease
T. Jubault, L. Monetta, A.-L. Lafontaine, A.P. Strafella, A.C. Evans, S. Chouinard, O. Monchi (Montreal, QC, Canada)</p> <p>Tu-137 Brain stem volume reduction in idiopathic Parkinson's disease assessed by anatomical MRI
T. Jubault, L. Monetta, S. Brambati, A.-L. Lafontaine, A.P. Strafella, S. Chouinard, O. Monchi (Montreal, QC, Canada)</p> <p>Tu-138 Reduced volume of the substantia nigra pars compacta determined by neuromelanin magnetic resonance imaging in patients with Parkinson's disease
K. Kashiwara, T. Imamura, S. Kawada, M. Ohno, T. Shinya (Okayama, Okayama, Japan)</p> <p>Tu-139 Susceptibility weighted MR imaging can differentiate progressive supranuclear palsy from multiple system atrophy and Parkinson's disease
A. Kishore, D. Gupta, J. Saini, K. Das, S. Sarma (Trivandrum, Kerala, India)</p> <p>Tu-140 Simple & complex kinesia in Parkinson's disease: Functional MRI study
S.-B. Koh, J.H. Kim, D.-Y. Kwon, J.H. Kim, K.-W. Park, D.-H. Lee (Seoul, Korea)</p> <p>Tu-141 Diffusion tensor imaging and tractography of the nigrostriatal and mesolimbic pathways on 3 Tesla MRI: Comparison of Parkinson's disease with normal controls
R. Kumari, S. Khushwaha, R. Gupta (Delhi, India)</p> <p>Tu-142 T2 relaxometry and quantitative diffusion tensor Imaging of the basal ganglia in tardive dyskinesia on 3 Tesla MRI
R. Kumari, R. Gupta, S. Khushwaha (Delhi, India)</p> |
|--|---|

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-143** The effect of levodopa on motor pathways in healthy subjects: A functional MRI (fMRI) study
M.M. Lewis, S. Sen, W. Chen, S. Lee, Y. Truong, M.J. McKeown, X. Huang (Hershey, Pennsylvania)
- Tu-144** Differential effects of age and disease duration on the neuro-cognitive deficits and cerebral glucose metabolism in PD
C.H. Lyoo, W.C. Kim, M.S. Lee (Seoul, Korea)
- Tu-145** Sparing of serotonin and norepinephrine transporter uptake compared to dopamine transporter uptake in early Parkinson's disease
K. Marek, D. Jennings, D. Russell, J. Batis, G. Tamagnan, J. Seibyl (New Haven, Connecticut)
- Tu-146** A systematic, comprehensive, blinded radiological study of MR findings in pathologically confirmed PSP, MSA and PD
L. Massey, D. Paviour, S. O'Sullivan, D. Burn, J. Holton, T. Revesz, A. Lees, R. Jager, C. Micallef (London, United Kingdom)
- Tu-147** Discrimination of patients with Parkinson's disease and healthy control subjects using MRI
R.A. Menke, J. Scholz, K.L. Miller, M. Zarei (Oxford, United Kingdom)
- Tu-148** Lasting visual hallucinations in Charles Bonnet like syndrome; fMRI correlates and the influence of rTMS
A.M. Meppelink, B.M. de Jong, J.H. van der Hoeven, T. van Laar (Groningen, Netherlands)
- Tu-413** A fast gray matter acquisition T1 inversion recovery (FGATIR) magnetic resonance imaging (MRI) sequence for direct high resolution visualization of subcortical structures
A. Sudhyadhom, I.U. Haq, K.D. Foote, M.S. Okun, F.J. Bova (Gainesville, Florida)
- We-122** Metabolic abnormalities in human primary dystonia: A magnetic resonance spectroscopy study
S. Meunier, R. Valabregue, M. Marjanska, Y. Worbe, M. Russo, T. Popa, E. Auerbach, D. Grabl, B. Degos, S. Sangla, C. Bonnet, M. Vidailhet, S. Lehericy (Paris, France)
- We-123** Aging effect on adenosine A2A receptors in putamen – A 11C-TMSX PET study
M. Mishina, K. Ishiwata, K. Ishii, M. Naganawa, Y. Kimura, M. Sakata, K. Oda, K. Ishibashi, M. Suzuki, S. Kobayashi, Y. Katayama (Inba-gun, Chiba, Japan)
- We-124** Usefulness of cardiac ¹²³I-MIBG scintigraphy in the differential diagnosis of parkinsonism
R. Miyamoto, H. Shibayama, F. Katada, S. Sato, T. Fukutake (Kamogawa City, Chiba, Japan)
- We-125** Changes of sensori-motor network in focal dystonia and its partial recovery under treatment with botulinum toxin
B. Mohammadi, K. Kollewe, A. Samii, R. Dengler, T.F. Münte (Hannover, Germany)
- We-126** Paraspinal muscle changes in Parkinson's disease patients with scoliosis
K.-Y. Murata, Y. Kajimoto, H. Miwa, T. Kondo (Wakayama, Japan)
- We-127** Functional MRI of the inferior olive in essential tremor
I. Nestrasil, X. Wu, P.J. Tuite, K.O. Bushara (Minneapolis, Minnesota)
- We-128** Use of DatScan in the University Hospitals Leicester neurology department. A retrospective study
E. Nikfehr, R.J. Abbott (Leicester, United Kingdom)
- We-129** Diffusion weighted imaging of the olfactory tract and its association with hyposmia in PD
M. Nocker, K. Seppi, M. Schocke, R. Esterhammer, I. Virgolini, S. Boesch, W. Poewe, C. Scherfler (Innsbruck, Austria)
- We-130** Quantitative comparison of MRI methods for pre-surgical localisation of the globus pallidus
R. O'Gorman, M. Footman, D. Lythgoe, M. Samuel, R. Selway, K. Ashkan, J. Jarosz (London, United Kingdom)
- We-131** MRI magnetic susceptibility mapping of target structures for deep brain stimulation (DBS)
K. Shmueli, R. O'Gorman, D. Lythgoe, M. Samuel, R. Selway, K. Ashkan, J. Jarosz (London, United Kingdom)
- We-132** Quantitative comparison of MRI methods for pre-surgical localisation of the subthalamic nucleus
R. O'Gorman, S. Wastling, D. Lythgoe, M. Samuel, R. Selway, K. Ashkan, J. Jarosz (London, United Kingdom)
- We-133** A study of cerebral atrophy in Parkinson's disease with voxel based specific regional analysis system for Alzheimer's disease
Y. Oe, T. Yamamoto, T. Abe, N. Tamura, N. Araki, E. Imabayasi, H. Matuda (Iruma-gun, saitama, Japan)
- We-134** Efficacy of scatter correction in I-123 MIBG scintigraphy for patients with parkinsonism
M. Ohira, K. Takahashi, J. Hashimoto, N. Suzuki (Tokyo, Japan)
- We-135** Metabolic alterations during visual stimulation in 6-hydroxydopamine rat model for Parkinson's disease – in vivo small animal positron emission tomography study
N. Oishi, M. Inoue, H. Yamauchi, H. Fukuyama (Kyoto, Japan)
- We-136** Reduced cardiac MIBG uptake is a potential biomarker for the presence of Lewy bodies
S. Orimo, T. Uchihara, A. Nakamura, A. Kakita, K. Wakabayashi, H. Takahashi (Tokyo, Japan)
- We-137** Impaired activity in basal ganglia/premotor networks preceding self-initiated sequential finger movements in writer's cramp
S. Paus, J. Jankowski, L. Scheef, M. Bewersdorff, H. Schild, T. Klockgether, H. Boecker (Bonn, Germany)
- We-138** Volume and iron content in basal ganglia and thalamus of Parkinson's disease patients: A 3T MR study
P. Perani, A. Cherubini, A. Francesca, O. Rascol, P. Celsis, J.-F. Demonet, A. Peppe, C. Caltagirone, F. Pontieri, G. Spalletta, U. Sabatini (Roma, Italy)
- We-139** Reductions in sulcal volume in Parkinson's disease without dementia
J.B. Pereira, N. Ibarretxe-Bilbao, E. Tolosa, Y. Compta, M.-J. Martí, C. Junque (Barcelona, Spain)
- We-140** Corticospinal and thalamofrontal pathways in Parkinson's disease. A diffusion tensor imaging study
A. Petridis, A. Papachristoudoulou, Z. Katsarou, P. Paladas, S. Bostantjopoulou (Thessaloniki, Greece)
- We-141** Effects of L-dopa on manual and speech movements in parkinsonian patients: A dual-task approach using fMRI
S. Pinto, A. Maillet, I. Tropriès, C. Henry-Lagrange, B. Debû, A. Krainik, S. Thobois, L. Lamalle, V. Fraix, P. Pollak (Aix-en-Provence, France)

ABSTRACT LISTING BY TOPIC

- | | | | |
|--------|---|--------|--|
| We-142 | The limbic-circuitry of Huntington's disease: A combined neuroimaging approach
M. Politis, N. Pavese, Y.F. Tai, L. Kiferle, D.J. Brooks, S.J. Tabrizi, R.A. Barker, P. Piccini (London, United Kingdom) | Th-127 | N279K MAPT mutation carriers (PPND kindred) show FLAIR hyperintensity in brainstem
K.J. Schweitzer, J. Slowinski, B. Boeve, C. Wider, C.Jr. Jack, H. Shinotoh, R.J. Uitti, A.J. Strongosky, D.F. Broderick, Z.K. Wszolek (Jacksonville, Florida) |
| We-143 | Caudate nucleus dopamine depletion, cognitive functions and brain metabolism in early Parkinson's disease: A [123I] FP-CIT SPECT and [18F]FDG PET study
C. Polito, V. Berti, E. Vanzi, S. Ramat, M.T. De Cristofaro, P. Marini, S. Sorbi, A. Pupi (Florence, Italy) | Th-128 | Task-specific recruitment of cerebello-thalamo-cortical motor circuitry during progression of Parkinson's disease
S. Sen, Y. Truong, M.M. Lewis, X. Huang (Chapel Hill, North Carolina) |
| We-144 | Differential diagnosis of pathologically-proven CBGD using pattern analysis of FDG PET
K. Poston, C. Tang, M. Bussa, R. Alcalay, T. Eckert, J.P. Vonsattel, C. Edwards, T. Flanagan, V. Dhawan, S. Fahn, D. Eidelberg (Stanford, California) | Th-129 | Wilson's disease: Two treatment modalities. Correlations to pre and post-treatment brain MRI
M. Spitz, M.L. do Desterro Costa, L.A. Bacheschi, C.C. Leite, L.T. Lucato, E.R. Barbosa (Rio de Janeiro, Brazil) |
| We-145 | Task specific activation deficits in basal ganglia nuclei are accentuated across time: A study in early stage, drug naive Parkinson's disease
J. Prodoehl, M.B. Spraker, D.M. Corcos, C.L. Comella, D.E. Vaillancourt (Chicago, Illinois) | Th-130 | Differential diagnosis of Parkinson's disease and essential tremor with transcranial sonography: A population-based study
H. Stockner, K. Seppi, S. Kiechl, G. Rungger, J. Willeit, W. Poewe, A. Gasperi (Innsbruck, Austria) |
| We-146 | Metabolic-morphometric correlates of preclinical compensation in asymptomatic heterozygous PINK1 mutation carriers
K. Reetz, C. Eggers, J. Hagenah, C. Gaser, H.R. Siebner, Y. von Cramon, G.R. Fink, C. Klein, R. Hilker, F. Binkofski (Lubeck, Germany) | Th-131 | Substantia nigra's hyperechogeneity: A mirror of Parkinson's disease?
M.H. Strothjohann, D. Djundja, G.A. Fuchs (Wolfach, Germany) |
| We-147 | Functional neuroanatomy of vocalization in PD patients: A functional correlation study
I. Rektorova, J. Barrett, M. Mikl, I. Rektor, T. Paus (Brno, Czech Republic) | Th-132 | Transcranial brain parenchyma sonography in Wilson's disease patients
M. Svetel, M. Mijajlovic, T. Pekmezovic, I. Petrovic, A. Tomic, N. Kresojevic, T. Stojkovic, M. Jecmenica Lukic, V.S. Kostic (Belgrade, Serbia) |
| We-148 | Position of active electrode contacts and basal ganglia activation during STN stimulation in Parkinson's disease
J. Roggendorf, T. Gasser, J. Voges, C. Seifried, J.C. Klein, S. Baudrexel, V. Sturm, R. Hilker (Frankfurt, Germany) | Th-133 | Basal ganglia dopamine and motor subtypes of Parkinson's disease
H. Tabu, N. Sawamoto, H. Kawashima, K. Ishizu, H. Fukuyama, R. Takahashi (Kyoto, Japan) |
| We-149 | Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: Evidence from a FP-CIT SPECT study
C. Rossi, D. Frosini, D. Volterrani, P. De Feo, E. Unti, L. Kiferle, V. Nicoletti, U. Bonuccelli, R. Ceravolo (Pisa, Italy) | Th-134 | Changes in brain metabolism and dysphagia in Parkinson's disease
A. Kikuchi, A. Takeda, T. Baba, N. Sugeno, M. Kobayashi, T. Hasegawa, E. Mori, Y. Itoyama (Sendai, Japan) |
| We-150 | Diffusion tensor Imaging and MR-tractography for characteristic of microstructural integrity of white matter in patients with Parkinson's disease (PD)
Z.Z. Rozhkova, I.N. Karaban', N.V. Karaban', T.N. Kalishuk-Slobodny (Kiev, Ukraine) | Th-135 | Mechanism of mirror movements in Parkinson's disease
A. Poisson, H. Gervais, J. Redoute, D. Ibarolla, J.C. Comte, E. Broussolle, S. Thobois (Bron, France) |
| Th-124 | Diagnostic values of diffusion weighted imaging for differentiating multiple system atrophy from Parkinson's disease
K. Sako, M. Mizobuchi, A. Nihira, T. Abe, H. Tanaka, M. Idogawa (Sapporo, Japan) | Th-136 | Dat scan examination – Benefit in clinical praxis
S. Tomic, S. Butkovic-Soldo, S. Misevic, K. Kralik (Osijek, Croatia, Croatia) |
| Th-125 | Automated subcortical optimization of cerebral MRI-atlas co-registration for improved electrode localization in deep brain stimulation
T. Schönecker, A. Kupsch, A. Kühn, G.-H. Schneider, K.-T. Hoffmann (Berlin, Germany) | Th-137 | Inter- and intraobserver reliability of substantia nigra sonography for the diagnosis of Parkinson's disease
S. van de Loo, U. Walter, S. Behnke, J. Hagenah, M. Lorenz, M. Sitzer, R. Hilker, D. Berg (Frankfurt am Main, Germany) |
| Th-126 | High resolution 3T diffusion tensor imaging-based tractography for differential diagnosis of parkinsonism – A pilot study
K. Schnopfhausen, J. Furtner, G. Kasprian, E. Auff, D. Prayer, W. Pirker (Vienna, Austria) | Th-138 | Overactivity of the left rostral putamen in asymptomatic carriers of a single mutant parkin allele in the context of a visuospatial response conflict
J.P.M. van der Vegt, M.M. Weiss, B.R. Bloem, F. Binkofski, C. Klein, H.R. Siebner (Nijmegen, Netherlands) |
| | | Th-139 | Dopamine agonists reduce baseline activity, but boost gambling related activity in the orbitofrontal cortex. A PET activation study in PD patients
T. van Eimeren, G. Pellecchia, J. Miyasaki, B. Ballanger, T. Steeves, S. Houle, A.E. Lang, A.P. Strafella (Toronto, Canada) |

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-140** Tonic stimulation of the orbitofrontal cortex by dopamine agonists in PD wipes out reward processing and increases risk taking behaviour: Are they at risk of gambling?
T. van Eimeren, B. Ballanger, G. Pellecchia, J. Miyasaki, R. Chuang, T. Steeves, A.E. Lang, A.P. Strafella (Toronto, Canada)
- Th-141** Equally normalized motor activation in medicated Parkinson-associated and sporadic PD
T. van Eimeren, C. Buhmann, J. Hagenah, P.P. Pramstaller, H.R. Siebner, C. Klein (Toronto, Canada)
- Th-142** Genotype-related changes in brain activity are influenced by the speed of task performance in non-manifesting carriers of a single mutant Parkin or PINK1 allele
B.F.L. van Nuenen, B.R. Bloem, J.P.M. van der Vegt, M.M. Weiss, F. Binkofski, C. Klein, H.R. Siebner (Nijmegen, Netherlands)
- Th-143** The reliability of transcranial duplex scanning in parkinsonian patients: comparison of different observers and ultrasound systems
A.M. Vlaar, S.C. Tromp, W.E. Weber, R.M. Hubens-Hustinx, W.H. Mess (Maastricht, Netherlands)
- Th-144** Antigen retrieval improves the immunoreactivity of cells and receptor sites of the basal ganglia on rat and human brains
R. Vontell, L. McGuinness, K. Goldring, D. David, S. John (London, United Kingdom)
- Th-145** Reduced neuron integrity in cerebellar peduncle in patients of progressive supranuclear palsy
C.H. Wang, W.-Y. Lin, C.-S. Lu, P.-S. Lu, Y.Y. Wai, J.J. Wang (Yung Ho City, Taipei County, Taiwan)
- Th-146** Increased resting state activity in patient of progressive supranuclear palsy
C.H. Wang, W.-Y. Lin, C.-S. Lu, H.H. Hung, Y.Y. Wai, J.J. Wang (Yung Ho City, Taipei County, Taiwan)
- Th-147** Color discrimination impairment in patients with Parkinson's disease and their regional cerebral blood flow changes
M. Watanabe, T. Takeda, A. Tamaoka (Tsukuba, Ibaraki, Japan)
- Th-148** Safety of a non standard protocol for postoperative MRI in DBS patients
L.M. Weise, G.-H. Schneider, A. Kupsch, J. Haumesser, K.-T. Hoffmann (Berlin, Germany)
- Th-149** Cerebral glucose metabolism in PD patients with and without dementia
Y.-H. Weng, K.-J. Lin, C.-S. Lu, T.-C. Yen, L.-H. Shen (Taoyuan, Taiwan)
- Th-150** Effects of dopaminergic treatment on putaminal dopamine turnover measured with 18F-dopa-PET in Parkinson's disease
M. Wolz, B. Beuthien-Baumann, M. Loehle, B. Herting, L. Oehme, J. van den Hoff, M. Perick, J. Kotzerke, H. Reichmann, A. Storch (Dresden, Germany)
- Mo-152** Use of anticholinergic drugs and impact on cognition in Parkinson's disease
U. Ehrt, K. Broich, J.P. Larsen, C. Ballard, A. Dag (Stavanger, Norway)
- Mo-153** "Espresso coffee" for the treatment of excessive daytime sleepiness in Parkinson's disease: Results of four pilot n-of-one clinical trials
J.J. Ferreira, L. Correia-Guedes, R.A. Freire, M. Coelho, M.M. Rosa, O. Rascol, C. Sampaio (Lisbon, Portugal)
- Mo-154** A systematic review of the incidence of fatigue as an adverse event in placebo-controlled trials for Parkinson's disease
J.J. Ferreira, T. Teodoro, D. Pires, T. Mestre, M. Coelho, M.M. Rosa, C. Sampaio (Lisbon, Portugal)
- Mo-414** Dramatic improvement in parkinsonism after sinemet therapy in a patient with severe Wilson's disease
D. Apetauerova, E. Bortan (Burlington, Massachusetts)
- Tu-149** Zinc-induced copper deficiency in Wilson's disease
J. Horvath, P. Beris, E. Giostra, P.-Y. Martin, P.R. Burkhard (Geneva, Switzerland)
- Tu-150** L-dopa therapy increases the homocysteine concentrations in the cerebrospinal fluid from patients with Parkinson's disease
C. Isobe, T. Abe, T. Murata, C. Ohtsuka, N. Hattori, Y. Terayama (Chitose-City, Hokkaido, Japan)
- Tu-151** Effect of levodopa on heart rate variability in Parkinson's disease
S.S. Jaideep, P.K. Pal, M. Ganeshan, T.N. Sathyaprakash (Bangalore, India)
- Tu-152** Valvular heart regurgitation and pergolide in Parkinson's disease: Follow-up of an observational study
C. Jean-Christophe, B. Anne-Marie, L. Lucette, I. Richard (Paris, France)
- Tu-153** Treatment with oral iron chelation in a case of neurodegeneration with brain accumulation
A. Kwiatkowski, P. Jissendi-Tchofo, C. Moreau, I. Vuillaume, P. Chinney, A. Destée, L. Defebvre, D. Devos (Lille, France)
- Tu-154** Pore-forming iron-induced alpha-synuclein oligomers – A target for developing compounds against pathological protein aggregation
J. Levin, K. Boetzel, T. Hoegen, M. Kostka, H. Kretzschmar, A. Giese (Munich, Germany)
- We-151** The HMG-CoA reductase inhibitor simvastatin reduces severity of L-dopa-induced abnormal involuntary movements in the MPTP-macaque model of Parkinson's disease
Q. Li, F. Tison, L. Negres Pages, O. Rascol, E. Bezard (Bordeaux, France)
- We-152** EFF0311, an antiparkinson full D1 dopamine agonist with longer duration and possible functional selectivity
R.B. Mailman, V. Murthy (Hershey, Pennsylvania)
- We-153** Overexpression of cannabinoid CB2 receptors results in decreased behavioral and neurochemical vulnerability to intracaudate administration of 6-hydroxydopamine
A. Ternianov, M.S. Garcia-Gutierrez, M.J. Cano, F. Navarrete, J.M. Perez-Ortiz, C. de Cabo, C. Leiva, M.F. Galindo, J. Manzanares (Alicante, Spain)

Neuropharmacology

- Mo-151** A pharmacoeconomic evaluation of botulinum toxin A therapy in the Philippines
J.T. Colacion, L.G. Fugoso, Jr., R.D.G. Jamora (Manila, Philippines)

ABSTRACT LISTING BY TOPIC

- We-154 The partial dopamine agonist and full serotonin (5-HT)1A agonist pardoprinox (SLV308) has antidepressant and anxiolytic-like properties in rats, a detailed pharmacological evaluation
C.R. Ashby, Jr., A.C. McCreary (Weesp, Netherlands)
- We-155 An environmental xenobiotic compound realise an neuroprotective effect against neurodegeneration of dopaminergic neurons from striatum nigra
A.G. Mititelu (London, United Kingdom)
- We-156 A metanalysis of neutralizing antibody conversion following a specific formulation of botulinum toxin type A (BoNTA, Allergan, Inc): An analysis of large clinical trials across five indications
M. Naumann, S. Abu-Shakra, T. Boodhoo, M.A. Miller-Messana, G. Demos, M.F. Brin (Augsburg, Germany)
- Th-151 Resveratrol, a polyphenol found in red wine, protects against rotenone-induced apoptosis through autophagy induction
T. Pan, W. Xie, W. Le, J. Jankovic (Houston, Texas)
- Th-152 Influence of tempo-rhythmic correction of gait method on expenses for pharmacological treatment of Parkinson's disease
D.V. Pokhabov, V.G. Abramov (Krasnoyarsk, Russian Federation)
- Th-153 The use of dopamine agonists (DAGs) in "de novo" Parkinson's disease patients (PDpts) first diagnosed after 70years old
J.M. Rabey, E. Dubronevsky, A. Miniovich, T. Prokhovic (Beer Yakov, Israel)
- Th-154 A placebo-controlled study of the efficacy of botulinum toxin A in the treatment of nocturnal leg cramps
M.-W. Seo, M.-H. Lim (Jeonju, Jeonbuk, Republic of Korea)
- Th-155 Does dopaminergic drugs induce a place preference in normal rat?
Y. Zengin, N. Authier, P.M. LLorca, F. Durif (Clermont Ferrand, France)
- Th-156 Botulinum toxin type A injection as a novel treatment for kinetic tremors associated with FXTAS
L. Zhang, L.L. Lua, P. Adams, R.J. Hagerman (Sacramento, California)
- Mo-157 Executive functions evaluation in patients with neurological form of Wilson's disease – according to performance of Tower of London, Wisconsin Card Sorting Test and General Health Questionnaire 28
G. Chabik (Warsaw, Poland)
- Mo-158 Effects of continuos application of L-dopa/carbidopa gel on psychiatric symptoms in advanced Parkinson's disease (PD)
K. Fox, T. Fox, K. Dietrich, A. Gies, H. Honig, R. Chaudhuri, A. Antonini, P. Martinez-Martin, A. Rüssmann, P. Odin (Bremerhaven, Bremen, Germany)
- Tu-156 Probable Fahr's disease presenting as bipolar disorder
R.P. Gandhi, K.K. Appleby, B.S. Appleby, L.B. Bahroo, F.L. Pagan (Washington, District of Columbia)
- Tu-157 Regulation of movement energetic costs is impaired in pre-symptomatic Huntington's disease (pHD) and in the early stages Parkinson's disease (PD)
D. Crupi, C. Moisello, A. Di Rocco, B. Perfetti, A. Feigin, D. Eidelberg, M.F. Ghilardi (New York, New York)
- Tu-158 Progressive supranuclear palsy impairs emotion recognition
B.C.P. Ghosh, A.J. Calder, P. Peers, A.D. Lawrence, J. Hodges, J.M. Rowe (Cambridge, United Kingdom)
- Tu-159 Contributors to naming impairment in corticobasal syndrome
R. Goldmann Gross, D.J. Libon, P. Moore, M. Grossman (Philadelphia, Pennsylvania)
- We-158 Limitations of traditional screening tools to detect depression in Parkinson's disease
J.E. Howard, S. Varanese, D. Penesetti, C. Morrison, S. Hirsch, R. Brown, A. DiRocco (New York, New York)
- We-159 Cognitive impairment in essential tremor without dementia
J.-S. Kim, I.-U. Song, Y.-S. Shim, K.-S. Lee, Y.-D. Kim, H.-T. Kim (Seoul, Korea)
- We-160 Anxiety and depression in children with Tourette syndrome versus epilepsy – Impact on quality of life, a comparative study
B. Lavenstein, S. Kushner-Weinstein, S. Weinstein (Washington, District of Columbia)
- We-161 The effects of expiratory muscle strength training (EMST) on the velar function in a patient with velopharyngeal incompetency
A.F. Saleem Amro, Y.S. Natour (Amman, Jordan, Jordan)
- Th-157 Alcohol pad application as a provocative test in diagnosing psychogenic movement disorders
K.H. Nawaz, V. Abbott, M.S. Siddiqui (Winston-Salem, North Carolina)
- Th-158 Prevalence of pseudobulbar affect in movement disorders and its relationship with mood symptoms
R.E. Strovd, M.S. Cartwright, M.S. Okun, M.S. Siddiqui (Winston-Salem, North Carolina)
- Th-159 Mood differences between women diagnosed with psychogenic movement disorders and psychogenic seizures
A.M. Strutt, J. Ferrera, S. Hill, M.K. York, L. Uber-Zak, T. Fogel, J. Jankovic (Houston, Texas)
- Th-160 Hemichorea-hemiballism caused by hyperglycemia associated with hypomania in acute stage: A brief report
C.-S. Su, J.-S. Liu, M.-Y. Lan, Y.-Y. Chang (Kaohsiung, Taiwan)

Non-motor Aspects of Movement Disorders (not PD): Dysautonomia

- Mo-155 Gustatory sweating presenting as autonomic manifestation of Parkinson's disease
P. Agarwal, A.F. Griffith, M. Borromeo Wesner (Kirkland, Washington)
- Tu-155 Pseudo-spinal cord transection as the initial manifestation of multiple system atrophy
S. Duerr, G. Wenning (Innsbruck, Austria)

Non-motor Aspects of Movement Disorders (not PD): Behavior

- Mo-156 Sexual Health in Parkinson's disease
J. Azevedo, A. Palha, M.J. Rosas, M. Esteves, M.A. Vieira-Coelho, C. Sousa, R. Fonseca, P. Linhares, C. Garrett, R. Vaz (Porto, Portugal)

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

Parkinson's disease: Behavioral disorders

- Mo-159** Neuropsychiatric disturbances in parkinsonian patients with and without freezing of gait
M. Amboni, M. Picillo, A. Cozzolino, K. Longo, A. Iavarone, P. Barone (Naples, Italy)
- Mo-160** Novelty seeking personality traits do not influence the risk of Parkinson's disease
G. Arabia, B.R. Grossardt, R.C. Colligan, J.H. Bower, D.M. Maraganore, J.E. Ahlskog, W.A. Rocca (Rochester, Minnesota)
- Mo-161** Piribedil improves apathy, depression and anxiety in Parkinson's disease
C. Ardouin, E. Lhommee, S. Thobois, H. Klinger, C. Lagrange, V. Fraix, J. Xie-Brustolin, A. Kistner, A. Juphard, S. Chabardes, E. Seigneuret, P. Mertens, E. Broussolle, P. Pollak, P. Krack (Grenoble Cedex 9, France)
- Mo-162** Observations on dopamine dysregulation syndrome
L.B. Bahroo, R.P. Gandhi, K.K. Appleby, F. Amjad, F.L. Pagan (Washington, District of Columbia)
- Mo-163** Creativity induced by dopamine agonists in Parkinson's disease
A. Batir, E. Lhommee, C. Ardouin, V. Fraix, E. Seigneuret, S. Chabardes, A.-L. Benabid, P. Pollak, P. Krack (Grenoble Cedex 9, France)
- Mo-164** Prevalence and phenomenology of psychosis in Parkinson's disease patients seen at an academic movement disorders clinic
N. Scoglio, K.M. Biglan (Rochester, New York)
- Mo-165** Retinal thickness and smell identification in early Parkinson's disease
T. Kelly, A. Belakovskiy, J. Glanternik, M. Hajee, R. Doty, I. Bodis-Wollner (Brooklyn, New York)
- Mo-166** Neuropsychiatric morbidity in a cohort of Parkinson's disease patients assessed for DBS: A prospective study
J. Bourke, K. Ashkan, M. Samuel, A. Costello, N. Hulse, C.C. Clough, R.S. Selway, J.M. Moriarty (London, United Kingdom)
- Mo-167** Development of a standardised postsurgical assessment of neuropsychiatric comorbidity in DBS patients
J. Bourke, K. Ashkan, M. Samuel, A. Costello, N. Hulse, C. Clough, R. Selway, J. Moriarty (London, United Kingdom)
- Mo-168** Disturbed behavioral function and enhanced sensitivity for psychoactive drugs in the rat 6-hydroxydopamine Parkinson model
A. Bowe, C. Lindemann, S. Friedrichs, J.K. Krauss, K. Schwabe (Hannover, Germany)
- Mo-169** Artistic productivity and Parkinson's disease
M. Canesi, M.L. Rusconi, C. Scarabelli, G. Cavallera, G. Pezzoli, A. Antonini (Milano, Italy)
- Mo-170** Deep brain stimulation and eating disorders
I. Chereau-Boudet, I. de Chazeron, F. Durif, I. Rieu, P.M. LLorca (Clermont-Ferrand, France)
- Mo-171** Memory decline in Parkinson's disease and correlation with cerebral atrophy and metabolism
P. Clavero, D. Garcia, L. Isabel, J.L. Zubietta, J. Arbizu, J. Obeso, M.C. Rodriguez-Oroz (Pamplona, Navarra, Spain)
- Mo-172** Freezing of gait in Parkinson's disease is sensitive to doorway width
D.A. Cowie, P. Limousin, A. Peters, L. Zrinzo, M. Hariz, B.L. Day (London, United Kingdom)

- Mo-173** Depression in Parkinson's disease
L. Cucos, O. Despina, L. Pendefunda (Iasi, Romania)
- Mo-174** The changing profile of Parkinson's disease-associated psychosis: A prospective study using the new NINDS-NIMH criteria
G. Fénelon, T. Soulas, F. Zenasni (Cetteil, France)
- Mo-175** Quetiapine improves visual hallucinations in PD but not through normalization of sleep architecture: Results from a double-blind polysomnography study
H.H. Fernandez, M.S. Okun, R.L. Rodriguez, I.A. Malaty, J. Romrell, A. Sun, S.S. Wu, S. Pillarisetty, A. Nyathappa, S. Eisenschek (Gainesville, Florida)
- Mo-176** Spouse behavior changes in follow up of Parkinson's disease
A. Feve, J.P. Brandel (Paris, France)
- Mo-415** Decision-making in impulsivity vs apathy associated with Parkinson's disease
I. Leroi, N. Hinvest, M. Andrews, R. Elliott, J. Byrne (Blackburn, Lancashire, United Kingdom)
- Tu-160** High incidence of impulse control disorders (ICD) in Parkinson's disease (PD) patients with sudden onset of sleep (SOOS) at the wheel
K.-I. Fujimoto, T. Kawakami, K. Ikeguchi, I. Nakano (Shimotsuke, Tochigi, Japan)
- Tu-161** Impulse control disorders in PD patients and their relationship to the dopamine dysregulation syndrome
K. Fusegi, N. Hattori, Y. Mizuno, H. Mori (Tokyo, Japan)
- Tu-162** Depressive and anxiety symptoms in idiopathic rapid eye movement sleep behavior disorder (RBD)
M. Tuineag, J. Montplaisir, R.B. Postuma, V. Latreille, I. Godin, J.-F. Gagnon (Montreal, Quebec, Canada)
- Tu-163** Depressive and anxiety symptoms in Parkinson's disease with rapid eye movement sleep behavior disorder (RBD)
V. Latreille, J. Montplaisir, R.B. Postuma, M. Tuineag, M. Panisset, J.-F. Gagnon (Montreal, Quebec, Canada)
- Tu-164** Motor impairment in rat model of Parkinson's disease (PD) exhibited at 20 weeks post lesion: Evidence from behavioral assessment
H.S. Gambhir, S. Vivekanandhan, V. Goyal, S. Singh, G. Shukla, R. Mathur, M. Behari (New Delhi, Delhi, India)
- Tu-165** Caregiver strain in Parkinson's disease is related to frontal behavioural impairment
R. Gerhard, D. Claudia, F. Thomas, F. Alexandra, S. Michaela, H. Stephanie, S. Walter (Linz, Austria)
- Tu-166** Clock drawing test in Parkinson's disease: association with different clinical features
A. Gunduz, S. Ertan, C. Aksoy Poyraz, F. Akcan, S. Ozekmekci, G. Kiziltan, T. Ertan, E. Eker (Istanbul, Turkey)
- Tu-167** Severity of cognitive deficit among patients with Parkinson's disease/Parkinson syndrome
H.D. Hambarzumyan, E.M. Gevorgyan, A.H. Karapetyan, M.E. Hakobyan, A.A. Karapetyan, H.M. Manvelyan (Yerevan, Armenia)
- Tu-168** Unimpaired reward learning but elevated temporal discounting in Parkinson's disease patients with impulse control disorders
C.R. Housden, S.S. O'Sullivan, E.M. Joyce, A.J. Lees, J.P. Roiser (London, United Kingdom)

ABSTRACT LISTING BY TOPIC

- Tu-169 Effects of bupropion on depression of Parkinson's disease: Open-label 12-week trial in Korea**
W.C. Kim, H.S. Kim, S.H. Oh, O.J. Kim, M.S. Lee (Seongnam, Kyunggi, Korea)
- Tu-170 A 5HT2A polymorphism is associated with pathological gambling in Parkinson's disease**
P. Bocquillon, A. Kreisler, C. Vaquero Lorenzo, J. Fernandez-Piqueras, M. Diaz Hernandez, F. Warembois, I. Vuillaume, L. Defebvre, A. Destée (Lille, France)
- Tu-171 Variants of DRD3 and GRIN2B and impulse control and related disorders in Parkinson's disease**
J.-Y. Lee, J.-Y. Lim, E.K. Lee, S.S. Park, H.J. Kim, J.S. Kim, B.S. Jeon (Seoul, Korea)
- Tu-172 Emotional dysfunction in Parkinson's disease: Depression or apathy?**
B. Leplow, Y. Paelecke-Habermann, H. Oelsner, A. Funke, S. Zierz, G. Ebersbach (Halle(Saale), Germany)
- Tu-173 Reward and decision-making in impulsivity in Parkinson's disease: An fMRI study**
I. Leroi, M. Andrews, S. McKie, R. Elliot (Blackburn, Lancashire, United Kingdom)
- Tu-174 Predictors of the impulsive and apathetic behavioural phenotypes in Parkinson's disease**
I. Leroi, M. Andrews, J. Byrne, A. Burns (Blackburn, Lancashire, United Kingdom)
- Tu-175 Premorbid personality in Parkinson's disease with impulsivity and apathy**
I. Leroi, E. Chilman, M. Andrews, J. Byrne (Blackburn, Lancashire, United Kingdom)
- We-163 Is retinal nerve fiber layer correlated with presence of hallucinations in patients with Parkinson's disease?**
C. Behr, C. Marcel, M. Anheim, L. Ballonzoli, C. Tranchant (Strasbourg, France)
- We-164 Blunted early emotional processing in patients with Parkinson's disease and isolated apathy**
M. Martinez-Corral, S. Martinez-Horta, G. Llebaria, A. Gironell, J. Kulisevsky (Barcelona, Spain)
- We-165 Contribution of cognitive control and response inhibition in the apathetic symptoms of Parkinson's disease**
S. Martinez-Horta, M. Martinez-Corral, G. Llebaria, A. Gironell, C. Garcia-Sanchez, J. Kulisevsky (Barcelona, Spain)
- We-166 Impairment of fine leg movements induced by STN DBS**
I. Martinez-Torres, A.L. Peters, E. Ramsay, D.C. Voyce, L. Zrinzo, P. Limousin, M.I. Hariz, P. Brown, B.L. Day (London, United Kingdom)
- We-167 Opposite effects of levodopa on conditioned behaviors**
F. Marzinzik, J. Wotka, M. Wahl, S. Graef, G. Biele, H. Hekeeren, F. Klostermann (Berlin, Germany)
- We-168 Accuracy demands differentially modulate impaired anticipatory control of object tilt and force sharing patterns during multi-digit grasping in Parkinson's disease**
T.L. McIsaac (New York, New York)
- We-169 Deep brain stimulation of subthalamic nuclei modulates recognition of emotional facial expressions at different spatial frequencies**
M. Mermilliod, L. Mondillon, P. Chambres, C. Auxiette, P. Derost, M. Ulla, A. Marques, I. Jalénques, F. Durif (Clermont-Ferrand, France)
- We-170 Are parkinsonian gait characteristics present in patients with SWEDDs?**
O.S. Mian, S.A. Schneider, P. Schwingenschuh, K.P. Bhatia, B.L. Day (London, United Kingdom)
- We-171 Anxiety disorders in Chinese patients with Parkinson's disease**
Y.K. Chen, V.C.T. Mok, K.S. Wong, G. Ungvari, J.Y. Lu, W.K. Tang (Shatin, Hong Kong)
- We-172 Symmetric Parkinson's disease and atypical degenerative parkinsonism: Common and differential aspects**
R.P. Munhoz, M. Moscovich, H. Fameli, L. Fill, H.A. Teive (Curitiba, PR, Brazil)
- We-173 Laterality of motor onset in patients with Parkinson's disease and impulse control disorders**
J.P. Nicolay, M. Tagliati (New York, New York)
- We-175 Reckless generosity in Parkinson's disease**
S.S. O'Sullivan, A.H. Evans, N.P. Quinn, A.J. Lees (London, United Kingdom)
- We-176 Increased dopamine neurotransmission in Parkinson's patients with Impulse control disorders in response to rewarding visual stimuli: A pilot study**
S.S. O'Sullivan, M. Politis, K. Wu, A.D. Lawrence, A.H. Evans, S.K. Bose, A.J. Lees, P. Piccini (London, United Kingdom)
- We-177 Nitric oxide synthase inhibitors effects on acute and chronic L-dopa-induced dyskinésias in the 6-OHDA rat model of Parkinson's disease**
F.E. Padovan-Neto, M.B. Echeverry, V. Tumas, E.A. Del Bel (Ribeirao Preto, Sao Paulo, Brazil)
- We-178 Patients and duodopa treatment. Psychiatric problems in patients before and after the stabilization of motor symptoms with duodopa**
S.W. Pedersen, J.B. Clausen (Glostrup, Denmark)
- We-179 Dimensional approach to depression in Parkinson's disease**
E. Pourcher, S. Remillard, H. Cohen (Quebec, Quebec, Canada)
- Th-161 A study of cognitive fatigue in Parkinson's disease**
J.B. Proemsey, B. Kluger, R. Rajagovindan, M. Ding, F. Skidmore, M. Okun, K. Heilman (Winter Springs, Florida)
- Th-162 Differences in gait characteristics of Parkinson's disease patients related to depression**
S. Radovanovic, V. Spica, N. Kresojevic, M. Jecmenica, A. Tomic, T. Stojkovic, I. Petrovic, V. Kostic (Belgrade, Serbia)
- Th-163 The course of depressive symptoms in early Parkinson's disease**
B. Ravina, J. Elm, R. Camicioli, P. Como, L. Marsh, J. Jankovic, D. Weintraub (Rochester, New York)
- Th-164 Nitric oxide production is decreased in the striatum of rats with L-dopa-induced dyskinesia**
A.C.D. Romano, F.E. Padovan-Neto, F.R. Ferreira, E.A. Del Bel (Ribeirao Preto, Sao Paulo, Brazil)
- Th-165 Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease**
G. Santangelo, C. Vitale, L. Trojano, F. Verde, A. Cozzolino, P. Barone (Naples, Italy)
- Th-166 Bilateral and partial lesions of the VTA dopaminergic neurons in rat: A model of parkinsonian apathy in rat?**
G. Drui, C. Carcenac, P. Krack, M. Savasta (Grenoble, France)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-167 Dopaminergic addiction to increase artistic creativity**
P. Schwingenschuh, R. Saurugg, P. Katschnig, E. Ott, K.P. Bhatia (London, United Kingdom)
- Th-168 Effects of DBS on and off on voice quality and fluency of speech**
D. Sidiis, T. Rogers, V. Godier, M. Tagliati, J.J. Sidiis (New York, New York)
- Th-169 Frequency of compulsive traits in 90 newly diagnosed patients with Parkinson's disease**
C. Siri, G. Santangelo, C. Roberto, P. Barone, M. Poletti, U. Bonuccelli, A. Caporali, F. Mancini, G. Pezzoli, A. Antonini (Milan, Italy)
- Th-170 Development of Synucleire: A novel small molecule that effectively reduces brain alpha-synuclein aggregation and improves motor dysfunction**
A.D. Snow, J. Cummings, M. Hudson, T. Lake, Q. Hu, J. Cam, E. Smith, L. Esposito (Kirkland, Washington)
- Th-171 Suicide and suicidal ideation in Parkinson's disease**
T. Stojkovic, T. Pekmezovic, A. Tomic, M. Jecmenica-Lukic, V. Spica, M. Svetel, E. Stefanova, I. Petrovic, E. Dzoljic, V.S. Kostic (Belgrade, Serbia)
- Th-172 Increased striatal dopamine release in parkinsonian patients with pathological gambling: A 11C raclopride PET study**
T.D.L. Steeves, J. Miyasaki, M. Zurowski, A.E. Lang, G. Pellecchia, T. van Eimeren, R. Rusjan, S. Houle, A.P. Strafella (Toronto, Canada)
- Th-173 Prevalence and clinical correlates of apathy and depression in Parkinson's disease**
H. Tachibana, M. Oguru, K. Kawabata, T. Oku, D. Danno (Nishinomiya, Hyogo, Japan)
- Th-174 Do affective symptoms depend on motor disability and activities of daily living in Armenian patients with Parkinson's disease?**
Z.D. Tavadyan, S.G. Khachatryan (Yerevan, Armenia)
- Th-175 Impairment of visuomotor control in Parkinson's disease**
Y. Terao, H. Fukuda, A. Yugeta, R. Hanajima, Y. Nomura, M. Segawa, Y. Ugawa (Tokyo, Japan)
- Th-176 Predictors of depressive symptoms in patients with Parkinson's disease**
B. Tserensodnom (Ulaanbaatar, Mongolia)
- Th-177 Is upper limb freezing related to freezing of gait in patients with Parkinson's disease?**
S.L. Vercruyse, J. Spijdooren, W. Vandenberghe, N. Deroost, N. Wenderoth, A. Nieuwboer (Leuven, Belgium)
- Th-178 Association between dopamine and serotonin transporter availability, psychiatric symptoms, and cognitive abilities in Parkinson's disease**
A. Newberg, E. Mamikonyan, N. Wintering, A. Siderowf, M. Stern, D. Weintraub (Philadelphia, Pennsylvania)
- Mo-179 Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicentre study of effects on non-motor symptoms using the PD non motor scale**
A. Antonini, P. Martinez-Martin, P. Odin, A. Martin, K.R. Chaudhuri (Milan, Italy)
- Mo-180 Glycopyrroniumbromide for the treatment of sialorrhea in Parkinson's disease**
M.E.L. Arbouw, K.L.L. Mavig, M. Koopmann, P.J.E. Poels, H.-J. Guchelaar, T.C.G. Egberts, C. Neef, J.P.P. van Vugt (Enschede, Netherlands)
- Mo-181 Which Parkinson's disease (PD) patients function well without levo-dopa (LDopa) treatment for more than 5 years?**
M. Au-Yeung, T.H. Tsui, C.M. Cheung, S. Hon, C.N. Lee, R. Li, E. Yeung (Hong Kong, China)
- Mo-182 Physical therapy (PT) in Parkinson's disease (PD): A systematic review of randomized controlled clinical trials**
C.A. Weiland, H. Baas (Hanau, Germany)
- Mo-183 LRRK2 G2019 mutation in Parkinson's disease: A clinical, neuropsychological and psychiatric study in a large Algerian cohort**
S. Belarbi, N. Hecham, S. Lesage, M.I. Keddiha, S. Benhabiles, Benhassine, A. Brice, M. Tazir (Algiers, Algeria)
- Mo-184 Transcranial direct current stimulation for the treatment of Parkinson's disease: A randomized, double-blind, sham-controlled study**
D. Benninger, M. Lomarev, G. Lopez, E. Wassermann, X. Li, E. Considine, M. Hallett (Bethesda, Maryland)
- Mo-185 Training dual tasking during gait in Parkinson's disease**
S.G. Brauer, M.E. Morris (Brisbane, Qld, Australia)
- Mo-186 Task switching during dual task gait training is difficult for people with Parkinson's disease**
S.G. Brauer, M.E. Morris, M. Woollacott, R.M. Lamont (Brisbane, Qld, Australia)
- Mo-187 Positron emission tomography (PET) study of preladenant in healthy male subjects**
D.J. Brooks, S. Warrington, A. Tendolkar, D.L. Cutler, J. Hunter (London, United Kingdom)
- Mo-188 Group therapy improves no motor aspects in patients with Parkinson's disease (PD)**
T. Capato, M.E. Piemonte (Sao Paulo, Brazil)
- Mo-189 Rythmical auditory cues improve balance control in PD patients**
T. Capato, M.E. Piemonte (Sao Paulo, Brazil)
- Mo-190 Rythmical cues has no influence in the improvement of gait performance in PD patients**
T. Capato, M.E. Piemonte (Sao Paulo, Brazil)
- Mo-191 Effects of robot-assisted gait training on freezing of gait in patients with Parkinson's disease**
V.C. Chang, M. Gianfrancesco, D. Benedicto, J. Friedman, A. Lo (Providence, Rhode Island)
- Mo-192 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease with sleep disturbances**
K.R. Chaudhuri, L. Giorgi, J. Statham (London, United Kingdom)

Parkinson's disease: Clinical Trials

- Mo-177 Observer bias in biological/surgical trials of novel Parkinson's disease therapies**
R.L. Alterman, M. Tagliati, W. Olanow (New York, New York)
- Mo-178 Intraputaminal AADC gene therapy for Parkinson's disease: Results of a phase 1 study**
M.J. Aminoff, C.W. Christine, P.A. Starr, P.S. Larson, J.L. Eberling, W.J. Jagust, R.A. Hawkins, H.F. VanBroeklin, K.S. Bankiewicz (San Francisco, California)

ABSTRACT LISTING BY TOPIC

Mo-193	Cholinergic augmentation in frequently falling subjects with Parkinson's disease K.A. Chung, B.M. Lobb, J.G. Nutt, F. Horak (Portland, Oregon)	Tu-181	Continuous levodopa/carbidopa gel therapy improves dyskinesias in Parkinson's disease T. Fox, H. Honig, K. Fox, R. Chauduri, A. Antonini, P. Martinez-Martin, S. Leimbach, P. Odin (Bremerhaven, Germany)
Mo-194	Effects of age and gender on preladenant pharmacokinetics in healthy subjects D.L. Cutler, A. Tendolkar, J. Hunter (Kenilworth, New Jersey)	Tu-182	A clinical pharmacology study to determine the selective and non-selective doses of the monoamine oxidase type B (MAO-B) inhibitor, rasagiline T. Goren, L. Adar, N. Sasson, Y. Weiss (Netanya, Israel)
Mo-195	Treatment disparities in Parkinson's disease N. Dahodwala, M. Xie, E. Noll, A. Siderowf, D.S. Mandell (Philadelphia, Pennsylvania)	Tu-183	External cueing and gait in Parkinson's disease: A controlled evaluation H.J. Griffin, R. Greenlaw, P. Limousin, K. Bhatia, N.P. Quinn, M. Jahanshahi (London, United Kingdom)
Mo-196	Addictive behaviors and Parkinson's disease I. de Chazeron, I. Chereau-Boudet, M. Ulla, B. Debilly, P. Derost, J. Perriot, L. Ouchchane, P.-M. LLorca, F. Durif (Clermont-Ferrand, France)	Tu-184	Environmental and occupational factors in Bulgarian patients with Parkinson's disease D.R. Hristova, I.S. Grozdev, Z.I. Zahariev (Plovdiv, Bulgaria)
Mo-197	Can a smell identification test predict the results of a DaT-Scan in patients with suspected Parkinson's disease: Interim analysis? S. Deshmukh, G. White, C. Sixsmith, R. Pickering, P. Kemp, H. Roberts, K. Amar (Southampton, Hampshire, United Kingdom)	Tu-185	Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson's disease R.A. Hauser, E. Pourcher, F. Michel, V. Mok, M. Onofri, S.B. Huyck, K. Wolski, M. Cantillon (Tampa, Florida)
Mo-198	Pilot randomized controlled trial of telemedicine for individuals with Parkinson's disease R. Dorsey, L. Deuel, A. Appler, S. Eason, B. George, A. Joseph, D. Miller, J. Polanowicz, J. Reminick, S. Smith, L. Viti, T. Voss, K. Biglan (Rochester, New York)	Tu-186	Pharmacokinetic profiling of pramipexole extended-release in Parkinson's disease (PD): Implications for dosing in PD patients with renal insufficiency R.A. Hauser, O. Rascol, P. Barone, A. Schapira, W. Poewe, Y. Mizuno, C. Dansikul, A. Staab, T. Lehr, S. Haertter, Pramipexole ER Switch Study Group (Tampa, Florida)
Mo-199	Alpha-2 adrenergic antagonist effects in Parkinson's disease T.D. Dimitrova, W. Bara-Jimenez, J.-M. Savola, E. Encarnacion, M.M. Mouradian, T.N. Chase (Washington, District of Columbia)	Tu-187	Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson's disease: Post hoc analysis of dose-finding study S.B. Huyck, K. Wolski, M. Cantillon (Kenilworth, New Jersey)
Mo-200	Dopamine transporter imaging in very long-standing Parkinson's disease R. Djaldetti, M. Lorberboym, Y. Karmon, M. Hellmann, E. Melamed (Petah Tiqva, Israel)	Tu-188	The PARS study: Enriching a population at-risk for Parkinson's disease D. Jennings, A. Siderowf, M. Stern, K. Marek, PARS Investigators (New Haven, Connecticut)
Mo-201	The effects of balance exercises in Parkinson's disease patients with a home based program B. Balci, B. Kara, B. Donmez Colakoglu, R. Cakmur (Izmir, Turkey)	Tu-189	Smell tests, transcranial sonography, and 123I-MIBG cardiac scintigraphy for early diagnosis of Parkinson's disease Y. Kajimoto, M. Izawa-Okawa, H. Miwa, T. Kondo (Wakayama City, Wakayama, Japan)
Mo-202	Sniffin sticks in Swahili: Smell testing in Tanzanian Parkinson's disease patients – A pilot feasibility study C.L. Dotchin, A. Jusabani, R.W. Walker (North Shields, Tyne and Wear, United Kingdom)	Tu-190	Clinical signs associated with levodopa-induced dyskinesia in Parkinson's disease S. Kipfer, M.A. Stephan, M. Schuepbach, A. Kaelin-Lang (Bern, BE, Switzerland)
Mo-416	Transdermal rotigotine results in suitable pharmacokinetic properties for various patient subpopulations J.-P. Elshoff, W. Cawello, R. Horstmann, M. Braun (Germany)	Tu-191	Long-term effects of amantadine for levodopa-induced dyskinesias and motor impairment in Parkinson's disease: Retrospective report S.A. Kuno, Y. Uchida, M. Ogawa (Kodaira, Tokyo, Japan)
Tu-178	Aplindore, a partial dopamine agonist, improves motor aspects of Parkinson's disease in a 14-day escalating dose paradigm J. DuToit, C. Coetzee, T. Grant, I. Shoulson, L. Rajachandran, R. Tschopp, K. Sprenger, S. Stankovic (London, Middlesex, United Kingdom)	Tu-192	Research and epidemiologic disease registries: The Washington State Parkinson's disease registry experience J.B. Leverenz, H.M. Kim, A. Samii, E. Martinez, M. Baca, S. Thomas, D.W. Tsuang, C.P. Zabetian (Seattle, Washington)
Tu-179	Effects of NMDA receptor antagonist on levodopa induced dyskinesia – Meta analysis of controlled clinical trials B. Elahi, X. Sun, R. Chen (Toronto, Ontario, Canada)	Tu-193	Fear of falling can independently predict future falls in people with Parkinson's disease M.K.Y. Mak, M.Y.C. Pang (Hong Kong, China)
Tu-180	Exploratory study of yoga as a therapeutic modality for Parkinson's disease A.E. Ferris, M.D. Welsh, G.J. Salem (Los Angeles, California)	Tu-194	Lumbar spine bone mineral density in patients with Parkinson's disease: Association with trunk muscle strength M.Y.C. Pang, M.K.Y. Mak (Hong Kong, China)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-195** Home-based rehabilitation to reduce falls and disability in Parkinson's disease: Protocol for a randomised controlled trial
C.L. Martin, M.E. Morris, H.B. Menz, N.F. Taylor, J.J. Watts, F. Huxham (Parkville, Victoria, Australia)
- Tu-196** An open-label extension study to determine the safety of pimavanserin in patients with Parkinson's disease and psychosis
R. Mills, A.D. Johnson, D. Bahr, H. Williams, S. Revell (San Diego, California)
- Tu-197** Automated auditory biofeedback training to enhance postural control and mobility in patients with Parkinson's disease: Preliminary results from SENSACTION-AAL
A. Mirelman, T. Herman, I. Meidan, L. Chiari, A. Zijlstra, S. Nicolai, J.M. Hausdorff (Tel Aviv, Israel)
- Tu-198** Clinical efficacy of istradefylline (KW-6002) in the treatment of Parkinson's disease: A randomized placebo-controlled study
Y. Mizuno, S. Kuno, M. Yamamoto, K. Hasegawa, T. Kondo (Tokyo, Japan)
- Tu-199** Gait analysis is more sensitive than finger tapping or UPDRS motor scores in assessment of the motor response to levodopa in Parkinson's disease
S.T. Moore, L. Shinawi, W.G. Ondo (New York, New York)
- Tu-200** A pilot study of the benefit of occupational therapy in Parkinson's disease
N.B. Herz, S.H. Mehta, S.M. Cosper, J. Westmeier-Shuh, A. Davis, A. Henneberger, J. Lamback, B. Lorden, C. Miller, P.D. Jackson, K.D. Sethi, J.C. Morgan (Augusta, Georgia)
- Tu-201** Carry-over effects of movement strategy training in Parkinson's disease
M.E. Morris, R. Iansek, B. Kirkwood, M. Danoudis, C.L. Martin (Parkville, Victoria, Australia)
- Tu-202** Evaluation of a computerized telephone system to monitor falls
M.A. van der Marck, M.Ph.C. Klok, S. Overeem, B.R. Bloem, M. Munneke (Nijmegen, Netherlands)
- Tu-203** Long-term efficacy and safety of zonisamide on Parkinson's disease: Up to 9 years
M. Murata, I. Kanazawa (Tokyo, Japan)
- Tu-414** Piribedil: First results of an observational study (PIR-001/K) investigating tolerability, effectiveness and prescribing practice of piribedil in Germany
W. Jost, K. Katrin (Wiesbaden, Germany)
- We-180** Is there a difference in the pharmacokinetics between entacapone and levodopa?
N. Nishikawa, M. Nagai, M. Kubo, H. Yabe, M. Nomoto (Toon, Ehime, Japan)
- We-181** Rasagiline as add on therapy in levodopa-treated patients with Parkinson's disease and motor fluctuations: A randomized placebo-controlled study
N. Oztekin, F. Oztekin, H. Okkan, F. Ak, S. Bilen (Ankara, Turkey)
- We-182** Amantadine given as adjuvant to levodopa in the treatment of levodopa induced dyskinesias and motor fluctuations in Parkinson's disease
N. Oztekin, F. Oztekin, H. Okkan, S. Bilen, F. Ak (Ankara, Turkey)
- We-183** Safety of recombinant human erythropoietin (rhEPO) in Parkinson's disease (PD): A three month report
I. Pedroso, M.L. Bringas, M. Alvarez, A. Aguila, L. Alvarez (Havana, Cuba)
- We-184** Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson's disease: Assessment with the revised MDS-UPDRS
W. Poewe, R. Hauser, A.E. Lang, ADAGIO Investigators (Innsbruck, Austria)
- We-185** Pramipexole extended-release is effective in early Parkinson's disease
W. Poewe, P. Barone, R.A. Hauser, Y. Mizuno, O. Rascol, A. Schapira, M. Haaksma, N. Juvel, Pramipexole ER Studies Group (Innsbruck, Austria)
- We-186** A non-randomised blinded comparison of entacapone (E) and conventional release (CR) with E and slow release (SR) levodopa (L) in Parkinson's disease (PD)
R. Iansek, S. Pollak, M. Makoutonina, B. Kirkwood (Melbourne, Victoria, Australia)
- We-187** Safety and tolerability profile of preladenant as an adjunct to L-dopa in patients with Parkinson's disease
E. Pourcher, F. Micheli, V. Mok, M. Onofrij, R.A. Hauser, S. Huyck, K. Wolski, M. Cantillon (Quebec City, Quebec, Canada)
- We-188** Following GDNF: Four year follow-up after bilateral intraputamenal infusion
T. Pretto, A. Dalvi, R. Penn (Chicago, Illinois)
- We-189** Effects of antiparkinsonian medications on forward and backward gait patterns in persons with Parkinson's disease (PD)
M.S. Bryant, D.H. Rintala, A.L. Fernandez, J.G. Hou, E.C.H. Lai, E.J. Protas (Galveston, Texas)
- We-190** Review of clinical trials and controversy of first drug of choice in Parkinson's disease
A.Q. Rana (Toronto, Canada)
- We-191** The effect of rasagiline in early Parkinson's disease (PD): The ADAGIO delayed start trial
O. Rascol, C.W. Olanow, ADAGIO Investigators (Toulouse, France)
- We-192** A longitudinal program for biomarker development in Parkinson's disease
B. Ravina, C. Tanner, D. DiEuliis, E. Flagg, I. Shoulson, Parkinson Study Group, LABS-PD Investigators (Rochester, New York)
- We-193** Efficacy and safety of botulinum toxin type B for the treatment of sialorrhea in Parkinson's disease (PD)
S. Reinhard, P. Hogan, F. Pagan, E. Pappert, W. Birmingham (Malvern, Pennsylvania)
- We-194** Rehabilitation in Parkinson's disease: The effect of cueing therapy on gait in a drug naïve population in the Hai district of northern Tanzania?
L. Rochester, D. Rafferty, C. Dotchin, O. Msuya, V. Minde, R. Walker (Newcastle upon Tyne, Tyne & Wear, United Kingdom)
- We-195** A maintained reduction in "off" time is achieved with ropinirole prolonged release in patients with advanced Parkinson's disease not optimally controlled with L-dopa
E. Ruzicka, B. Hersh, R. Pahwa, N. Earl (Prague, Czech Republic)

ABSTRACT LISTING BY TOPIC

- | | | | |
|--------|--|--------|--|
| We-196 | A Canadian approach to exercise rehabilitation: A systematic evaluation of strategies to reduce the symptoms of Parkinson's disease
M.D. Sage, Q.J. Almeida (Waterloo, Ontario, Canada) | Th-181 | Rasagiline provides benefits in the symptoms of fatigue in patients with early Parkinson's disease
F. Stocchi, ADAGIO Investigators (Rome, Italy) |
| We-197 | Pilot study of the efficacy and safety of piclozotan in Parkinson's disease patients with L-dopa induced motor complications
J.I. Sage, R.A. Hauser, M.E. Cordon, M.A. Gonzalez, Y. Tani, M. Koyama, S.C. Apfel, R.F. Reed, M. Okamoto, J.M. Gertner (New Brunswick, New Jersey) | Th-182 | Ropinirole prolonged release is effective in reducing "off" time in patients with advanced Parkinson's disease even at low doses
F. Stocchi, L. Giorgi, N. Earl, R. Pahwa (Rome, Italy) |
| We-198 | A multicenter randomized control trial of amantadine for dyskinesia in Parkinson's disease
H. Sawada, T. Oeda, S. Kuno, M. Nomoto, K. Yamamoto (Kyoto, Japan) | Th-183 | Symptom control in patients with advanced Parkinson's disease: Ropinirole prolonged release versus ropinirole immediate release
F. Stocchi, L. Giorgi, B. Hunter, A.H.V. Schapira (Rome, Italy) |
| We-199 | Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease
A. Schapira, P. Barone, R.A. Hauser, Y. Mizuno, W. Poewe, O. Rascol, M. Busse, N. Juhel, Pramipexole ER Studies Group (London, United Kingdom) | Th-184 | Treadmill-walking with music shows a synergistic improvement in gait and balance in patients with Parkinson's disease: A randomized controlled trial
A. Shankar, N. Labelle, L. Derwent, S. Bonfield, M. Eliasziw, B. Hu, O. Suchowersky (Calgary, Alberta, Canada) |
| We-200 | Progression of subtle motor signs in asymptomatic heterozygous PINK1 mutation carriers: A clinical follow-up investigation
A. Schmidt, J. Hagenah, N. Brueggemann, V. Tadic, L. Kertelje, M. Kasten, C. Klein (Luebeck, Germany) | Th-185 | Effect of stair-walking exercise in Parkinson patients
A. Suputtatada, R. Bhidayasiri, U. Charoensantiurai (Bangkok, Thailand) |
| We-201 | Questionnaire for Parkinson's disease as a screening instrument for Thais
S. Setthawatcharawanich, P. Sathirapanya, K. Phabphal, K. Limapichart (HatYai, Songkhla, Thailand) | Th-186 | Safety and tolerability of long-term treatment with ropinirole prolonged release in patients with early or advanced Parkinson's disease
A. Szczudlik, B. Hunter, J. Statham, N. Earl, R.A. Hauser (Krakow, Poland) |
| We-202 | Trails of multivitamins/antioxidant and nutritional supplements in Parkinson's disease patients
S.N. Siddiqui, M. Behari, V. Subbaiah, M. Manral (New Delhi, Delhi, India) | Th-187 | Long term pramipexole monotherapy in patients with tremor-dominant early Parkinson's disease
H. Takahashi, F. Yoshii, K. Fujimoto, T. Kawakami, R. Hishida, H. Chiba, S. Takagi (Isehara, Kanagawa, Japan) |
| We-203 | Isradipine plasma concentrations in patients with early Parkinson's disease taking isradipine CR, a dihydropyridine Ca channel antagonist
T. Simuni, A. Martel, M. Avram, C. Zadikoff, A. Videncovic, D.J. Surmeier (Chicago, Illinois) | Th-188 | Shortened T2 relaxation time at 3-T in the substantia nigra pars compacta of patients with Parkinson's disease and multiple system atrophy
W. Takao, M. Iki, K. Kashihara, T. Shinya (Okayama, Okayama, Japan) |
| We-204 | Is there the association between high-sensitivity C-reactive protein level and idiopathic Parkinson's disease?
I.-U. Song, J.-S. Kim, W.-G. Byeon, K.-S. Lee (Seoul, Republic of Korea) | Th-189 | The effectiveness of a multi-day training program for people with Parkinson's in increasing knowledge about and involvement in clinical research
R.A. Elliott, N.L. Rabin, V.L. Todaro (New York, New York) |
| We-205 | Detecting freezing of gait in Parkinson's disease with an ambulatory monitor
A.D. Speelman, A. Weiss, J.M. Hausdorff, M. van Nimwegen, A.H. Snijders, B.R. Bloem, M. Munneke (Nijmegen, Netherlands) | Th-190 | An open label, parallel-group, repeat-dose study to investigate the effects of end stage renal disease (ESRD) and haemodialysis on the pharmacokinetics (PK) of ropinirole
D. Tompson, D. Hewens, N. Earl, D. Oliveira, J. Taubel, S. Swan, L. Giorgi (Harlow, United Kingdom) |
| We-405 | Changes in early morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD)
R. Pahwa, W. Poewe, K. Lyons, B. Boroojerdi (Kansas City) | Th-191 | Aspiration and swallowing in Parkinson's disease and rehabilitation with EMST: The ASPIRE study
M.S. Troche, M.S. Okun, J.C. Rosenbek, N. Musson, H.H. Fernandez, R.L. Rodriguez, J. Romrell, C.M. Sapienza (Gainesville, Florida) |
| Th-179 | Turning behavior in patients with Parkinson's disease with and without freezing of gait
J. Spildooren, S. Vercruyse, K. Desloovere, J. Vandebossche, B. Callewaert, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium) | Th-192 | Motivations and concerns of Parkinson's disease patients to participate in clinical trials
A. Valadas, M. Coelho, M. Finisterra, A. Noronha, M. Rosa, C. Sampaio, J. Ferreira (Lisbon, Portugal) |
| Th-180 | Ropinirole prolonged release offers patients with advanced Parkinson's disease greater opportunity to reduce their daily "off" time than ropinirole immediate release
F. Stocchi, L. Giorgi, B. Hunter, J. Statham, A.H.V. Schapira (Rome, Italy) | Th-193 | Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease
F. Valdeoriola, C. Moreno, C. Gaig, Y. Compta, C. Pont, M. Buongiorno, C. Coronell (Barcelona, Spain) |
| | | Th-194 | Rationale and design of the ParkFit study: A randomized controlled trial to increase physical activity in patients with Parkinson's disease
M. van Nimwegen, A. Speelman, K. Smulders, S. Overeem, G. Borm, F. Backx, B.R. Bloem, M. Munneke (Nijmegen, Netherlands) |

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-195** Botulinum toxin type A (BTX-A) in the management of levodopa-induced cervical dyskinésias in Parkinson's disease: A double-blind, randomized, placebo-controlled crossover study
J.E. Vaughan, A.P. Duker, N. Jones, M. Gartner, A. Sahay, F.J. Revilla, A.J. Espay (Cincinnati, Ohio)
- Th-196** Does botulinum toxin improve gait in Parkinson's disease?
D. Volpe, S. Biguzzi, S. Rinaldo, C. Lettieri, R. Eleopra, A. Scutari (Venice, Italy)
- Th-197** Cerebrospinal fluid markers of neurodegeneration in Parkinson's disease
H. Vranova, M. Nevrly, J. Mares, P. Kanovsky, D. Stejskal (Olomouc, Czech Republic)
- Th-198** Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease: Results from 4 years
R. Watts, R. Pahwa, K. Lyons, B. Boroojerdi (Birmingham, Alabama)
- Th-199** Atomoxetine for the treatment of depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study
D. Weintraub, S. Mavandadi, S. Horn, H. Hurtig, A. Siderowf, J. Duda, M. Stern (Philadelphia, Pennsylvania)
- Th-200** Possible Parkinson's disease revealed by a pure head resting tremor
J. Xie-Brustolin, J. Gan, H. Gervais-Bernard, A.-E. Vallet, E. Broussolle, S. Thobois (Lyon, France)
- Th-201** Neuroprotection trials in Parkinson's disease
T.C. Yaltho, R.G. Hart, L.A. Pearce, B.M. Ravina, J.R. Marler (Houston, Texas)
- Th-202** The efficacy and safety of switching from dopamine agonists to pramipexole in patients with advanced Parkinson's disease
M. Ye, W.G. Liu (Nanjing, China)
- Th-203** A triple-blinded, randomized placebo-controlled, multicenter phase II study of efficacy and safety of VF-08, a Chinese herbal medicine mixture, in treatment of Parkinson's disease
J.H.M. Yeung, M. Auyeyung, Y.F. Cheung, J. Chan, P.W. Ng, H.L. Li, K.S. Wong, V. Mok (Hong Kong, Hong Kong)
- Th-204** Magnetic resonance imaging findings of shoulders in Parkinson's disease
A. Yucel, O. Yilmaz-Kusbeci (Afyon, Turkey)
- Th-205** Discrimination between healthy subjects and patients with Parkinson's disease using the PLM test and a levodopa challenge test
T. Zackrisson, B. Eriksson, B. Holmberg, B. Johnels, T. Thorlin (Gotehnburg, Sweden)
- Th-206** Laryngeal electromyography in patients with voice complaints at different stages of Parkinson's disease
A.P. Zarzur, B. Cataldo, E. Fonoff, A. Duprat (Sao Paulo, SP, Brazil)

Parkinson's disease: Cognition

- Mo-203** Frequency and profile of mild cognitive impairment in Parkinson's disease: A multicentre meta-analysis of neuropsychological data
D. Aarsland, K. Bronnick, D. Weintraub, K. Marder, D. Burn, L.M. Allcock, R.A. Barker, C. Williams-Gray, T. Foltyne, C. Janvin, J.P. Larsen, M. Emre (Stavanger, Norway)
- Mo-204** A novel task to probe impulsivity in Parkinson's disease
R. Adam, P.M. Bays, V. Singh-Curry, P. Bain, M. Husain (London, United Kingdom)
- Mo-205** L-dopa plasma levels and executive functions in Parkinson's disease
G. Albani, S. Cattaldo, I. Mori, R. Pignatti, L. Pradotto, A. Mauro (Piancavallo, Verbania, Italy)
- Mo-206** Neuropsychological consequences of bilateral versus unilateral subthalamic deep brain stimulation in Parkinson's disease
F. Andelman (Tel-Aviv, Israel)
- Mo-207** Magnitude estimation in Parkinson's disease
C. Andersen, B. Kluger, C. Garvan, S. Classen, H. Fernandez, M. Mennemeier, D. McCarthy (Gainesville, Florida)
- Mo-208** Influence of cognitive status and dementia in Parkinson's disease on latency of reflexive eye movements
C.F. Graham, M.R. MacAskill, L. Livingston, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)
- Mo-209** Two-year clinical follow-up of a cohort with Parkinson's disease and other parkinsonisms. The PRIAMO study
A. Antonini, PaRkInson and Non Motor SymptOms Study Group (Milan, Italy)
- Mo-210** The role of the subthalamic nucleus (STN) in cognitive processing in Parkinson's disease: A local field potential study
A. Anzak, L. Gaynor, M. Beigi, P. Limousin, M. Hariz, L. Zrinzo, P. Brown, M. Jahanshahi (London, United Kingdom)
- Mo-211** Rasagiline and cognitive improvement in Parkinson's disease
L.B. Bahroo, B.S. Kightlinger, R.P. Gandhi, F.L. Pagan (Washington, District of Columbia)
- Mo-212** DBS of the STN improves learning of weak cue-outcome associations on the weather prediction task in Parkinson's disease
M. Beigi, L. Wilkinson, D. Lagnado, M. Jahanshahi (London, United Kingdom)
- Mo-213** Automated 3D mapping of hippocampal and caudate atrophy and ventricular enlargement in Parkinson's disease with and without dementia
M.K. Beyer, L.G. Apostolova, A.E. Green, K.S. Hwang, J.S. Morra, Y.-Y. Chou, C. Avedissian, P.M. Thompson, C.C. Janvin, J.P. Larsen, J.L. Cummings, D. Aarsland (Stavanger, Norway)
- Mo-214** Spatial remapping of cortico-striatal connectivity in Parkinson's disease – A resting state fMRI study
R.C. Helmich, L.C. Derikx, M. Bakker, R. Scheeringa, I. Toni, B.R. Bloem (Nijmegen, Netherlands)
- Mo-215** Brief cognitive assessment in the early stages of Parkinson's disease
P. Bugalho, J. Vale (Lisboa, Portugal)
- Mo-216** Parkinson's disease and intentionality: Deficits in representation of intention
P. Butler, P. McNamara, R. Durso (Boston, Massachusetts)

ABSTRACT LISTING BY TOPIC

- | | |
|---|---|
| <p>Mo-217 Parkinson's disease and religiosity: Deficits in the automatic activation of religious concepts
P. Butler, P. McNamara, R. Durso (Boston, Massachusetts)</p> <p>Mo-218 Neuropsychological functioning in Parkinson's mild cognitive impairment
N. Fisher, R. Camicioli (Edmonton, Alberta, Canada)</p> <p>Mo-219 Mild cognitive impairment and questionable dementia in older Parkinson's disease patients without dementia
R.M. Camicioli, J.L. Sabino, N.J. Fisher (Edmonton, Alberta, Canada)</p> <p>Mo-220 Parkinson's disease dementia mechanisms of cortical neuron dysfunction
J.N. Caviness, D.G. Walker, T. Beach, C.H. Adler, M.W. Sabbagh, D. Conner, H. Shill, E. Driver-Dunckley, V.G. Evidente, L.F. Lue (Scottsdale, Arizona)</p> <p>Mo-221 Activity of daily living to define the dementia in the patient with Parkinson's disease
S.-M. Cheon, J.H. Kang, H.-S. Kim, K.W. Park, J.W. Kim (Busan, Republic of Korea)</p> <p>Mo-222 Tau and phospho-tau cerebrospinal levels correlate with temporal and frontal gray matter reduction in Parkinson's disease and Parkinson's disease with dementia
Y. Compta, N. Ibarretxe-Bilbao, C. Junque, N. Bargallo, J. Braga-Pereira, F. Valdeoriola, E. Munoz, E. Tolosa, M.J. Marti (Barcelona, Catalonia, Spain)</p> <p>Mo-223 A prospective series of neuropsychological outcomes after deep brain stimulation for the treatment of Parkinson's disease
A.R. Costello, H. Al Khamees, J. Moriarty, J. Bourke, N. Hulse, R. Selway, C. Clough, K. Ashkan, M. Samuel (London, United Kingdom)</p> <p>Mo-225 Cognitive impairment in subjects with Parkinson's disease is associated with hippocampal atrophy and ventricular enlargement
J.E. Duda, J.V. Noorigian, D. Weintraub, P.J. Moberg, C. Davatzikos, K. Deepthi, S.X. Xie, C.M. Clark, A.D. Siderowf (Philadelphia, Pennsylvania)</p> <p>Tu-204 Stimulation of the subthalamic nucleus in Parkinson's disease: A 5 year follow-up of cognition
A. Duits, B. Dandachi-Fitzgerald, A. Winogrodzka, V. Visser-Vandewalle (Maastricht, Netherlands)</p> <p>Tu-205 Apathy: A predictive factor of dementia in Parkinson's disease
K. Dujardin, M. Delliaux, C. Dernoncourt, P. Sockeel, L. Defebvre (Lille, France)</p> <p>Tu-206 Neuropsychological deficits associated with the via mesolimbico-mesocortical and prefrontal-caudate in patients with Parkinson's disease
H. Duran Meza, F. Jimenez Ponce, J. Soto, N. Gonzalez, D. Trejo Martinez (Mexico City, Mexico)</p> <p>Tu-207 Changes in tau transcription occurring as a function of tau genotype in Parkinson's disease (PD) cortex: A pathogenic substrate for the dementia of PD?
J.R. Evans, M. Ban, S.J. Sawcer, M.G. Spillantini, R.A. Barker (Cambridge, Cambridgeshire, United Kingdom)</p> <p>Tu-208 Useful field of view as a reliable screening measure of driving performance in people with Parkinson's disease: Results of a pilot study
S. Classen, O. Shechtman, M. Okun, H.H. Fernandez (Gainesville, Florida)</p> | <p>Tu-209 The Montreal Cognitive Assessment (MoCA): A screening tool for mild cognitive impairment (MCI) in idiopathic rapid eye movement sleep behavior disorder (RBD)
C. Desjardins, R.B. Postuma, S. Joncas, J. Montplaisir, V. Latreille, J.-F. Gagnon (Montreal, Quebec, Canada)</p> <p>Tu-210 Mild cognitive impairment (MCI) in idiopathic rapid eye movement sleep behavior disorder (RBD)
J.-F. Gagnon, M. Vendette, R.B. Postuma, C. Desjardins, J. Massicotte-Marquez, J. Montplaisir (Montreal, Quebec, Canada)</p> <p>Tu-211 The effect of viewing graspable objects in Parkinson's disease (PD)
A. Galpin, E. Poliakoff, J. Dick, S. Tipper (Salford, United Kingdom)</p> <p>Tu-212 Cognitive complaint as a prodromal symptom in Parkinson's disease?
B.K. Gerton, D.W. Tsuang, E.R. Peskind, T.J. Montine, J.B. Leverenz (Seattle, Washington)</p> <p>Tu-213 Impaired narrative processing in Parkinson's disease
R. Goldmann Gross, C. Farag, A. Siderowf, H. Hurtig, M. Stern, S. Horn, A. Colcher, M. Grossman (Philadelphia, Pennsylvania)</p> <p>Tu-214 Self-complexity in Parkinson's disease is predicted by depression
E. Harris, P. McNamara, R. Durso (Boston, Massachusetts)</p> <p>Tu-215 Defective visual perception in patients with Parkinson's disease: The impairment of preattentive visual processing
Y. Higashi, H. Kamada, M. Tabata, K. Hirayama, T. Ishioka, E. Mori (Himeji, Japan)</p> <p>Tu-216 Is there a link between lower and higher order visual deficits in early Parkinson's disease: A case-control study?
G. Hipp, M. Vaillant, V. Pieri, N.J. Diederich (Luxembourg, Luxembourg)</p> <p>Tu-217 Is there a link between olfactory dysfunction and recognition of facial disgust in early Parkinson's disease?
G. Hipp, M. Vaillant, V. Pieri, N.J. Diederich (Luxembourg, Luxembourg)</p> <p>Tu-218 Decision making, risk and dopamine in sub-groups of Parkinson's disease
V. Singh-Curry, N. Bunzeck, R. Perry, S. Molloy, P. Bain, E. Düzel, M. Husain (London, United Kingdom)</p> <p>Tu-219 <i>a</i>-synuclein pathology in the claustrum is associated with dementia in Parkinson's disease
M.E. Kalaitzakis, S.M. Gentleman, R.K.B. Pearce (London, United Kingdom)</p> <p>Tu-220 Parkinson's disease dementia (PDD) diagnosis according to the new movement disorders task force recommendations: Clinical and cognitive characteristics
M. Kiesmann, J.-B. Chanson, T. Vogel, M. Berthel, K. Georges (Strasbourg, France)</p> <p>Tu-221 Effects of cognitive-linguistic load on spatial and temporal gait parameters during on-off medication cycles in Parkinson's disease
L.L. LaPointe, C.G. Maitland, J.A.G. Stierwalt, L. Apel (Tallahassee, Florida)</p> <p>Tu-222 Executive dysfunction in Parkinson's disease
P.N. Lau, M.S. Chong, I.S.H. Seah, W.S. Lim, W.L. Au, L.C.S. Tan (Singapore, Singapore)</p> |
|---|---|

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-223** Can silent ischemic cerebral lesions clinically affect cognitive impairment in patients with Parkinson's disease accompanied by mild dementia?
K.-S. Lee, Y.-D. Kim, I.-U. Song, J.-S. Kim (Seoul, Republic of Korea)
- Tu-224** Performance over time on two brief cognitive screening measures in Parkinson's disease (PD) and Huntington's disease (HD)
S.L. Lessig, J. Goldstein, J.P. Corey-Bloom (La Jolla, California)
- Tu-225** Influence of different classification criteria on the interpretation of group differences in PD-MCI
I. Liepelt, A. Vogel, G. Baysal, J. Godau, A. Gaenslen, K.J. Schweitzer, A. Di Santo, D. Berg (Tuebingen, Germany)
- Tu-226** Prediction of cognitive impairment associated with Parkinson's disease by short latency afferent inhibition
S.-H. Lin, S.-Y. Chen, S.-T. Tsai (Hualien City, Hualien, Taiwan)
- Tu-227** Assessment of the progression of cognitive impairment in Parkinson's disease using the MDS-UPDRS
G. Llebaria, J. Pagonabarraga, C. Garcia-Sanchez, B. Pascual-Sedano, A. Gironell, J. Kulisevsky
- We-206** Urate correlates with cognitive performance in Parkinson's disease
W.-F. Luo, X.-J. Wang, L.-J. Wang, L. Wang, C.-F. Liu (Suzhou, Jiangsu, China)
- We-207** Psychometric attributes of the Parkinson's disease-cognitive rating scale
P. Martinez-Martin, C. Prieto-Jurczynska, B. Frades-Payo, S. Donate, C. Rodriguez-Blazquez, J. de Pedro-Cuesta (Madrid, Spain)
- We-208** Relating neuropsychological test performance to everyday cognitive functioning in Parkinson's disease
K.R. McDonald, E. Poliakoff, J.P. Dick, M.W. Kellett, A.R. Crossman (Manchester, United Kingdom)
- We-209** Verbal recall is impaired in Parkinson's disease without dementia
M. Menéndez, R. Ribacoba, J. Rodriguez-Ferreiro, F. Lobo, F. Cuetos (Mieres, Asturias, Spain)
- We-210** Olfactory function as a predictor of cognitive impairments in Parkinson's disease
A. Fusari, J.A. Molina Arjona, H. Ellgring, B. Garcia-Rodriguez (Madrid, Spain)
- We-211** Appreciation of indirect requests in Parkinson's disease
L. Monetta, T. Jubault, A. Strafella, A.-L. Lafontaine, A. Ptito, O. Monchi (Quebec, Quebec, Canada)
- We-212** Dopaminergic medication exaggerates the experience of voluntary motor control in Parkinson's disease
J.W. Moore, S.A. Susanne, P. Schwingenschuh, G. Moretto, K.P. Bhatia, P. Haggard (London, United Kingdom)
- We-213** Relationship between apathy and cognitive abilities in depressed PD patients
C. Morrison, S. Varanese, S. Hirsch, J. Howard, H. Hamid, A. Di Rocco (New York, New York)
- We-214** Hallucinations/vivid dreams in Parkinson's disease patients. Preliminary results from the French PARKMIP/COPARK cohort study
V. Cochen, L. Nègre-Pages, S. Perez-Lloret, R. Debs, P. Damier, A. Destée, F. Tison, O. Rascol (Toulouse, France)
- We-215** Effect of cognitive dual-task on balance in Parkinson's disease
R.M. Allen, P. Carlson-Kuhta, J.V. Jacobs, J.G. Nutt, F.B. Horak (Portland, Oregon)
- We-216** Implicit sequence learning on the serial reaction time in Parkinson's disease: The effects of training hand and repeated testing
I. Obeso, L. Wilkinson, E. Casabona, M.L. Bringas, M. Alvarez, M.C. Rodriguez-Oroz, N. Pavon, L. Alvarez, R. Macias, J.A. Obeso, M. Jahanshahi (London, United Kingdom)
- We-217** Decision-making in Parkinson's disease patients with and without pathological gambling
M. Rossi, E. Roldan, D. de Achaval, S. Perez-lloret, D. Cerquetti, A. Cammarota, M.I. Nouzeilles, R. Fahrer, M. Merello, R. Leiguarda (Buenos Aires, Argentina)
- We-218** Neuropsychological differences between Parkinson's disease patients with and without mild cognitive impairment
M. Petrova, M. Raycheva, Y. Zhelev, L. Traykov (Sofia, Bulgaria)
- We-219** Dementia in Parkinson's disease – Correlation with phenotype of the disease and behavioral changes
M. Petrovic, E. Stefanova, Z. Knezevic, Z. Idrizovic, V. Kostic (Kragujevac, Serbia)
- We-220** Deficiency to divide in patients with Parkinson's disease: Correlation with gait and balance dysfunction
M.E. Piemonte, L.E.R. Vale (Sao Paulo, Brazil)
- We-221** Dual task training enhances motor and attentional deficits in patients with Parkinson's disease
C. Bedeschi, B. Loureiro, J. Ibrahim, C. Cardoso, E. Okamoto, L.E. Ribeiro do Valle, M.E. Piemonte (Sao Paulo, Brazil)
- We-222** Deficiency to divide attention in patients with Parkinson's disease: Psychophysical results
M.E. Piemonte, L.E.R. Vale (Sao Paulo, Brazil)
- We-223** Impairment in communicative effectiveness in Parkinson's disease
E.K. Plowman-Prine, M.S. Okun, C.M. Sapienza, S.L. Pollock, C. Jacobson, J.C. Rosenbek (Gainesville, Florida)
- We-224** Motor imagery in Parkinson's disease
I. Reuter, S. Mehnert, M. Kaps (Giessen, Hessen, Germany)
- We-225** Executive function based on semantic memory is impaired in Parkinson's disease without dementia
R. Ribacoba, M. Menéndez, F. Lobo, J. Rodriguez-Ferrero, F. Cuetos (Mieres, Asturias, Spain)
- We-226** Prevalence of Parkinson's disease dementia according to the clinical diagnostic criteria proposed by Movement Disorders Society
B. Baldivia, S. Batistela, J. Cavalheiro, C. Duarte, S.M. Brucki, M.S. Rocha (Sao Paulo, Brazil)
- We-227** Parkinson's disease dementia prevalence rates according to diagnostic levels proposed by Movement Disorder Society
B. Baldivia, S. Batistela, J. Cavalheiro, C. Duarte, S.M. Brucki, M.S. Rocha (Sao Paulo, SP, Brazil)
- We-228** Action verbal fluency in DP patients
I.T. Rodrigues, J.F. Ferreira, A.C. Castro-Caldas, M. Coelho, M.M. Rosa (Lisboa, Portugal)

ABSTRACT LISTING BY TOPIC

- | | |
|---|--|
| <p>Th-207 Gender specific impact of antiparkinsonian medication on mood and cognition
S. Roeske, A. Spottke, O. Kaut, U. Wüllner (Bonn, Germany)</p> <p>Th-208 Detecting functionally significant cognitive impairment in PD
E.W. Rosenthal, J. Eppig, K.A. Duey, L. Brennan, M. Forry, H.I. Hurtig, D. Weintraub, J. Karlawish, A.D. Siderowf (Philadelphia, Pennsylvania)</p> <p>Th-209 1H MRS for determination of therapeutic efficacy in PIRIBEDIL-treated patients with Parkinson's disease (PD)
I.N. Karaban', Z.Z. Rozhkova, N.V. Karaban', T.N. Kalishuk-Slobodyn (Kiev, Ukraine)</p> <p>Th-210 Cognitive improvement after duodenal levodopa infusion in Parkinson's disease
C. Sanchez-Castaneda, J. Campdelacreu, M. Juncadella, J. Miro, S. Jauma, M. Calopa, F.R. Rubio (Hospital de Llobregat, Spain)</p> <p>Th-211 Selective attention in Parkinson's disease: An investigation with the priming-of-popout paradigm
E. Seiss, L. Wilkinson, M. Eimer, M. Jahanshahi (Guildford, United Kingdom)</p> <p>Th-212 Stochastic sequence learning in Parkinson's disease
M. Seo, M. Beigi, M. Jahanshahi, B.B. Averbeck (London, United Kingdom)</p> <p>Th-213 Defining the neurocognitive profile of an Ashkenazi Jewish (AJ) Parkinson's disease (PD) population with the LRRK2 G2019S mutation
V.L. Shanker, P. Soto, M. Sethi, R. Saunders-Pullman, L. Severt, C. Palmese, S.B. Bressman (New York, New York)</p> <p>Th-214 CSF biomarkers of AD in PD patients with and without cognitive impairment suggest a subset with concomitant AD
A. Siderowf, J.E. Duda, S.X. Xie, L.M. Shaw, D. Weintraub, S.T. Moelter, P.J. Moberg, E. Rosenfeldt, M. Diloyan, J.Q. Trojanowski, H.I. Hurtig, C.M. Clark (Philadelphia, Pennsylvania)</p> <p>Th-215 Three-dimensional analysis of gait of patients with Parkinson's disease during the accomplishment of the dual task
D. Speciali, E. Oliveira, P. Lucareli, F. Pereira, N. Santos, A. Fracini (Sao Paulo, Brazil)</p> <p>Th-216 Working memory and emotional face processing in Parkinson's disease
L. Subramanian, M.C. Jackson, J.J. Vattakachery, D.E.J. Linden, J.V. Hindle (Bangor, Wales, United Kingdom)</p> <p>Th-217 Detecting cognitive impairment in patients with Parkinson's disease by use the Addenbrooke's Cognitive Examination Revised (ACE-R)
J. Svátová, D. Dolezil, S. Skutilová (Prague, Czech Republic)</p> <p>Th-218 Comparison of cognitive dysfunction in Parkinson's disease and Machado-Joseph disease
I. Tamura, A. Takei, S. Hamada, S. Homma, T. Hamada, K. Tashiro (Sapporo, Hokkaido, Japan)</p> <p>Th-219 Bilateral subthalamic nucleus deep brain stimulation for the treatment of medically refractory Parkinson's disease: Effects on neuropsychiatric tests
G.R. Toczył, F. Revilla, G.T. Mandybur (Cincinnati, Ohio)</p> <p>Th-220 Sentence production in Parkinson's disease: Effects of conceptual and task complexity
M.S. Troche, L.J.P. Altmann, H.H. Fernandez, M.S. Okun, C.M. Sapienza (Gainesville, Florida)</p> | <p>Th-221 Internally-guided executive functioning predicts memory impairments in Parkinson's disease
T.H. Turner, A. Delambo, V. Salak, K. Bergmann, V. Hinson (Charleston, South Carolina)</p> <p>Th-222 Increased rear-end collisions in drivers with Parkinson's disease
E.Y. Uc, M. Rizzo, D. Liu, S.W. Anderson, J.D. Dawson (Iowa City, Iowa)</p> <p>Th-223 Prospective memory in de novo Parkinson's disease patients
E. Unti, C. Pagni, D. Frosini, C. Rossi, G. Tognoni, U. Bonuccelli, L. Murri, R. Ceravolo (Pisa, Italy)</p> <p>Th-224 CHIP mediates PINK1 ubiquitination, degradation and aggregation
Y. Liu, Y. Zhang, X. Zhang, L. Wang, S. Li, W. Song, Y. Fu, D. Xiao, L. Wang (GuangZhou, China)</p> <p>Th-225 Validity of the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) for detection of cognitive impairment in Parkinson's disease
S. Stewart, S. Nazem, A. Siderowf, J. Duda, A. Colcher, S. Horn, H. Hurtig, M. Stern, D. Weintraub (Philadelphia, Pennsylvania)</p> <p>Th-226 Dance for Parkinson's disease: Eight years of collaboration of Brooklyn Parkinson group (BPG), a chapter of National Parkinson Foundation and Mark Morris Dance Group (MMDG), a renowned company
O.M. Westheimer, I. Bodis-Wollner (Brooklyn, New York)</p> <p>Th-227 Patients with Parkinson's disease learn to control complex systems via procedural as well as non-procedural learning
L. Wilkinson, M. Osman, M. Beigi, C. Sanchez Castaneda, M.J. Jahanshahi (London, United Kingdom)</p> <p>Th-228 Effects of STN DBS on antisaccade and frontal lobe function in Parkinson's disease
A. Yugeta, Y. Terao, H. Fukuda, R. Okiyama, F. Yokochi, M. Taniguchi, H. Takahashi, R. Hanajima, Y. Ugawa (Tokyo, Japan)</p> <p>Th-229 Comparative study about cognitive performances on patients with Parkinson's disease
C. Zaharia, V. Tudorica, D. Stanca, D. Pirs Coveanu, C. Albu, O. Alexandru (Craiova, Romania)</p> |
|---|--|

Parkinson's disease: Dysautonomia

- | | |
|---|--|
| <p>Mo-226 Global alteration in postganglionic neuronal function affects whole body kinetics of MIBG in patients with Parkinson's disease
M. Bandettini di Poggio, S. Morbelli, C. Marini, R. Marchese, E. Pomposelli, L. Avanzino, G. Sambuceti, G. Abbruzzese (Genova, GE, Italy)</p> <p>Mo-227 Paroxysmal sympathetic storm in a patient with Parkinson's disease with dementia: Case report
T. Abe, M. Fukui, K. Itokawa, T. Yamamoto, N. Tamura, N. Araki (Iruma-gun, Saitama, Japan)</p> <p>Mo-229 Correlation between odor identification and MIBG myocardial scintigraphy in patients with Parkinson's disease: Preliminary results
L. Bartolomei, M. Salgarello, M. Pontarin, R. L'Eario, D. Cecchin (Vicenza, Italy)</p> <p>Mo-230 Heart rate variability as a biomarker for Parkinson's disease
M.A. Brodsky, J. McNames (Portland, Oregon)</p> | |
|---|--|

Poster presentation information can be found on page 19.

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Mo-231** Incidence of quantitative sudomotor axon reflex test (QSART) abnormalities in patients diagnosed with idiopathic Parkinson's disease
J. Cristini, P.A. Hanna, M. Rosenberg (Edison, New Jersey)
- Mo-232** An evaluation of autonomic function in idiopathic Parkinson's disease using wavelet analysis
J. Cristini, P.A. Hanna, M. Rosenberg (Edison, New Jersey)
- Mo-233** Do anosmia, orthostasis, and constipation progress differently in Parkinson's disease?
A.L. Ramjit, L. Sedig, J. Leibner, S.S. Wu, Y. Dai, M.S. Okun, R.L. Rodriguez, I. Malaty, H.H. Fernandez (Gainesville, Florida)
- Tu-228** Is rhinorrhea an intrinsic symptom of PD?
L. Sedig, A. Ramjit, J. Leibner, Y. Dai, S.S. Wu, C.E. Jacobson IV, M.S. Okun, R.L. Rodriguez, I.A. Malaty, H.H. Fernandez (Gainesville, Florida)
- Tu-229** Botulinum toxin A injection in the detrusor muscle to treat overactive bladder syndrome and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy
A. Giannantoni, A. Rossi, E. Mearini, M. Del Zingaro, M. Porena, A. Berardelli (Perugia, Italy)
- Tu-230** A case series of peripheral neuropathy (PN) and Parkinson's disease (PD)
F.A. Gondim, A.A. Peixoto, Jr., G.R. Oliveira, S.S. Silva, Jr., W.H. Goes, W.B. Alves, C.M. Castro-Costa (Fortaleza, Ceara, Brazil)
- Tu-231** Clinical features of idiopathic Parkinson's disease and their correlation with autonomic function testing
P.A. Hanna, J. Cristini, M. Rosenberg (Edison, New Jersey)
- Tu-232** Autonomic dysfunction in Parkinson's disease and multiple system atrophy: Evaluation with eye drop test and MIBG scintigraphy
F. Kanda, N. Yasui, T. Seki, T. Ueda, T. Oda, K. Sekiguchi, H. Hamaguchi (Kobe, Japan)
- Tu-233** The frequency of autonomic failure symptoms in Parkinson's disease: Is initial presentation sympathetic or parasympathetic?
N. Kresojevic, M. Svetel, A. Tomic, T. Stojkovic, M. Jecmenica Lukic, V. Spica, I. Petrovic, E. Stefanova, V.S. Kostic (Belgrade, Serbia)
- Tu-234** Can the EKG be used to identify prodromal PD? Assessment of heart rate variability (HRV) during wakefulness in patients with RBD
R. Azhu Valappil, J.E. Black, M.J. Broderick, O. Carrillo, E. Frenette, S.S. Sullivan, C.M. Tanner, J.W. Langston (Sunnyvale, California)
- Tu-235** Pilocarpine-induced myotic response is greater in PD than in MSA patients
S. Lanzafame, G. Mostile, D. Contrafatto, L. Raciti, V. Sorbello, A. Luca, A. Nicoletti, M. Zappia (Catania, Italy)
- We-229** Alterations of enteric neurons in Parkinson's disease assessed by colonoscopy biopsies
T. Lebouvier, P. Damier, E. Coron, P. Derkinderen, M. Neunlist (Nantes, France, Metropolitan)
- We-230** MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from parkinsonism predominant multiple system atrophy
W.Y. Lee, E.J. Chung, W.T. Yoon, B.J. Kim, G.H. Lee, J. Cho, J. Ahn (Seoul, Republic of Korea)
- We-231** Parkinson's disease is associated with a decreased risk of hypertension
T. Ortega-León, M. Muñoz-Pasadas, C. Pinana-Plaza, B. Espejo-Martínez, L. Santos-Martín, M.J. Pérez-Navarro, F. Escamilla-Sevilla, Á. Ortega-Moreno, A. Minguez-Castellanos (Granada, Spain)
- We-232** A mathematical model from heart rate variability analysis to distinguish between de novo Parkinson's disease patients and controls
A. Monge-Argiles, A. García-Sánchez, J. Roca-Dorda, M.D. Ortega-Ortega, C. Leiva-Santana (Alicante, Spain)
- We-157** Autonomic and sensory symptoms are frequent and of mild severity in patients with incident, untreated PD
B. Müller, K. Haugarvoll, G.O. Skeie, J.P. Larsen, O.-B. Tysnes (Bergen, Norway)
- We-233** Non-motor dysfunction prevalence among Mexican Parkinson's disease patients
M. Rodríguez-Violante, A. Cervantes-Arriaga, M. López-Gómez, A. Villar-Velarde, T. Corona (Mexico City, Mexico)
- We-234** Lewy body diseases spectrum by myocardial sympathetic degeneration
R. Sakakibara, M. Kishi, E. Ogawa, T. Ogata, H. Haruta (Sakura, Japan)
- We-235** Reduced bowel movements preceding Parkinson's disease: A case-control study
R. Savica, B.R. Grosshardt, J.M. Carlin, J.H. Bower, J.E. Ahlskog, D.M. Maraganore, W.A. Rocca (Rochester, Minnesota)
- We-236** Long term blood pressure in Parkinson's disease
S. Sommer, B. Aral, W. Jost (Wiesbaden, Germany)
- Th-230** Dysautonomia frequently occurs prior to the onset and diagnosis of tremor dominant Parkinson's disease (PD)
M.K. Sanghera, R.J. Buchanan, R.M. Stewart (Dallas, Texas)
- Th-231** Clinical characteristics of a family with Perry syndrome due to a DCTN1 mutation
Y. Tsuboi, H. Watanabe, C. Wider, Z.K. Wszolek, M.J. Farrer (Fukuoka, Japan)
- Th-232** Urinary disturbances precede the classical motor symptoms of Parkinson's disease?
T. Uchiyama, R. Sakakibara, T. Yamamoto, T. Ito, T. Yamanishi, T. Hattori, S. Kuwabara (Chiba, Japan)
- Th-233** Dysautonomia in patients with Parkinson's disease (PD)
A.F. Vasilenko (Chelyabinsk, Russian Federation)
- Th-234** Heart rate variability as a measure of autonomic dysfunction in Parkinson's disease: Clinical correlates
R. Walker, B. Wood, H. Blackett (North Shields, Tyne and Wear, United Kingdom)
- Th-235** Screening for orthostatic hypotension in patients with Parkinson's disease may help to decrease morbidity and mortality: Database analysis from acute rehabilitation facility
K. Wilford, A. Leonard, T. Ellis, J. DePiero, D. Katz, A. Hohler (Boston, Massachusetts)
- Th-236** Body weight dynamics in Parkinsonian patients
A.Y. Yablonskaya, N.V. Fedorova (Moscow, Russian Federation)
- Th-237** Salivary composition in Parkinson's disease
O. Yilmaz-Kusbeci, T. Koken, H. Demirbas, B. Koca (Afyonkarahisar, Turkey)

ABSTRACT LISTING BY TOPIC

Parkinson's disease: Electrophysiology

- Mo-234** Pedunculopontine and subthalamic deep brain stimulation affects motor cortex network function
B.R. Aravamuthan, C.E. Hatch, R.A. French, N.I. Novikov, D.A. Bergstrom, J.R. Walters (Bethesda, Maryland)
- Mo-235** Lack of efficiency of levodopa treatment on motor cortex excitability in dyskinetic patients with Parkinson's disease
L. Barbin, C. Leux, C. Meyniel, P. Sauleau, J.M. N'Guyen, Y. Pereon, P. Damier (Nantes, France)
- Mo-236** An atlas-based computerized method to estimate the anatomical localization of preoperative electrophysiological recordings in deep brain stimulation of parkinsonian patients
S. Fernandez Vidal, M.-L. Welter, E. Bardinet, A. Buot, A. Teillant, L. Mallet, C. Karachi, J. Yelnik (Paris, France)
- Mo-237** Interlimb coordination in Parkinson's disease during split belt locomotion
A.H. Snijders, A. Delval, W. Mahabier, V. Weerdesteyn, L. Defebvre, J. Duysens, B.R. Bloem (Nijmegen, Netherlands)
- Mo-238** Relationship between essential tremor and Parkinson's disease – Clinical and neurophysiological study
D. Bogdanova, I. Milanov (Sofia, Bulgaria)
- Mo-239** Emotional processing within the subthalamic nucleus in human
A. Buot, M.-L. Welter, C. Karachi, J.-B. Pochon, E. Bardinet, J. Yelnik, L. Mallet (Paris, France)
- Mo-240** Abnormal cerebellar inhibition by transcranial magnetic stimulation in Parkinson's disease
F. Carrillo, F.J. Palomar, F. Diaz-Corrales, V. Conde, P. Porcacchia, M. Fernandez del Olmo, G. Koch, P. Mir (Seville, Spain)
- Mo-241** Cortical plasticity in Parkinson's disease (PD) with levodopa-on
W.-L. Chuang, R.-S. Chen, Y.-Z. Huang, S.-C. Lai, C.-S. Lu (Taoyuan, Taiwan)
- Mo-242** Decrease of beta frequency power in the subthalamic nucleus (STN) after pallidotomy in patients with Parkinson's disease (PD)
M.F. Contarino, L.J. Bour, M. Bot, P. van den Munckhof, J.D. Speelman, P.R. Schuurman, R.M.A. de Bie (Amsterdam, Netherlands)
- Mo-243** Modulation of sensorimotor integration by intermittent theta-burst stimulation in Parkinson's disease
A. Degardin, F. Cassim, D. Devos, L. Defebvre, P. Derambure, H. Devanne (Lille, France)
- Mo-244** Objective detection of freezing of gait elicited by obstacle avoidance during treadmill walking in Parkinson's disease
A. Delval, A. Snijders, V. Weerdesteyn, J. Duysens, L. Defebvre, N. Giladi, B. Bloem (Lille, France)
- Mo-245** Reflex inhibition following electrical stimulation of muscle tendons is not influenced by different motor tasks in healthy subjects and parkinsonian patients
U. Dillmann, P. Weber, G. Surges, J. Spiegel, K. Fassbender, C. Krick, G. Fuss (Homburg/Saar, Germany)
- Mo-417** Effects of deep brain stimulation on sensory evoked fields of parkinsonian patients
K. Airaksinen, J.P. Mäkelä, S. Taulu, A. Ahonen, J. Pohjola, J. Nurminen, E. Pekkonen (Helsinki, Finland)
- Mo-418** Discrete wavelet transformation in gait analysis: Comparison of methods in healthy subjects and parkinsonian patients
C. Massing, C. Fehringer, A.K. Louis, Y. Johann, S. Bechtel, K. Fassbender, U. Dillmann, G. Hohenberg (Homburg/Saar, Saarbruecken, Germany)
- Tu-236** Resonance in subthalamo-cortical circuits in Parkinson's disease
A. Eusebio, A. Pogosyan, S. Wang, B. Averbeck, L. Doyle Gaynor, S. Cantiniaux, T. Witjas, P. Limousin, J.-P. Azulay, P. Brown (London, United Kingdom)
- Tu-237** Deep brain stimulation can suppress pathological synchronisation in Parkinson's disease
A. Eusebio, L. Doyle Gaynor, E. Bye, T. Foltyne, L. Zrinzo, K. Ashkan, W. Thevathasan, T. Aziz, P. Brown (London, United Kingdom)
- Tu-238** Gait analysis in healthy subjects and parkinsonian patients: Analysis of side asymmetries
C. Fehringer, C. Massing, T. Heider, G. Hohenberg, A.K. Louis, Y. Johann, S. Bechtel, U. Dillmann (Homburg/Saar, Germany)
- Tu-239** Camptocormia: neurophysiological pattern in Parkinson's disease and parkinsonisms
M. Ferlisi, F. Pimazzoni, E. Frasson, E. Dall'Ora, E. Fincati, N. Rizzuto, L. Bertolaso (Verona, Italy)
- Tu-240** Low-frequency repetitive transcranial magnetic stimulation and off-phase motor symptoms in Parkinson's disease
S.R. Filipovic, J.C. Rothwell, K. Bhatia (Beograd, Serbia)
- Tu-241** Differential connectivity between subthalamic area and forearm muscle in Parkinson's patients with tremor
E. Florin, C. Reck, M. Himmel, M. Maarouf, A. Schnitzler, V. Sturm, G.R. Fink, L. Timmermann (Juelich, Cologne, Duesseldorf, Germany)
- Tu-242** An integrative approach to characterize coordination-stabilographic profile in Parkinson's disease and non-parkinsonian patients versus healthy control subjects
M.I. Gospodinov (Sofia, Bulgaria)
- Tu-243** Lack of facilitation by a triad-conditioned TMS at 40Hz in PD
R. Hanajima, Y. Terao, S. Okabe, S. Nakatani-Enomoto, T. Furubayashi, M. Hamada, A. Yugeta, H. Matsumoto, S. Tsuji, Y. Ugawa (Tokyo, Japan)
- Tu-244** Repetitive transcranial magnetic stimulation in complex treatment of Parkinson's disease patients
Y. Holets, S. Likhachev, A. Borisenko (Minsk, Belarus)
- Tu-245** Lack of plasticity in the motor cortex (M1) is a primary marker of Parkinson's disease (PD) and is L-dopa sensitive only when motor dysfunction sets in: A TMS study
T. Joseph, S. Meunier, A. Kishore (Thiruvananthapuram, Kerala, India)
- Tu-246** The characteristics of sequence effect in Parkinson's disease: Placebo-controlled, four-way crossover study of levodopa and rTMS
S.Y. Kang, T. Wasaka, E.A. Shamim, S. Auh, Y. Ueki, G.J. Lopez, T. Kida, S.-H. Jin, N. Dang, M. Hallett (Seoul, Republic of Korea)
- Tu-247** Non-linear surface EMG indices as determinants of UPDRS motor scores in Parkinson's disease patients
M. Kankaanpää, S. Rissanen, A. Meigal, M. Tarvainen, P. Karjalainen, J. Nuutinen, I. Tarkka, O. Airaksinen (Kuopio, Finland)

Poster presentation information can be found on page 19.

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-248** Sensory temporal discrimination and mental rotation of corporal objects in patients with early-onset parkinsonism, positive or negative for mutations in the parkin gene, compared to healthy controls
P. Katschnig, G. Kagi, P. Schwingenschuh, J.C. Rothwell, K.P. Bhatia (London, United Kingdom)
- Tu-249** The effects of levodopa and the posterior subthalamic DBS on the task-related EEG theta activity in patients with Parkinson's disease
M. Kitagawa, J.-I. Murata, H. Saito, T. Nagamine (Sapporo, Japan)
- Tu-415** Objective quantification of neuromotor symptoms in Parkinson's disease: A feasibility study for the implementation of a portable, computerized measurement tool
S. Papapetropoulos, H.L. Katzen, B.K. Scanlon, A. Guevara, G. Mitsu, C. Singer, B.E. Levin (Miami, Florida)
- We-237** Movement related potentials in Parkinson's disease patients
N. Klepac, V. Isgum, Z. Mubrin, L. Unusic, M. Titlic (Zagreb, Croatia)
- We-239** Specificity and sensitivity of routine neurophysiological tremor analysis as a diagnostic tool for parkinsonian tremor
N. Kovacs, I. Balas, Z. Aschermann, D. Varga, S. Komoly, F. Nagy (Pecs, Baranya Megye, Hungary)
- We-240** Relation between abnormalities of prepulse inhibition of blink reflex and levodopa resistant freezing of gait in Parkinson's disease
A. Kwiatkowski, H. Devanne, F. Cassim, C. Moreau, A. Destée, P. Derambure, L. Defebvre, D. Devos (Lille, France)
- We-241** Nonlinear features of basal ganglia neurons in Parkinson's disease patients
J. Lim, M.K. Sanghera, R.J. Buchanan (Temple, Texas)
- We-242** Towards adaptive DBS: LFP recordings during levodopa and DBS administration
S. Marceglia, L. Rossi, G. Foffani, S. Mrakic-Sposta, F. Bracchi, S. Barbieri, A. Priori (Milan, Italy)
- We-243** Inadequate modulation of cortical excitability with voluntary contraction in Parkinson's disease
H. Morita, M. Kodaira, Y. Shimojima, S.-I. Ikeda (Matsumoto, Nagano, Japan)
- We-244** Apomorphine-induced changes in the oscillatory activity of the cortex and basal ganglia from control rats
M.J. Nicolas, J. Lopez-Azcarate, M. Alegre, M. Perez-Alcazar, M. Valencia, J. Artieda (Pamplona, Navarra, Spain)
- We-245** Disturbed large-scale brain networks in Parkinson's disease
K.T.E. Olde Dubbelink, D. Stoffers, J.L.W. Bosboom, E.Ch. Wolters, C.J. Stam, H.W. Berendse (Amsterdam, Netherlands)
- We-246** Analysis of random saccades in early-to mild-stage Parkinson's disease
J.-H. Park, S.-A. Park, T.-K. Lee, K.-B. Sung (Bucheon-si, Gyeonggi-do, Republic of Korea)
- We-247** Impaired bilateral coordination of gait and upper extremity rhythmic movements in Parkinson's disease: Association with freezing of gait
M. Plotnik, T. Herman, E. Shaviv, M. Brozgol, N. Giladi, J.M. Hausdorff (Tel Aviv, Israel)
- We-406** MEG before and after implantation of deep brain stimulator in a parkinsonian patient
K. Airaksinen, J.P. Mäkelä, S. Taulu, A. Ahonen, J. Pohjola, J. Nurminen, M. Butz, A. Schnitzler, E. Pekkonen (Helsinki, Finland)
- Th-238** Automated biofeedback assistance for freezing of gait in patients with Parkinson's disease
M. Plotnik, M. Bächlin, I. Meidan, D. Roggen, G. Troster, N. Giladi, J.M. Hausdorff (Tel Aviv, Israel)
- Th-239** Bladder dysfunction in an acute experimental model of unilateral medial forebrain lesion
C.C. Santos, C. Fuellhase, R. Soler, S. Vishwajit, G. Badlani, K.-E. Andersson (Winston-Salem, North Carolina)
- Th-240** L-dopa and STN stimulation effects on pneumophonic coordination in parkinsonian dysarthria: Intra-oral pressure measurements
M. Sarr, S. Pinto, J. Ludovic, P. Alain, G. Alain, E. Robert, T. Bernard, V. François (Aix-en-Provence, France)
- Th-241** Stretch reflex gain in Parkinson patients studied during a dynamic tracking task
V. Stanislaus, J.A. Burne (Lidcombe, Sydney, NSW, Australia)
- Th-242** Stretch reflex gain and biomechanical measures of joint stiffness show no correlation in Parkinson's disease
V. Stanislaus, J.A. Burne (Lidcombe, Sydney, NSW, Australia)
- Th-243** Neurophysiological correlates of muscular pain in Parkinson's disease
M. Tinazzi, S. Recchia, S. Simonetto, M. Manfredi, A. Fiaschi, G. Moretto, M. Valeriani (Verona, Italy)
- Th-244** Modulation of neural activity during mental simulation and imitation of a motor task on young, elderly and Parkinson's disease subjects: A comparison of simple vs complex task
L.E. Tremblay, C.M. Tardif (Ottawa, Ontario, Canada)
- Th-245** Force-dependent interhemispheric connectivity in Parkinson's disease (PD)
G. Tropini, J. Chiang, S. Palmer, Z.J. Wang, M.J. McKeown (Vancouver, Canada)
- Th-246** Different wave conformations of movement-related cortical potentials in de novo Parkinson's disease with and without rest tremor
M.-K. Lu, Y.-T. Hseu, Z.-C. Chen, H.-T. Shih, Y.-W. Yung, C.-H. Tsai (Taichung, Taiwan)
- Th-247** Gait pattern of Parkinson patients at different treadmill-induced walking speeds
T. Vogt, F. Lüssi (Mainz, Germany)
- Th-248** Electromagnetic articulography assessment of tongue function in non-dysarthric speakers with Parkinson's disease
M.N. Wong, B.E. Murdoch, B.-M. Whelan, J. Bailey, L. Goozee (Brisbane, Queensland, Australia)
- Th-249** Pain threshold and tolerance in parkinsonian patients with and without pain
S. Zambito Marsala, R. Vitaliani, S. Recchia, F. Fabris, C. Marchini, G. Defazio, A. Fiaschi, G. Moretto, B. Giometto, M. Tinazzi (Belluno, Verona, Treviso, Bari, Italy)
- Th-250** Coexistence of altered firing patterns in the basal ganglia and thalamus in patients with Parkinson's disease
P. Zhuang, M. Hallett, X. Li, Y. Zhang, J. Li, Y. Li (Beijing, China)

ABSTRACT LISTING BY TOPIC

- Th-410** Alterations of the visual pathway in Parkinson's disease patients: Understanding visuospatial abnormalities in this condition
D. Salinas, I. Amorin, M. Gutierrez, Vazquez, R. Buzo (Montevideo, Uruguay)

Parkinson's disease: Neuropharmacology

- Mo-246** Do different pharmacological treatments have different effects on saccadic eye movement abnormalities in Parkinson's disease?
C.A. Antoniades, Z. Xu, R.H.S. Carpenter, R.A. Barker (Cambridge, United Kingdom)
- Mo-247** Astrocyte-proliferating effect and neuroprotective effect against 6-OHDA-induced dopaminergic neurodegeneration of a novel anti-parkinsonian agent zonisamide
M. Asanuma, I. Miyazaki (Okayama, Japan)
- Mo-248** Efficacy of double-blind, placebo-controlled pramipexole against depression in Parkinson's disease
P. Barone, W. Poewe, E. Tolosa, O. Rascol, D. Massey, C. Debieuve, S. Albrecht (Naples, Italy)
- Mo-249** Efficacy of pramipexole for motor function and activities of daily living in Parkinson's disease and associated depression
P. Barone, W. Poewe, E. Tolosa, O. Rascol, D. Massey, C. Debieuve, S. Albrecht (Naples, Italy)
- Mo-250** Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
E. Dellapina, A. Gerdet-Mas, F. Ory-Magne, L. Pourcel, F. Calvas, M. Galitzky, C. Thalamas, P. Payoux, C. Brefel-Courbon (Toulouse, France)
- Mo-251** Neuroprotective effect of glucocorticoids in parkinsonism is mediated by the expression of glucocorticoid receptor in dopaminergic neurons
M.A. Carrillo-Conesa, C. Barcia, S. Guerreiro, V. de Pablos, E. Fernandez-Villalba, E.C. Hirsch, F. Tronche, P.P. Michel, S. Vyas, M.T. Herrero (Murcia, Spain)
- Mo-252** Continuous subcutaneous apomorphine infusion (CSAI) in advanced Parkinson's disease: The west Australian experience
H. Chan, S. Walters, M. Frank, J. Rodrigues, R. Stell (Perth, Western Australia, Australia)
- Mo-253** Metabolic profils of the striatum and the NAc detected by proton magnetic resonance spectroscopy (¹H MRS) in vivo in the MPTP-intoxicated mouse, before and after levodopa
C. Chassain, G. Bielicki, C. Keller, J.-P. Renou, F. Durif (Clermont-Ferrand, France)
- Mo-254** Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopamine neuronal damage in mouse model of Parkinson's disease
S.-D. Chen, J. Pan, Q. Xiao, Z.-Q. Wang, Z. Hong (Shanghai, China)
- Mo-255** Identification of glial-cell-line-derived neurotrophic factor-regulated proteins of striatum in mouse model of Parkinson's disease
S.-D. Chen, Z. Hong, J. Liu, J. Pan, Q. Xiao (Shanghai, China)
- Mo-256** Brain metabotropic glutamate receptor 5 in Parkinson's disease patients with motor complications
B. Ouattara, L. Gregoire, M. Morissette, F. Gasparini, A. Rajput, O. Hornykiewicz, A.H. Rajput, B. Gomez-Mancilla, T. Di Paolo (Quebec City, Quebec, Canada)
- Mo-257** Effects of ropinirole prolonged-release on sleep disturbances in Parkinson's disease
P. Dusek, J. Buskova, J. Roth, R. Jech, E. Ruzicka (Praha, Czech Republic)
- Mo-258** Fluoxetine does not impair motor function in patients with Parkinson's disease
E. Dzoljic, Z. Todorovic, M. Mijajlovic, I. Kovacevic, M. Pokrajac, M. Prostran, V. Kostic (Belgrade, Serbia)
- Mo-259** Effects of the novel opioid peptide MMP-2200 in rat models of Parkinson's disease
T. Fallik, X. Yue, L.A. Zuniga, R.L. Polt, S.J. Sherman (Tucson, Arizona)
- Mo-260** The effect of dopaminergic medication on tests of deftness compared to bradykinesia and rigidity in Parkinson's disease
H.H. Fernandez, K.C. Stewart, M.S. Okun, R.L. Rodriguez, I.A. Malaty, J. Alberts, C.J. Hass (Gainesville, Florida)
- Mo-419** The effect of high dose orally disintegrating tablet selegiline (Zelapar® ODT-S), a selective monoamine oxidase B inhibitor, on monoamine oxidase A and synaptic dopamine re-uptake in the human brain
M.L. Gilmore, J. Logan, G.-J. Wang, D. Alexoff, J.M.J. Hammond, J.S. Fowler (Aliso Viejo, California)
- Tu-250** The histamine H₂ receptor antagonist, famotidine, reduces L-dopa-induced motor complications in the MPTP-lesioned macaque model of Parkinson's disease
S.H. Fox, T.H. Johnston, A. Vandermeij, J.M. Brotchie (Toronto, Ontario, Canada)
- Tu-251** DJ-1 mediated control of cell death is dependent of its proteolysis
E. Giaime, C. Sunyach, C. Frédéric, C. Alves da Costa (Sophia Antipolis, France)
- Tu-253** Whether or not amantadine sulfate does prevent to disease progression in Parkinson's disease?
K. Hasegawa, N. Kawashima, E. Horiuchi, T. Yokoyama, H. Kowa (Sagamihara, Kanagawa, Japan)
- Tu-254** Factors affecting the time to levodopa-induced dyskinésias
I. Molchadski, A.D. Korczyn, O.S. Cohen, O. Tunkel, L. Ephraty, E. Kozlova, S. Hassin-Baer (Ramat-Gan, Israel)
- Tu-255** The relationship between daytime sleepiness associated with non-ergot dopamine agonist therapy and renal function in Parkinson's disease
M.-A. Higuchi, Y. Baba, R. Onozawa, K. Fukuyama, T. Yamada (Fukuoka, Japan)
- Tu-256** The ability of UWA-0101 to enhance anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate may result from mixed, though selective, inhibition of dopamine and serotonin re-uptake
T.H. Johnston, P. Huot, S.H. Fox, M.J. Piggott, J.M. Brotchie (Toronto, Ontario, Canada)
- Tu-257** PYM0028, an orally active neurotrophic factor inducer, is neurorestorative following MPTP-administration in a mouse model of Parkinson's disease
T.H. Johnston, J.B. Koprich, J.M. Brotchie, P.A. Howson, A. Orsi (Toronto, Ontario, Canada)
- Tu-258** Antiparkinsonian activities of istradefylline (KW-6002), pramipexole and entacapone in MPTP-treated common marmosets
T. Kanda, T. Tahiro (Shizuoka, Japan)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-259 Longitudinal study of the levodopa motor response in Parkinson's disease: Effects of cognitive decline on motor function**
J.E. Alty, B.G. Clissold, C.D. McColl, K.R. Reardon, M. Shiff, P.A. Kempster (Melbourne, Victoria, Australia)
- Tu-260 Effect of combination therapy of IV amantadine and drug holiday in PD patients with motor fluctuations: Pharmacodynamic analysis of L-dopa response**
M.J. Kim, S.R. Kim, K.-A. Kim, H.-W. Shin, M.C. Lee, C.S. Lee (Seoul, Korea)
- Tu-261 Priming for L-dopa-induced dyskinesia is inhibited by blockade of calcium-permeable AMPA receptors in the 6-OHDA-lesioned rat model of Parkinson's disease**
C. Kobylecki, A.R. Crossman, P. Ravenscroft (Manchester, United Kingdom)
- Tu-262 Change of tapping speed during short examinations of 32 seconds in Parkinson's disease before and under dopaminergic therapy**
P.H. Kraus, P. Klotz, W. Kohlhepp, S. Peters, H. Przuntek, A. Hoffmann (Bochum, Germany)
- Tu-263 A daily dose of dopaminergic medications in Parkinson's disease; clinical correlates and a posteriori equation of the dose**
J.-Y. Lee, J.W. Kim, W.Y. Lee, J.-M. Kim, T.-B. Ahn, H.-J. Kim, J. Cho, J.Y. Yun, B.S. Jeon (Seoul, Korea)
- Tu-264 Systemic L-dopa deplete the striatal serotonin release in rats with nigro-striatal dopaminergic denervation**
T. Maeda, J. Yoshida, K. Kudo, K. Nagata (Akita, Japan)
- Tu-416 Clinical and therapeutic aspects in Parkinson's disease**
A. Hancu, M. Butuman, M. Kaivanifard, D. Zguma (Constanta, Romania)
- We-248 Effect of the metabotropic glutamate antagonist MPEP on levodopa-induced dyskinesias and the striatal regulation of vesicular glutamate transporters**
C. Marin, M. Bonastre, E. Aguilar, A. Jiménez (Barcelona, Spain)
- We-249 Extrastriatal dopamine in the basal ganglia: Effect of dopaminergic denervation of the subthalamic nucleus**
C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso (Barcelona, Spain)
- We-250 Sequential bilateral model of parkinsonism in rats: Behavioral and molecular study**
C. Marin, E. Iglesias, E. Aguilar, G. Mengod, R. Cortés, C. Juri, J.A. Obeso (Barcelona, Spain)
- We-251 How to avoid skin nodules with subcutaneous continuous apomorphine infusion**
M.-H. Marion, A. Leake, S. Gay (London, United Kingdom)
- We-252 Effect of rotenone toxicity on PINK1 mutated cells**
P.M. Mehta, C.M. Sue (Sydney, NSW, Australia)
- We-253 Effect of hemizygotic parkin suppression in APPswe mutant mice**
J. Perucho, M.J. Casarejos, J.A. Rodriguez, I. Rubio, I. Ampuero, A. Gomez, I. Rodal, R.M. Solano, L. Rodriguez, E. Carro, J. Garcia de Yebenes, M.A. Mena (Madrid, Spain)
- We-254 Parkin deletion causes amyloidosis in mice overexpressing human mutated Tau**
J.A. Rodriguez, J. Perucho, L. Rodriguez, M.J. Casarejos, R.M. Solano, A. Gomez, I. Rodal, M. Serrano, I. Ampuero, A. Martinez, J. Garcia de Yebenes, M.A. Mena (Madrid, Spain)
- We-255 Enriched environment affects striatal glutamate following dopamine loss**
N.R. Sashkin, J.E. Sweeney, M. Mendes, C. Moore, L.B. Dirling, R.J. Koch, R.H. Walker, C.K. Meshul (Portland, Oregon)
- We-256 Effects of zonisamide on experimental parkinsonian tremors in rats**
H. Miwa, T. Kubo, K. Hama-Kobayashi, Y. Kajimoto, T. Kondo (Wakayama City, Japan)
- We-257 L-dopa treatment-specific induction of metallothionein in reactive astrocytes in the striatum of parkinsonian model and its neuroprotective effects against dopaminergic neurotoxicity**
I. Miyazaki, M. Asanuma (Okayama, Japan)
- We-258 Retrospective statistical analysis of the incidence of serotonin toxicity in patients taking rasagiline and anti-depressants in clinical trials**
E.B. Montgomery, M. Panisset (Madison, Wisconsin)
- We-259 Symptomatic efficacy of mucuna pruriens seed extract in rodent model of Parkinson's disease**
M. Morelli, S. Pontis, A. Pinna, N. Schintu, L. Spina, R. Longoni, N. Simola, M. Ballero, K. Sanjay (Cagliari, Italy)
- We-260 The effect of rotigotine transdermal patch on non motor symptoms of Parkinson's disease: A clinical observational study using the PD non motor symptoms scale**
Y. Naidu, C. Davidson, S. Tluk, P. Martinez-Martin, K.R. Chaudhuri (London, United Kingdom)
- We-261 Initiation of apomorphine infusion in advanced Parkinson's disease and effect on non motor symptoms compared to non-invasive strategies**
Y. Naidu, S. Tluk, A. Martin, S. Jacobs, C. Davidson, C. Richards, P. Martinez-Martin, K.R. Chaudhuri (London, United Kingdom)
- We-407 Memantine improves L-dopa induced dyskinesias**
S. Varanese, J. Howard, A. Di Rocco (New York, New York)
- We-418 Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies**
A. Samii, M. Etminan, M.O. Wiens, S. Jafari (Seattle, Washington)
- Th-251 Decreased cholesterol in olfactory mucosa-derived cells from Parkinson's disease patients with leucine-rich repeat kinase 2 mutations**
K.Y. Ng, V. Smooty, V. Dedov, B. Garner, G. Halliday, A. Mackay-Sim, C. Sue, K. Double (Randwick, New South Wales, Australia)
- Th-252 17-AAG protects against rotenone-induced apoptosis in SH-SY5Y cells via HSP70 induction**
T. Pan, W. Xie, J. Jankovic, W. Le (Houston, Texas)
- Th-253 A Phase II, double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients: An interim-analysis**
S. Perez-Lloret, M. Uberti, G. Nano, D. Katzman, E. Gamzu, M. Merello (Buenos Aires, Argentina)
- Th-254 Should we concern about the cost of medical treatment for Parkinson's disease? A case study from developing country**
R. Pinzon, E.B. Budiarti (Yogyakarta, DI Yogyakarta, Indonesia)

ABSTRACT LISTING BY TOPIC

- Th-255** Easy switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage
O. Rascol, P. Barone, C. Debieuvre, R.A. Hauser, Y. Mizuno, W. Poewe, L. Salin, A. Schapira, M. Sohr, Pramipexole ER Switch Study Group (Cede, France)
- Th-256** Effect of zonisamide on apoptosis in a SH-SY5Y cell line
S. Kawajiri, S. Saiki, Y. Machida, S. Sato, T. Hatano, S.-I. Kubo, N. Hattori (Tokyo, Japan)
- Th-258** Adenosine A2A receptor inactivation in neuronal elements is neuroprotective in a model of Parkinson's disease
N. Schintu, A.R. Carta, A. Kachroo, K. Xu, M. Morelli, M.A. Schwarzschild (Cagliari, Italy)
- Th-259** Parkinson's disease tremor is diminished with relaxation guided imagery
I. Schlesinger, O. Benyakov, I. Erikh, S. Suraiya, Y. Schiller (Haifa, Israel)
- Th-260** Report on rasagiline – Antidepressant interactions in routine clinical practice, long-term follow up and issues of compliance
A.G. Guevara Salcedo, H. Jiang, A. Pandey, C. Sengun, F. Nahab, A. Russell, C. Singer (Miami, Florida)
- Th-261** In vivo assessment of degeneration of the nigrostriatal dopaminergic tract in MPTP-treated monkeys with 18F-FECNT positron emission tomography
G. Masilamoni, J. Votaw, L. Howell, J. Bogenpohl, T. Wichmann, Y. Smith (Atlanta, Georgia)
- Th-262** Potential neuroprotective effects of metabotropic glutamate receptor type 5 (mGluR5) antagonist in MPTP-treated monkeys
G. Masilamoni, D. Alagille, V. Reddy, K. Delevich, J. Bogenpohl, J. Votaw, G. Tamagnan, T. Wichmann, Y. Smith (Atlanta, Georgia)
- Th-263** L-dopa effects on dysphagia in Parkinson's disease: A videofluoroscopic analysis
M.-N. Sert, M. Baudo, B. Teston, D. Gayraud, L. Jankowski, A. Purson, F. Viallet (Aix en Provence, France)
- Th-264** Vitamin D deficiency in a cohort of patients with Parkinson's disease
M. Wasay, A. Yousuf, I. Azam (Karachi, Pakistan)
- Th-411** Amantadine for refractory "dyskinetic storm" in emergency room
I. Ybot Gorrín, F. Vivancos Matellano, E. Díez Tejedor (Madrid, Madrid, Spain)
- Mo-264** Fear of falling has a greater influence than other aspects of gait disorders on quality of life in patients with Parkinson's disease
H. Brozova, J. Stochl, J. Roth, E. Ruzicka (Prague, Czech Republic)
- Mo-265** Three-dimensional gait patterns of Parkinson's disease patients who fall: A prospective study
M.H. Cole, G.K. Kerr, J.M. Wood, P.A. Silburn (Kelvin Grove, Queensland, Australia)
- Mo-266** Delivering medication on time in Parkinson's disease
P. Cotton, H. Fleary, C. Kobylecki, K.R. McDonald, J.P. Dick, M.W. Kellett, M.A. Silverdale (Salford, United Kingdom)
- Mo-267** An audit of practice against National Institute of Clinical Excellence (NICE) guidelines for the diagnosis and management of Parkinson's disease (PD)
R. Dobson, D. Bindman, A.J. Lindahl (Coventry, United Kingdom)
- Mo-268** Validating the ADCS-ADL against performance-based measures of ADL in PD/PDD
K.A. Duey, P. Britnell, E. Rosenthal, L. Brennan, A. Siderowf, T. Giovannetti (Philadelphia, Pennsylvania)
- Mo-269** Effectiveness of an inpatient movement disorders program for patients with Parkinson's disease and predictors of rehabilitation outcome
T. Ellis, D.I. Katz, T.J. DePiero, D.K. White, C.L. Hehl, A. Leonard, V. Allen, K. Griffith, J. Dentino, M. Gardner, H. Phenix, K. Wilford, A.D. Hohler, M. Saint-Hilaire (Boston, Massachusetts)
- Mo-270** The prevalence, associated factors, and impact of drooling in Parkinson's disease
J. Leibner, A.L. Ramjit, L. Sedig, Y. Dai, S.S. Wu, C. Jacobson IV, M.S. Okun, R.L. Rodriguez, I.A. Malaty, H.H. Fernandez (Gainesville, Florida)
- Mo-271** Impact of STN-DBS on health-related quality of life in patients with Parkinson's disease
J.M. Ferrara, A. Diamond, A. Davidson, M. Almaguer, J. Jankovic (Houston, Texas)
- Mo-420** Impact of a support program in spouses of parkinsonian patients evaluated with the Zarit Caregiver Burden Inventory: A randomized study
J.-P. Brandel, L. Defebvre, C. Tranchant, J.-P. Azulay, A. Schneider, S. Rusinek, M. Willard, M. Poinsart, A. Rousseva, D. Renon, D. Boumedien, M. Ziegler (Paris, France)
- Tu-265** The impact of subtype and disease duration on quality of life in Parkinson's disease
I.J. Oh, M.C. Schiess, G. Van Horn, E. Furr Stimming (Houston, Texas)
- Tu-266** Costs of illness in a Russian cohort of patients with Parkinson's disease
Y. Winter, S. von Campenhausen, G. Popov, J. Reese, J. Klotsche, K. Botzel, E. Gusev, W. Oertel, R. Dodel, A. Guekht (Moscow, Russian Federation)
- Tu-267** Activities of daily living and health-related quality of life in persons with newly diagnosed Parkinson's disease, according to subtype of disease
G.-M. Hariz, J. Linder, M. Edstroem, L. Forsgren (Umea, Sweden)

Parkinson's disease: Quality of Life/Caregiver burden

- Mo-261** Quality of life in patients with Parkinson's disease: Importance of gait disorders and rehabilitation using the method of tempo-rhythmic correction
D.V. Pokhabov, V.G. Abramov (Krasnoyarsk, Russian Federation)
- Mo-262** Parkinsonian dysarthria Uruguayan experience in a multidisciplinary team (open trial)
B. Aguiar, R. Aljanati, M. Martinovic, V. Pomar, R. Buzo, A. Ojeda, N. Gonzalez, G. Montaldo, L. Aguerre, G. Nogueira, V. Raggio (Montevideo, Uruguay)
- Mo-263** Hyperhidrosis and quality of life in Parkinson's disease
P.J. Browne, D. O'Donovan, T. Counihan (Galway, Ireland)

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-268** Outpatient assessment program visit reduces hospitalizations in patients with Parkinson's disease
L. Miller, B.P. Hersh (Boston, Massachusetts)
- Tu-269** Special aspects of Parkinsons disease. Disturbing factors of the natural course of the disease
N. Homayoon, R. Saurugg, K. Wenzel, E. Ott (Graz, Austria)
- Tu-270** Video assisted swallowing therapy for patients with Parkinson's disease
Y. Manor, D. Freud, N. Giladi, R. Mootanah, D. Klepikov, J.T. Cohen (Tel Aviv, Israel)
- Tu-271** Appropriate timing of introducing feeding gastrostomy for Parkinson's disease patients with dysphagia
L. Matsumoto, A. Iwata, S. Tsuji (Tokyo, Japan)
- Tu-272** Parkinson's disease service improvement in accordance with National Institute for Health and Clinical Excellence (UK)
S. Mavinamne, A. Sugumaran, S. Abraham (Wrexham, United Kingdom)
- Tu-273** Neuropsychiatric symptoms in Parkinson's disease: A caregiver perspective
I. Menéndez, G. Morís (Aviles, Asturias, Spain)
- Tu-274** Non-motor symptoms: An important contributor to the quality of life in Parkinson's disease
G. Mihailescu, C. Mihailescu, C.I. Popa, S.M. Nica, I. Davidescu (Bucuresti, Romania)
- Tu-275** Validity and reliability of Hong Kong Chinese version Parkinson's disease Questionnaire-8
C.Y.K. Lau, A.Y.Y. Chan, J.H.M. Yeung, V.C.T. Mok (Hong Kong SAR, China)
- Tu-417** The use of laser walking aids to improve gait in a patient with Parkinson's disease – A case report
F.A. Lindop (Derby, Derbyshire, United Kingdom)
- We-262** Pain in patients with Parkinson's disease with or without motor fluctuation
S.M. Nica, G. Mihailescu, I.E. Davidescu (Bucharest, Romania)
- We-263** Vitamin D and bone density assessments are rarely obtained in veterans with Parkinson's disease (PD)
A.L. Peterson, J.P. Duckart, J.F. Quinn, J.G. Nutt (Portland, Oregon)
- We-264** The relationship between quality of life and swallowing in Parkinson's disease: The effects of depression
E.K. Plowman-Prine, M.S. Troche, J.C. Rosenbek, M.S. Okun, C.M. Sapienza (Gainesville, Florida)
- We-265** The relationship between quality of life and swallowing in Parkinson's disease: A preliminary Investigation
E.K. Plowman-Prine, M.S. Okun, C.M. Sapienza, S.L. Pollock, C. Jacobson, M.S. Troche, S.S. Wu, J.C. Rosenbek (Gainesville, Florida)
- We-266** The effect of gym training on multiple outcomes in Parkinson's disease: A pilot randomised waiting-list controlled trial
E. Poliakoff, A. Galpin, K. McDonald, J. Dick, M. Kellett, S. Hayes, A. Wearden (Manchester, United Kingdom)
- We-267** Effects of parkinsonism on quality of life in welding exposed shipyard workers
R.C. Harris, J.I. Lundin, S.R. Criswell, L.M. Good, C.S. Sterling, B.A. Evanoff, H. Checkoway, B.A. Racette (St. Louis, Missouri)
- We-268** Is Parkinson's disease a motor or non motor disorder?
A.Q. Rana (Toronto, Canada)
- We-269** Characterisation of Restless Legs like syndrome in Parkinson's disease
P. Reddy, Y. Naidu, N. Suleyman, S. Tluk, P. Odin, G. Macphee, F. Stocchi, A.H.V. Schapira, K.R. Chaudhuri (London, United Kingdom)
- We-270** Comparison of depression, anxiety and quality of life in PSP and MSA
A. Schrag, S. Sheikh, N. Quinn, A. Lees, C. Selai, D. Mathias, I. Litvan, A. Lang, J. Bower, D. Burn, P. Lowe, M. Jahanshahi (London, United Kingdom)
- We-408** Sleep disturbances and sleep benefit in Parkinson's disease out-patients: An interview study
R. Nagano, Y. Tsukamoto, R. Kumazawa, H. Takahashi, H. Chiba, S. Takagi (Isehara, Kanagawa, Japan)
- Th-265** Advanced stage of Parkinson's disease and non-motor fluctuations
I. Smolentseva, E. Sozinova (Moscow, Russian Federation)
- Th-266** Health-related quality of life in Australians with Parkinson's disease
S.-E. Soh, J. McGinley, H.B. Menz, J. Watts, R. Iansek, A.T. Murphy, M.E. Morris (Melbourne, Victoria, Australia)
- Th-267** Rate of disease progression among patients with Parkinson's disease in Singapore
L.C. Tan, Y. Zhao, I.S. Seah, P.-N. Lau, W.-L. Au, N. Luo, S.-C. Li, H.-L. Wee (Singapore, Singapore)
- Th-268** Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early Parkinson's disease in the United States
R. Farkouh, M.R. Wilson, M.L. Tarrants, J. Castelli-Haley, C. Armand (Kansas City, Missouri)
- Th-269** Disease burden and treatment patterns of Parkinson's disease in a long term care setting
S. Narayanan, M.L. Tarrants, J. Castelli-Haley (Kansas City, Missouri)
- Th-270** Driving ability in Parkinson's disease patients: What is your method of assessment?
S.W.K. Atherton, A.M. Thomson (Salford, Greater Manchester, United Kingdom)
- Th-271** Efficacy of self-management rehabilitation on quality of life outcomes in Parkinson's disease
L. Tickle-Degnen, T. Ellis, M. Saint-Hilaire, C.A. Thomas, R.C. Wagenaar (Medford, Massachusetts)
- Th-272** Type and intensity of daily energy expenditures among Parkinson's disease patients based upon their body weight
M. Trail, N.J. Petersen, N. Nelson, E.C. Lai (Houston, Texas)
- Th-273** How do patients with Parkinson's disease reach their diagnosis? In relation to their initial symptoms and the medical institutions/clinic they first visited
Y. Tsukamoto, R. Nagano, R. Kumazawa, H. Takahashi, H. Chiba, S. Takagi (Isehara, Kanagawa, Japan)
- Th-274** Assessment of medical care for patients with Parkinson's disease during hospitalization
L.J. Wu, C.T. Ward, S. Moore, J.G. Hou, N. Nelson, L. Fincher, F. Atassi, E.C. Lai (Houston, Texas)
- Th-275** Supporting caregivers in PD: A Survey
D. Breslow, C. Zadikoff, S. Dunlop, T. Kuhta, L. Marsh, K. Nichols, A. Videncovic, A. Martel, K. Williams, T. Simuni (Chicago, Illinois)

ABSTRACT LISTING BY TOPIC

- Th-412 Is levodopa sparing strategy optimally practiced in young onset Parkinson's disease?**
A.Q. Rana (Toronto, Canada)
- Parkinson's disease: Rating scales**
- Mo-272 Prevalence of wearing-off symptoms among Czech Parkinson's disease patients treated with L-dopa – Pilot analysis of the E.W.O study**
M. Bares, I. Rektorova, R. Jech, K. Farnikova, J. Roth, E. Ruzicka, P. Kanovsky, I. Rektor, K. Chroust, T. Pavlik (Brno, Czech Republic)
- Mo-273 The motor UPDRS assessed via telemedicine is reliable and valid**
K.M. Biglan, L.M. Deuel, A. Appler, A. Joseph, D. Miller, J. Polanowicz, S. Smith, L. Viti, R. Dorsey (Rochester, New York)
- Mo-274 Detecting asymmetries in balance control in Parkinson's disease patients with system identification techniques**
T.A. Boomstra, E.H.F. van Asseldonk, J.P.P. van Vugt, H. van der Kooij, B.B. Bloem (Nijmegen, Netherlands)
- Mo-275 Predictors of patient- and physician-reported satisfaction/ease-of-use ratings with rasagiline in Parkinson's disease**
P.O. Buck, J. Castelli-Haley, J.B. Conner (Kansas City, Missouri)
- Mo-276 NMSQuest, NMSS and SCOPA-AUT metric properties in Mexican Parkinson's disease population**
A. Cervantes-Arriaga, M. Rodríguez-Violante, M. López-Gómez, A. Villar-Velarde, T. Corona (Mexico City, Mexico)
- Mo-277 Dynamic posturography in evaluation of balance in patients of Parkinson's disease with normal pull test**
M. Ganeshan, P.K. Pal, A. Gupta, T.N. Sathyaprakash (Bangalore, Karnataka, India)
- Mo-278 Teaching program for the Unified Dyskinesia Rating Scale**
C.G. Goetz, J.G. Nutt, G.T. Stebbins, T.A. Chmura (Chicago, IL)
- Mo-279 Applying the nonmotor symptoms questionnaire to a Singaporean population**
L.J. Jaffe, L. Tan, W.-L. Au, P.N. Lau (San Diego, California)
- Mo-280 UPDRS rater training: Assessing raters' ratings**
R. Gaur, S. De Santi, H.H. Fernandez, R.L. Rodriguez, R. Kakati (Newark, Delaware)
- Tu-276 Can falls be accurately predicted in people with Parkinson's disease?**
G.K. Kerr, C.J. Worringham, M.H. Cole, P. Lacharez, J.M. Wood, P.A. Silburn (Brisbane, Queensland, Australia)
- Tu-277 Non-motor symptoms in de novo Parkinson's disease before and after dopaminergic treatment**
H.-J. Kim, S.-Y. Park, Y.-J. Cho, K.-S. Hong, J.-Y. Cho, S.-Y. Seo, D.-H. Lee, B.S. Jeon (Goyang-si, Gyeonggi-do, Republic of Korea)
- Tu-278 Development of a non-motor fluctuation assessment instrument (NoMoFA) for Parkinson's disease**
G. Kleiner-Fisman, G. Naglie, A. Davis, R. Martine, M.B. Stern, W.C. Holmes, A.E. Lang (Toronto, Ontario, Canada)
- Tu-279 Multidisciplinary team management in Parkinson's disease: The role of occupational therapy**
M. Makoutonina, R. Iansek, B. Kirkwood (Melbourne, Victoria, Australia)
- Tu-280 Impact of rate of motor progression on patient-rated outcomes in Parkinson's disease (PD)**
T.M. Mangin, A. Siderowf (Portland, Oregon)
- Tu-281 Depression in Parkinson's disease and essential tremor**
C.-J. Mao, J.-P. Chen, W.-D. Hu, J.-F. Liu, D.-Q. Chen, C.-F. Liu (Suzhou, Jiangsu, China)
- Tu-282 International validation of the non-motor symptoms scale: Comparison with the pilot study**
P. Martinez-Martin, C. Rodriguez-Blazquez, K. Abe, K.B. Bhattacharyya, B.R. Bloem, J. Carod-Artal, B. Dill, R. Esselink, C. Falup-Pecurariu, M. Gallardo, P. Mir, Y. Naidu, A. Nicoletti, K. Sethi, Y. Tsuboi, J.J. van Hilten, M. Visser, M. Zappia, K.R. Chaudhuri (Madrid, Spain)
- Tu-283 Convergent validity of the non-motor symptoms scale (NMSS) in Parkinson's disease**
P. Martinez-Martin, C. Rodriguez-Blazquez, K. Abe, K.B. Bhattacharyya, B.R. Bloem, J. Carod-Artal, B. Dill, R. Esselink, C. Falup-Pecurariu, M. Gallardo, P. Mir, Y. Naidu, A. Nicoletti, K. Sethi, Y. Tsuboi, J.J. van Hilten, M. Visser, M. Zappia, K.R. Chaudhuri (Madrid, Spain)
- We-271 Non- motor staging of Parkinson's disease (PD) and early longitudinal follow up results from an international study**
P. Martinez-Martin, R. Sherman, Y. Naidu, C. Richards, P. Odin, F. Stocchi, G. Macphee, A.H.V. Schapira, K.R. Chaudhuri (Madrid, Spain)
- We-272 Achieving excellent inter-rater reliability on the SAPS in a psychosis in Parkinson's disease study using raters with limited SAPS experience**
D.S. Miller, A. Kott, R. Mills (Wayne, Pennsylvania)
- We-273 A validation study of the Chinese wearing off Questionnaire 9-symptom for Parkinson's disease**
A. Chan, Y.F. Cheung, M. Au-Yeung, J. Yeung, T.H. Chung, K.L. Tsang, C. Lau, J. Chan, V. Mok (Hong Kong, China)
- We-274 Non declaration of non motor symptoms (NMS) of PD: An international study using the NMSQuest**
Y. Naidu, P. Martinez-Martin, T. Mitra, S. Tluk, F. Stocchi, G. Macphee, P. Odin, A.H.V. Schapira, K. Sethi, K.R. Chaudhuri (London, United Kingdom)
- We-275 Impact of an exercise program on patients with Parkinson's disease and on their physiotherapists practice**
F. Ory Magne, S. Grolleau, N. Fabre, C. Gu, C. Mohara, C. Pastorelli, C. Wygryznowicz, S. Tardez, J. Marchat, P. Marque, C. Brefel Courbon (Toulouse, France)
- We-276 Development of a QOL-oriented severity scale for Parkinson's disease (A novel QOL-oriented severity scale for Parkinson's disease)**
C. Otsuka, M. Kudo, S. Obara, K. Konno, Y. Terayama, N. Suzuki, K. Tanaka, F. Yoshii, N. Tanahashi, H. Tachibana (Morioka, Iwate pref., Japan)
- We-277 Development of a new olfactory function scale for Parkinson's disease patients**
D. Cerquetti, M. Rossi, S. Perez-Lloret, P. Millar-Vernetti, G. Nano, A. Carosella, M. Merello (Buenos Aires, Argentina)
- We-278 Wearable sensor system for monitoring motor function in Parkinson patients**
S.H. Roy, H.S. Nawab, D.L. Gilmore, S. Chang, B.T. Cole, C.A. Thomas, M.-H. Saint-Hilaire, J.F. Jabre, C.J. De Luca (Boston, Massachusetts)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-276** Investigating the relationship between UPDRS symptom assessment and an objective movement outcome assessment of Parkinson's disease
M.D. Sage, Q.J. Almeida, E.A. Roy (Waterloo, Ontario, Canada)
- Th-277** Validation of the WHO-5 wellbeing index as a screening tool for Parkinson's disease depression
C.B. Schneider, M. Pilhatsch, M. Rifati, W.H. Jost, F. Wodarz, G. Ebersbach, D. Djundja, G.A. Fuchs, A. Gies, P. Odin, G. Reifschneider, H. Reichmann, M. Wolz, A. Bottesi, M. Bauer, A. Storch (Dresden, Germany)
- Th-278** A probabilistic approach for patient classification in Parkinson's disease
N. White, H. Johnson, K. Mengersen, P. Silburn, G. Mellick, N. Dissanayaka (Brisbane, Queensland, Australia)
- Th-279** Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease
M.H. Chagas, V. Tumas, G.G.R. Rodrigues, J.E.C. Hallak, J.A.S. Crippa (Ribeirao Preto, SP, Brazil)
- Th-280** Can an accelerometer enhance Timed-Up & Go test sensitivity among patients with Parkinson's disease?
A. Weiss, N. Inbar-Borovsky, I. Maidan, M. Brozgol, M. Plotnik, N. Giladi, J.M. Hausdorff (Tel Aviv, Israel)
- Th-281** Defining a test score for status assessment during motor fluctuations in Parkinson's disease
J. Westin, M. Memedi, S. Ghiamati, D. Nyholm, M. Dougherty, T. Groth (Borlange, Sweden)
- Th-282** Validation of a home environment test battery for status assessment in patients with advanced Parkinson's disease
J. Westin, M. Schiavella, M. Memedi, D. Nyholm, M. Dougherty, T. Groth, A. Antonini (Borlange, Sweden)
- Th-283** Parkinson's disease. 10-year follow up
R.M. Zaidan (Riyadh, Saudi Arabia)
- Mo-286** Pathological correlates of sleep disturbances in Parkinson's disease
M.E. Kalaitzakis, S.M. Gentleman, R.K.B. Pearce (London, United Kingdom)
- Mo-421** A small scale study of sleep disturbances in Parkinson's disease
E.M. Morgan, M. Oliver, LLandough Day Hospital Team (Cardiff, Wales, United Kingdom)
- Mo-422** Paroxysmal nocturnal behaviours in parkinsonian syndrome extrapyramidal diseases: Not only RBD
C. Pacchetti, M. Terzaghi, A. Repetto, M. Ossola, R. Zangaglia, R. Manni (Pavia, Italy)
- Tu-284** Is insomnia related to motor disability or affective symptoms in Armenian Parkinson's disease patients?
S.G. Khachatryan, Z.D. Tavadyan (Yerevan, Armenia)
- Tu-285** Sleep-related problems in patients with Parkinson's disease
H. Lee, D. Lee, B. Chung, C. Kim, S.H. Yun (Daegu, Korea)
- Tu-286** Factors related to clinically probable REM sleep behavior disorder in Parkinson's disease
J.E. Lee, Y.H. Sohn, K.S. Kim, H.-W. Shin, Y.J. Kim (Seoul, Korea)
- Tu-287** Sleep disorders in Parkinson's disease in Singapore
L.L. Lim, S. Koh, S. Su, S. Fook-Chong, E.K. Tan (Singapore, Singapore)
- Tu-418** State space dynamics of sleep and wakefulness in healthy controls and Parkinson patients
J. Sarnthein, E. Werth, C.L. Bassetti, C.R. Baumann (Zurich, Switzerland)
- We-279** REM sleep behavior disorder in patients with Parkinson's disease and atypical parkinsonism
R.P. Munhoz, H.A. Teive, L. Fillia, H. Fameli (Curitiba, PR, Brazil)
- We-280** Association between REM sleep behavior disorders and 123I-meta-iodobenzylguanidine MIBG scintigraphic findings in patients with Parkinson's disease
T. Nomura, Y. Inoue, Y. Uemura, K. Nakashima (Yonago, Japan)
- We-281** Impulse control disorders in Parkinson's disease are associated with increased sleep disturbance
S.S. O'Sullivan, C.M. Loane, A.D. Lawrence, A.H. Evans, P. Piccini, A.J. Lees (London, United Kingdom)
- We-409** Sleep-related falling out of bed in Parkinson's disease
A.G. Guevara Salcedo, A. Pandey, A. Eduljee, D.M. Wallace, S. Papapetropoulos, F. Nahab, C. Singer (Miami, Florida)
- Th-284** REM sleep behavior disorder severity scale: A video classification of RBD in Parkinson's disease
F. Sixel-Doring, M. Schweitzer, B. Mollenhauer, C. Trenkwalder (Kassel, Germany)
- Th-121** The clinical characteristics of periodic limb movements in REM sleep behavior disorder
T. Sasai, Y. Inoue (Tokyo, Japan)
- Th-285** A screening tool for REM behavior disorder in Parkinson's disease
A. Videncovic, T. Kuhta, C. Zadikoff, K. Williams, A. Martel, C. Giblin, T. Simuni (Chicago, Illinois)

Parkinson's disease: Sleep disorders

- Mo-281** Clinical profile of Parkinson's disease patients with subjective sleep disturbances
M. Boczarska-Jedynak, B. Jasinska-Myga, M. Smilowski, G. Opala (Katowice, Poland)
- Mo-282** Midbrain hyperechogenicity and impaired olfactory function in patients with idiopathic REM sleep behavior disorder
F. Brugger, H. Stockner, A. Iranzo, K. Seppi, M. Serradell, V. Gschliesser, B. Frauscher, J. Santamaria, B. Hoegl, E. Tolosa, W. Poewe (Innsbruck, Austria)
- Mo-283** REM behavior sleep disorder is associated with non frontal cognitive dysfunction in early stage Parkinson's disease
P. Bugalho, J. Alves da Silva, B. Neto (Lisboa, Portugal)
- Mo-284** Dreaming and cognition in the early stages of Parkinson's disease
P. Bugalho, T. Paiva (Lisboa, Portugal)
- Mo-285** Sleep-disordered breathing in patients with idiopathic Parkinson's disease
N. Ito, S. Chiba, H. Furuyama, S. Tanaka, Y. Ohkubo, M. Nonaka, N. Kobayashi, K. Inoue, T. Warabi (Sapporo, Japan)

ABSTRACT LISTING BY TOPIC

- Th-286** Study of non-motor symptoms in patients with Park2: RBD, olfactory functions, and cardiac sympathetic nervous system
A. Yoritaka, Y. Inoue, Y. Shimo, Y. Shimo, N. Hattori (Tokyo, Japan)
- Th-413** Effect of controlled-release levodopa/carbidopa on the microstructure of sleep in Parkinson's disease (PD)
S. Wailke, G. Deuschl, J. Volkmann (Kiel, Germany)

Parkinsonism (secondary and parkinsonism-plus)

- Mo-287** Campocormia in Parkinson's disease
K. Abe, Y. Uchida, N. Kawano (Kobe, Japan)
- Mo-288** Vascular parkinsonism: New classification proposal
F. Alarcon, R. Salinas, W. Laguasi, J.C. Maldonado, G. Dueñas (Quito, Ecuador)
- Mo-289** Neurological presentation of chronic heroin encephalopathy
N. Amosova, O. Krivonos, E. Sozinova (Moscow, Russian Federation)
- Mo-290** Medically intractable diaphragmatic myoclonus complicating corticobasal degeneration
S. Baez-Torres, N. Galvez-Jimenez (Weston, Florida)
- Mo-291** Can vascular parkinsonism be differentiated from idiopathic Parkinson's disease? A systematic review
S. Kalra, D.G. Grosset, H.T.S. Benamer (Wolverhampton, United Kingdom)
- Mo-292** Secondary parkinsonism in the pediatric population: A case of radiation-induced parkinsonism
G. Bernard, S. Chouinard (Montreal, Quebec, Canada)
- Mo-293** High prevalence of chronic primary intracerebral hemorrhage in vascular parkinsonism
Y.-Y. Chang, J.-S. Liu, Y.-F. Chen, C.-S. Su, Y.-L. Tseng, M.-Y. Lan (Kaohsiung, Taiwan)
- Mo-294** Objective quantification of the pattern of habitual physical activity in advanced Parkinson's disease
S. Chastin, L. Rochester, D. Jones, K. Baker, D. Burn, M. Granat (Glasgow, Scotland, United Kingdom)
- Mo-295** The relationship of cerebral white matter lesions and clinical severity in patients with vascular parkinsonism
Y.-F. Chen, Y.-Y. Chang, M.-Y. Lan, C.-S. Su, J.-S. Liu (Kaohsiung County, Taiwan)
- Mo-296** Acquired hepatocerebral degeneration and Wilson's disease: Differential diagnosis
J. Damasio, C. Ramos, H. Miranda, M. Magalhaes (Porto, Portugal)
- Mo-297** Acquired olfactory impairment in a transgenic rat expressing the human mutated alpha-synuclein
C. Boyer, R. Thinard, P. Naveilhan, P. Damier, L. Lescaudron (Nantes, France)
- Mo-298** Levodopa (L-dopa) responsive parkinsonism in a 16 year-old male with brainstem infiltrating astrocytoma
C.K. Sagert, K. Dashtipour (Loma Linda, California)
- Mo-299** Natural history and predictors of survival in a cohort of southern Italy PSP patients
C. dell'Aquila, S. Zoccolella, V. Cardinali, M. de Mari, G. Iliceto, P. Lamberti (Bari, Italy)
- Mo-300** The EMSA natural history study: Data from the final analysis
S. Duerr, M. Kollensperger, F. Geser, K. Seppi, W. Poewe, G. Wenning, European MSA-Study Group (Innsbruck, Austria)
- Mo-301** Movement disorders in paraneoplastic limbic encephalitis-Ma 2 , NMDA R. Comparatives with Whipple's disease diagnoses
S.G. Echebarria (Las Arenas, Spain)
- Mo-302** Acquired hepatocerebral degeneration
R. Fernandez-Rodriguez, A. Contreras, M. Salcedo, J. Guzman de Viloria, F. Grandas (Madrid, Spain)
- Mo-303** Differentiation of guadeloupean parkinsonism and progressive supranuclear palsy by multimodal magnetic resonance imaging
D. Galanaud, A. Harmann, A. Lannuzel, M.-J. Bienaimée, N. Jodoin, Y. Agid, S. Lehéricy, M. Vidailhet (Paris, France)
- Mo-304** Paleoneurological reappraisal of movement disorders, parkinsonism, neurodegenerative and age-related diseases
J.A. Ghika (Sion, Switzerland)
- Mo-305** Clinical and pathologic findings in a parkinsonism family
D.A. Grimes, D.E. Bulman, N. Kock, L. Racacho, J. Woulfe (Ottawa, Ontario, Canada)
- Mo-306** Longitudinal monitoring of gait and mobility in Parkinson's disease (PD) using an instrumented timed up and go test (iTUG)
F. Horak, C. Zampieri, A. Salarian, P. Carlson-Kuhta, K. Aminian, J. Nutt (Portland, Oregon)
- Mo-423** Neuropsychological tests versus FP-CIT SPECT to differentiate idiopathic Parkinson's disease (IPD) from multiple system atrophy (MSA). A study with follow-up
A. Delabie, S. Dethy, V. Donckels, A. Vervaet, A. Hambye (La Louviere, Belgium)
- Mo-424** Neurocysticercosis, cerebral blood flow velocity (CBFv) and CSF-related movement disorders
S.G. Echebarria (Las Arenas, Spain)
- Mo-425** PSP-like syndrome developing after aortic aneurysm repair: Two case reports
E. Haberfeld, S. Frucht (New York, New York)
- Mo-426** High neck tone in Parkinson's disease is associated with reduced mobility
F. Erika, P. Carlson, J. Nutt, V. Gurinkel, F. Horak (Portland, Oregon)
- Mo-427** Nicotinic receptor activation and imbalance in progressive supranuclear palsy: An open-label experience with varenicline
J.L. Juncos, K.L. Sullivan, T.A. Zesiewicz (Atlanta, Georgia)
- Tu-288** Treatment with rivastigmin in progressive supranuclear palsy – First results of a phase II open label study
H. Huber, K. Srulijes, I. Liepelt, D. Berg (Tubingen, Germany)
- Tu-289** Glucocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophies in Polish patients – Preliminary report
Z. Jamrozik, A. Lugowska, J. Slawek, H. Kwiecinski (Warsaw, Poland)
- Tu-290** Preserved cardiac 123I-MIBG uptake and lack of severe autonomic dysfunction in a PARK9 patient
K. Kanai, K. Arai, M. Asahina, H. Tomiyama, Y. Kuwabara, T. Uchiyama, Y. Sekiguchi, M. Funayama, N. Hattori, S. Kuwabara (Chiba, Japan)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-291 Subacute dopa-responsive parkinsonism after successful surgical treatment of aqueductal stenosis**
K. Kinugawa, J.-F. Lepeintre, E. Itti, I. Mari, V. Czernecki, F. Heran, S. Clémenceau, M. Vidailhet, E. Roze (Paris, France)
- Tu-292 Dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) share a common fingerprint in glucose and dopamine metabolism**
J.C. Klein, C. Eggers, S. Baudrexel, R. Hilker (Frankfurt am Main, Germany)
- Tu-293 HIV-associated parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy**
C. Kobylecki, M.A. Silverdale, J.P.R. Dick, M.W. Kellett (Manchester, United Kingdom)
- Tu-294 PERFORM: A system for the continuous remote monitoring of patients with neurodegenerative diseases and the objective evaluation of patient status**
S. Konitsiotis, K. Baga, D. Fotiadis, A. Tzallas, M. Diakou, S. Tsouli (Ioannina, Greece)
- Tu-295 The characteristics of Parkinson's disease patients in Greece. A cross sectional hospital-based outpatient study**
G. Mentenopoulos, S. Bostanzopoulou, Z. Katsarou, G. Tagaris, P. Stathis, S. Konitsiotis (, Greece)
- Tu-296 A patient with cerebrotendinous xanthomatosis and levodopa-responsive secondary parkinsonism**
N. Kovacs, A. Sebok, Z. Aschermann, D. Varga, S. Komoly, Z. Pfund (Pecs, Baranya Megye, Gambia)
- Tu-297 Unsteadiness among patients with Parkinson's disease: A posturographic study**
G.-H. Lee, C.-M. Lee, Y.-M. Song, J.-H. Kim (Cheon-An, Choong-Nam, Korea)
- Tu-298 Direct modulation of striatal dopamine release by preterminal glutamate afferences on 6OHDA lesioned rats**
V. Leviel, K. Dzahini, F. Stoll, C. Dentresangle, M. Lecavorsin, A. Bertrand, I. Detraz, M. Savasta (Bron, Rhone, France)
- Tu-299 ATP13A2 mutation is rare in patients with early-onset or familial Parkinson's disease in Chinese population**
C.-H. Lin, E.-K. Tan, M.-L. Chen, L.C. Tan, H.-Q. Lim, G.S. Chen, R.-M. Wu (Taipei, Taiwan)
- Tu-300 Different phenotypes correlate to joint findings of dopaminergic transporter and receptor images in progressive supranuclear palsy**
W.-Y. Lin, K.-J. Lin, Y.-H. Weng, T.-C. Yen, L.-H. Shen, M.-H. Liao, C.-S. Lu (Taipei, Taiwan)
- Tu-301 Diagnostic accuracy in 18 cases of pathologically confirmed corticobasal degeneration**
H. Ling, S. O'Sullivan, D. Paviour, L. Massey, J. Holton, T. Revesz, A. Lees (London, United Kingdom)
- Tu-302 Prospective differentiation of multiple system atrophy from Parkinson's disease**
A. Lipp, S. Paola, A. Eric, R.D. Fealey, T.L. Gehrking, S.D. Weigand, D.M. Sletten, J.A. Gehrking, K.K. Nickander, W. Singer, D.M. Maraganore, G.K. Wenning, C.M. Shults, P.A. Low (Berlin, Germany)
- Tu-303 The potential red flags in early parkinsonism**
K. Longo, P. Barone, G. De Michele, L. Santoro, M. Rocco, A. De Rosa, A. Cozzolino, M.T. Pellecchia (Naples, Italy)
- Tu-304 Intrathecal baclofen therapy slows progressive disability in multiple system atrophy**
A. Madan, M.C. Schiess (Houston, Texas)
- Tu-305 Total tau and P-tau cerebrospinal fluid levels in distinct clinical phenotypes of progressive supranuclear palsy**
W. Maetzler, K. Srulijes, E. Dietzel, S. Bauer, D. Berg (Tuebingen, Germany)
- Tu-306 Combination of clonidine growth hormone test and cardiac I123 MIBG SPECT to differentiate multiple system atrophy from idiopathic Parkinson's disease**
C. Marcel, M. Anheim, N. Andrianatoandro, I. Namer, C. Tranchant (Strasbourg, France)
- Tu-419 Atypical Parkinsonism: A moving target the change of diagnosis over the course of disease based on clinical presentation, DAT and IBZM scan and CSF in 153 consecutive patients**
L. Korbo, S. Mardosiene, T. Henriksen, S. Bech, L. Salvesen, L. Friberg, K. Winge (Copenhagen, Denmark)
- Tu-420 Rasagiline and the improvement of motor scores and cognition in multiple system atrophy**
A. Landen, L.B. Bahroo, F.L. Pagan (Washington, District of Columbia)
- Tu-421 Freezing of gait improved by venlafaxine**
J. Leegwater-Kim, W.L. Severt (Burlington, Massachusetts)
- Tu-422 Novel throwing sign discriminates patients with progressive supranuclear palsy**
C. Sáez-Zea, C. Carnero-Pardo, Á. Ortega-Moreno, M.J. Pérez-Navarro, L. Montiel-Navarro, B. Espejo-Martínez, F. Escamilla-Sevilla, A. Mínguez-Castellanos (Granada, Spain)
- Tu-423 Phenotypes of dysarthria in progressive supranuclear palsy (PSP)**
G. Mallien, G. Ebersbach (Beelitz-Heilstatten, Brandenburg, Germany)
- We-282 Successful liver transplantation in a patient presenting Wilson's disease with severe neurological impairment**
W. Meissner, M. Neau-Cransac, J. Saric, J.-M. Trocello, F. Woimant, V. De-Ledinghen (Pessac, France)
- We-283 Dyspnea as red flag in "minimal change" multiple system atrophy**
W. Meissner, A. Vital, D. Guehl, F. Tison (Pessac, France)
- We-284 Poor mobility, falls and fractures in patients with parkinsonism**
A. Michael, P. Wallis, P. Crome (Dudley, West Midlands, United Kingdom)
- We-285 Multiple systematrophy project: A multidisciplinary diagnostic approach**
D. Monaco, F. Ciccioppo, L. Marchionne, I. Borelli, F. Anzellotti, L. Bonanni, M. Onofrj, A. Thomas (Chieti, Italy)
- We-286 Posterior alien hand phenomena as the first manifestation of HIV encephalopathy**
R.P. Munhoz, H. Famelli, T.F. Lyra, H.A. Teive (Curitiba, PR, Brazil)
- We-287 Infectious causes of parkinsonism**
R.P. Munhoz, H. Famelli, H.A. Teive, L.C. Werneck (Curitiba, PR, Brazil)
- We-288 A SPECT image analysis in patients with Parkinson's disease and Parkinson related disorders**
Y.K. Nakao, A. Satoh, M. Seto, M. Ochi, M. Tsujihata (Nishisonogi-gun, Nagasaki, Japan)

ABSTRACT LISTING BY TOPIC

- We-289** Neuropsychiatry complications after liver transplantation in a patient with Wilson's disease: A case report
E. Nikfekr, D. Nicholl (Birmingham, United Kingdom)
- We-290** Clinical syndromes and disease progression in progressive supranuclear palsy
D. Ottaviani, R. Elble, C. Colosimo, G. Fabbrini, A. Berardelli, D.R. Williams (Rome, Italy)
- We-291** The spectrum of pathological involvement in Japanese patients with multiple system atrophy: A population-bound phenotype distribution
T. Ozawa, M. Tada, O. Onodera, A. Kakita, T. Shimohata, H. Takahashi, M. Nishizawa (Niigata, Japan)
- We-292** Assessment of praxis function in patients with multiple system atrophy
S. Ozekmekci, H. Apaydin, S. Ertan, D. Uluduz, O. Erturk, G. Kenangil, E. Erginoz (Istanbul, Turkey)
- We-293** Secondary parkinsonism and intraventricular subependymoma of the brain
N. Oztekin, F. Oztekin, S. Gencler (Ankara, Turkey)
- We-294** Juvenile parkinsonism: Clinical aspects of parkinsonism in children and adolescents
T. Pearson, M. Rotstein, R. Pons, S. Fahn (New York, New York)
- We-295** Pregabalin-induced parkinsonism: A case report
S. Perez-Lloret, M. Amaya, M. Merello (Buenos Aires, Argentina)
- We-296** Cough and Parkinson's disease: Effects of expiratory muscle strength training (EMST)
T.E. Pitts, D. Bolser, K. Lewandowski, M. Troche, C. Sapienza (Gainesville, Florida)
- We-297** Ocular movement studies yield early diagnosis in pathologically-proven atypical progressive supranuclear palsy (PSP)
A.M. Hardwick, J.C. Rucker, K. Gustaw, M.L. Cohen, R.J. Leigh, R.P. Friedland, D.E. Riley (Cleveland, Ohio)
- We-298** Echogenicity of the substantia nigra in different types of parkinsonism-potential clinical utility. Preliminary results
K. Sadowski, M. Serafin-Król, A. Friedman (Warsaw, Poland)
- We-299** Role of vascular lesions load on neuropsychological profile of patients with parkinsonism
G. Santangelo, C. Vitale, L. Trojano, D. De Gaspari, K. Longo, A. Antonini, P. Barone (Naples, Italy)
- We-300** Neuroimaging features in addicts with manganese-ephedrone exposure
K. Sikk, P. Taba, S. Haldre, D. Nyholm, T. Danfors, J. Sørensen, L. Thurfjell, R. Raininko, R. Eriksson, S.-M. Aquilonius (Tartu, Estonia)
- We-301** Olfaction in progressive supranuclear palsy (PSP)
L. Silveira-Moriyama, G. Hughes, A. Church, H. Ayling, D.R. Williams, A. Petrie, J. Holton, T. Revesz, A. Kingsbury, H.R. Morris, D.J. Burn, A.J. Lees (London, United Kingdom)
- We-302** Olfactory heterogeneity in LRRK2 related parkinsonism
L. Silveira-Moriyama, R.P. Munhoz, M. de Jesus Carvalho, S. Raskin, E. Rogaeva, T.S. Moriyama, P. de Carvalho Aguiar, R.A. Bressan, O.G.P. Bassotini, L.A. Andrade, R. Ranvaud, E.R. Barbosa, H.A. Teive, A.J. Lees (London, United Kingdom)
- We-410** A novel presentation of Bickerstaff's brainstem encephalitis with parkinsonism and anti-asialo GM1 antibodies
M. Mathur, K. Dombrowski, A. Jalil, G. Rakocevic, D. Kremens, T.-W. Liang, A. Zangaladze (Philadelphia, Pennsylvania)
- We-411** Severe parkinsonism in acute monoxid carbone intoxication
M.A. Rafai, N. Midafi, F.Z. Boulaajaj, B. El Moutawakkil, I. Slassi (Casablanca, Morocco)
- We-412** Is arm dystonia in corticobasal degeneration more common on the non-dominant side?
A.Q. Rana (Toronto, Canada)
- We-413** Combination of blephrospasm and apraxia of eye lid opening in progressive supranuclear palsy and its treatment
A.Q. Rana (Toronto, Canada)
- We-414** Multiple system atrophy – Diagnostic in routine clinical practice
S. Skutilova, J. Bednarik (Brno, CZ, Czech Republic)
- Th-287** The runny nose sign in multiple system atrophy
R.M. Simoes, A. Constantino, D. Houghton, E. Gibadullina, I. Litvan (Amadora, Portugal)
- Th-288** Objective measurement of different aspects of hypokinetic dysarthria in patients with progressive supranuclear palsy (PSP) as compared to patients with Parkinson's disease (PD)
S. Skodda, U. Schlegel (Bochum, Germany)
- Th-289** Degeneration in different parkinsonian syndromes relates directly to astrocyte type and astrocyte protein expression
Y.J.C. Song, G.M. Halliday, J.L. Holton, T. Lashley, H. McCann, T.R. Revesz (Randwick, NSW, Australia)
- Th-290** Olfactory function in patients with drug-induced parkinsonism and de novo Parkinson's disease
S.-K. Song, Y.H. Sohn, P.H. Lee (Seoul, Korea)
- Th-291** An atypical case of Pantothenate kinase-associated neurodegeneration presenting as late-onset parkinsonism
J.-H. Seo, J-S Kim, S.-K. Song, P.H. Lee, Y.H. Sohn (Seoul, Korea)
- Th-292** Hypodipsia discriminates PSP from PD and MSA
M. Stamelou, H. Christ, W.H. Oertel, G.U. Hoeglinger (Marburg, Germany)
- Th-293** Transcranial brain sonography findings in discriminating between idiopathic Parkinson's disease and atypical parkinsonism
E. Stefanova, M. Mijajlovic, L. Ziropadja, T. Stojkovic, M. Jecmenica-Lukic, V. Spica, A. Tomic, M. Svetel, V. Kostic (Belgrade, Serbia)
- Th-294** Mechanism of the cerebrospinal fluid removal test responsible for improving the gait disturbance in patients with iNPH, as evaluated using the XeCT-CBF method
N. Suzuki, S. Takahashi, T. Dembo, K. Oki, H. Kimura (Shinjuku-ku, Tokyo, Japan)
- Th-295** Clinical and [123I] FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism (DIP)
M. Tinazzi, A. Antonini, T. Bovi, I. Pasquin, M.M.D. Steinmayr, G. Moretto, A. Fiaschi, S. Ottaviani (Verona, Italy)
- Th-296** Parkinsonism in HIV-infected patients on highly active antiretroviral therapy
S. Tisch, B.J. Brew (Sydney, NSW, Australia)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-297 Patient-based evaluation of autonomic failure (AF) symptoms by the SCOPA-AUT scale in multiple system atrophy (MSA)**
N. Damon-Perrière, V. Cochen-Decock, W. Meissner, J.-M. Senard, O. Rascol, F. Tison (Pessac, France)
- Th-298 Rehabilitation of dysphagia in progressive supranuclear palsy**
M.S. Troche, H.H. Fernandez, M.S. Okun, R.L. Rodriguez, J.C. Rosenbek, C.M. Sapienza (Gainesville, Florida)
- Th-299 Clinical patterns of idiopathic and vascular parkinsonism in Georgian population**
I.V. Verulashvili (Tbilisi, Georgia)
- Th-300 The nigro-striatal pathway in Creutzfeldt-Jakob disease**
A. Vital, P.O. Fernagut, M.H. Cantron, E. Bezard, M.L. Martin Negrier, C. Vital, F. Tison (Bordeaux, France)
- Th-301 Multiple system atrophy is not a TDP-43 proteinopathy**
F. Geser, J. Malunda, G.K. Wenning, V.M.-Y. Lee, J.Q. Trojanowski (Innsbruck, Tyrol, Austria)
- Th-302 The middle cerebellar pendule in diagnostics of MSA and PSP revisited – An MRI study**
K. Winge, T. Ullberg, J.K. Nielsen, A. Lokkegaard, A.F. Christensen (Copenhagen, Denmark)
- Th-303 A presumed case of dopa-responsive encephalitis lethargica (von Economo's encephalitis) in a Sub-Saharan African child**
J.J. Wold, S.A. Kareus, D.R. Renner (Salt Lake City, Utah)
- Th-304 Overlap syndromes: parkinsonism and motor neuron disease**
R.M. Wolf Gilbert, S. Fahn, L.P. Rowland (New York, New York)
- Th-305 Sequential MRI changes in a Parkinson variant of multiple system atrophy (MSA-P)**
T. Yamawaki, K. Yamada, K. Sakurai, S. Sasaki (Nagoya, Aichi, Japan)
- Th-414 Richardson's syndrome versus progressive supranuclear palsy-parkinsonism (PSP-P): First results of a cross-sectional study**
K. Sruljic, W. Maetzler, S. Bauer, E. Dietzel, C. Becker, J. Pomper, D. Berg (Tuebingen, Germany)
- Th-415 Clinical comparison between atypical parkinsonism and Parkinson's disease**
B. Tserensodnom, B. Khadsuren, D. Ulziibayar (Ulaanbaatar, Mongolia)
- Th-416 Atypical parkinsonism associated with cirrhosis: Acquired hepatocerebral degeneration**
F. Varlibas, D. Aygun, G. Yuksel, H. Tireli (Istanbul, Turkey)
- Th-417 Preclinical multiple system atrophy: A neuropathological case report in a 81-year-old man with isolated REM sleep behavioral disorder**
F. Viallet, A. Maues De Paula, B. Bonnefoi, D. Gayraud, M. Julou, M.-C. Sault, J.-F. Pellissier (Aix en Provence, France)
- Th-418 A clinical study of the effect of large volume lumbar puncture on gait in progressive supranuclear palsy**
M. Eller, D.R. Williams (Melbourne, Victoria, Australia)
- Mo-307 Long-term evaluation of quality of life provided by bilateral subthalamic stimulation in patients with Parkinson's disease**
J.-P. Azulay, T. Witjas, T. Morel, P. Auquier (Marseille, France)
- Mo-308 Relationships between physical and psychological variables and quality of life in a population of adult members of the French association of Gilles de la Tourette syndrome**
F. Galland, L. Malet, D. Morand, A. Hartmann, P. Derost, F. Durif, I. Jalenques (Clermont-Ferrand, France)
- Mo-309 Management of spasticity and dystonia in children with acquired brain injury with rehabilitation and botulinum toxin A**
E. Guettard, E. Roze, M. Vidailhet, A. Laurent-Vannier, M. Chevignard (Paris, France)
- Tu-307 Quality of life in Serbian patients with Parkinson's disease**
M. Jecmenica Lukic, L. Ziropadja, A. Potrebit, T. Stojkovic, A. Tomic, V. Spica, I. Petrovic, M. Svetel, E. Stefanova, V.S. Kostic (Belgrade, Serbia, Serbia)
- Tu-308 Is the coping style associated with quality of life in persons with Parkinson's disease ?**
E. Kerckhofs, M. Van Der Voorde (Brussels, Belgium)
- We-303 Pain and quality of life in mild to moderate Parkinson's disease patients**
L.M. Muntean, L.D. Perju-Dumbrava, N.M. Tohanean, L.C. Perju-Dumbrava (Cluj-Napoca, Romania)
- We-304 The impact of young onset Parkinson's disease on quality of life and well-being**
D.W. Perera, M.M. Wickremaratchi, M. Moran, E. Morgan, D. Davies, A. Jones, D. Sastry, R. Weiser, C. Butler, Y. Ben-Shlomo, H.R. Morris (Cardiff, United Kingdom)
- Th-306 Consequences of subthalamic deep brain stimulation in patients with Parkinson's disease: The impact of coping and age on change in quality of life and motor functioning**
T. Soulas, S. Sultan, J.-M. Gurruchaga, S. Palfi, J.-P. Nguyen, G. Fenelon (Creteil, France)
- Th-307 Cause and place of death of patients with idiopathic Parkinson's disease**
S. Pennington, K. Snell, M. Lee, R. Walker (Tyne and Wear, United Kingdom)

Quality of life/caregiver burden in Movement Disorders

- Rating scales**
- Mo-310 Short and comprehensive assessment of praxis production: Reliability and validity of a new test of upper limb apraxia (TULIA)**
T. Vanbellingen, B. Kersten, B. Van Hemelrijck, A. Van de Winckel, M. Bertschi, R. Mueri, W. De Weerdt, S. Bohlhalter (Bern, Switzerland)
- Mo-311 Unified Freezing of Gait Rating Scale (UFOGS)**
J. Crémers, G. Garraux (Liege, Belgium)
- Mo-312 Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders**
S.R. Criswell, C. Sterling, L. Good, B. Evanoff, B.A. Racette (Saint Louis, Missouri)
- Tu-309 Graphic of UKPDRS: A practical way for the management of the Parkinson's disease**
M.M. Cruzeiro, A. Pacheco, L.A. Pires (Juiz de Fora, Minas Gerais, Brazil)

ABSTRACT LISTING BY TOPIC

- Tu-310 Scale for the assessment and rating of ataxia (SARA) in Friedreich ataxia patients**
C. Marelli, S. Tezenas du Montcel, P. Charles, C.-M. Vincitorio, A. Brice, A. Dürr (Paris, France)
- Tu-311 Severity ranges on the MDS-UPDRS motor examination: Comparison to CGI-severity scores**
C.G. Goetz, G.T. Stebbins, V. Simkus (Chicago, Illinois)
- We-305 Predictors of recurrent falling in healthy older adults: The importance of both executive function and gait**
T. Herman, A. Mirelman, M. Brozgol, A. Jacobs, N. Giladi, J.M. Hausdorff (Tel Aviv, Israel)
- We-306 An exploratory analysis of the factor structure of the scale for the assessment of positive symptoms (SAPS) in Parkinson's disease patients with psychosis**
D. Bahr, A.D. Johnson, H. Williams, R. Mills (San Diego, California)
- We-307 A case report of 4 patients with Parkinson's disease dementia (PDD) who were assessed pre and post treatment with rivastigmine**
C. Johnson, L. Brown (Derby, United Kingdom)
- We-308 Evaluation of patients with tropical spastic paraparesis using the spastic paraplegia rating scale**
R.A. Kruschewsky, I.B.M. Barreto, N.F. Bernardo, C.L. Cöuras, B.G. Castro-Filho (Salvador, Bahia, Brazil)
- Th-308 Validating rating performance of a new rating scale for levodopa-induced dyskinesia (LIDS)**
P.A. LeWitt, L.R. Kingery, J. Savola (Southfield, Michigan)
- Th-309 Neuropsychiatric inventory in Wilson's disease**
V. Spica, M. Svetel, A. Potrebit, T. Pekmezovic, N. Kresojevic, A. Tomic, M. Jecmenica Lukic, T. Stojkovic, N. Dragasevic, E. Stefanova, R. Jesic, V.S. Kostic (Belgrade, Serbia)
- Th-310 Minimal clinically important change and the MDS-UPDRS motor examination**
G.T. Stebbins, C.G. Goetz, V. Siomkus (Chicago, Illinois)
- Th-311 Analysis of clock drawing (CD), Mini Mental Status Examination (MMSE) and quantitative subsystem performance (QSP) in Parkinson's disease (PD) using nonlinear causal resource analysis (NCRA)**
R.M. Stewart, G.V. Kondraske, K. Chisty, S. Hussan, M. Movahid (Dallas, Texas)
- Mo-317 Augmentation in long-term therapy of the Restless Legs syndrome with transdermal rotigotine – A retrospective systematic analysis of two large open-label 1-year trials**
H. Benes, D. Garcia-Borreguero, R. Allen, R. Kohnen (Schwerin, Germany)
- Mo-318 Maintenance of efficacy and long-term tolerability of gabapentin enacarbil compared with placebo in subjects with Restless Legs syndrome**
M.A. Cramer Bornemann, R.K. Bogan, C.A. Kushida, P.V. Tran, S.E. DeRossett, R.W. Barrett (Minneapolis, Minnesota)
- Mo-319 A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics and tolerability of gabapentin enacarbil in subjects with Restless Legs syndrome**
K.C. Cundy, R. Lal, K. Zomorodi, H. Atluri, W. Luo, D. Chen, J. Hurt, D. Bonzo, M.-L. Lassauzet, S.E. DeRossett (Santa Clara, California)
- Mo-320 Gabapentin enacarbil improves sleep in subjects with moderate-to-severe primary Restless Legs syndrome**
S.E. DeRossett, C.A. Kushida, P.M. Becker, A.L. Ellenbogen, D.M. Canafax, R.W. Barrett (Research Triangle Park, North Carolina)
- Mo-428 Gabapentin enacarbil relieves pain associated with Restless Legs syndrome**
S.E. DeRossett, C.A. Kushida, P.M. Becker, A.L. Ellenbogen, D.M. Canafax, R.W. Barrett (Research Triangle Park, North Carolina)
- Tu-312 No evidence for cognitive dysfunction or depression in patients with mild Restless Legs syndrome**
E. Driver-Dunckley, D. Connor, J. Hentz, M. Sabbagh, L. Vedders, H. Shill, V. Evidente, J. Caviness, C. Adler (Scottsdale, Arizona)
- Tu-314 Double-blind, placebo-controlled treatment of idiopathic Restless Legs syndrome with pregabalin: Effects on sleep architecture**
D. Garcia-Borreguero, O. Larrosa, J. Albares, M. Pascual, C. Fernandez, C. Palacios (Madrid, Spain)
- Tu-315 26-week effects of pramipexole on quality of life in Restless Legs syndrome**
B. Högl, W. Poewe, D. Garcia-Borreguero, L. Ferini-Strambi, C. Trenkwalder (Innsbruck, Austria)
- Tu-316 Improvement of depressive symptoms, RLS symptoms and sleep in patients with moderate to severe idiopathic RLS and at least mild depressive symptoms under a therapy with ropinirole immediate release: A multicentre, randomised, placebo-controlled study**
M. Hornyak, H. Benes, R. Kohnen, N. Banik, S.W. Schoen, L. Bergmann (Freiburg, Germany)
- Tu-317 Efficacy, safety, and dose-response of pramipexole (PPX) in Japanese patients with primary Restless Legs syndrome (RLS); a randomized, double-blind trial**
Y. Inoue, K. Kuroda, K. Hirata, N. Uchimura, T. Kagimura, T. Shimizu (Tokyo, Japan)
- Tu-318 The prevalence of Restless Legs syndrome in Thai Parkinson's disease patients**
P. Jagota, T. Asawavichienjinda, R. Bhidayasiri (Bangkok, Thailand)

Restless Legs syndrome

- Mo-313 Isolated Restless Arm syndrome associated with severe iron deficiency: A case report**
N. Afsar, D. Ince-gunal, K. Agan, O. Us (Istanbul, Turkey)
- Mo-314 Thermal hypoesthesia differentiates secondary RLS due to small fiber neuropathy from idiopathic RLS**
C.G. Bachmann, R. Rolke, M. Sommer, G. Pavlakovich, S. Happe, R.-D. Treede, W. Paulus (Goettingen, Germany)
- Mo-315 An open label pilot study assessing gender, ethnic, behavioral, and response differences of transdermal rotigotine for the treatment of Restless Legs syndrome (RLS)**
S. Baez-Torres, N. Galvez-Jimenez, E. Veliz (Weston, Florida)
- Mo-316 Carotid intima-media thickness in patients with idiopathic Restless Legs syndrome**
J.S. Baik, J.H. Kim, Y.D. Kim (Seoul, Korea)

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Tu-319 Motor performance in patients with Restless Legs syndrome**
F.J. Jiménez-Jiménez, L. Rubio, M. Calleja, H. Alonso-Navarro, L. Turpín-Fenoll, B. Pilo-de-la Fuente, J.F. Plaza-Nieto, P.J. García-Ruiz, J.A.G. Agúndez (Arganda del Rey, Madrid, Spain)
- Tu-320 Iron deficiency and Restless leg syndrome in attention deficit hyperactivity disorder**
M. Kapisyzi, D. Dobi, F. Berberi, J. Kruja (Tirana, Albania)
- Tu-321 Discrete spinal cord functional abnormalities in patients with Restless Legs syndrome revealed by electrophysiological study of H- and patellar reflexes**
S. Kerr, A. Bentley, D. Anderson, W. McKinon (Johannesburg, South Africa)
- Tu-424 Gabapentin enacarbil improves mood, quality of life, and functioning in subjects with primary Restless Legs syndrome**
S.E. DeRossett, C.A. Kushida, P.M. Becker, A.L. Ellenbogen, D.M. Canafax, R.W. Barrett (Research Triangle Park, North Carolina)
- We-309 Atypical and interesting cases of Restless Legs syndrome**
I. Kinoshita (Nagasaki, Japan)
- We-310 Transcranial brain sonography in idiopathic Parkinson's disease with and without Restless Legs syndrome**
D.-Y. Kwon, W.-K. Seo, M.-H. Song, M.-H. Park, S.-B. Koh, K.-W. Park, D.-H. Lee (Ansan-City, Gyunggi-Do, Republic of Korea)
- We-311 A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with Restless Legs syndrome**
D.O. Lee, R. Ziman, A.T. Perkins, J.S. Poceta, A.S. Walters, S.E. DeRossett, R.W. Barrett (Greenville, North Carolina)
- We-312 SWITCH: An open-label prospective study of switching from pramipexole to ropinirole in RLS**
S.H. Mehta, S.S. Iyer, R.K. Bogan, P.D. Jackson, R. Prakash, J. Prozonic, J.C. Morgan, K.D. Sethi (Augusta, Georgia)
- We-313 Restless Legs syndrome in adult Celiac disease**
M. Moccia, P. Barone, L. Ferini Strambi, R. Erro, S. Marelli, R. Tortora, F. Zingone, C. Ciacci (Naples, Italy)
- We-314 Effect of tildin/naloxon for the acute management of RLS-associated periodic limb movements in sleep: An observational study**
M. Morelli-Canelo, F. Sixel-Doering, C. Trenkwalder (Kassel, Germany)
- We-315 Intravenous iron dextran for severe refractory Restless Legs syndrome**
W.G. Ondo (Houston, Texas)
- We-316 Detection of patients with Restless Legs syndrome in outpatient clinic: Primary results from Slovak Republic**
G.A. Ramos Rivera, J. Martinkova, M. Juracicova, J. Benetin, P. Valkovic (Bratislava, Slovakia (Slovak Republic))
- We-415 Restless Arms syndrome: Report of 2 cases**
W.O. Arruda, R.P. Munhoz, H.A. Teive (Curitiba, PR, Brazil)
- Th-312 Medical conditions associated with Restless Legs syndrome: Anxiety disorder is on first line**
S. Sahin, N. Cinar, T. Okluoglu, M.O. Bilge, G. Sezgin, S. Karsidag (Istanbul, Turkey)
- Th-313 Clinical and genetic study of a large Dutch family with autosomal dominant Restless Legs syndrome**
A.M. Sas, A. Maat, S.L. Bakker, A. Di Fonzo, A.J. Boon, V. Bonifati (Rotterdam, Netherlands)
- Th-314 Restless Legs syndrome in stroke patients**
I. Schlesinger, I. Erikh, E. Sprecher, D. Yarnitsky (Haifa, Israel)
- Th-315 Long-term open-label study to evaluate the safety and efficacy of pramipexole (PPX) in Japanese patients with primary Restless Legs syndrome (RLS)**
T. Shimizu, Y. Inoue, K. Kuroda, K. Hirata, N. Uchimura, T. Kagimura (Akita, Japan)
- Th-316 Prevalence of sleep disorders in children with movement disorders**
T.B. Soman (Toronto, Ontario, Canada)
- Th-317 Peripheral neuropathy in patients with Parkinson's disease and Restless Legs syndrome**
H. Streitová, L. Mlcáková, E. Minks, J. Bednarík, M. Bareš (Brno, Czech Republic)
- Th-318 26-week effects of placebo-controlled pramipexole on overall severity, night/day symptoms, and augmentation risk in Restless Legs syndrome**
C. Trenkwalder, B. Högl, D. Garcia-Borreguero, L. Ferini-Strambi, W. Poewe, S. Brenner, M. Sohr (Kassel, Germany)
- Th-319 Effects of rotigotine transdermal system on quality of life in idiopathic Restless Legs syndrome**
D. Garcia-Borreguero, C. Trenkwalder, R. Kohnen, L. Ferini-Strambi, E. Schollmayer (Kassel, Germany)
- Th-320 Remission rates with rotigotine transdermal system in idiopathic RLS: Combined results from two 6-month, double-blind, placebo-controlled trials**
R. Allen, W. Hening, C. Trenkwalder, E. Schollmayer, R. Kohnen (Kassel, Germany)
- Th-321 Restless Legs syndrome and Parkinson's disease: Is there a relation between both disorders?**
D. Verbaan, S.M. van Rooden, M. Visser, J.J. van Hilten, R.M. Rijsman (Leiden, Netherlands)
- Th-419 Dilemma of epilepsy, sleep disorder or movement disorder – A difficult differential diagnosis**
A.Q. Rana (Toronto, Canada)

Spasticity

- Mo-321 Muscle hyperactivity after stroke: Long term follow up of prevalence and current treatment practice**
F. Adib Saberi, D. Dressler (Hamburg, Germany)
- Mo-322 Analysis of surgical intrathecal [i.t.] baclofen [ITB] implant results emphasizing revision surgery in a mixed pediatric/adult population**
Y.M. Awaad, N. Roosen, K. McIntosh, M. Waines (Bloomfield Hills, Michigan)
- Mo-323 NT201 (Xeomin®; botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies**
M. Barnes, A. Schnitzler, A. Amaral e Silva, M. Aquilar, A. Lehnert-Batar, P. Minnasch (Newcastle upon Tyne, United Kingdom)
- Mo-324 Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy**
C.H.F. Camargo, H.A.G. Teive, R.P. Munhoz, M. Zonta, G.C. Silva, N. Becker, L.C. Werneck (Curitiba, Parana, Brazil)
- Mo-325 Pediatric safety experience with Myobloc®**
W. Birmingham, E. Salazar-Grueso (Malvern, Pennsylvania)

ABSTRACT LISTING BY TOPIC

- | | |
|--|---|
| <p>Mo-326 Changes in trunk muscle activation and respiratory kinematics during speech following intensive voice treatment (LSVT LOUD) for children with spastic cerebral palsy
C. Boliek, C. Fox, J. Norton, L.S. Gan, E. Archibald, E. Knuttila, C. Rosborough, A. L'Abbe (Edmonton, Alberta, Canada)</p> <p>Mo-429 Elective bilateral above the knee amputation in T4-complete spinal cord injury: A case report
M.S. Jaffe (San Diego, California)</p> <p>Tu-322 Botulinum neurotoxins for post-stroke spasticity in adults: A systematic review
A.E. Elia, G. Filippini, D. Calandrella, A. Albanese (Milan, Italy)</p> <p>Tu-323 Improvement of Isaacs' syndrome (generalized neuromyotonia) by botulinum toxin injections
O. De Fabregues, J. Gamez (Barcelona, Spain)</p> <p>Tu-324 Spasticity in public developmental centers for adults with intellectual disability: A survey of medical directors
C.E. Gill, H.M. Taylor, M.S. Putman, D. Charles (Nashville, Tennessee)</p> <p>Tu-325 SPG15 is the second cause of hereditary spastic paraparesis with thin corpus callosum
C. Goizet, A. Boukhris, D. Maltete, L. Guyant-Marechal, S. Hanein, C. Mhiri, P. Coutinho, A. Durr, A. Brice, G. Stevanin (Paris, France)</p> <p>Tu-326 Repeated injections of NT 201 (botulinum neurotoxin free from complexing proteins) in upper limb post-stroke spasticity patients
P. Kanovsky, I. Sassin, G. Comes, S. Grafe, T. Platz, NT 201 Study Group (Olomouc, Czech Republic)</p> <p>Tu-425 Stiff Man syndrome good outcome after methylprednisolone pulse
M.A. Rafai, S. Oumari, F.Z. Boulaajaj, B. El Moutawakkil, I. Sassi (Casablanca, Morocco)</p> <p>We-317 Effect of extracorporeal shock wave therapy on spastic hypertonia in stroke patients
P. Manganotti, C. Guerra, E. Amelio (Verona, VR, Italy)</p> <p>We-318 Clinical and electrophysiological characteristics of post-stroke spasticity – an attempt to correlate
U. Meenakshisundaram, R.G. Reddy (Chennai, Tamilnadu, India)</p> <p>We-319 Botulinum toxin therapy in chronic lower limb spasticity
S. Mehnert, A. Schoene-Adibo, I. Reuter (Giessen, Germany)</p> <p>We-320 Treatment of spasticity in the lower limbs with botulinum toxin (Dysport®): A retrospective analysis
M. Muengersdorf, W. Raffauf (Berlin, Germany)</p> <p>We-321 Post stroke spasticity: Somatosensory cortex activation changes after botulinum toxin type A injections
M. Nevrly, R. Opavsky, P. Otruba, H. Vranova, P. Hlustik, P. Kanovsky (Olomouc, Czech Republic)</p> <p>We-322 Our experience in using the botulinum toxin at spastic children
L. Padure, G. Onose (Bucharest, Romania)</p> <p>Th-322 The use of complementary therapies for hemifacial spasm
P. Ratnagopal, S.H. Wahab, K. Hussein, E.K. Tan (Singapore, Singapore)</p> | <p>Th-323 The Asian botulinum toxin – A (Dysport®) clinical trial designed for early post-stroke spasticity (ABCDE-S trial)
R.L. Rosales, K.K. He, Asian Botulinum Toxin Study Group (MetroManila, Philippines)</p> <p>Th-324 Autosomal dominant hereditary spastic paraparesis: Clinical and genetic study of 3 Chinese families
S. Zhang, M. Ma, D. Fang, Y. Yang, H.F. Shang (Chengdu, China)</p> <p>Th-325 Six cases of SCA3/MJD patients that mimic hereditary spastic paraparesis in clinic
L. Shen, Y.-G. Wang, J.-L. Wang, J. Du, J. Chen, B.-S. Tang (Changsha, Hunan, China)</p> <p>Th-326 Progressive spastic paraparesis as a novel presentation of fragile X premutation – A case report
P. Tidswell (Preston, Lancashire, United Kingdom)</p> <p>Th-327 Classification of posture and movement patterns in patients with arm spasticity and recommendations for treatment with botulinum toxin A (Dysport®): ULTRA class concept (upper limb treatment algorithm & classification)
H. Heftner, W. Jost, A. Reissig, J. Wissel (Beelitz-Heilstatten, Germany)</p> |
|--|---|

Surgical Therapy: Parkinson's disease

- Mo-327** Violating the ventricular wall increases length of stay following subthalamic DBS surgery for Parkinson's disease
R.L. Alterman, Y. Gologorsky, D. Weisz, S. Ben-Haim, M. Tagliati (New York, New York)
- Mo-328** Motor and cognitive effects of subthalamic nucleotomy in one hundred patients with Parkinson's disease
L. Alvarez, R. Macias, N. Pavon, M.C.O. Rodriguez, J.A. Obeso (Havana City, Cuba)
- Mo-329** Effect of subthalamic nucleus lesion on cognitive control of voluntary movements
M.S. Alvarez, M.S. Alvarez, E.A. Casabona, L.G. Alvarez, R.A. Macias (Havana City, Cuba)
- Mo-330** Calvarium erosion resulting from deep brain stimulator wire
K.K. Appleby, L.B. Bahroo, C.G. Kalhorn, F.L. Pagan (Washington, District of Columbia)
- Mo-331** Deep brain stimulator complication due to braided extension wires
K.K. Appleby, L.B. Bahroo, C.G. Kalhorn, F.L. Pagan (Washington, District of Columbia)
- Mo-332** Deep brain stimulation in advanced age patients with Parkinson's disease
A. Athanasia, T.A. Georgios, S. Vassiliki, K.E. Clementine (Athens, Greece)
- Mo-333** Turning apathetic after subthalamic nucleus (STN) deep brain stimulation (DBS) in a Parkinson's disease (PD) patient with impulse control disorder (ICD)
M. AuYeung, K.N. Hung, W.Y. Lee, T.H. Tsui (Hong Kong, China)
- Mo-334** Cerebral activity changes induced by PPN stimulation in advanced PD patients: A [15O] H₂O PET study
B. Ballanger, A.M. Lozano, E. Moro, T. van Eimeren, C. Hamani, R. Chen, R. Cilia, S. Houle, Y.Y. Poon, A.E. Lang, A.P. Strafella (Toronto, Ontario, Canada)

The Movement Disorder Society's

13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

Mo-335	Deep brain stimulation of the subthalamic nucleus and apathy in Parkinson's disease: Utility of the frontal systems behaviour scale (FrSBe)	Tu-329	Disruption of the melanocortin system caused by bilateral subthalamic nucleus stimulation (STN-DBS) in Parkinson's disease (PD)
	P.-S. Berta, G.-S. Carmen, M. Joan, R. Rodrigo, G. Alexandre, M.-C. Merce, P. Javier, C. Antonia, K. Jaime (Barcelona, Spain)		F. Escamilla-Sevilla, M. Munoz-Pasadas, M.J. Pérez-Navarro, C. Pinana-Plaza, C. Sáez-Zea, T. Ortega-León, M.J. Katati, G. Piérdola-Maroto, J.M. Martín-Linares, Á. Ortega-Moreno, A. Mínguez-Castellanos (Granada, Spain)
Mo-336	Oscillatory activity quantification of the subthalamic nucleus in Parkinson's disease and a normalization procedure to compare patients with or without prior pallidotomy	Tu-330	Effects of PPN area stimulation on gait disorders in PD
	L.J. Bour, F.M. Contarino, M. Bot, H.D. Speelman, P. Van den Munckhof, R. Schuurman, R.M.A. De Bie (Amsterdam, Netherlands)		M.U. Ferraye, B. Debû, V. Fraix, L. Goetz, S. Chabardès, E. Lhommée, C. Ardouin, C. Lagrange, P. Krack, E. Seigneuret, A.L. Benabid, P. Pollak (Grenoble, France)
Mo-337	Cerebral venous infarction: An avoidable complication of deep brain stimulation surgery	Tu-331	Effects of unilateral pedunculopontine nucleus deep brain stimulation (PPN-DBS) in parkinsonian patients with prominent freezing of gait (FOG)
	T. Morishita, A. Burdick, M.S. Okun, C. Jacobson, K.D. Foote (Gainesville, Florida)		N.B. Galifianakis, P.A. Starr, P.S. Larson, G.A. Glass, M.M. Volz, S.L. Heath, J.L. Ostrem (San Francisco, California)
Mo-338	Accurate and prospective recording of DBS adverse events: Do these complications affect quality of life?	Tu-332	Pedunculopontine nucleus deep brain stimulation (PPN-DBS)-induced oscillopsia: Implications for mechanisms of visual fixation
	A. Burdick, H.H. Fernandez, M.S. Okun, C. Jacobson, K.D. Foote (Gainesville, Florida)		N.B. Galifianakis, A.J. Green, A. Boxer, P.A. Starr, P.S.S. Larson, A. Jafari, J.L. Ostrem (San Francisco, California)
Mo-339	Localization and anatomo-clinical correlation of DBS electrodes contacts in the MLR in Parkinson's disease	Tu-333	Case report of successful deep brain stimulation for early stage Parkinson's disease
	S. Chabardès, L. Goetz, N. Torres, M. Ferraye, E. Seigneuret, B. Debu, B. Piallat, V. Fraix, C. Mainieri, E. Bardinet, J. Yelnik, J.F. Lebas, P. Pollak, A.L. Benabid (Grenoble, France)		C.E. Gill, T.L. Davis, P.E. Konrad, O.A. Lankford, M.J. Bliton, D. Charles (Nashville, Tennessee)
Mo-340	Targeting the subthalamic nucleus for deep brain stimulation – A comparative study between magnetic resonance images alone and the fusion with computed topographic Images	Tu-334	New onset reverse sensory gest (rSG) in DYT1 dystonia treated with GPi DBS
	S.-Y. Chen, S.-T. Tsai, S.-H. Lin (Hualien, Taiwan)		V. Goyal, G. Shukla, S. Singh, M. Behari (New Delhi, India)
Mo-341	Subthalamic nucleus-deep brain stimulation modulates thermal sensation and pain thresholds in Parkinson's disease	Tu-335	Atypical speech abnormality following initiation of deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson's disease (PD)
	D. Ciampi de Andrade, Y. Beaugendre, J.-M. Gurruchaga, D. Boërio, C. Goujon, H. Lepetit, S. Palfi, J.-P. Lefaucheur (Creteil, France)		F. Gupta, C. Cho, D. Sidois, J.J. Sidois, R.L. Alterman, M. Tagliati (Oradell, New Jersey)
Mo-342	Levels of the light subunit of neurofilament triplet protein in the cerebrospinal fluid from patients with Parkinson's disease treated with bilateral subthalamic nucleus stimulation	Tu-336	Effects of subthalamic nucleus stimulation on cognition and mood in Parkinson's disease (PD)
	R. Constantinescu, L. Rosengren, B. Johnels, O. Corneliusson, H. Zetterberg, B. Holmberg (Goteborg, Sweden)		J.D. Häner, M.W.M. Schüpbach, M.A. Stephan, K. Gutbrod, A. Kaelin-Lang (Bern, Switzerland)
Mo-343	Modification of emotional states by bilateral stimulation of the subthalamic nucleus in a patient with Parkinson's disease	Tu-337	Stimulation of the ventral intermediate thalamic nucleus in tremor dominant parkinsonian patients with previous subthalamic nucleus stimulation: A case report
	P. Boon, B. Dandachi-FitzGerald, A. Duits, Y. Temel, V. Visser-Vandewalle, M. Van den Hout (Maastricht, Netherlands)		P. Hagen, A. Kühn, G.-H. Schneider, L. Weise, D. Gruber, A. Kivi, A. Kupsch (Berlin, Germany)
Mo-344	Continuous dopaminergic stimulation by intraduodenal infusion of levodopa in advanced Parkinson's disease: Efficacy and safety	Tu-338	Neuroleptic malignant-like syndrome after discontinuation of deep brain stimulation
	A. Annic, D. Devos, D. Seguy, K. Dujardin, A. Destee, L. Defebvre (Lille, France)		K. Hashimoto, T. Kadowaki, A. Nakamura, S. Aiba, K. Hirata (Mibu, Tochigi, Japan)
Tu-327	Unilateral STN-DBS in PD: Reappraisal and new insights	Tu-339	Subthalamic nucleus stimulation in patients with Parkinson's disease due to the LRRK2 G2019S mutation
	S.G. Echebarria (Las Arenas, Spain)		S. Hassin-Baer, O.S. Cohen, Y. Balash, Z. Israel, I. Fried, H. Strauss, A. Hillel, N. Giladi, E. Friedman, A. Orr-Urtreger, T. Gurevich (Ramat-Gan, Israel)
Tu-328	Task-specific bilateral arm freezing in subthalamic nucleus deep brain stimulation (STN DBS) in Parkinson's disease (PD)	Tu-340	The impact of deep brain stimulation on parkinsonian gait during dual tasking
	S.A. Elias (Boston, Massachusetts)		E. Sery, A. Weiss, Z. Israel, J.M. Hausdorff (Jerusalem, Israel)
		Tu-341	Effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor
			H. Iwamuro, F. Yokochi, R. Okiyama, M. Taniguchi, H. Takahashi, I. Hamada (Fuchu, Japan)

ABSTRACT LISTING BY TOPIC

- Tu-342 Predicting motor outcomes following STN DBS for Parkinson's disease: A probabilistic approach**
N. White, P. Silberstein, P. Silburn, T. Coyne, R. Cook, L. Jones, D. Wasson, G. Fraachia, H. Johnson, K. Mengersen (St Leonards, NSW, Australia)
- Tu-343 Stability of effects of STN stimulation for Parkinson's disease and cost of treatment at 5 years: A single-centre study from India**
A. Kishore, R. Rao, D. Panikar, G. Sarma, S. Sarma (Trivandrum, Kerala, India)
- Tu-344 Analysis of the exclusion causes for bilateral subthalamic deep brain stimulation**
N. Kovacs, I. Balas, Z. Aschermann, D. Varga, J. Janszky, S. Komoly, C. Llumiguano, T. Doczi, F. Nagy (Pecs, Baranya Megye, Hungary)
- We-323 Hardware-related complications of deep brain stimulation: A review of 221 cases**
J. Li, Y. Zhang, Y. Li (Beijing, China)
- We-324 Pallidotomy abolishes STN lesion induced dyskinesias in Parkinson's disease without further deterioration**
R. Macias, N. Pavon, G. Lopez, M.C.R. Oroz, J.A. Obeso (Havana City, Cuba)
- We-325 Deep brain stimulation of the subthalamic nucleus improves bradykinesia in Parkinson's disease**
H.A. Miranda, A.P. Duker, F.J. Revilla (Cincinnati, Ohio)
- We-326 Bilateral subthalamic stimulation for Parkinson's disease deteriorates frontal cortex function in early periods after operation**
S. Natori, G. Oyama, Y. Shimo, N. Hattori (Tokyo, Japan)
- We-327 A prospective and controlled study into the effect of subthalamic nucleus stimulation on freezing of gait**
A. Nieuwboer, B. Nuttin, S. Verheyse, J. Spildooren, L. Billiet, W. Vandenberghe (Leuven, Belgium)
- We-328 Brain tissue changes following deep brain stimulation**
K. Nolte, M. Kronenburger, J. Burgunder, V. Coenen, J. Weis, J. Krauss (Aachen, Germany)
- We-329 Anesthesia for deep brain stimulation in adults and children: Evolution of technique**
I. Osborn, S. Deiner, J. Brallier, P. Reinhard, D. Weicz, Y. Chestnut, B. Sullivan, R. Alterman (New York, New York)
- We-330 Motor and neuropsychological outcomes of bilateral STN DBS in advanced Parkinson's disease (PD)**
M.K. Panigrahi, N.K. Venigalla, R. Mridula, S.A. Jabeen, M.A. Kanikannan, R. Borgohain (Hyderabad, AP, India)
- We-331 Changing from high to low frequency stimulation of the STN in Parkinson: Enthusiasm from a case report**
M. Panisset, M. Phan, S. Diab, T.-T. Le, M. Lemay, E. Sirois-Bergeron, A. Sadikot (Montreal, Quebec, Canada)
- We-332 Post-traumatic hyperkinesias in patients with Parkinson's disease with stimulation of the subthalamic nucleus**
K.A.M. Pauls, C. Reck, M.T. Barbe, M. Maarouf, V. Sturm, G.R. Fink, L. Timmermann (Cologne, Germany)
- We-333 Value of subthalamic multiple microelectrode recordings and intraoperative stimulation in Parkinson's disease**
C. Reck, M. Maarouf, L. Wojtecki, S. Groiss, E. Florin, V. Sturm, G.R. Fink, A. Schnitzler, L. Timmermann (Cologne, Germany)
- We-334 Deep brain stimulation of the subthalamic nucleus improves balance in Parkinson's disease**
F.J. Revilla, A.P. Duker, G. Mandybur, H.A. Miranda, S. Paul, A. Espay, A. Bhattacharya (Cincinnati, Ohio)
- We-335 Use of 3 Tesla MRI for direct localization of subthalamic nucleus: Preliminary experience and comparison with conventional targeting**
G.K. Ricciardi, M. Longhi, G. Tommasi, E. Fincati, L. Bertolasi, A. Nicolato, R.I. Foroni, S. Ottaviani, M. Tinazzi, G. Moretto, M. Gerosa, A. Beltramello (Verona, Italy)
- We-336 Does deep brain stimulation of the STN in advanced Parkinson's disease change habitual physical activity?**
L. Rochester, K. Baker, D. Jones, J. Godwin, D. Burn (Newcastle upon Tyne, Tyne & Wear, United Kingdom)
- We-337 Improvement of gait and resolution of mycolonus with high frequency stimulation of the rostral brainstem. Case report**
A. Sadreddin, G. Moguel-Cobos, C. Reed (Phoenix, Arizona)
- We-338 Impulse control disorder in STN-DBS cases in PD patients**
H. Saiki, H. Toda, M. Yamanegi, R. Nagata, A. Ozaki, M. Takahashi, H. Hayashi, N. Nishida, K. Ueda, J. Takahashi, S. Matsumoto (Osaka, Japan)
- We-339 Deep brain stimulation (DBS) in Parkinson's disease (PD) patients-carriers of mutations in the glucocerebrosidase (GBA) gene**
H. Shabtai, Y. Balash, E. Ash, A. Hilel, A. Orr-Urtreger, I. Frid, Z. Israeli, N. Giladi, T. Gurevich (Tel Aviv, Israel)
- We-340 Globally increased cerebral blood flow (CBF) during high-frequency deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson's disease (PD)**
J.J. Sidtis, M. Tagliati, D. Sidtis, V. Dhawan, D. Eidelberg (Orangeburg, New York)
- Th-328 Long term bilateral stimulation of the pedunculopontine nucleus improves balance and gait stability and alleviates falls in Parkinson's disease**
P.A. Silburn, G.K. Kerr, M.H. Cole, T. Coyne, F. Sinclair, R. Wilcox (Brisbane, Queensland, Australia)
- Th-329 Risk factors for intracranial hemorrhage during deep brain stimulation surgery**
R.E. Strohd, S. Bajaj, M.S. Cartwright, T.L. Ellis, K.H. Nawaz, S.S. Tatter, M.S. Siddiqui (Winston-Salem, North Carolina)
- Th-330 Deep brain stimulation – Timing of generator replacement**
M. Takanashi, K. Sakou, H. Nakamura (Sapporo, Japan)
- Th-331 Deep brain stimulation of the subthalamic nucleus. Our experience in 53 patients**
M.S. Themistocleous, E.J. Boviatsis, P. Stathis, G. Tagaris, D.E. Sakas (Athens, Greece)
- Th-332 Evaluation of brain damage during movement disorders surgery with the utilization of the S100b protein**
M.S. Themistocleous, E.J. Boviatsis, P. Stathis, A. Kouyialis, C. Psachoulia, D.E. Sakas (Athens, Greece)
- Th-333 Comparison of surgical outcomes with unilateral, staged bilateral, and bilateral subthalamic stimulation for advanced Parkinson's disease**
H. Toda, H. Saiki, K. Ueda, S. Matsumoto, J. Takahashi (Osaka, Japan)
- Th-334 Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease: A large single centre study of motor effects and severe adverse events**
M. Toft, B. Lilleeng, J. Ramm-Pettersen, L. Pedersen, I. Skogseid, G.K. Roeste, E. Dietrichs (Oslo, Norway)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Th-335 Subthalamic deep brain stimulation for young onset Parkinson's disease
S.-T. Tsai, S.-H. Lin, Y.-C. Chou, H.-Y. Hung, C.-W. Li, Y.-H. Pan, S.-Y. Chen (Hualien, Taiwan)
- Th-336 STN DBS versus GPi DBS in refractory freezing of gait in Parkinson's disease: A case report
M.M. Volz, P.A. Starr, S.M. Khandhar, W.J. Marks, J.L. Ostrem (San Francisco, California)
- Th-337 Pre-selection for deep brain stimulation in patients with Parkinson's disease: The STIMULUS screening tool
T. Wächter, M.-C. Adolfo, C. Aguilar, H. Stoeverlaar (Tubingen, Germany)
- Th-338 Evoked magnetic fields from subthalamic deep brain stimulation in Parkinson's disease measured by magnetoencephalography
H.C. Walker, J.F. Killen, C.J. Schrandt, A.L. Yildirim, B.L. Guthrie, R.L. Watts, E.B. Montgomery, R.C. Knowlton (Birmingham, Alabama)
- Th-339 Effects of subthalamic nucleus lesions and short-term stimulation upon striatal glutamate release in awake intact and 6-hydroxydopamine-lesioned rats
R.H. Walker, R.J. Koch, C. Moore, J. Sweeney, C.K. Meshul (Bronx, New York)
- Th-340 Gamma knife subthalamotomy in Parkinson's disease: Long-term follow-up
T. Witjas, J.P. Azulay, A. Eusebio, J.C. Peragut, J. Régis (Marseille, France)
- Th-341 Dramatically efficacy of deep brain stimulation for a patient with Parkinson's disease with olfactory hallucination
M. Yamamoto, E. Hoshiyama, T. Kadokawa, A. Nakamura, K. Hirata (Mibu, Tochigi, Japan)
- Th-342 Electric current distribution in the pedunculopontine nucleus region: A 2D atlas-based structural computational model
N. Yousif, A. Thekkeyil Kunath, D. Nandi, P. Bain, R. Bayford, X. Liu (London, United Kingdom)
- Th-343 Deep brain stimulation for movement disorders in a series of 276 patients
Z. Yuqing, L. Yongjie, L. Jianyu (Beijing, China)
- Th-344 Is REM sleep behavior disorder associated with a less favorable outcome of STN-DBS in PD?
M. Zibetti, L. Rizzi, L. Colloca, A. Cinquepalmi, L. Castelli, M. Lanotte, L. Lopiano (Torino, Italy)
- Th-345 Asymptomatic deep venous thrombosis in advanced Parkinson's disease: Implications for DBS surgery
M. Zibetti, M. Rosso, A. Cinquepalmi, S. Valpreda, C. Rabbia, M. Lanotte, L. Lopiano (Torino, Italy)
- Mo-348 Combined neurostimulation therapy (DBS and SCS) for orthostatic tremor: A case report
S. Biguzzi, M. Haefele, C. Lettieri, C. Mantovan, G. Devigili, C. Conti, M. Brollo, G. Trincia, E. Cagliari, M. Bevilacqua, M. Barca, P. Fontana, G. Pinato, R. Eleopra (Mestre-Venice, Italy)
- Mo-349 Lifetime of impulse generators for deep brain stimulation in dystonia
C. Blahak, H.-H. Capelle, H. Baezner, T. Kinfe, M.G. Hennerici, J.K. Krauss (Mannheim, Germany)
- Mo-350 Micrographia induced by bilateral pallidal deep brain stimulation for segmental dystonia
C. Blahak, H.-H. Capelle, H. Baezner, T. Kinfe, M.G. Hennerici, J.K. Krauss (Mannheim, Germany)
- Mo-351 Prevalence of Twiddler's syndrome as a cause of deep brain stimulation hardware failure
A. Burdick, I. Haq, M.S. Okun, H.E. Ward, F. Bova, C. Jacobson, D. Bowers, P. Zeilman, K.D. Foote (Gainesville, Florida)
- Mo-352 Rehabilitation and orthopedic management of Stiff Person syndrome
A.C. Clairmont, K.E. Lindberg, N. Goldstein (Columbus, Ohio)
- Mo-353 Deep brain stimulation for Holmes' tremor
N. de Pennington, Z. Oliphant, P. Holland, J.S. Brittan, C. Joint, T.Z. Aziz (Oxford, United Kingdom)
- Mo-354 Effects of contact location in a cohort of 41 parkinsonian treated by deep brain stimulation of subthalamic nucleus area
P. Derost, U. Miguel, M. Ana, L. Jean-Jacques, D. Franck (Clermont-Ferrand, France)
- Tu-345 Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow up and literature review
D.J. DiLorenzo, J. Jankovic, R.K. Simpson, H. Takei, S.Z. Powell (Houston, Texas)
- Tu-346 Spinal cord stimulation for painful legs and moving toes syndrome
M.-P. Fournier-Gosselin, A.M. Lozano, R.S. Chuang, A.E. Lang, C.V. Torres, A.-L. Lopez-Rios (Toronto, Ontario, Canada)
- Tu-347 Long term effects of pallidal deep brain stimulation in tardive dystonia
D. Gruber, T. Trottenberg, A. Kivi, T. Schoenecker, U.A. Kopp, K.T. Hoffmann, G.H. Schneider, A.A. Kühn, A. Kupsch (Berlin, Germany)
- Tu-348 Deep brain stimulation (DBS) for hyperkinetic disorders
J. Guridi, M.C. Rodriguez-Oroz, M. Alegre, J.A. Obeso (Pamplona, Spain)
- Tu-349 Rescue of post-DBS benefit by correction of lead migration in a patient with dystonic head jerking
I.U. Haq, K.D. Foote, A. Sudhyadhom, F. Bova, C.E. Jacobson, M.S. Okun (Gainesville, Florida)
- Tu-350 Vim DBS in spinocerebellar ataxias with intention tremor
T. Hashimoto, K. Yoshida, S.-I. Ikeda, T. Goto (Matsumoto, Japan)
- Tu-351 Deep brain stimulation in Huntington's disease – Report of a case
A. Hotter, K.J. Mair, S. Hering, K. Seppi, G.K. Wenning, E. Wolf, J. Mueller, W. Eisner, W. Poewe (Innsbruck, Austria)

Surgical Therapy: Other Movement Disorders

- Mo-345 Control of tremor in multiple sclerosis with bilateral stimulation of the caudal zona incerta
D.E. Agombar, S. Javed, L. Mooney, S. Khan, S.S. Gill (Bristol, United Kingdom)
- Mo-346 DBS in pantothenate kinase deficiency
D. Apetauerova, J. Zani, J. Shils, B. Darras, E. Bortan, J. Arle (Burlington, Massachusetts)
- Mo-347 Thalamic DBS for tremor in IgM paraproteinemic demyelinating polyneuropathy
C. Bayreuther, M. Borg, D. Fontaine, E. Delmont, A. Chaussenot, C. Lebrun (Nice, France)

ABSTRACT LISTING BY TOPIC

- Tu-352 Long-term follow-up of pallidal deep brain stimulation for secondary dystonias**
I.U. Isaia, J. Volkmann, R.L. Alterman, M.H. Mehdorn, M. Pinsker, R. Reese, G. Deuschl, M. Tagliati (Monza, Italy)
- Tu-353 Longitudinal study of microlesion effect on bradykinesia after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease**
O.S. Klepitskaya, M.M. Koop, H.M. Bronte-Stewart (Aurora, Colorado)
- Tu-354 Number of microelectrode recording passes during bilateral staged vs. unstaged deep-brain stimulation surgery for Parkinson's disease**
O.S. Klepitskaya, J.J. Fowler, B.M. Kluger, S.G. Ojemann (Aurora, Colorado)
- Tu-355 Effects of thalamic deep brain stimulation for Tourette-syndrome on the sense of smell**
L. Ackermans, M. Kronenbuerger, Y. Temel, T. Hummel, J.B. Schulz, V. Visser-Vandewalle (Aachen, NRW, Germany)
- We-341 Ten to five years follow-up after subthalamic DBS for advanced Parkinson's disease**
A. Landi, R. Cilia, D. Pirillo, F. Vergani, A. Antonini, G. Pezzoli, C. Ferrarese, E.P. Sganzerla (Monza, Italy)
- We-342 Dancing neurostimulators in a patient with myoclonus-dystonia (DYT11)**
E. Lobsien, D. Gruber, L.M. Weise, G.-H. Schneider, A.A. Kuehn, A. Kupsch (Berlin, Germany)
- We-343 Chronic thalamic stimulation in the management of multiple sclerosis related tremor**
F. Luessi, J. Sollors, E. Fucik, P. Stoeter, P. Grunert, M. Glaser, F. Thoemke, T. Vogt (Mainz, Germany)
- We-344 Holmes tremor responding to dual electrode thalamic deep brain stimulation**
N. Mahant, S. Chen, B.K. Owler (Sydney, NSW, Australia)
- We-345 Pantothenate kinase-associated neurodegeneration dystonia treated with subthalamic nucleus deep brain stimulation. Preliminary report**
T.S. Mandat, H. Koziara, P. Nauman, T. Kmiec, T. Tykocki, W. Bonicki (Warsaw, Poland)
- We-346 Deep brain stimulation for dystonic cerebral palsy: Early experience**
W.A. Marks, J. Honeycutt, F. Acosta, Jr., M.A. Reed (Fort Worth, Texas)
- We-347 Improvement of tics after subthalamic nucleus deep brain stimulation**
I. Martinez-Torres, M.I. Hariz, L. Zrinzo, T. Foltyne, P. Limousin (London, United Kingdom)
- We-348 Deep brain stimulation (DBS) of the globus pallidus interna (GPI) in status dystonicus**
L.K. Mooney, S. Javed, S. Khan, K.R. O'Sullivan, S.S. Gill (Bristol, United Kingdom)
- We-349 Actual performance of the rechargeable Medtronic implantable pulse generator (Activa-RC) for deep brain stimulation (DBS) therapy in dystonia: A case report**
M.J. Naushahi, S. O'Riordan, P.G. Bain, T.Z. Aziz, D. Nandi (London, United Kingdom)
- We-350 Camptocormia – Response to bilateral globus pallidus interna stimulation in three patients**
S. O'Riordan, A. Paluzzi, X. Liu, T.Z. Aziz, D. Nandi, P.G. Bain (London, United Kingdom)
- We-351 Treatment of cervical dystonia with deep brain stimulation (DBS) of the globus pallidus interna (GPI)**
K.R. O'Sullivan, S. Javed, S. Khan, A. Whone, S.S. Gill (Bristol, United Kingdom)
- Th-346 Effect of spinal cord stimulation on pain and axial symptoms in progressive supranuclear palsy with intractable low back pain**
R. Onozawa, M.-A. Higuchi, Y. Baba, K. Fukuyama, T. Yamada (Fukuoka, Japan)
- Th-347 Neuropathic pain in Parkinson's disease: Prevalence, interest of DN4 questionnaire**
F. Ory Magne, A. Aranda, S. Grolleau, C. Brefel Courbon (Toulouse, France)
- Th-348 The number and nature of emergency room encounters in patients with deep brain stimulators**
A.S. Resnick, K.D. Foote, R.L. Rodriguez, I.A. Malaty, J.L. Moll, N.E. Krock, M.M. Medley, A. Burdick, I.U. Haq, M.S. Okun (Gainesville, Florida)
- Th-349 Chronic thalamic deep brain stimulation in ataxia telangiectasia (A-T; Louis-Bar-Syndrome)**
C. Schrader, H.H. Capelle, T.M. Kinfe, R. Dengler, D. Dressler, J.K. Krauss (Hannover, Germany)
- Th-350 Motor Gpi DBS for rare movement disorders. Reports of three cases of chorea and NBIA**
D. Servello, M. Sassi, A. Brambilla, S. Defendi, C. Menghetti, M. Porta (Milan, Milan, Italy)
- Th-351 Nucleus accumbens (NAC) deep brain stimulation (DBS) in refractory Tourette syndrome (rTS): Our experience with de-novo and rescue surgery in 4 patients**
D. Servello, M. Sassi, S. Defendi, A. Brambilla, C. Menghetti, M. Porta (Milan, Italy)
- Th-352 Unsuccessful revision of Vim DBS leads in essential tremor (ET) patients with late failures: Three cases**
L.C. Shih, E. Papavassiliou, D. Tarsy (Boston, Massachusetts)
- Th-353 The effect of GPi-DBS combined with thalamotomy in patient with secondary focal dystonia**
S.-K. Song, D.S. Shim, P.H. Lee, J.W. Chang, Y.H. Sohn (Seoul, Korea)
- Th-354 Outcome of pallidal stimulation in primary and secondary axial dystonia**
M. Tait, M. Samuel, J. Bourke, A. Costello, N. Hulse, J. Moriarty, R. Selway, K. Ashkan (London, United Kingdom)
- Th-355 Effects of pallidal deep brain stimulation in primary dystonia: A case report**
L. Unusic, N. Klepac, D. Chudy, S. Hajnsek (Zagreb, Croatia)
- Th-356 Pedunculopontine nucleus stimulation in pure akinesia with gait freezing**
D.R. Williams, R. Bittar (Melbourne, Victoria, Australia)

Tics/Stereotypies

- Mo-355 Long-term outcome of thalamic deep brain stimulation in two patients with Tourette syndrome**
L. Ackermans, A. Duits, Y. Temel, A. Winogrodzka, F. Peeters, E. Beuls, V. Visser-Vandewalle (Maastricht, Netherlands)
- Mo-356 Striatal cholinergic neurons, a key for stopping stereotypies**
V. Aliane, S. Pérez, J.-M. Deniau, M.-L. Kemel (Paris, France)

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- Mo-358 The execution of unimanual and bimanual repetitive finger movements in patients with Tourette syndrome**
L. Avanzino, E. Grandis, M. Mirabelli, A. Tacchino, M. Bove, D. Martino, E. Pelosin, E. Veneselli, G. Abbruzzese (Genova, GE, Italy)
- Mo-359 The use of levetiracetam to treat tics in children and adolescents with Tourette syndrome**
Y.M. Awaad (Riyadh, Saudi Arabia)
- Mo-360 Tourette syndrome in the movies: A critical review**
B.R. Barton, G. Stebbins, K. Kompoliti (Chicago, Illinois)
- Mo-361 Coordinated care models for Gilles de la Tourette syndrome: Impact on co-morbidities and patient health perception**
B.A. Bernard, G.T. Stebbins, S. Siegel, T. Schultz, C. Hays, M. Morrissey, S. Leurgans, C.G. Goetz (Chicago, Illinois)
- Mo-430 Myobloc responsive tics triggered by unpleasant sensation: A report of 2 cases**
M.V. Alvarez (Lackland AFB, Texas)
- Tu-356 Lack of tic suppression in a case of accumbens/capsular region deep brain stimulation for Tourette syndrome**
A. Burdick, K.D. Foote, W. Goodman, T. Murphy, N. Ricciutti, H.E. Ward, I. Haq, M.S. Okun (Gainesville, Florida)
- Tu-357 Aripiprazole in adolescents affected by Tourette syndrome**
F. Cardona, V. Neri, A. Paris, P.R. Silvestri, N. Vanacore (Rome, Italy)
- Tu-358 Prevalence and clinical characteristics of tics and other repetitive movement disorders in children with mental retardation**
E. Cubo, J. Cordero, J.M. Trejo, S. Saez, V. Ausin, V. Delgado, A. Martin, J. Macarron, E. Louis, J. Benito (Burgos, Spain)
- Tu-359 Tourette syndrome in adults**
R.N. Gelineau-Kattner, J. Jankovic, A.L. Davidson (Houston, Texas)
- Tu-360 Repetitive behaviours in patients with Tourette syndrome**
K. Gocyla, A. Kalbarczyk, P. Janik (Warsaw, Poland)
- Tu-361 A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome**
J. Jankovic, J. Jimenez-Shahed, L.W. Brown (Houston, Texas)
- Tu-426 Improvement in vocal & motor tics following DBS of motor GPi for Tourette syndrome, not accompanied by subjective improvement in quality of life – A case report**
T. Foltyne, I. Martinez-Torres, L. Zrinzo, E. Joyce, A. Cavanna, M. Jahanshahi, P. Limousin, M. Hariz (London, United Kingdom)
- We-352 Glutamic acid and gamma-aminobutyric acid (GABA) concentrations in serum of patients with Tourette syndrome**
A. Kalbarczyk, P. Janik, M. Gutowicz, A. Baranczyk-Kuzma, H. Kwiecinski (Warsaw, Poland)
- We-353 Coprolalia and copropraxia in Polish patients with Tourette syndrome**
M. Sitek, A. Kalbarczyk, P. Janik (Warsaw, Poland)
- We-354 Weight and height distribution in children with Tourette syndrome**
K. Kompoliti, G.T. Stebbins, C.G. Goetz (Chicago, Illinois)
- We-355 Substance use disorder in adult Tourette syndrome**
D.G. Lichter (Buffalo, New York)
- We-356 Time processing in children with Tourette syndrome**
D. Martino, C.M. Vicario, G. Defazio, F. Spata, R. Giacchè, G. Rappo, L. Catalano, F. Cardona (Bari, Italy)
- We-357 Bradykinesia in patients with obsessive-compulsive disorder**
G. Moretti, I. Berardelli, M. Pasquini, G. Fabbrini, M. Leoni, M. Biondi, A. Berardelli (Rome, Italy)
- We-416 Stereotypy following status epilepticus due herpetic encephalitis. Probable Klüver-Bucy syndrome**
C.A. Twardowschy, L. de Paola, C.E.S. Salvado, R.P. Munhoz, H.A.G. Teive (Curitiba, Parana, Brazil)
- We-417 Videotape analysis of childhood masturbation mimicking as paroxysmal dystonia**
B. Namashivayam, R. Ramalingam, M. Thirugnanasambandam, D. Aruna, N. Muthukrisnan (Salem, India)
- Th-357 Multiple targets deep brain stimulation (DBS) for the treatment of refractory Tourette syndrome (rTS): Our experience with a long-term follow-up evaluation**
M. Porta, M. Sassi, A. Brambilla, C. Menghetti, S. Defendi, D. Servello (Milan, Milan, Italy)
- Th-358 Inverse relationship between thalamic and orbitofrontal volumes in obsessive-compulsive disorder: Magnetic resonance imaging study and meta-regression**
J.-Y. Rotge, B. Dilharreguy, B. Aouizerate, C. Martin-Guehl, D. Guehl, N. Jaafari, N. Langbour, B. Bioulac, J. Tignol, M. Allard, P. Burbaud (Bordeaux, France)
- Th-359 Age at tic remission in patients with Tourette syndrome**
L.A. Rubenstein, D.R. Shprecher, S.A. Frank, R.M. Kurlan (Rochester, New York)
- Th-360 Extrastriatal abnormalities of dopaminergic function in Tourette syndrome: An FLB 457 PET study**
T.D.L. Steeves, J.H. Ko, D.M. Kideckel, P. Sandor, A.E. Lang, S. Houle, A.P. Strafella (Toronto, Ontario, Canada)
- Th-361 Antisaccade and countermanding tasks as pathophysiologic paradigms of motor control in Gilles de la Tourette syndrome (GTS)**
P.C. van Meerbeeck, S. Rivaud, Y. Worbe, P. Pouget, A. Hartmann, B. Gaymard (Paris, France)
- Th-362 Motor tics of the neck: A possible cause of stroke and brachial plexopathy in a child with Tourette syndrome**
P.C. van Meerbeeck, E. Deniau, A. Hartmann (Paris, France)
- Th-420 Bilateral synchronous hemifacial spasm (HFS) after bilateral Bell's palsy (BP)**
M. Velickovic, W. Tse (New York, New York)

Tremor

- Mo-362 Cognitive impairment in persons with essential tremor: Preliminary results from Carmel cohort study of essential tremor**
S. Badarny, G. Sinoff, S. Honigman (Haifa, Israel)
- Mo-363 Spirography in essential tremor and parkinsonism**
M. Knoebel, P.G. Bain (London, United Kingdom)
- Mo-364 Post-traumatic movement disorders**
E.J. Chung, H.S. Lee, C.J. Lim, B.J. Suk (Busan, Korea)
- Mo-365 Orthostatic tremor and motor cognition**
M.W. Cowey, D.R. Williams (Melbourne, Victoria, Australia)
- Mo-366 The smiling tremor**
J. Czerny, C. Cordivari, P. Schwingenschuh, M. Esposito, K.P. Bhatia (London, United Kingdom)
- Mo-367 Late onset dystonia in essential tremor (ET)**
A. Deik, V. Shanker, R. Saunders-Pullman, L. Severt, S.B. Bressman (New York, New York)

ABSTRACT LISTING BY TOPIC

- | | |
|---|--|
| <p>Mo-368 Lower limb rest tremor – A red flag for the diagnosis of Parkinson's disease
M. Hellmann, A. Shteinmetz, E. Melamed, R. Djaldetti (Petah Tiqva, Israel)</p> <p>Mo-369 Are patients with psychogenic movement disorders and psychogenic non-epileptic seizures one and the same?
E. Driver-Dunckley, C. Stonnington, D. Locke, K. Noe (Scottsdale, Arizona)</p> <p>Mo-370 Transcranial sonography in patients with essential tremor
J. Ebentheuer, M. Canelo, B. Otte, T. Claudia (Kassel, Germany)</p> <p>Mo-371 Case of orthostatic tremor responsive to bilateral thalamic deep brain stimulation
V.G.H. Evidente, J.N. Caviness, B. Falk, R. Hillman, M.K. Lyons (Scottsdale, Arizona)</p> <p>Mo-372 Use of Nintendo Wiimote(R) to evaluate postural tremor after DBS
J.Y. Fang, T.L. Davis (Nashville, Tennessee)</p> <p>Mo-373 Tremor associated with chronic inflammatory demyelinating peripheral neuropathy
M. Gallardo, A. Soto (Caracas, Venezuela)</p> <p>Mo-374 The Glass-scale: A simple tool to determine severity and stage in essential tremor
A. Gironell, M. Martínez-Corral, J. Pagonabarraga, J. Kulisevsky (Barcelona, Catalonia, Spain)</p> <p>Tu-362 Differential neuroscientific analyses of the pathological tremor
M.I. Gospodinov (Sofia, Bulgaria)</p> <p>Tu-363 Case report of tremor and deep brain nuclei hyperintensities in Kabuki syndrome
C. Grunseich, T. Fishbein, F. Berkowitz, E.A. Shamim (Washington, District of Columbia)</p> <p>Tu-364 Audiogenic startle response in patients with orthostatic tremor
A. Gunduz, M.E. Kiziltan, G. Kiziltan, I. Sayilar, G. Benbir, O. Uyanik (Istanbul, Turkey)</p> <p>Tu-365 High-dose 1-Octanol in essential tremor: Further evidence for mechanism of action mediated through octanoic acid
D. Haubenberger, F. Nahab, C. Toro, L. Wittevrongel, C. Lungu, J.A. McLane, M. Hallett (Bethesda, Maryland)</p> <p>Tu-366 Clustering of dystonia in some pedigrees with autosomal dominant (AD) essential tremor (ET) suggests the existence of a distinct genetic subtype of ET
P. Hedera, F.T. Phibbs, J.Y. Fang, M.K. Cooper, T.L. Davis (Nashville, Tennessee)</p> <p>Tu-367 Double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor
J.M. Ferrara, C. Kenney, A.L. Davidson, L. Shinawi, A.M. Kissel, J. Jankovic (Houston, Texas)</p> <p>Tu-368 Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor
F.J. Jiménez-Jiménez, L. Rubio, H. Alonso-Navarro, M. Calleja, B. Pilo-de-la-Fuente, J.F. Plaza-Nieto, J. Benito, P.J. García-Ruiz, J.A.G. Agúndez (Madrid, Spain)</p> <p>Tu-369 Dystonic tremor as the initial manifestation of brain tumor
J. Kim, S. Ahn, H. Kim (Gwangju, Korea)</p> | <p>Tu-370 Is there white matter pathology in essential tremor? An optimised diffusion tensor imaging study
J.C. Klein, B. Lorenz, S. Baudrexel, J.-S. Kang, S. Smith, R. Deichmann, R. Hilker (Frankfurt am Main, Germany)</p> <p>Tu-371 Delayed-onset parkinsonian tremor after a mesencephalic lesion
T. Lampreia, P. Bugalho, P. Soares, L. Santos (Lisboa, Portugal)</p> <p>Tu-372 Changes in physiological tremor induced by acute hypoxia
A.G. Legros, H.R. Marshall, J. Gow, A. Beuter, M. Corbacio, B. Cheung, A.W. Thomas, F.S. Prato, R.Z. Stodilka (London, Ontario, Canada)</p> <p>Tu-373 Focal task-specific hand tremor with using scissors
H.-I. Ma, Y.J. Kim, B.-N. Kim, S.Y. Kang, B.-C. Lee (Anyang, Gyeonggi-Do, Korea)</p> <p>Tu-374 Associated neurological diagnosis in orthostatic tremor: A case series
T.A. Mestre, A.E. Lang, J.M. Miyasaki, C. Marras, R. Chen, S.H. Fox (Toronto, Ontario, Canada)</p> <p>We-358 Correlation between KinesiaTM system assessments and clinical TETRAS scores in patients with essential tremor
G. Mostile, J.P. Giuffrida, O.R. Adam, A. Davidson, J. Jankovic (Houston, Texas)</p> <p>We-359 Tremor in a cohort of patients with Inflammatory Bowel disease (IBD)
G.R. Oliveira, P.S. Aquino, E.D. Louis, A.M. Costa, L.G. Pinho, S.S. Silva, Jr., L.L. Braga, M.H.L.P. Souza, F.A. Gondim (Fortaleza, Ceara, Brazil)</p> <p>We-360 Task specific writing tremor: Series and outcomes
W.G. Ondo, P. Satija, M. Ummat (Houston, Texas)</p> <p>We-361 The cognitive profile of essential Tremor-Parkinson's disease (ET-PD) group
B. Ozan, D.I. Gunal, C. Turkmen, A. MollaHasanoglu, H. Ankarali (Istanbul, Turkey)</p> <p>We-362 Holmes tremor may be a treatment challenge
A.Q. Rana (Toronto, Canada)</p> <p>We-363 Task specific tremor type B, with more difficulty writing numbers than letters
A.Q. Rana (Toronto, Ontario, Canada)</p> <p>We-364 Multiple sclerosis associated with a midline truncal tremor
A.Q. Rana (Toronto, Canada)</p> <p>We-365 Isolated facial tremor could be diagnostic chellange
A.Q. Rana (Toronto, Canada)</p> <p>We-366 The electrophysiological confirmation of simple bent and locked knee manoeuvres for clinical diagnosis and management of orthostatic tremor
W.A. Robert, J.D. O'Sullivan, S.A. Peter, C.H. Michael, M. Steven, K.K. Graham (Brisbane, QLD, Australia)</p> <p>We-367 Gradual disappearance of essential tremor due to a cerebellar tumour
C. Rottschy, M. Kronenbuerger, V. Csontos, J. Montagne, S.B. Eickhoff, J.B. Schulz (Aachen, Germany)</p> <p>We-368 Deep brain stimulation in the treatment of essential tremor – An evaluation of 61 cases
U. Sandvik, A. Fytagoridis, G.-M. Hariz, L.-O. Koskinen, P. Blomstedt (Umea, Sweden)</p> |
|---|--|

Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- We-369 Objective quantification of lower limb tremor characteristics in Parkinson's disease
B.K. Scanlon, A. Guevara-Salcedo, B.E. Levin, H.L. Katzen, C. Singer, S. Papapetropoulos (Miami, Florida)
- We-370 Holmes tremor: Clinical and neuroimaging study
A. Gajos, A. Bogucki, M. Schinwelski, W. Soltan, S. Budrewicz, M. Rudzinska, A. Majos, M. Gorska-Chrzastek, M. Bienkiewicz, J. Kusmierenk, J. Slawek (Gdansk, Pomorskie, Poland)
- Th-364 Tremor in immune-mediated neuropathies
P. Schwingenschuh, P. Katschnig, M.P. Lunn, H. Manji, K.P. Bhatia, M.M. Reilly, M.J. Edwards (London, United Kingdom)
- Th-365 Membrane mechanisms for essential tremor
A.G. Shaikh, K. Miura, L.M. Optican, S. Ramat, R.M. Tripp, D.S. Zee (Baltimore, Maryland)
- Th-366 Pseudo-nystagmus – Clinical presentation and quantitative features
A.G. Shaikh, D.S. Zee (Baltimore, Maryland)
- Th-367 Synchronous inferior olive discharge and superimposed cerebellar learning explain irregular eye oscillations in oculopalatal tremor
A.G. Shaikh, S. Hong, K. Liao, J. Tian, D. Solomon, D.S. Zee, R.J. Leigh, L.M. Optican (Baltimore, Maryland)
- Th-368 Further theory on the mechanism of DBS in tremor control
J.E. Arle, J.L. Shils (Burlington, Massachusetts)
- Th-369 Are there clinical features associated with the development of Parkinson's disease in essential tremor?
R.M. Simoes, A. Constantino, D. Houghton, E. Louis, I. Litvan (Amadora, Portugal)
- Th-370 Solitary parkinsonian signs in essential tremor may herald the eventual appearance of Parkinson's disease
A.G. Guevara Salcedo, A. Pandey, F. Nahab, C. Sengun, S. Papapetropoulos, A. Russell, C. Singer (Miami, Florida)
- Th-371 Chopstick-induced task specific tremor: A case report
K.Y. Tay, E.C. Pica, L.C.S. Tan (Singapore, Singapore)
- Th-372 The computer-based tremor analyzer for clinic
E.M. Timanin, E.V. Eremin, A.V. Gustov, M.A. Ustimkina (Nizhny Novgorod, Russian Federation)
- Th-373 Dystonic tremor and essential tremor differ by width of the tremor frequency peak
K.G. Tuck, M.W. Cowey, D.R. Williams (Melbourne, Victoria, Australia)
- Th-374 The cerebellar signs and saccades abnormalities in essentials tremor
M. Wójcik, M. Rudzinska, M. Dec, A. Szczudlik (Krakow, Poland)
- Th-375 Botulinum toxin treatment of a drug resistant head tremor induced by a pontomesencephalic stroke
B. Wuschitz, G. Kranz, G. Kasprian, E. Auff, B. Voller (Vienna, Austria)
- Th-376 Cardiac MIBG SPECT in essential tremor
M. Yamamoto, Y. Kageyama, M. Sakai, T. Nakayama (Takamatsu, Japan)
- Parkinson's disease: Phenomenology**
- Mo-375 New unified staging system for Lewy body disorders
C.H. Adler, J.N. Caviness, H.A. Shill, M.N. Sabbagh, D.J. Connor, D. Walker, L.F. Lue, L. Sue, L. Vedders, J.G. Hentz, T.G. Beach, Arizona PD Consortium (Scottsdale, Arizona)
- Mo-377 The accuracy of clinical diagnosis of tremor dominant Parkinson's disease in a specialist hospital setting: A blinded videotape study
N.P.S. Bajaj, V.K. Gontu, J. Birchall, J. Patterson, D.G. Grosset, A.J. Lees (Nottingham, Nottinghamshire, United Kingdom)
- Mo-378 Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease
S. Bannier, J.L. Berdague, A. Daulny, F. Durif (Clermont Ferrand, France)
- Mo-379 Impaired sense of smell as early indicator of Parkinson's disease
I. Bilic (Split, Croatia)
- Mo-380 Falls and freezing of gait in Parkinson's disease
I. Bilic (Split, Croatia)
- Mo-381 Disturbances in gait and interlimb coordination in Parkinson's disease patients with freezing of gait
S.W. Mahabier, A.H. Snijders, A. Delval, S. Overeem, B.R. Bloem (Nijmegen, Netherlands)
- Mo-382 Auditory cueing and obstacle avoidance in Parkinson's disease patients
S.W. Mahabier, A. Delval, S. Overeem, V. Weerdesteyn, B.R. Bloem (Nijmegen, Netherlands)
- Mo-383 Non-motor symptoms in Parkinson's disease
R. Borgohain, N.K. Venigalla, R. Mridula, S.A. Jabeen, M.A. Kanikannan (Hyderabad, AP, India)
- Mo-384 Upper extremity freezing in two patients with Parkinson's disease
M. Borromeo-Wesner, P. Agarwal, A.F. Griffith (Kirkland, Washington)
- Mo-385 Long-term effects of high frequency stimulation (HFS) on tremor in Parkinson's disease (PD): A case study
C. Cho, F. Gupta, D. Weisz, J.-M. Gracies, R. Alterman, M. Tagliati (New York, New York)
- Mo-386 Segmental progression scores in PD and cross-sectional team results in movement disorders office-based work-up
S.G. Echebarria (Las Arenas, Spain)
- Mo-387 Motor response in Parkinson's disease patients treated with continuous infusion of apomorphine or of duodopa or with STN deep brain stimulation
A.E. Elia, C. Dollenz, L.M. Romito, P. Soliveri, C.N. Homann, A. Albanese (Milan, Italy)
- Mo-388 Prodromal non-motor symptoms of Parkinson's disease, long-term ineffective non-dopaminergic treatment and subsequent response to dopaminergic medication: A retrospective study
K. Farnikova, P. Kanovsky (Olomouc, Czech Republic)
- Mo-389 Modulation of gait symmetry by subthalamic stimulation improves intractable freezing of gait
A. Fasano, H. Stolze, J. Volkmann, G. Deuschl, J. Herzog (Rome, Italy)

ABSTRACT LISTING BY TOPIC

- Mo-390** Parkinson's disease patients with freezing of gait: Evidence for a specific impairment at the beginning of the single-support phase of the gait cycle
L. Gruendlinger, J.M. Srygley, K. Dagan, M. Plotnik, N. Giladi, J.M. Hausdorff (Tel Aviv, Israel)
- Mo-431** Pregnancy in a patient with Parkin-positive, juvenile-onset Parkinson's disease
A.F. Griffith, M. Borromeo-Westner, P. Agarwal (Kirkland, Washington)
- Tu-375** A timeline for Parkinson's disease
C.H. Hawkes, K. Del Tredici, H. Braak (London, United Kingdom)
- Tu-376** Positive family history of essential tremor influences the motor phenotype of Parkinson's disease
P. Hedera, J.Y. Fang, F.T. Phibbs, M.K. Cooper, T.L. Davis (Nashville, Tennessee)
- Tu-377** Parkinson's disease and falls in means of public transport
A. Plasch, A. Haubenhofer, K. Wenzel, R. Saurugg, B. Melisch, F. Fazekas, S. Fuchs, C.N. Homann (Graz, Austria)
- Tu-378** Serum uric acid concentrations in patients with Parkinson's disease
Y. Iwasaki, K. Kawabe, O. Kano, Y. Yoshii, K. Ikeda (Tokyo, Japan)
- Tu-379** Clinical characteristics of Parkinson's disease patients with headache
T. Iwashita, K. Takahashi, M. Shibata, T. Shimizu, N. Suzuki (Tokyo, Japan)
- Tu-380** Brisk tendon reflexes in idiopathic Parkinson's disease – Is it worth neuroimaging?
H.M. Raghib, H. Kumar, M.S. Jog (London, Ontario, Canada)
- Tu-381** Chewing gum significantly improves swallow frequency in patients with Parkinson's disease – A pilot study
A. South, S. Somers, M.S. Jog (London, Ontario, Canada)
- Tu-382** Prevalence of speech impairments in Parkinson's disease: A systematic review
J.G. Kalf, B.J.M. de Swart, B.R. Bloem, M. Munneke (Nijmegen, Netherlands)
- Tu-383** Prevalence of drooling in Parkinson's disease: A matter of definition
J.G. Kalf, B.J.M. de Swart, B.R. Bloem, M. Munneke (Nijmegen, Netherlands)
- Tu-384** Drooling in Parkinson's disease is a motor disorder
J.G. Kalf, L. van den Engel, B.R. Bloem, M.M. Munneke, B.J. de Swart, M.J. Zwarts (Nijmegen, Netherlands)
- Tu-385** Pulmonary function and relative factors in Parkinson's disease
N. Kawashima, E. Horiuchi, K. Hasegawa, S. Matsunaga, N. Soda, A. Kumon, M. Saruwatari, S. Nagumo (Fujisawa, Kanagawa, Japan)
- Tu-386** Dissociation of cardinal motor signs in Parkinson's disease patients
S.-B. Koh, D.-Y. Kwon, S.-H. Lee, S. Hong, K.-W. Park, D.-H. Lee (Seoul, Korea)
- Tu-387** Age of Parkinson's disease onset as a predictor for the development of dyskinesias
S. Ku, G.A. Glass (San Francisco, California)
- Tu-388** How common is the postural instability and gait difficulty (PIGD) subtype in patients with newly diagnosed Parkinson's disease?
J. Linder, M. Edström, L. Forsgren (Umea, Sweden)
- Tu-389** Autonomic nervous system in Parkinson's disease: New evidence on the relationship to freezing of gait
I. Maidan, A. Mirelman, A. Weiss, M. Plotnik, N. Inbar, N. Giladi, J. Hausdorff (Tel Aviv, Israel)
- Tu-390** Presentation of Parkinson's disease in a Pakistani cohort of patients
A. Malik, A. Latif, T. Haider, S. Ali (Karachi, Sindh, Pakistan)
- Tu-391** Defective consolidation of anticipatory balance strategy selection in Parkinson's disease (PD)
R. Mazzocchio, R. della Volpe, P. Piu, A. Biasella, F. Ginanneschi, R. Spidalieri, T. Popa, M. Bonifazi, A. Rossi (Siena, Italy)
- We-371** Fatigue in Parkinson's disease: Clinical aspects and exploring peripheral autonomic dysfunction as a mechanism using cardiac MIBG scans
V. Metta, P. Martinez-Martin, B. Corcoran, M. Buxton-Thomas, H. Gage, Y. Naidu, K.K. Chaudhuri (London, United Kingdom)
- We-372** Body mass index, abdominal circumference and the risk of falls in Parkinson's disease
R.P. Munhoz, V. Balderrama, P.G. David-Joao, T.G.B. Lozovoy, T.G. Lyra, H.A. Teive, C.B. Ribas (Curitiba, PR, Brazil)
- We-373** Homocysteinemia, postural instability and risk of falls in non-demented patients with Parkinson's disease
R.P. Munhoz, T.G. Lyra, A.P. Gomes, H.A. Teive, C.B. Rubas (Curitiba, PR, Brazil)
- We-374** Prospective assessment of falls in patients with Parkinson's disease with motor fluctuations
Y. Okuma, J. Fukae, B.R. Bloem (Izunokuni, Shizuoka, Japan)
- We-375** Reasons for ER consultation in a population with parkinsonism
E. Sirois-Bergeron, M. Panisset (Montreal, Quebec, Canada)
- We-376** Action observation and motor priming: Can we influence the rate of self-paced movements in patients with Parkinson's disease?
E. Pelosin, L. Avanzino, A. Tacchino, M. Bove, G. Abbruzzese (Genova, GE, Italy)
- We-377** Cross-sectional study on non-motor symptoms in an Argentine population of Parkinson's disease patients
C.M. Peralta, J. Toibaro, O.S. Gershmanik (Capital Federal, Buenos Aires, Argentina)
- We-378** Cross-sectional study on non-motor symptoms in an Colombian population of Parkinson's disease patients
C.M. Peralta, J. Toibaro, O.S. Gershmanik (Capital Federal, Buenos Aires, Argentina)
- We-379** Dysarthria in Parkinson's disease patients: A cross-sectional survey
S. Perez-Lloret, L. Nègres-Pages, M. Merello, P. Damier, A. Destée, F. Tison, O. Rascol (Toulouse, France)
- We-380** L-dopa induced dyskinesia in Parkinson's disease patients. Preliminary analysis from the French PARKMIP/COPARK cohort study after 24-months follow-up
S. Perez-Lloret, L. Nègre-Pages, E. Bezard, P. Damier, A. Destée, F. Tison, O. Rascol (Toulouse, France)


Poster presentation information can be found on page 19.

The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders

ABSTRACT LISTING BY TOPIC

- We-381 Mortality rate in Parkinson's disease. Preliminary results from the French PARKMIP/COPARK cohort after 24-months follow-up
L. Nègres-Pages, S. Perez-Lloret, P. Damier, A. Destée, F. Tison, O. Rascol (Toulouse, France)
- We-382 Dysphagia and hypersalivation in Parkinson's disease: A cross-sectional survey
S. Perez-Lloret, L. Nègres-Pages, M. Merello, P. Damier, A. Destée, F. Tison, O. Rascol (Toulouse, France)
- We-383 Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease
B. Post, D. Muslimovic, N. van Geloven, H. Speelman, B. Schmand, R. de Haan (Amsterdam, Netherlands)
- We-384 Camptocormia in Parkinson's disease
R.C.P. Prado, L.C. Ferreira (Aracaju, Sergipe, Brazil)
- We-385 Clinical correlations of fatigue in Parkinson's disease
M.S. Rocha, J. Cavalheiro, C. Duarte, B. Baldivia, M.S. Rocha (Sao Paulo, SP, Brazil)
- We-386 The clinical features of African-Brazilian patients with Parkinson's disease
A.L.Z. Rosso, D.H. Nicareta, F.H.R. Costa, M.L. Silva, A.F.P. Gondar, C.S. Miranda, J.S. Pereira, A.J. Lees (Rio de Janeiro, RJ, Brazil)
- Th-377 Parkinson's disease – Characteristics of disease onset in a veteran population
A.I. Sarwar, E.C. Lai (Houston, Texas)
- Th-378 Variable expression of nonmotor fluctuations in clinical subtypes of Parkinson's disease
M. Seki, K. Takahashi, T. Iwashita, N. Suzuki (Tokyo, Japan)
- Th-379 Clinico-pathological study of subtypes in Parkinson's disease
M. Selikhova, D.R. Williams, P.A. Kempster, T. Reverz, A.J. Lees (London, United Kingdom)
- Th-380 "Staircase" saccadic intrusions in early Parkinson's disease
A.G. Shaikh, M. Xu, R. Shadmehr, S. Grill, D.S. Zee (Baltimore, Maryland)
- Th-381 Clinical characteristics of weight losers in Parkinson's disease
J.C. Sharma, M. Hasoon (Newark, Notts., United Kingdom)
- Th-382 Progression of motor symptoms in Parkinson's disease – A community hospital-based observational study
H. Shibayama, N. Imoto, F. Katada, S. Sato, R. Takeuchi, T. Fukutake (Kamogawa City, Chiba, Japan)
- Th-383 Discordance between physician and patient recognition of motor fluctuations in Parkinson's disease
J.B. Medalie, K.E. Anderson, A.L. Gruber-Baldini, R.M. Mullins, S.B. Mitchell, S.G. Reich, P.S. Fishman, W.J. Weiner, L.M. Shulman (Baltimore, Maryland)
- Th-384 Dysprosody in Parkinson's disease and correlations to UPDRS motor score
S. Skodda, U. Schlegel (Bochum, Germany)
- Th-385 The effect of L-dopa on speech in Parkinson's disease
S. Skodda, U. Schlegel (Bochum, Germany)
- Th-386 Side of onset of motor symptoms cannot be predicted from premorbid handedness of patients with Parkinson's disease
J. Stochl, K.A. Hagtvet, H. Brozova, J. Klempir, J. Roth, E. Ruzicka (Prague, Czech Republic)
- Th-387 Subcellular localization of DJ-1 in the mouse brain and cultured cell lines
Y. Usami, S. Imai, T. Hatano, S.-I. Kubo, N. Hattori (Bunkyo, Tokyo, Japan)
- Th-388 Patterns of motor and non-motor features in Parkinson's disease
S.M. van Rooden, M. Visser, D. Verbaan, J. Marinus, J.J. van Hilten (Leiden, Netherlands)
- Th-389 Slowly and fast progressing symptoms in Parkinson's disease (PD): A new approach to the early diagnosis and determination of the stage
A.F. Vasilenko, Y.S. Shamurov (Chelyabinsk, Russian Federation)
- Th-390 Freezing of gait in patients with Parkinson's disease. Three years of follow-up
L. Vela, J.A. Pareja, J.L. Dobato, F.J. Barriga, M. Baron, Y. Macias, M.D. Martin, B. de la Casa (Alcorcon, Madrid, Spain)
- Th-391 Suppression of levodopa-induced dyskinesias by sensory stimuli
K. Wenzel, P. Schwingenschuh, C.-N. Homann, Z. Pirtosek (Graz, Stmk., Austria)
- Th-392 Effect of smoking on disease progression in male idiopathic Parkinson's disease patients
J.Y. Choi, Y.H. Hong, S.E. Lee, S.W. Yong (Suwon, Republic of Korea)

Libra®
DBS Systems



A POWERFUL NEW OPTION FOR OPTIMAL PARKINSON'S DISEASE THERAPY

Introducing the Libra® DBS Systems from St. Jude Medical. Along with the proven therapy benefits of earlier DBS delivery systems, this system features the LibraXP™ IPG, the thinnest, highest-capacity dual-channel primary cell IPG on the market—part of a family of IPGs built on a platform of durability and quality demonstrated in more than 45,000 neurostimulation implants. With the Libra family of IPGs and St. Jude Medical's comprehensive portfolio of DBS products, you now have more choice in therapy optimization to better meet the unique needs of your patients with Parkinson's disease.

Experience Control. MDS booth 2.



Indications: The Libra Deep Brain Stimulation (DBS) System is indicated for use in unilateral or bilateral stimulation of the thalamus, globus pallidus interna (GPI) or subthalamic nucleus (STN) in patients with levodopa-responsive Parkinson's disease.

Libra and LibraXP are trademarks of Advanced Neuromodulation Systems, Inc. doing business as St. Jude Medical Neuromodulation Division. ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2009 St. Jude Medical. All rights reserved.

Not available in all markets.



Connecting with science

“UCB is connecting science in new ways, notably chemistry and biology, illuminating the biological pathways involved in severe diseases.”

UCB has a passionate, long-term commitment to finding more effective treatments for several specific neurological diseases, immunological disorders and cancers. Our challenge is to help patients and families living with the physical and social burden of severe diseases. It holds out the promise of a new generation of therapies that will enable them to enjoy more normal, everyday lives.

www.ucb.com